[Federal Register: August 11, 2004 (Volume 69, Number 154)]
[Rules and Regulations]               
[Page 48915-49781]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr11au04-15]                         
 

[[Page 48915]]

-----------------------------------------------------------------------

Part II





Department of Health and Human Services





-----------------------------------------------------------------------



Centers for Medicare & Medicaid Services



-----------------------------------------------------------------------



42 CFR Parts 403, 412, et al.



Medicare Program; Changes to the Hospital Inpatient Prospective Payment 
Systems and Fiscal Year 2005 Rates; Final Rule


[[Page 48916]]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 403, 412, 413, 418, 460, 480, 482, 483, 485, and 489

[CMS-1428-F]
RIN 0938-AM80

 
Medicare Program; Changes to the Hospital Inpatient Prospective 
Payment Systems and Fiscal Year 2005 Rates

AGENCY: Centers for Medicare and Medicaid Services (CMS), HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: We are revising the Medicare hospital inpatient prospective 
payment systems (IPPS) for operating and capital-related costs to 
implement changes arising from our continuing experience with these 
systems; and to implement a number of changes made by the Medicare 
Prescription Drug, Improvement, and Modernization Act of 2003 that was 
enacted on December 8, 2003. In addition, in the Addendum to this final 
rule, we describe the changes to the amounts and factors used to 
determine the rates for Medicare hospital inpatient services for 
operating costs and capital-related costs. These changes are applicable 
to discharges occurring on or after October 1, 2004. We also are 
setting forth rate-of-increase limits as well as policy changes for 
hospitals and hospital units excluded from the IPPS that are paid in 
full or in part on a reasonable cost basis subject to these limits.
    Among the policy changes that we are making are: Changes to the 
classification of cases to the diagnosis-related groups (DRGs); changes 
to the long-term care (LTC)-DRGs and relative weights; changes in the 
wage data, labor-related share of the wage index, and the geographic 
area designations used to compute the wage index; changes in the 
qualifying threshold criteria for and the approval of new technologies 
and medical services for add-on payments; changes to the policies 
governing postacute care transfers; changes to payments to hospitals 
for the direct and indirect costs of graduate medical education; 
changes to the payment adjustment for disproportionate share rural 
hospitals; changes in requirements and payments to critical access 
hospitals (CAHs); changes to the disclosure of information requirements 
for Quality Improvement Organization (QIOs); and changes in the 
hospital conditions of participation for discharge planning and fire 
safety requirements for certain health care facilities.

DATES: The provisions of this final rule are effective on October 1, 
2004.

FOR FURTHER INFORMATION CONTACT:
    Jim Hart, (410) 786-9520, Operating Prospective Payment, Diagnosis-
Related Groups (DRGs), Wage Index, New Medical Services and Technology, 
Standardized Amounts, Hospital Geographic Reclassifications, Postacute 
Care Transfers, and Disproportionate Share Hospital Issuesp; Tzvi 
Hefter, (410) 786-4487, Capital Prospective Payment, Excluded 
Hospitals, Graduate Medical Education, Critical Access Hospitals, and 
Long-Term Care (LTC)-DRGs Issues;
    Mary Collins, (410) 786-3189, CAH Bed Limits and Distinct Part Unit 
Issues; John Eppinger, (410) 786-4518, CAH Periodic Interim Payment 
Issues; Maria Hammel, (410) 786-1775, Quality Improvement Organization 
Issues; Siddhartha Mazumdar, (410) 786-6673, Rural Community Hospital 
Demonstration Project Issues; Jeannie Miller, (410) 786-3164, 
Bloodborne Pathogens Standards, Hospital Conditions of Participation 
for Discharge Planning, and Fire Safety Requirements Issues; Dr. Mark 
Krushat, (410) 786-6809; and Dr. Anita Bhatia, (410) 786-7236, Quality 
Data for Annual Payment Update Issues.

SUPPLEMENTARY INFORMATION:

Availability of Copies and Electronic Access

    Copies: To order copies of the Federal Register containing this 
document, send your request to: New Orders, Superintendent of 
Documents, P.O. Box 371954, Pittsburgh, PA 15250-7954. Specify the date 
of the issue requested and enclose a check or money order payable to 
the Superintendent of Documents, or enclose your Visa or Master Card 
number and expiration date. Credit card orders can also be placed by 
calling the order desk at (202) 512-1800 or by faxing to (202) 512-
2250. The cost for each copy is $10.00. As an alternative, you can view 
and photocopy the Federal Register document at most libraries 
designated as Federal Depository Libraries and at many other public and 
academic libraries throughout the country that receive the Federal 
Register.
    This Federal Register document is also available from the Federal 
Register online database through GPO Access, a service of the U.S. 
Government Printing Office. Free public access is available on a Wide 
Area Information Server (WAIS) through the Internet and via 
asynchronous dial-in. Internet users can access the database by using 
the World Wide Web; the Superintendent of Documents home page address 
is http://www.access.gpo.gov/nara_docs/, by using local WAIS client 

software, or by telnet to swais.access.gpo.gov, then login as guest (no 
password required). Dial-in users should use communications software 
and modem to call (202) 512-1661; type swais, then login as guest (no 
password required).

Acronyms

ACGME--Accreditation Council on Graduate Medical Education
AHIMA--American Health Information Management Association
AHA--American Hospital Association
AOA--American Osteopathic Association
ASC--Ambulatory Surgical Center
BBA--Balanced Budget Act of 1997, Pub. L. 105-33
BIPA--Medicare, Medicaid, and SCHIP [State Children's Health 
Insurance Program] Benefits Improvement and Protection Act of 2000, 
Pub. L. 106-554
BLS--Bureau of Labor Statistics
CAH--Critical access hospital
CART CMS--Abstraction & Reporting Tool
CBSAs--Core-Based Statistical Areas
CC--Complication or comorbidity
CMS--Centers for Medicare & Medicaid Services
CMSA--Consolidated Metropolitan Statistical Area
COBRA--Consolidated Omnibus Reconciliation Act of 1985, Pub. L. 99-
272
CoP--Condition of Participation
CPI--Consumer Price Index
CRNA--Certified registered nurse anesthetist
DRG--Diagnosis-related group
DSH--Disproportionate share hospital
ESRD--End-stage renal disease
FDA--Food and Drug Administration
FQHC--Federally qualified health center
FSES--Fire Safety Evaluation System
FTE--Full-time equivalent
FY--Federal fiscal year
GME--Graduate medical education
HCRIS--Hospital Cost Report Information System
HIPC--Health Information Policy Council
HIPAA--Health Insurance Portability and Accountability Act of 1996, 
Pub. L. 104-191
HHA--Home health agency
HPSA--Health Professions Shortage Area
ICD-9-CM--International Classification of Diseases, Ninth Revision, 
Clinical Modification
ICD-10-PCS--International Classification of Diseases, Tenth Edition, 
Procedure Coding System
ICF/MRs--Intermediate care facilities for the mentally retarded
IME--Indirect medical education
IPPS--Acute care hospital inpatient prospective payment system
IPF--Inpatient psychiatric facility
IRF--Inpatient rehabilitation facility
JCAHO--Joint Commission on the Accreditation of Healthcare 
Organizations
LAMA--Left Against Medical Advice
LTC-DRG--Long-term care diagnosis-related group

[[Page 48917]]

LTCH--Long-term care hospital
LSC--Life Safety Code
MCE--Medicare Code Editor
MCO--Managed care organization
MDC--Major diagnostic category
MDH--Medicare-dependent small rural hospital
MedPAC--Medicare Payment Advisory Commission
MedPAR--Medicare Provider Analysis and Review File
MEI--Medicare Economic Index
MGCRB--Medicare Geographic Classification Review Board
MMA--Medicare Prescription Drug, Improvement, and Modernization Act 
of 2003, Pub. L. 108-173
MPFS--Medicare Physician Fee Schedule
MSA--Metropolitan Statistical Area
NECMA--New England County Metropolitan Areas
NCHS--National Center for Health Statistics
NCVHS--National Committee on Vital and Health Statistics
NFPA--National Fire Protection Association
NPR--Notice of Program Reimbursement
NQF--National Quality Forum
NVHRI--National Voluntary Hospital Reporting Initiative
OES--Occupational Employment Statistics
OIG--Office of the Inspector General
OMB--Executive Office of Management and Budget
O.R.--Operating room
OSCAR--Online Survey Certification and Reporting (System)
OSHA--Occupational Safety and Health Act
PACE--Programs of All-Inclusive Care for the Elderly
PIP--Periodic interim payment
PMS--Performance Measurement System
PMSAs--Primary Metropolitan Statistical Areas
PPS--Prospective payment system
PRA--Per resident amount
ProPAC--Prospective Payment Assessment Commission
PRRB--Provider Reimbursement Review Board
PS&R--Provider Statistical and Reimbursement System
QIO--Utilization and Quality Control Quality Improvement 
Organization
RHC--Rural health clinic
RHQDAPU--Reporting Hospital Quality Data for Annual Payment Update
RRC--Rural referral center
SCH--Sole community hospital
SNF--Skilled nursing facility
SOCs--Standard occupational classifications
SOM--State Operations Manual
SSA--Social Security Administration
SSI--Supplemental Security Income
TEFRA--Tax Equity and Fiscal Responsibility Act of 1982, Pub. L. 97-
248
UHDDS--Uniform Hospital Discharge Data Set

Table of Contents

I. Background
    A. Summary
    1. Acute Care Hospital Inpatient Prospective Payment System 
(IPPS)
    2. Hospitals and Hospital Units Excluded from the IPPS
    a. IRFs
    b. LTCH
    c. IPFs
    3. Critical Access Hospitals (CAHs)
    4. Payments for Graduate Medical Education (GME)
    B. Provisions of the Medicare Prescription Drug, Improvement, 
and Modernization Act of 2003
    C. Summary of the Provisions of the May 18, 2004 Proposed Rule
    1. Changes to the DRG Reclassifications and Recalibrations of 
Relative Weights
    2. Changes to the Hospital Wage Index
    3. Other Decisions and Changes to the PPS for Inpatient 
Operating and GME Costs
    4. Changes to the PPS for Capital-Related Costs
    5. Changes for Hospitals and Hospital Units Excluded from the 
IPPS
    6. Changes to QIO Disclosure of Information Requirements
    7. Changes Relating to Medicare Provider Agreements: Bloodborne 
Pathogens Standards, Hospital Conditions of Participation for 
Discharge Planning, and Fire Safety Requirements for Certain Health 
Care Facilities
    8. Determining Prospective Payment Operating and Capital Rates 
and Rate-of-Increase Limits
    9. Impact Analysis
    10. Recommendation of Update Factor for Hospital Inpatient 
Operating Costs
    11. Discussion of Medicare Payment Advisory Commission 
Recommendations
    D. Public Comments Received in response to the May 18, 2004 IPPS 
Proposed Rule
II. Changes to DRG Classifications and Relative Weights
    A. Background
    B. DRG Reclassifications
    1. General
    2. MDC 1 (Diseases and Disorders of the Nervous System): 
Intracranial Hemorrhage and Stroke With Infarction
    3. MDC 5 (Diseases and Disorders of the Circulatory System)
    a. Heart Assist System Implant
    b. Cardiac Resynchronization Therapy and Heart Failure
    c. Combination Cardiac Pacemaker Devices and Lead Codes
    d. Treatment of Venous Bypass Graft [Conduit] with 
Pharmaceutical Substance
    4. MDC 6 (Diseases and Disorders of the Digestive System): 
Artificial Anal Sphincter
    5. MDC 8 (Diseases and Disorders of the Musculoskeletal System 
and Connective Tissue)
    a. 360 Spinal Fusions
    b. Multiple Level Spinal Fusion
    c. Insertion of Spinal Disc Prostheses and Other Spiral Devices
    6. MDC 15 (Newborns and Other Neonates with Conditions 
Originating in the Perinatal Period)
    7. MDC 20 (Alcohol/Drug Use and Alcohol/Drug Induced Organic 
Mental Disorders): Drug-Induced Dementia
    8. MDC 22 (Burns): Burn Patients on Mechanical Ventilation
    9. Pre-MDC: Tracheostomy
    10. Medicare Code Editor (MCE) Changes
    11. Surgical Hierarchies
    12. Refinement of Complications and Comorbidities (CC) List
    13. Review of Procedure Codes in DRGs 468, 476, and 477
    a. Moving Procedure Codes from DRG 468 or DRG 477 to MDCs
    b. Reassignment of Procedures among DRGs 468, 476, and 477
    c. Adding Diagnosis or Procedure Codes to MDCs
    14. Pancreatic Islet Cell Transplantation in Clinical Trials
    15. Changes to the ICD-9-CM Coding System
    16. Other Issues
    a. Craniotomy Procedures
    (1) Unruptured Cerebral Aneurysms
    (2) GLIADEL[reg] Chemotherapy Wafers
    (3) DRG 3 (Craniotomy Age 0-17)
    b. Coronary Stent Procedures
    c. Severe Sepsis
    d. Implantable Cardiac Defibrillators
    e. Intestinal Transplantation
    f. Cochlear Implants
    g. Artificial Hearts
    h. Left Atrial Appendage Devices: DRG Assignment for New Code 
37.90
    i. Carotid Artery Stents
    j. Acute Intermittent Porphyria
    C. Recalibration of DRG Weights
    D. LTC-DRG Reclassifications and Relative Weights for LTCHs for 
FY 2005
    1. Background
    2. Changes in the LTC-DRG Classifications
    a. Background
    b. Patient Classifications into DRGs
    3. Development of the FY 2005 LTC-DRG Relative Weights
    a. General Overview of Development of the LTC-DRG Relative 
Weights
    b. Data
    c. Hospital-Specific Relative Value Methodology
    d. Low-Volume LTC-DRGs
    4. Steps for Determining the FY 2005 LTC-DRG Relative Weights
    5. Out of Space Comments Relating to the LTCH PPS Payments Rates
    E. Add-On Payments for New Services and Technologies
    1. Background
    2. Other Provisions of Section 503 of Pub. L. 108-173
    3. FY 2005 Status of Technology Approved for FY 2004 Add-On 
Payments
    a. Drotrecogin Alfa (Activated)--Xigris[reg]
    b. InFUSETM (Bone Morphogenetic Proteins (BMPs) for 
Spinal Fusions)
    4. Reevaluation of FY 2004 Applications That Were Not Approved
    5. FY 2005 Applicants for New Technology Add-On Payments
    a. InFUSETM Bone Graft (Bone Morphogenetic Proteins 
(BMPs) for Tibia Fractures)
    b. Norian Skeletal Repair System (SRS)[reg] Bone Void Filler
    c. InSync[reg] Defibrillator System (Cardiac Resynchronization 
Therapy with Defibrillation (CRT-D))
    d. GliaSite[reg] Radiation Therapy System (RTS)
    e. Natrecor[reg]--Human B-Type Natriuretic Peptide (hBNP)
    f. Kinetra[reg] Implantable Neurostimulator for Deep Brain 
Stimulation

[[Page 48918]]

    g. Intramedullary Skeletal Kinetic Distractor (ISKD)
    h. ActiconTM Neosphincter
    i. TandemHeartTM Percutaneous Left Ventricular Assist 
System
    j. AquadexTM System 100 Fluid Removal System (System 
100)
III. Changes to the Hospital Wage Index
    A. Background
    B. Revised OMB Definitions for Geographical Statistical Areas
    1. Current Labor Market Areas Based on MSAs
    2. Core-Based Statistical Areas
    3. Revised Labor Market Areas
    a. New England MSAs
    b. Metropolitan Divisions
    c. Micropolitan Areas
    d. Transition Period
    C. Occupational Mix Adjustment to FY 2005 Index
    1. Development of Data for the Occupational Mix Adjustment
    2. Calculation of the Occupational Mix Adjustment Factor and the 
Occupational Mix Adjusted Wage Index
    D. Worksheet S-3 Wage Data for the FY 2005 Wage Index Update
    E. Verification of Worksheet S-3 Wage Data
    F. Computation of the Unadjusted Wage Index
    G. Computation of the FY 2005 Blended Wage Index
    H. Revisions to the Wage Index Based on Hospital Redesignation
    1. General
    2. Effects of Reclassification
    3. FY 2005 Issues
    a. FY 2005 MGCRB Reclassifications
    b. Implementation of New MSAs
    c. Redesignations under Section 1886(d)(8)(B) of the Act
    d. Reclassifications Under Section 508 of Public Law 108-173
    e. Wage Index Adjustment Based on Commuting Patterns of Hospital 
Employees
    (1) Data
    (2) Qualifying Counties
    (3) The Adjustment
    (4) Automatic Adjustments
    4. FY 2005 Reclassifications
I. Requests for Wage Index Data Corrections
    1. Worksheet S-3 Wage Data
    2. Occupational Mix Data
    3. All FY 2005 Wage Index Data
    J. Revision of the Labor-Related Share of the Wage Index
IV. Other Decisions and Changes to the IPPS for Operating Costs and 
GME Costs
    A. Postacute Care Transfer Payment Policy
    1. Background
    2. Changes to DRGs Subject to the Postacute Care Transfer Policy
    B. Payments for Inpatient Care in Providers That Change 
Classification Status During a Patient Stay
    C. Geographic Reclassifications--Definitions of Urban and Rural 
Areas
    1. Revised MSAs
    2. Transition Period for DSH Payments to Redesignated Hospitals
    D. Equalization of Urban and Rural Standardized Amounts
    E. Reporting of Hospital Quality Data for Annual Hospital 
Payment Update
    1. Background
    2. Requirements for Hospital Reporting of Quality Data
    3. Submission of Hospital Data for FYs 2006 and 2007
    4. Regulation Change
    F. Revision of the Labor-Related Share of the Hospital Wage 
Index
    G. Wage Index Adjustment for Commuting Patterns of Hospital 
Employees
    H. Additional Payments for New Medical Services and Technology: 
Policy Changes
    I. Rural Referral Centers
    1. Case-Mix Index
    2. Discharges
    J. Additional Payments to Hospitals with High Percentage of End-
Stage Renal Disease (ESRD) Discharges
    K. Indirect Medical Education (IME) Adjustment
    1. IME Adjustment Factor Formula Multipliers
    2. IME Adjustment Formula Multiplier for Redistributed FTE 
Resident Slots
    3. Counting Beds and Patient Days for Purposes of Calculating 
the IME Adjustment and DSH Adjustment
    4. Technical Changes
    L. Payment to Disproportionate Share Hospitals (DSHs)
    1. Background
    2. Enhanced DSH Adjustment for Rural Hospitals and Urban 
Hospitals with Fewer Than 100 Beds
    3. Counting Beds and Patient Days for the IME and DSH 
Adjustments
    a. Provisions of the FY 2004 Proposed Rule, Responses to Public 
Comments, and Provisions of the FY 2005 Final Rule
    1. Unoccupied Beds
    2. Observation Services and Swing-bed Skilled Nursing Services
    3. Dual-Eligible Patient Days
    4. Medicare+Choice (M+C) Days
    M. Payment Adjustments for Low-Volume Hospitals
    N. Medicare Geographic Classification Review Board (MGCRB) 
Reclassifications
    1. Background
    2. Standardized Amount Reclassification Provisions
    3. Reclassification of Urban Rural Referral Centers
    4. Special Circumstances of Sole Community Hospitals (SCHs) in 
Low Population Density States
    5. Possible Reclassifications for Dominant Hospitals and 
Hospitals in Single-Hospital MSAs
    6. Special Circumstances of Hospitals in All-Urban States
    7. Geographic Reclassifications for (SNFs)
    O. Payment for Direct Graduate Medical Education
    1. Background
    2. Reductions of and Increases in Hospitals' FTE Resident Caps 
for GME Payment Purposes under Section 422 of Pub. L. 108-173
    a. General Background on Methodology for Determining the FTE 
Resident Count
    b. Reduction of Hospitals' FTE Resident Caps under the 
Provisions of Section 422 of Pub. L. 108-173
    c. Hospitals Subject to the FTE Resident Cap Reduction
    d. Exemption from FTE Resident Cap Reduction for Certain Rural 
Hospitals
    e. Determining the Estimated Number of FTE Resident Slots 
Available for Redistribution
    f. Determining the Possilbe Reduction to a Hospital's FTE 
Resident Cap
    (1) Reference Resident Level--General
    (2) Expansion of an Existing Program
    (3) Audits of the Reference Cost Reporting Periods
    (4) Expansions Under Newly Approved Programs
    (5) Affiliations
    g. Criteria for Determining Hospitals That Will Receive 
Increases in Their FTE Resident Caps
    h. Application Process for the Increases in Hospitals' FTE 
Resident Caps
    i. CMS Evaluation of Applications for Increases in FTE Resident 
Caps
    j. IME Adjustment Formula Multiplier for Redistributed FTE Slots 
and the Application of Locality-Adjusted National Average Per 
Resident Amount (PRA)
    k. Application of Section 422 to Hospitals That Participate in 
Demonstration Projects or Voluntary Reduction Programs
    l. Application of Section 422 to Hospitals That File Low 
Utilization Medicare Cost Reports
    m. CMS Evaluation Form
    n. Application Process and CMS Central and Regional Office 
Mailing Addresses for Receiving Increases in FTE Resident Caps
    3. Direct GME Initial Residency Period
    a. Background
    b. Direct GME Initial Residency Period Limitation: Simultaneous 
Match Issue
    c. Exception to Initial Residency Period for Geriatric Residency 
or Fellowship Programs
    4. Per Resident Amount: Extension of Update Limitation on High-
Cost Programs
    5. Residents Training in Nonhospital Settings
    a. Background
    b. Moratorium on Disallowances of Allopathic or Osteopathic 
Family Practice Residents Training Time in Nonhospital Settings
    (1) Cost Reports That Are Settled Between January 1, 2004 and 
December 31, 2004
    (2) Family Practice Residents That Are Training in Nonhospital 
Settings Between January 1, 2004 and December 31, 2004
    c. Requirements for Written Agreements for Residency Training in 
Nonhospital Settings
    P. Rural Community Hospital Demonstration Program
    Q. Special Circumstances of Hospitals Facing High Malpractice 
Insurance Rate Increases
    V. Changes to the PPS for Capital-Related Costs
    A. Background
    B. Payments to Hospitals Located in Puerto Rico
    C. Exception Payment for Extraordinary Circumstances

[[Page 48919]]

    D. Treatment of Hospitals Previously Reclassified for the 
Operating IPPS Standardized Amounts
    E. Geographic Classification and Definition of Large Urban Area
    1. Core-based Statistical Areas
    2. Metropolitan Divisions
VI. Changes for Hospitals and Hospital Units Excluded from the IPPS
    A. Payments to Excluded Hospitals and Hospital Units
    1. Payments to Existing Excluded Hospitals and Hospital Units
    2. Updated Caps for New Excluded Hospitals and Units
    3. Implementation of a PPS for IRFs
    4. Implementation of a PPS for LTCHs
    5. Development of a PPS for IPFs
    6. Technical Changes and Corrections
    a. Change Related to Establishment of Payments for Excluded 
Hospitals
    b. Technical Correction Related to Long-Term Care Hospitals
    7. Report of Adjustment (Exceptions) Payments
    B. Criteria for Classification of Hospitals-Within-Hospitals
    C. Critical Access Hospitals (CAHs)
    1. Background
    2. Payment Amounts for CAH Services
    3. Condition for Application of Special Professional Service 
Payment Adjustment
    4. Coverage of Costs for Certain Emergency Room On-Call 
Providers
    5. Authorization of Periodic Interim Payments for CAHs
    6. Revision of the Bed Limit for CAHs
    7. Authority to Establish Psychiatric and Rehabilitation 
Distinct Part Units of CAHs
    8. Waiver Authority for Designation of a CAH as a Necessary 
Provider
    9. Payment for Clinical Diagnostic Laboratory Tests
    10. Continued Participation by CAHs in Counties Reclassified as 
Urban Based on the 2000 Census
    11. Technical Changes in Part 489
VII. Changes to the Disclosure of Information Requirements for 
Quality Improvement Organizations (QIOs)
    A. Background
    B. Provisions of the May 18, 2004 Proposed. Regulations
    C. Technical Changes
VIII. Policy Changes Relating to Medicare Provider Agreements for 
Compliance with Bloodborne Pathogens Standards, Hospital Conditions 
of Participation, and Fire Safety Requirements for Certain Health 
Care Facilities
    A. Conditions of Participation for Discharge Planning
    1. Background
    2. Implementation
    3. Provisions of the Proposed Regulations
    B. Compliance with Bloodborne Pathogens Standards
    1. Background
    2. Provisions of the Proposed Regulations
    C. Fire Safety Requirements for Certain Health Care Facilities
    1. Background
    2. Proposed Changes to the Regulations
IX. MedPAC Recommendations
X. Other Required Information
    A. Requests for Data from the Public
    B. Collection of Information Requirements
    C. Waiver of Proposed Rulemaking for Technical Correction to 
LTCH Regulations

Regulation Text

Addendum--Schedule of Standardized Amounts Effective with Discharges 
Occurring On or After October 1, 2004 and Update Factors and Rate-of-
Increase Percentages Effective With Cost Reporting Periods Beginning On 
or After October 1, 2004

I. Summary and Background
II. Changes to Prospective Payment Rates for Hospital Inpatient 
Operating Costs for FY 2005
    A. Calculation of the Adjusted Standardized Amount
    1. Standardization of Base-Year Costs or Target Amounts
    2. Computing the Average Standardized Amount
    3. Updating the Average Standardized Amount
    4. Other Adjustments to the Average Standardized Amount
    a. Recalibration of DRG Weights and Updated Wage Index--Budget 
Neutrality Adjustment
    b. Reclassified Hospitals--Budget Neutrality Adjustment
    c. Outliers
    d. Section 410A of Pub.L. 108-173 Rural Community Hospital 
Demonstration Program Adjustment
    5. FY 2005 Standardized Amount
    B. Adjustments for Area Wage Levels and Cost-of-Living
    1. Adjustment for Area Wage Levels
    2. Adjustment for Cost-of-Living in Alaska and Hawaii
    C. DRG Relative Weights
    D. Calculation of Prospective Payment Rates for FY 2005
    1. Federal Rate
    2. Hospital-Specific Rate (Applicable Only to SCHs and MDHs)
    a. Calculation of Hospital-Specific Rate
    b. Updating the FY 1982, FY 1987, and FY 1996 Hospital-Specific 
Rates for FY 2005
    3. General Formula for Calculation of Prospective Payment Rates 
for Hospitals Located in Puerto Rico Beginning On or After October 
1, 2004 and Before October 1, 2005
    a. Puerto Rico Rate
    b. National Rate
III. Changes to Payment Rates for Acute Care Hospital Inpatient 
Capital-Related Costs for FY 2005
    A. Determination of Federal Hospital Inpatient Capital-Related 
Prospective Payment Rate Update
    1. Capital Standard Federal Rate Update
    a. Description of the Update Framework
    b. Comparison of CMS and MedPAC Update Recommendation
    2. Outlier Payment Adjustment Factor
    3. Budget Neutrality Adjustment Factor for Changes in DRG 
Classifications and Weights and the Geographic Adjustment Factor
    4. Exceptions Payment Adjustment Factor
    5. Capital Standard Federal Rate for FY 2005
    6. Special Capital Rate for Puerto Rico Hospitals
    B. Calculation of Inpatient Capital-Related Prospective Payments 
for FY 2005
    C. Capital Input Price Index
    1. Background
    2. Forecast of the CIPI for FY 2005
    IV. Changes to Payment Rates for Excluded Hospitals and Hospital 
Units: Rate-of-Increase Percentages
V. Payment for Blood Clotting Factor Administered to Hemophilia 
Inpatients

Tables

    Table 1A--National Adjusted Operating Standardized Amounts, 
Labor/Nonlabor (71.1 Percent Labor Share/28.9 Percent Nonlabor Share 
If Wage Index Is Greater Than 1)
    Table 1B--National Adjusted Operating Standardized Amounts, 
Labor/Nonlabor (62 Percent Labor Share/38 Percent Nonlabor Share If 
Wage Index Is Less Than or Equal to 1)
    Table 1C--Adjusted Operating Standardized Amounts for Puerto 
Rico, Labor/Nonlabor
    Table 1D--Capital Standard Federal Payment Rate
    Table 2--Hospital Case-Mix Indexes for Discharges Occurring in 
Federal Fiscal Year 2003; Hospital Average Hourly Wage for Federal 
Fiscal Years 2003 (1999 Wage Data), 2004 (2000 Wage Data), and 2005 
(2001 Wage Data) Wage Indexes and 3-Year Average of Hospital Average 
Hourly Wages
    Table 3A1--FY 2005 and 3-Year* Average Hourly Wage 
for Urban Areas by MSA
    Table 3A2--FY 2005 3-Year* Average Hourly Wage for 
Urban Areas by CBSA
    Table 3B1--FY 2005 and 3-Year* Average Hourly Wage 
for Rural Areas by MSA
    Table 3B2--FY 2005 and 3-Year* Average Hourly Wage 
for Rural Areas by CBSA
    Table 4A1--Wage Index and Capital Geographic 
Adjustment Factor (GAF) for Urban Areas by MSA
    Table 4A2--Wage Index and Capital Geographic 
Adjustment Factor (GAF) for Urban Areas by CBSA
    Table 4B1--Wage Index and Capital Geographic 
Adjustment Factor (GAF) for Rural Areas by MSA
    Table 4B2--Wage Index and Capital Geographic 
Adjustment Factor (GAF) for Rural Areas by CBSA
    Table 4C1--Wage Index and Capital Geographic 
Adjustment Factor (GAF) for Hospitals That Are Reclassified by MSA
    Table 4C2--Wage Index and Capital Geographic 
Adjustment Factor (GAF) for Hospitals That Are Reclassified by CBSA
    Table 4F1--Puerto Rico Wage Index and Capital 
Geographic Adjustment Factor (GAF) by MSA
    Table 4F2--Puerto Rico Wage Index and Capital 
Geographic Adjustment Factor (GAF) by CBSA
    Table 4G--Pre-Reclassified Wage Index for Urban Areas
    Table 4H--Pre-Reclassified Wage Index for Rural Areas
    Table 4J--Wage Index Adjustment for Commuting Hospital Employees 
(Out-

[[Page 48920]]

Migration) In Qualifying Counties--FY 2005
    Table 5--List of Diagnosis-Related Groups (DRGs), Relative 
Weighting Factors, and Geometric and Arithmetic Mean Length of Stay 
(LOS)
    Table 6A--New Diagnosis Codes
    Table 6B--New Procedure Codes
    Table 6C--Invalid Diagnosis Codes
    Table 6D--Invalid Procedure Codes
    Table 6E--Revised Diagnosis Code Titles
    Table 6F--Revised Procedure Code Titles
    Table 6G--Additions to the CC Exclusions List
    Table 6H--Deletions from the CC Exclusions List
    Table 7A--Medicare Prospective Payment System Selected 
Percentile Lengths of Stay: FY 2003 MedPAR Update March 2004 GROUPER 
V21.0
    Table 7B--Medicare Prospective Payment System Selected 
Percentile Lengths of Stay: FY 2003 MedPAR Update March 2004 GROUPER 
V22.0
    Table 8A--Statewide Average Operating Cost-to-Charge Ratios-July 
2004
    Table 8B--Statewide Average Capital Cost-to-Charge Ratios--July 
2004
    Table 9A1--Hospital Reclassifications and 
Redesignations by IndividualHospital--FY 2005 by MSA
    Table 9A2--Hospital Reclassifications and 
Redesignations by IndividualHospital--FY 2005 by CBSA-FY 2005
    Table 9B--Hospital Reclassifications and Redesignation by 
Individual Hospital Under Section 508 of Public Law 108-173--FY 2004
    Table 10--Geometric Mean Plus the Lesser of .75 of the National 
Adjusted Operating Standardized Payment Amount (Increased to Reflect 
the Difference Between Costs and Charges) or .75 of One Standard 
Deviation of Mean Charges by Diagnosis-Related Groups (DRGs)--July 
2004
    Table 11--FY 2005 LTC-DRGs, Relative Weights, Geometric Average 
Length of Stay, and \5/6\ths of the Geometric Average Length of Stay
    Appendix A--Regulatory Impact Analysis
    Appendix B--Recommendation of Update Factors for Operating Cost 
Rates of Payment for Inpatient Hospital Services

I. Background

A. Summary

1. Acute Care Hospital Inpatient Prospective Payment System (IPPS)
    Section 1886(d) of the Social Security Act (the Act) sets forth a 
system of payment for the operating costs of acute care hospital 
inpatient stays under Medicare Part A (Hospital Insurance) based on 
prospectively set rates. Section 1886(g) of the Act requires the 
Secretary to pay for the capital-related costs of hospital inpatient 
stays under a prospective payment system (PPS). Under these PPSs, 
Medicare payment for hospital inpatient operating and capital-related 
costs is made at predetermined, specific rates for each hospital 
discharge. Discharges are classified according to a list of diagnosis-
related groups (DRGs).
    The base payment rate is comprised of a standardized amount that is 
divided into a labor-related share and a nonlabor-related share. The 
labor-related share is adjusted by the wage index applicable to the 
area where the hospital is located; and if the hospital is located in 
Alaska or Hawaii, the nonlabor-related share is adjusted by a cost-of-
living adjustment factor. This base payment rate is multiplied by the 
DRG relative weight.
    If the hospital treats a high percentage of low-income patients, it 
receives a percentage add-on payment applied to the DRG-adjusted base 
payment rate. This add-on payment, known as the disproportionate share 
hospital (DSH) adjustment, provides for a percentage increase in 
Medicare payments to hospitals that qualify under either of two 
statutory formulas designed to identify hospitals that serve a 
disproportionate share of low-income patients. For qualifying 
hospitals, the amount of this adjustment may vary based on the outcome 
of the statutory calculations.
    If the hospital is an approved teaching hospital, it receives a 
percentage add-on payment for each case paid under the IPPS (known as 
the indirect medical education (IME) adjustment). This percentage 
varies, depending on the ratio of residents to beds.
    Additional payments may be made for cases that involve new 
technologies or medical services that have been approved for special 
add-on payments. To qualify, a new technology or medical service must 
demonstrate that it is a substantial clinical improvement over 
technologies or services otherwise available, and that, absent an add-
on payment, it would be inadequately paid under the regular DRG 
payment.
    The costs incurred by the hospital for a case are evaluated to 
determine whether the hospital is eligible for an additional payment as 
an outlier case. This additional payment is designed to protect the 
hospital from large financial losses due to unusually expensive cases. 
Any outlier payment due is added to the DRG-adjusted base payment rate, 
plus any DSH, IME, and new technology or medical service add-on 
adjustments.
    Although payments to most hospitals under the IPPS are made on the 
basis of the standardized amounts, some categories of hospitals are 
paid the higher of a hospital-specific rate based on their costs in a 
base year (the higher of FY 1982, FY 1987, or FY 1996) or the IPPS rate 
based on the standardized amount. For example, sole community hospitals 
(SCHs) are the sole source of care in their areas, and Medicare-
dependent, small rural hospitals (MDHs) are a major source of care for 
Medicare beneficiaries in their areas. Both of these categories of 
hospitals are afforded this special payment protection in order to 
maintain access to services for beneficiaries (although MDHs receive 
only 50 percent of the difference between the IPPS rate and their 
hospital-specific rates if the hospital-specific rate is higher than 
the IPPS rate).
    Section 1886(g) of the Act requires the Secretary to pay for the 
capital-related costs of inpatient hospital services ``in accordance 
with a prospective payment system established by the Secretary.'' The 
basic methodology for determining capital prospective payments is set 
forth in our regulations at 42 CFR 412.308 and 412.312. Under the 
capital PPS, payments are adjusted by the same DRG for the case as they 
are under the operating IPPS. Similar adjustments are also made for IME 
and DSH as under the operating IPPS. In addition, hospitals may receive 
an outlier payment for those cases that have unusually high costs.
    The existing regulations governing payments to hospitals under the 
IPPS are located in 42 CFR part 412, subparts A through M.
2. Hospitals and Hospital Units Excluded From the IPPS
    Under section 1886(d)(1)(B) of the Act, as amended, certain 
specialty hospitals and hospital units are excluded from the IPPS. 
These hospitals and units are: Psychiatric hospitals and units; 
rehabilitation hospitals and units; long-term care hospitals (LTCHs); 
children's hospitals; and cancer hospitals. Various sections of the 
Balanced Budget Act of 1997 (Pub. L. 105-33), the Medicare, Medicaid 
and SCHIP (State Children's Health Insurance Program) Balanced Budget 
Refinement Act of 1999 (Pub. L. 106-113), and the Medicare, Medicaid, 
and SCHIP Benefits Improvement and Protection Act of 2000 (Pub. L. 106-
554) provide for the implementation of PPSs for rehabilitation 
hospitals and units (referred to as inpatient rehabilitation facilities 
(IRFs)), psychiatric hospitals and units (referred to as inpatient 
psychiatric facilities (IPFs)), and LTCHs, as discussed below. 
Children's hospitals and cancer hospitals continue to be paid under 
reasonable cost-based reimbursement.
    The existing regulations governing payments to excluded hospitals 
and hospital units are located in 42 CFR parts 412 and 413.

[[Page 48921]]

a. IRFs
    Under section 1886(j) of the Act, as amended, rehabilitation 
hospitals and units (IRFs) have been transitioned from payment based on 
a blend of reasonable cost reimbursement subject to a hospital-specific 
annual limit under section 1886(b) of the Act and prospective payments 
for cost reporting periods beginning January 1, 2002, through September 
30, 2002, to payment at 100 percent of the Federal rate effective for 
cost reporting periods beginning on or after October 1, 2002 (66 FR 
41316, August 7, 2001; 67 FR 49982, August 1, 2002; and 68 FR 45674, 
August 1, 2003). The existing regulations governing payments under the 
IRF PPS are located in 42 CFR part 412, subpart P.
b. LTCHs
    Under the authority of sections 123(a) and (c) of Public Law 106-
113 and section 307(b)(1) of Public Law 106-554, LTCHs are being 
transitioned from being paid for inpatient hospital services based on a 
blend of reasonable cost-based reimbursement under section 1886(b) of 
the Act to 100 percent of the Federal rate during a 5-year period, 
beginning with cost reporting periods that start on or after October 1, 
2002. For cost reporting periods beginning on or after October 1, 2006, 
LTCHs will be paid 100 percent of the Federal rate (May 7, 2004 LTCH 
PPS final rule (69 FR 25674)). LTCHs may elect to be paid based on 100 
percent of the Federal rate instead of a blended payment in any year 
during the 5-year transition period. The existing regulations governing 
payment under the LTCH PPS are located in 42 CFR part 412, subpart O.
c. IPFs
    Sections 124(a) and (c) of Public Law 106-113 provide for the 
development of a per diem PPS for payment for inpatient hospital 
services furnished in IPFs under the Medicare program, effective for 
cost reporting periods beginning on or after October 1, 2002. This 
system must include an adequate patient classification system that 
reflects the differences in patient resource use and costs among these 
hospitals and maintains budget neutrality. We published a proposed rule 
to implement the PPS for IPFs on November 28, 2003 (68 FR 66920). The 
November 28, 2003, proposed rule proposed an April 1, 2004, effective 
date for purposes of ratesetting and calculating impacts. However, the 
proposed rule was unusually complex because it proposed a completely 
new payment system for inpatient hospital services furnished by 
psychiatric hospitals and units and the public requested additional 
time to comment. As a result, we extended the comment period for the 
proposed rule. Thus, we are still in the process of analyzing public 
comments and developing a final rule for publication. Consequently, an 
April 1, 2004, effective date for the IPF PPS is no longer possible.
3. Critical Access Hospitals (CAHs)
    Under sections 1814, 1820, and 1834(g) of the Act, payments are 
made to critical access hospitals (CAHs) (that is, rural hospitals or 
facilities that meet certain statutory requirements) for inpatient and 
outpatient services on a reasonable cost basis. Reasonable cost is 
determined under the provisions of section 1861(v)(1)(A) of the Act and 
existing regulations under 42 CFR parts 413 and 415.
4. Payments for Graduate Medical Education (GME)
    Under section 1886(a)(4) of the Act, costs of approved educational 
activities are excluded from the operating costs of inpatient hospital 
services. Hospitals with approved graduate medical education (GME) 
programs are paid for the direct costs of GME in accordance with 
section 1886(h) of the Act; the amount of payment for direct GME costs 
for a cost reporting period is based on the hospital's number of 
residents in that period and the hospital's costs per resident in a 
base year. The existing regulations governing payments to the various 
types of hospitals are located in 42 CFR part 413.
    On August 1, 2003, we published a final rule in the Federal 
Register (68 FR 45346) that implemented changes to the Medicare 
hospital inpatient prospective payment systems for both operating cost 
and capital-related costs, as well as changes addressing payments for 
excluded hospitals and payments for GME costs. Generally these changes 
were effective for discharges occurring on or after October 1, 2003. On 
October 6, 2003, we published a document in the Federal Register (68 FR 
57731) that corrected technical errors made in the August 1, 2003, 
final rule.

B. Provisions of the Medicare Prescription Drug, Improvement, and 
Modernization Act of 2003

    On December 8, 2003, the Medicare Prescription Drug, Improvement, 
and Modernization Act of 2003 (MMA), Public Law 108-173, was enacted. 
Public Law 108-173 made a number of changes to the Act relating to 
prospective payments to hospitals for inpatient services, payments to 
excluded hospitals and units, and payments to CAHs. This final rule 
implements amendments made by the following sections of Pub. L. 108-
173:
     Section 401, which provides that, for discharges occurring 
in a fiscal year beginning with FY 2004 under the IPPS, Medicare will 
pay hospitals in rural and small urban areas in the 50 States using the 
standardized amount (computed for the previous fiscal year) that would 
be used to pay hospitals in large urban areas (or beginning with FY 
2005, for all hospitals in the previous fiscal year), increased by the 
appropriate market basket percentage increase. One standardized amount 
for hospitals in Puerto Rico would be established that would equal the 
amount for hospitals in large urban areas in Puerto Rico.
     Section 402, which provides that for discharges occurring 
on or after April 1, 2004, the DSH payment adjustment for a hospital 
that is not a large urban or large rural hospital will be calculated 
using the current DSH adjustment formula for large urban hospitals, 
subject to a limit of 12 percent for any of these hospitals that are 
not rural referral centers. (There is no limit on the DSH payment 
percentage for rural referral centers.)
     Section 403, which provides that, for discharges occurring 
on or after October 1, 2004, a hospital's labor-related share to which 
the wage index is applied will be decreased to 62 percent of the 
standardized amount when such a change will result in higher total 
payments to the hospital. This provision also applies to the labor-
related share of the standardized amount for hospitals in Puerto Rico.
     Section 405(a), which provides that inpatient, outpatient, 
and covered SNF services provided by a CAH will be reimbursed at 101 
percent of reasonable costs for services furnished to Medicare 
beneficiaries. This provision is applicable to payments for services 
furnished during cost reporting periods beginning on or after January 
1, 2004.
     Section 405(b), which expands coverage of the costs 
associated with covered Medicare services furnished by on-call 
emergency room providers in CAHs to include services furnished by 
physician assistants, nurse practitioners, and clinical nurse 
specialists, effective for costs incurred for services furnished on or 
after January 1, 2005.
     Section 405(c), which provides that eligible CAHs may 
receive payments for their inpatient services on a periodic interim 
payment (PIP) basis, effective with payments made on or after July 1, 
2004.
     Section 405(d), which allows CAHs to elect to receive 
payments under the

[[Page 48922]]

optional payment method (a payment encompassing both inpatient CAH 
services and physician and practitioner services to outpatients) even 
if some practitioners do not reassign to the CAH their rights to bill 
for professional services to CAH outpatients. This provision applies to 
cost reporting periods occurring on or after July 1, 2004, except that 
in the case of a CAH that made an election of the optional payment 
method before November 1, 2003, the provision applies to cost reporting 
periods beginning on or after July 1, 2001.
     Section 405(e), which increases the limit on the number of 
beds that a CAH may have for acute care from 15 to 25 beds. This 
provision applies to CAH designations made before, on, or after January 
1, 2004. Any election made in accordance with the regulations 
promulgated to implement this provision will only apply prospectively.
     Section 405(g), which provides that a CAH may establish 
psychiatric and rehabilitation distinct part units and limits the 
number of beds in each unit to no more than 10. Services in these 
distinct part units will be paid under the respective payment 
methodology applicable to these distinct-part units. This provision 
applies to cost reporting periods beginning on or after October 1, 
2004.
     Section 405(h), which terminates a State's authority to 
waive the location requirement for a CAH by designating the CAH as the 
necessary provider, effective January 1, 2006. A grandfathering 
provision is included for CAHs that are certified as necessary 
providers prior to January 1, 2006, which allows any CAH that is 
designated as a necessary provider in its State's rural health plan 
prior to January 1, 2006, to maintain its necessary provider 
designation.
     Section 406, which provides for a graduated adjustment to 
the inpatient prospective payment rates to account for the higher costs 
associated with hospitals described under section 1886(d) of the Act 
that are located more than 25 road miles from another subsection (d) 
hospital and that have less than 800 discharges during a fiscal year, 
effective for discharges occurring on or after October 1, 2004. The 
increase in these payments must be based on the empirical relationship 
between the standardized cost per case for such hospitals and the total 
number of discharges of these hospitals and the amount of the 
additional incremental costs (if any) associated with that number of 
discharges, may not be greater than 25 percent, and the determination 
of the percentage payment increase is not subject to administrative or 
judicial review.
     Section 410A, which authorizes the Secretary to establish 
a demonstration program to test the feasibility and advisability of the 
establishment of rural community hospitals to furnish covered inpatient 
hospital services to Medicare beneficiaries. The Secretary must select 
no more than 15 rural community hospitals to participate in the 
demonstration. The Secretary must implement the demonstration program 
not later than January 1, 2005, but may not implement the program 
before October 1, 2004.
     Section 422(a), which provides that a hospital's GME FTE 
resident cap will be reduced, and the reduction will be redistributed 
among other hospitals if the hospital's resident count is less than its 
resident cap (rural hospitals with less than 250 acute care inpatient 
beds will be exempt) in a particular reference period. This provision 
is effective for cost reporting periods beginning on or after July 1, 
2005.
     Section 422(b), which specifies that the formula 
multiplier for the IME adjustment is 0.66 for FTE residents 
attributable to redistributed resident positions, effective for 
discharges occurring on or after July 1, 2005.
     Section 501, which provides the update factor for payments 
for hospital inpatient operating costs for FY 2005 and subsequent 
fiscal years is the market basket percentage increase. For FYs 2005 
through 2007, the update factor will be the market basket percentage 
increase minus 0.4 percentage points for any ``subsection (d) 
hospital'' that does not submit hospital quality data on 10 measures as 
specified by the Secretary.
     Section 502, which modifies the IME formula multiplier to 
be used in the calculation of the IME adjustment for midway through FY 
2004 and provides a new schedule of formula multipliers for FYs 2005 
and thereafter.
     Section 503(a), which includes a requirement for updating 
the ICD-9-CM diagnosis and procedure codes in April 1 of each year, in 
addition to the current process of annual updates on October 1 of each 
year. This change will not affect Medicare payments or DRG 
classifications until the fiscal year that begins after that date.
     Section 503(b), which provides for changes to the 
threshold amount for determining eligibility of new technologies or 
medical services for add-on payments; provides for public input on 
applications for new technology or medical service add-on payments 
prior to the publication of a proposed rule; provides for 
reconsideration of applications received for FY 2004 that were denied; 
provides for preference in the use of DRG adjustments; and provides 
that new technology or medical service payments shall not be budget 
neutral. This provision is effective for fiscal years beginning in FY 
2005.
     Section 504, which increases the national portion of the 
operating PPS payment rate for hospitals in Puerto Rico from 50 percent 
of the Federal rate to 75 percent of the Federal rate and decreases the 
Puerto Rico portion of the operating PPS payment from 50 percent to 25 
percent, effective for discharges occurring on or after October 1, 
2004. For the period of April 1, 2004, through September 30, 2004, 
payments for hospitals in Puerto Rico will be based on 62.5 percent 
Federal rate and 37.5 percent of the Puerto Rico rate.
     Section 505, which provides for an increase in a 
hospital's wage index value to take into consideration a commuter wage 
adjustment for hospital employees who reside in a county and work in a 
different area with a higher wage index.
     Section 508, which provides for the establishment of a 
one-time process for a hospital to appeal its geographic classification 
for wage index purposes. By law, any reclassification resulting from 
this one-time appeal applies for a 3-year period to discharges 
occurring on or after April 1, 2004.
     Section 711, which freezes the annual CPI-U updates to 
hospital-specific per resident amount (PRAs) for GME payments for those 
PRAs that exceed the ceiling, effective for cost reporting periods 
beginning FY 2004, through FY 2013.
     Section 712, which provides for an exception to the 
initial residency period for purposes of direct GME payments for 
geriatric residency or fellowship programs that allows the 2 years 
spent in an approved geriatric program to be counted as part of the 
resident's initial training period, but not to count against any 
limitation on the initial residency period. This provision is effective 
for cost reporting periods beginning on or after October 1, 2003.
     Section 713, which, during a 1-year moratorium period of 
January 1, 2004 through December 31, 2004, allows hospitals to count 
allopathic or osteopathic family practice residents training in 
nonhospital settings for IME and direct GME purposes, without regard to 
the financial arrangement between the hospital and the teaching 
physician practicing in the nonhospital setting to which the resident 
is assigned.
     Section 733, which provides for Medicare payment of 
routine costs, as

[[Page 48923]]

well as costs relating to the transplantation and appropriate related 
items and services, for Medicare beneficiaries participating in a 
clinical trial involving pancreatic islet cell transplantation, 
beginning no earlier than October 1, 2004.
     Section 926, which requires the Secretary to make 
information publicly available that enables hospital discharge 
planners, Medicare beneficiaries, and the public to identify skilled 
nursing facilities (SNFs) that are participating in the Medicare 
program, and requires a hospital, as part of its discharge planning, to 
evaluate a patient's need for SNF care.
     Section 947, which requires that, by July 1, 2004, 
hospitals not otherwise subject to the Occupational Safety and Health 
Act (OSHA) (or a State occupational safety and health plan that is 
approved under section 18(b) of that Act) must comply with the OSHA 
bloodborne pathogens (BBP) standard as part of their Medicare provider 
agreements.

C. Summary of the Provisions of the May 18, 2004 Proposed Rule

    On May 18, 2004, we published a proposed rule in the Federal 
Register (69 FR 28196) that set forth proposed changes to the Medicare 
IPPS for operating costs and for capital-related costs in FY 2005 and 
to implement the provisions of Pub. L. 108-173 specified in section 
I.B. of this preamble. We also set forth proposed changes relating to 
payments for GME costs, payments to certain hospitals and units that 
continue to be excluded from the IPPS and paid on a reasonable cost 
basis, payments for DSH, requirements and payments for CAHs, conditions 
of participation for hospitals relating to discharge planning and fire 
safety requirements, requirements for Medicare provider agreements 
relating to bloodborne pathogen standards, and QIO disclosure of 
information requirements. These changes were proposed to be effective 
for discharges occurring on or after October 1, 2004, unless otherwise 
noted.
    The following is a summary of the major changes that we proposed to 
make:
1. Changes to the DRG Reclassifications and Recalibrations of Relative 
Weights
    As required by section 1886(d)(4)(C) of the Act, we proposed annual 
adjustments to the DRG classifications and relative weights. Based on 
analyses of Medicare claims data, we proposed to establish a number of 
new DRGs and make changes to the designation of diagnosis and procedure 
codes under other existing DRGs.
    Among the proposed changes discussed were:
     Restructuring and retitling of several DRGs to reflect 
expanded coverage of heart assist systems such as ventricular assist 
devices (VAD) or left ventricular assist devices (LVAD) as destination 
(or permanent) therapy for end-stage heart failure patients who are not 
candidates for heart transplantation: DRG 103 (Heart Transplant or 
Implant of Heart Assist System) (proposed title change), DRG 104 
(Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac 
Catheterization) and DRG 105 (Cardiac Valve and Other Major 
Cardiothoracic Procedures Without Cardiac Catheterization), and DRG 525 
(Other Heart Assist System Implant) (proposed title change).
     Addition of pacemaker device and lead procedure code 
combinations that could lead to the assignment of DRG 115 (Permanent 
Cardiac Pacemaker Implant with Acute Myocardial Infarction, Heart 
Failure, or Shock or ACID Lead or Generator Procedures) and DRG 116 
(Other Permanent Cardiac Pacemaker Implant).
     Movement of the procedure code for 360 spinal fusion from 
DRG 496 (Combined Anterior/Posterior Spinal Fusion) to DRG 497 (Spinal 
Fusion Except Cervical With CC) and DRG 498 (Spinal Fusion Except 
Cervical Without CC).
     Addition of combination codes, which also include heart 
failure, to the list of major problems under DRG 387 (Prematurity With 
Major Problems) and DRG 389 (Full-Term Neonate With Major Problems).
     Modification of DRGs 504 through 509 under MDC 22 (Burns) 
to recognize the impact of long-term mechanical ventilation on burn 
cases and renaming DRG 504 as proposed title ``Extensive Burns or Full 
Thickness Burns With Mechanical Ventilation 96+ Hours With Skin Graft'' 
and DRG 505 as proposed title ``Extensive Burns or Full Thickness Burns 
With Mechanical Ventilation 96+ Hours Without Skin Graft.''
     Deletion of DRG 483 (Tracheostomy for Face, Mouth, and 
Neck Diagnoses) and splitting the assignment of cases to two proposed 
new DRGs on the basis of the performance of a major operating room 
procedure: proposed new DRGs 541 and 542 (Tracheostomy With Mechanical 
Ventilation 96+ Hours or Principal Diagnosis Except Face, Mouth, and 
Neck Diagnosis With and Without Major Operating Room Procedure, 
respectively).
    We also presented our reevaluation of FY 2004 applicants for add-on 
payments for high-cost new medical services and technologies, and our 
analysis of FY 2005 applicants (including public input, as directed by 
Public Law 108-173, obtained in a town hall meeting).
    We proposed the annual update of the long-term care diagnosis-
related group (LTC-DRG) classifications and relative weights for use 
under the LTCH PPS for FY 2005.
2. Changes to the Hospital Wage Index
    We proposed revisions to the wage index and the annual update of 
the wage data. Specific issues addressed included the following:
     The FY 2005 wage index update, using wage data from cost 
reporting periods that began during FY 2001.
     Revision of the labor market areas as a result of OMB 
revised definitions of geographical statistical areas.
     A discussion of the collection of occupational mix data 
and the occupational mix adjustment to the wage index that we proposed 
to apply beginning October 1, 2004.
     Revisions to the wage index based on hospital 
redesignations and reclassifications, including changes that reflect 
the new OMB standards for assignment of hospitals to geographic areas.
     The adjustment to the wage index based on commuting 
patterns of hospital employees who reside in a county and work in a 
different area with a higher wage index, to implement section 505 of 
Public Law 108-173.
     A discussion of eligible hospitals reclassified under the 
one-time appeals process under section 508 of Public Law 108-173.
     Changes to the labor-related share to which the wage index 
is applied in determining the PPS rate for hospitals located in 
specific geographic areas, to implement section 403 of Public Law 108-
173.
     The revised timetable for reviewing and verifying the wage 
data that will be in effect for the FY 2005 wage index.
3. Other Decisions and Changes to the PPS for Inpatient Operating and 
GME Costs
    In the proposed rule, we discussed a number of provisions of the 
regulations in 42 CFR parts 412 and 413 and set forth proposed changes 
concerning the following:
     Expansion of the current postacute care transfer policy.
     Payments for inpatient care in providers that change 
classification status during a patient stay.
     Changes in the definitions of urban and rural areas for 
geographic reclassification purposes.
     Equalization of the standardized amount for urban and 
rural hospitals.

[[Page 48924]]

     The reporting of hospital quality data as a condition for 
receiving the full annual payment update increase.
     Revision of the regulations to reflect the revision of the 
labor share of the wage index.
     Revision of the regulations to reflect the wage index 
adjustment for commuting patterns of hospital employees who live in one 
county and commute to work in other areas with higher level wages.
     Changes in the threshold amount for eligibility for new 
medical services and technology add-on payments.
     Revision to our policy on additional payments to hospitals 
with high percentages of ESRD discharges.
     Changes to the IME adjustment formula multipliers, and the 
formula multiplier applicable to redistribution of unused numbers of 
FTE resident slots.
     Changes in DSH adjustment payments to rural and small 
urban hospitals.
     Payment adjustments for low-volume hospitals.
     Changes in policy affecting hospitals that apply as a 
group for reclassification and a discussion of possible 
reclassifications for dominant hospitals and hospitals in single-
hospital MSAs.
     Changes in policies governing payments for direct GME, 
including the redistribution of unused FTE resident slots; changes in 
the GME initial residency period; extension of the update limitation on 
hospital-specific per resident amounts; and changes in the policies on 
residents training in nonhospital settings, including written 
agreements for teaching physician compensation.
     An announcement of the rural community hospital 
demonstration to be established under section 410A of Public Law 108-
173 and the opportunity for eligible hospitals to apply for 
participation in the demonstration program.
     A solicitation of public comments on the effect of 
increases in malpractice insurance premiums on hospitals participating 
in the Medicare program and beneficiary access of services.
4. Changes to the PPS for Capital-Related Costs
    In the proposed rule, we discussed the payment requirements for 
capital-related costs and proposed changes relating to capital payments 
to hospitals located in Puerto Rico, changes in the policies on 
exception payments for extraordinary circumstances, treatment of 
hospitals previously reclassified for the operating standardized 
amounts, and capital payment adjustments based on the proposed changes 
in geographic classifications.
5. Changes for Hospitals and Hospital Units Excluded From the IPPS
    In the proposed rule, we discussed the following proposed revisions 
and clarifications concerning excluded hospitals and hospital units and 
CAHs:
     Changes in the payment rate for new excluded hospitals.
     Changes to the criteria for determining payments to 
hospitals-within-hospitals.
     Changes to the policies governing payment to CAHs, 
including a change in the payment percentage for services furnished by 
CAHs; changes in the rules governing the election by a CAH of the 
optional method of payment; expansion of the payment to emergency room 
on-call providers to include physician assistants, nurse practitioners, 
and clinical nurse specialists; authorization for the making of 
periodic interim payments (PIPs) for CAHs for inpatient services 
furnished; revision of the bed count limit for CAHs from 15 to 25 acute 
care beds; proposed requirements for establishing psychiatric and 
rehabilitation distinct part units in CAHs; and termination of the 
location requirement for a CAH by designating the CAH as a necessary 
provider.
6. Changes to QIO Disclosure of Information Requirements
    In the proposed rule, we discussed our proposed clarification of 
the requirements for disclosure by QIOs of information on institutions 
and practitioners collected in the course of the QIO's quality 
improvement activities.
7. Changes Relating to Medicare Provider Agreements, Hospital 
Conditions of Participation, and Fire Safety Requirements for Certain 
Health Care Facilities
    We proposed to--
     Require hospitals, as part of the discharge planning 
standard under the Medicare hospital conditions of participation, to 
furnish a list of Medicare-participating home health agencies to 
patients who are expected to receive home health services after 
discharge and to provide information on Medicare-certified SNFs to 
patients who are likely to need posthospital extended care services.
     Require that Medicare provider agreements include 
provisions that would ensure that all hospital employees who may come 
into contact with human blood in the course of their duties are 
provided proper protection from bloodborne pathogens.
     Correct a technical error relating to the application of 
the 2000 edition of the Life Safety Code as the fire safety 
requirements for certain health care facilities; and clarify the 
effective date for the prohibition on the use of roller latches in 
these facilities.
8. Determining Prospective Payment Operating and Capital Rates and 
Rate-of-Increase Limits
    In the Addendum to the May 18, 2004, proposed rule, we set forth 
proposed changes to the amounts and factors for determining the FY 2005 
prospective payment rates for operating costs and capital-related 
costs. We also established the proposed threshold amounts for outlier 
cases. In addition, we addressed update factors for determining the 
rate-of-increase limits for cost reporting periods beginning in FY 2005 
for hospitals and hospital units excluded from the PPS.
9. Impact Analysis
    In Appendix A of the proposed rule, we set forth an analysis of the 
impact that the proposed changes would have on affected hospitals.
10. Recommendation of Update Factor for Hospital Inpatient Operating 
Costs
    In Appendix B of the proposed rule, as required by sections 
1886(e)(4) and (e)(5) of the Act, we provided our recommendations of 
the appropriate percentage changes for FY 2005 for the following:
     A single average standardized amount for all areas for 
hospital inpatient services paid under the IPPS for operating costs 
(and hospital-specific rates applicable to SCHs and MDHs).
     Target rate-of-increase limits to the allowable operating 
costs of hospital inpatient services furnished by hospitals and 
hospital units excluded from the IPPS.
11. Discussion of Medicare Payment Advisory Commission Recommendations
    Under section 1805(b) of the Act, the Medicare Payment Advisory 
Commission (MedPAC) is required to submit a report to Congress, no 
later than March 1 of each year, that reviews and makes recommendations 
on Medicare payment policies. MedPAC's March 2004 recommendation 
concerning hospital inpatient payment policies addressed only the 
update factor for inpatient hospital operating costs and capital-
related costs under the IPPS and for hospitals and distinct part 
hospital units excluded from the IPPS. This recommendation was 
addressed in Appendix B of the May 18, 2004,

[[Page 48925]]

proposed rule. For further information relating specifically to the 
MedPAC March 1 report or to obtain a copy of the report, contact MedPAC 
at (202) 220-3700 or visit MedPAC's Web site at: http://www.medpac.gov.


D. Public Comments Received in Response to the May 18, 2004 Proposed 
Rule

    We received over 30,000 timely items of correspondence containing 
multiple comments on the May 18, 2004 proposed rule. Summaries of the 
public comments and our responses to those comments are set forth below 
under the appropriate heading.
    Comment Period: One commenter indicated that, under the 
Administrative Procedures Act (APA), 5 U.S.C. 553(b), the 60-day 
comment period should have started from the date the proposed rule was 
published in the Federal Register, not the date the rule was placed on 
the CMS Web site.
    Response: We believe publication of the proposed rule is fully 
consistent with the law. The APA does not prescribe any specific length 
for the comment period. In addition, the proposed rule was placed on 
display at the Office of the Federal Register and a copy of the rule 
also appeared on our Web site. The substance of the rule was fully 
available on the Web site, as well as on display at the Office of the 
Federal Register. Finally, we note that, in accordance with section 
1886(d) of the Act, the Secretary is required to ensure that the 
updated IPPS rates are in place at the beginning of the Federal fiscal 
year, or by October 1, 2004. Our priority is to ensure that hospitals 
receive their final updated rates for the new fiscal year.

II. Changes to DRG Classifications and Relative Weights

A. Background

    Section 1886(d) of the Act specifies that the Secretary shall 
establish a classification system (referred to as DRGs) for inpatient 
discharges and adjust payments under the IPPS based on appropriate 
weighting factors assigned to each DRG. Therefore, under the IPPS, we 
pay for inpatient hospital services on a rate per discharge basis that 
varies according to the DRG to which a beneficiary's stay is assigned. 
The formula used to calculate payment for a specific case multiplies an 
individual hospital's payment rate per case by the weight of the DRG to 
which the case is assigned. Each DRG weight represents the average 
resources required to care for cases in that particular DRG, relative 
to the average resources used to treat cases in all DRGs.
    Congress recognized that it would be necessary to recalculate the 
DRG relative weights periodically to account for changes in resource 
consumption. Accordingly, section 1886(d)(4)(C) of the Act requires 
that the Secretary adjust the DRG classifications and relative weights 
at least annually. These adjustments are made to reflect changes in 
treatment patterns, technology, and any other factors that may change 
the relative use of hospital resources. The changes to the DRG 
classification system and the recalibration of the DRG weights for 
discharges occurring on or after October 1, 2004, are discussed below.

B. DRG Reclassifications

1. General
    Cases are classified into DRGs for payment under the IPPS based on 
the principal diagnosis, up to eight additional diagnoses, and up to 
six procedures performed during the stay. In a small number of DRGs, 
classification is also based on the age, sex, and discharge status of 
the patient. The diagnosis and procedure information is reported by the 
hospital using codes from the International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM).
    For FY 2004, cases are assigned to one of 518 DRGs in 25 major 
diagnostic categories (MDCs). Most MDCs are based on a particular organ 
system of the body. For example, MDC 6 is Diseases and Disorders of the 
Digestive System. This approach is used because clinical care is 
generally organized in accordance with the organ system affected. 
However, some MDCs are not constructed on this basis because they 
involve multiple organ systems (for example, MDC 22 (Burns)). The table 
below lists the 25 MDCs.

[[Page 48926]]

[GRAPHIC] [TIFF OMITTED] TR11AU04.000

    In general, cases are assigned to an MDC based on the patient's 
principal diagnosis before assignment to a DRG. However, for FY 2004, 
there are eight DRGs to which cases are directly assigned on the basis 
of ICD-9-CM procedure codes. These DRGs are for heart, liver, bone 
marrow, lung, simultaneous pancreas/kidney, and pancreas transplants 
and for tracheostomies. Cases are assigned to these DRGs before they 
are classified to an MDC. The table below lists the current eight pre-
MDCs.
[GRAPHIC] [TIFF OMITTED] TR11AU04.001

    Within most MDCs, cases are then divided into surgical DRGs and 
medical DRGs. Surgical DRGs are based on a hierarchy that orders 
operating room (O.R.) procedures or groups of O.R. procedures by 
resource intensity.

[[Page 48927]]

Medical DRGs generally are differentiated on the basis of diagnosis and 
age (less than or greater than 17 years of age). Some surgical and 
medical DRGs are further differentiated based on the presence or 
absence of a complication or a comorbidity (CC).
    Generally, nonsurgical procedures and minor surgical procedures 
that are not usually performed in an operating room are not treated as 
O.R. procedures. However, there are a few non-O.R. procedures that do 
affect DRG assignment for certain principal diagnoses, for example, 
extracorporeal shock wave lithotripsy for patients with a principal 
diagnosis of urinary stones.
    Patient's diagnosis, procedure, discharge status, and demographic 
information is fed into the Medicare claims processing systems and 
subjected to a series of automated screens called the Medicare Code 
Editor (MCE). The MCE screens are designed to identify cases that 
require further review before classification into a DRG.
    After patient information is screened through the MCE and any 
further development of the claim is conducted, the cases are classified 
into the appropriate DRG by the Medicare GROUPER software program. The 
GROUPER program was developed as a means of classifying each case into 
a DRG on the basis of the diagnosis and procedure codes and, for a 
limited number of DRGs, demographic information (that is, sex, age, and 
discharge status).
    After cases are screened through the MCE and assigned to a DRG by 
the GROUPER, the PRICER software calculates a base DRG payment. The 
PRICER calculates the payments for each case covered by the IPPS based 
on the DRG relative weight and additional factors associated with each 
hospital, such as IME and DSH adjustments. These additional factors 
increase the payment amount to hospitals above the base DRG payment.
    The records for all Medicare hospital inpatient discharges are 
maintained in the Medicare Provider Analysis and Review (MedPAR) file. 
The data in this file are used to evaluate possible DRG classification 
changes and to recalibrate the DRG weights. However, in the July 30, 
1999, IPPS final rule (64 FR 41500), we discussed a process for 
considering non-MedPAR data in the recalibration process. In order for 
us to consider using particular non-MedPAR data, we must have 
sufficient time to evaluate and test the data. The time necessary to do 
so depends upon the nature and quality of the non-MedPAR data 
submitted. Generally, however, a significant sample of the non-MedPAR 
data should be submitted by mid-October for consideration in 
conjunction with the next year's proposed rule. This allows us time to 
test the data and make a preliminary assessment as to the feasibility 
of using the data. Subsequently, a complete database should be 
submitted by early December for consideration in conjunction with the 
next year's proposed rule.
    Many of the changes to the DRG classifications are the result of 
specific issues brought to our attention by interested parties. We 
encourage individuals with concerns about DRG classifications to bring 
those concerns to our attention in a timely manner so they can be 
carefully considered for possible inclusion in the next proposed rule 
and so any proposed changes may be subjected to public review and 
comment. Therefore, similar to the timetable for interested parties to 
submit non-MedPAR data for consideration in the DRG recalibration 
process, concerns about DRG classification issues should be brought to 
our attention no later than early December in order to be considered 
and possibly included in the next annual proposed rule updating the 
IPPS.
    In the May 18, 2004, proposed rule, we proposed numerous changes to 
the DRG classification system for FY 2005. The changes we proposed to 
the DRG classification system for FY 2005, the public comments we 
received concerning the proposed changes, the final DRG changes, and 
the methodology used to recalibrate the DRG weights are set forth 
below. The changes we are implementing in this final rule will be 
reflected in the revised FY 2005 GROUPER version 22.0 and effective for 
discharges occurring on or after October 1, 2003. Generally, our DRG 
analysis in the May 18, 2004, proposed rule was based on data from the 
December 2003 update of the FY 2003 MedPAR file.
    Unless otherwise noted in this final rule, our DRG analysis is 
based on data from the March 2004 update of the FY 2003 MedPAR file, 
which contains hospital bills received through March 31, 2004, for 
discharges in FY 2003.
2. MDC 1 (Diseases and Disorders of the Nervous System): Intracranial 
Hemorrhage and Stroke With Infarction
    In the May 18, 2004, proposed rule, we noted that it had come to 
our attention that the title of DRG 14 (Intracranial Hemorrhage and 
Stroke With Infarction) may be misleading because it implies that a 
combination of conditions exists when the DRG is assigned. When we 
developed this title, we did not intend to imply that a combination of 
conditions exists. Therefore, we proposed to change the title of DRG 14 
to read ``Intracranial Hemorrhage or Cerebral Infarction''.
    We received one comment on this proposal in support of the DRG 
title change. Therefore, we are adopting as final the proposed change 
of the title of DRG 14 to ``Intracranial Hemorrhage or Cerebral 
Infarction''.
3. MDC 5 (Diseases and Disorders of the Circulatory System)
a. Heart Assist System Implant
    Circulatory support devices, also known as heart assist systems, 
ventricular assist devices (VADs) or left ventricular assist devices 
(LVADs), offer a surgical alternative for end-stage heart failure 
patients. This type of device is often implanted near a patient's 
native heart and assumes the pumping function of the weakened heart's 
left ventricle. In many cases, heart transplantation would be the 
treatment of choice for this type of patient. However, the low number 
of donor hearts limits this treatment option.
    We have reviewed the payment and DRG assignment for this type of 
device many times in the past. The reader is referred to the August 1, 
2002 IPPS final rule (67 FR 49989) for a complete listing of those 
discussions.
    In the August 1, 2002, final rule (67 FR 49990), we attempted to 
clinically and financially align VAD procedures by creating new DRG 525 
(Heart Assist System Implant). We also noted that cases in which a 
heart transplant also occurred during the same hospitalization episode 
would continue to be assigned to DRG 103 (Heart Transplant). At that 
time, we announced that DRG 525 would consist of any principal 
diagnosis in MDC 5, plus one of the following surgical procedure codes:
     37.62, Insertion of nonimplantable heart assist system.
     37.63, Repair of heart assist system.
     37.65, Implant of external heart assist system.
     37.66, Insertion of implantable heart assist system.
    (To avoid confusion, we note that the titles of codes 37.62, 37.63, 
37.65, and 37.66 have been revised for FY 2005 through the ICD-9-CM 
Coordination and Maintenance Committee process as reflected in Table 
6F, Revised Procedure Code Titles in the Addendum to this final rule.)
    Commenters on the May 19, 2003, proposed rule that preceded the 
August 1, 2003, IPPS (FY 2004) final rule notified us that procedure 
code 37.66

[[Page 48928]]

was neither a clinical nor a financial match to the rest of the 
procedure codes now assigned to DRG 525. We did not modify DRG 525 for 
FY 2004. We agreed that we would continue to evaluate whether to make 
further changes to DRG 525. After publication of the August 1, 2003, 
final rule, we again reviewed the MedPAR data concerning DRG 525, and 
came to the conclusion that procedure code 37.62 is different in terms 
of clinical procedures and resource utilization from the other 
procedure codes assigned to DRG 525. Therefore, in a correction to the 
August 1, 2003, IPPS (FY 2004) final rule, published on October 6, 2003 
(68 FR 57733), we revised the composition of DRG 525 by correcting the 
assignment of procedures to DRG 525 in light of the lower charges 
associated with procedure code 37.62. We moved code 37.62 into DRG 104 
(Cardiac Valve and Other Major Cardiothoracic Procedures With Cardiac 
Catheterization) and DRG 105 (Cardiac Valve and Other Major 
Cardiothoracic Procedures Without Cardiac Catheterization), and left 
procedure codes 37.63, 37.65, and 37.66 into DRG 525.
    In addition, we have evaluated a request for expanded coverage for 
VADs and LVADs as destination (or permanent) therapy for end-stage 
heart failure patients who are not candidates for heart 
transplantation. VADs and LVADs had been approved for support of blood 
circulation post-cardiotomy (effective for services performed on or 
after October 18, 1993) and as a bridge to heart transplant (effective 
for services performed on or after January 22, 1996) to assist a 
damaged or weakened heart in pumping blood. The criteria that must be 
fulfilled in order for Medicare coverage to be provided for these 
purposes have been previously discussed in the August 1, 2000, final 
rule (65 FR 47058), and can also be accessed online at: http://www.cms.gov/manuals/pm_trans/r2ncd1.pdf
.

    As a result of that review, effective for services performed on or 
after October 1, 2003, VADs have been approved as destination therapy 
for patients requiring permanent mechanical cardiac support. Briefly, 
VADs used for destination therapy are covered only if they have 
received approval from the FDA for that purpose, and the device is used 
according to the FDA-approved labeling instructions. VADs are covered 
for patients who have chronic end-stage heart failure (New York Heart 
Association Class IV end-stage left ventricular failure for at least 90 
days with a life expectancy of less than 2 years). Implanting 
facilities as well as patients must also meet all of the additional 
conditions that are listed in the national coverage determination for 
artificial hearts and related devices, which is posted on the above CMS 
website.
    In the May 18, 2004, proposed rule, we again reviewed the FY 2003 
MedPAR data for all cases in which a VAD had been implanted, using the 
criterion of any case containing a procedure code of 37.66. We found a 
total of 65 cases in 3 DRGs: DRG 103 (Heart Transplant); DRG 483 
(Tracheostomy With Mechanical Ventilation 96+ Hours or Principal 
Diagnosis Except Face, Mouth, and Neck Diagnoses); and DRG 525 (Heart 
Assist System Implant). The following table displays our findings:
[GRAPHIC] [TIFF OMITTED] TR11AU04.002

    The remaining 354 cases in DRG 103 that did not report code 37.66 
had average charges of $282,578. The remaining 171 cases in DRG 525 
that did not contain code 37.66 had an average length of stay of 12.39 
days and average charges of $168,388. The 45 cases in DRG 525 with code 
37.66 accounted for 26 percent of the cases. However, the average 
charges for these cases are approximately $140,340 higher than the 
average charges for cases in DRG 525 that did not report code 37.66.
    Commenters on the FY 2004 final rule suggested adding code 37.66 to 
DRG 103. We were concerned with the timing of that comment, as it was 
received after publication of the proposed rule. We noted that the 
commenters' suggestions on the structure of the DRGs involved were 
significant, and that change of that magnitude should be subject to 
public review and comment. We also noted that we would evaluate the 
suggestion further (68 FR 45370). However, as one of the indications 
for this device has become destination therapy, and as this new 
indication is more clinically aligned with DRG 103, in the May 18, 2004 
proposed rule, we proposed to remove procedure code 37.66 from DRG 525 
and assign it to DRG 103. We also proposed to change the title of DRG 
103 to ``Heart Transplant or Implant of Heart Assist System''. The 
proposed restructured DRG 103 included any principal diagnosis in MDC 
5, plus one of the following surgical procedure codes:
     33.6, Combined heart-lung transplantation.
     37.51, Heart transplantation.
     37.66, Insertion of implantable heart assist system.
    In addition to the proposed changes to DRG 103, we proposed to 
change the title of DRG 525 to ``Other Heart Assist System Implant.''
    Comment: A number of commenters recommended that we continue to 
examine the MedPAR data for code 37.66 and heart transplants to confirm 
that the weight is accurate. Some of these commenters noted that the 
weight might need to be increased in either the short term or next 
year. One commenter who, we believe, did not have access to the 
proposed rule, suggested the same proposed changes that were included 
in the proposed rule.
    Response: We will continue to evaluate the assignment of these 
codes annually for clinical and resource coherence. We point out that 
the relative weights are determined based on a formula and the formula 
is based on historic hospital charges. To increase one weight in a 
manner not consistent with the formula would skew other weights, in 
addition to distorting our mandated budget neutrality provision.
    Comment: Two commenters requested clarification concerning patients 
who receive the implantable heart assist system as a bridge to 
transplant and are discharged and subsequently return for a heart 
transplant. The commenters

[[Page 48929]]

wanted to know if DRG 103 would be assigned in both cases.
    Response: DRG 103 would be assigned to the case when a VAD is 
implanted. It would also be assigned when the patient returns to the 
hospital for a heart transplant. However, we take this opportunity to 
clarify that only one DRG 103 payment will be made per admission. If a 
patient has both the VAD and a heart transplant during the same 
hospital admission, DRG 103 would be paid only once. Depending on the 
circumstances, the case may qualify for cost outlier status, which is 
designed to defray some of the additional expenses of the case.
    Comment: One commenter suggested that the term ``Insertion'' in the 
code title for 37.66 be changed to ``Implant'' to more accurately 
reflect the resource intense nature of the VAD implant.
    Response: We regret that we cannot accommodate this request. The 
cardiac device code titles have been discussed at the two previous ICD-
9-CM Coordination and Maintenance Committee meetings (December 2003 and 
April 2004). At those meetings, we asked for comments about the code 
titles, and in response to public comment, we removed the term 
``Implant'' and substituted ``Insertion'' in the title. As noted 
elsewhere in this preamble, the codes in Table 6 of the Addendum are 
not subject to comment. The codes themselves are final at the time the 
proposed rule is published, which gives our industry partners the 
opportunity to put them into their printed and electronic programs 
without the concern that they may be changed later in the rulemaking 
process.
    Comment: One commenter urged CMS to retain a common DRG assignment 
for procedure codes 37.65 and 37.66. The commenter believed that 
assigning these two procedure codes to different DRGs would not ensure 
that payment is adequate to allow hospitals to provide mechanical 
circulatory support therapies, as clinically indicated, and in a cost-
efficient manner. The commenter further believed that payment for 
implantable VADs (code 37.66) at a higher level than external VADs 
(code 37.65) would create financial incentives unrelated to, and 
potentially at odds with, clinical considerations, which would skew 
device choice and increase Medicare program costs. The commenter stated 
that the initial use of the least expensive device that can provide the 
necessary therapeutic benefit leads to the best clinical outcomes and 
the lowest total system costs. The commenter encouraged CMS to adopt a 
prudent payment policy and an adequate test of whether a patient's 
heart will recover before an implantable VAD procedure is undertaken.
    Response: We reviewed data on DRG 525 in the FY 2003 MedPAR file 
and are summarizing the findings below:
[GRAPHIC] [TIFF OMITTED] TR11AU04.003

    We believe that the data on the length of stay and average charges 
demonstrate considerable differences in the two VAD devices. The 
implantable VAD (code 37.66) had a length of stay more than three times 
longer than that of the external VAD (code 37.65), and charges that 
average over $100,000 per case greater than those of the external VAD. 
To comply with this commenter's suggestion and leave both codes in the 
same DRG would result in overpayment of external VAD procedures and 
underpayment of the implantable VADs. We do not find either alternative 
acceptable.
    We will continue to closely monitor DRGs 103 and 525 on an annual 
basis, and will review our data using the specific procedure codes that 
comprise these two DRGs.
    Comment: One commenter stated that the MedPAR data on charges for 
FY 2003 VAD cases used to develop and defend the proposal to assign 
procedure codes 37.65 and 37.66 to different DRGs are an inadequate 
basis for the proposal. The commenter stated that the FY 2003 data on 
code 37.66 used in support of the proposal (to move these cases to DRG 
103) must be comprised primarily of bridge-to-transplant cases, as the 
use of VADs for destination therapy was only recently approved. 
Therefore, the commenter believes, any destination therapy patients in 
the data must have been clinical trial patients. The commenter asserted 
that these clinical trial patients were a sicker group of patients than 
would normally be found, and that they received more ancillary services 
during the course of the trial than would be likely in normal clinical 
practice. As a result, the data for these patients would be skewed to 
higher average charges and longer lengths of stay.
    Response: The data associated with code 37.66 reflect the insertion 
of an implantable VAD. We do not have a method of capturing the intent 
of the physician upon insertion of this device. When the chest is 
opened and the device is inserted, we have no way of determining if 
this patient requires the device as a bridge-to-transplant as the 
patient awaits a donor organ, or if this VAD is to be considered 
destination therapy. Code 37.66 captures only the procedure performed 
and the device inserted.
    The following table represents FY 2002 data in DRG 525.

[[Page 48930]]

[GRAPHIC] [TIFF OMITTED] TR11AU04.004

    When we compare the above table containing FY 2002 data to the 
previous table containing FY 2003 data, we find similar results in 
length of stay and average charges for codes 37.63, 37.65, and 37.66. 
The FY 2003 data show only one case with code 37.62: it is difficult to 
draw any meaningful conclusions based on one case. These data represent 
cases before bridge-to-transplant was a covered indication for VAD. As 
the data in the 2 years are so similar, we believe that we have 
correctly reassigned code 37.66 to DRG 103.
    Comment: One commenter stated that DRG 525, as amended on October 
1, 2003, to include every type of mechanical circulatory support device 
requiring a sternotomy and multiple-day support, constituted a 
clinically coherent group of surgeries encompassing a range of device 
types and costs. The commenter stated that, as the device types in that 
DRG grouping are available in the same hospital mechanical circulatory 
support programs, blended reimbursement did not constitute a financial 
impediment to proper clinical choice. The commenter stated that the FY 
2003 iteration of DRG 525 should be preserved, which would allow the 
dynamics of the clinical setting and the market to determine the choice 
among available VADs.
    Response: We are aware that reimbursement dynamics may have an 
influence on the practice of medicine. However, we are also aware that 
the placement of cases reporting code 37.66 in DRG 525 may cause a 
financial hardship for hospitals. The movement of code 37.66 to DRG 103 
is appropriate from the perspective of resource utilization, and will 
also alleviate some of the disincentive to offer this procedure to 
patients who meet the medical criteria for implantation.
    Comment: One commenter noted that coverage of VAD procedures should 
be limited to Medicare-certified transplant centers. The commenter also 
noted that VAD implants assigned to DRG 103 are limited to those 
[hospitals] using devices that are approved by the FDA for use outside 
the inpatient hospital setting.
    Response: Section 60--Durable Medical Equipment in the Medicare 
Coverage Manual sets forth our requirements concerning the use of VADs. 
The manual states:
     The VAD must be used in accordance with the FDA approved 
labeling instructions;
     The patient is approved and listed as a candidate for 
heart transplantation by a Medicare-approved heart transplant center; 
and
     The implanting site, if different than the Medicare-
approved transplant center, must receive the Medicare-approved heart 
transplant center under which the patient is listed prior to 
implantation of the VAD.
    In conjunction with the data review of DRGs 103 and 525, we also 
evaluated DRGs 104 and 105. DRGs 104 and 105 were restructured in FY 
2003 by moving code 37.62 into them. We examined the MedPAR data and 
found that the average charges for DRGs 104 and 105 were $113,667 and 
$82,899, respectively, for cases not reporting code 37.62, while cases 
containing code 37.62 had average charges of $124,559 and $166,129, 
respectively.
    The removal of code 37.66 from DRG 525 would have the effect of 
clinically realigning that DRG to be more coherent. As a result of the 
proposal to remove code 37.66 from DRG 525 and assign it to DRG 103, we 
also proposed to remove code 37.62 from DRGs 104 and 105 and assign it 
back into DRG 525. The average charges for code 37.62 in DRGs 104 and 
105 ($124,559 and $166,129) more closely matched the average charges 
reported for the 171 cases in DRG 525, absent code 37.66 ($168,388).
    We indicated that the proposed new DRG 525 would consist of any 
principal diagnosis in MDC 5, plus the following surgical procedure 
codes:
     37.52, Implantation of total replacement heart system*
     37.53, Replacement or repair of thoracic unit of total 
replacement heart system*
     37.54, Replacement or repair of other implantable 
component of total replacement heart system*
---------------------------------------------------------------------------

    * These codes represent noncovered services for Medicare 
beneficiaries. However, it is our longstanding practice to assign 
every code in the ICD-9-CM classification to a DRG. Therefore, they 
have been assigned to DRG 525.
---------------------------------------------------------------------------

     37.62, Insertion of nonimplantable heart assist system
     37.63, Repair of heart assist system
     37.65, Implant of external heart assist system
    We received one comment in support of this portion of our proposal. 
Based on the rationale described above, we are adopting the proposed 
changes to DRGs 103, 104, and 105 as final without modification.
b. Cardiac Resynchronization Therapy and Heart Failure
    In the May 18, 2004 proposed rule, we addressed a request we had 
received from a manufacturer of a Cardiac Resynchronization Therapy 
Defibrillator (CRT-D) device for a modification to DRG 535 (Cardiac 
Defibrillator Implant With Cardiac Catheterization With Acute 
Myocardial Infarction/Heart Failure/Shock) and DRG 536 (Cardiac 
Defibrillator Implant With Cardiac Catheterization Without Acute 
Myocardial Infarction/Heart Failure/Shock). The commenter pointed out 
that defibrillator device implantations, including the CRT-D type of 
defibrillator, are assigned to DRG 535 when the patient also has a 
cardiac catheterization and has either an acute myocardial infarction, 
heart failure, or shock as a principal diagnosis. If the

[[Page 48931]]

patient receiving the defibrillator implant and cardiac catheterization 
does not have a principal diagnosis of acute myocardial infarction, 
heart failure, or shock, the cases are assigned to DRG 536.
    The commenter requested that cases be assigned to DRG 535 when the 
patient has heart failure as either a principal diagnosis or a 
secondary diagnosis. The commenter stated that patients receive a CRT-D 
(as opposed to other types of defibrillators) when they have both heart 
failure and arrhythmia. The commenter was concerned that some coders 
may sequence the heart failure as a secondary diagnosis, which would 
result in the patient being assigned to DRG 536.
    As stated earlier, DRGs 535 and 536 are split based on the 
principal diagnosis of acute myocardial infarction, heart failure, or 
shock. Cases are not assigned to DRG 535 when heart failure is a 
secondary diagnosis.
    The commenter described a scenario where a patient was admitted 
with heart failure for an evaluation of the need for a CRT-D implant. 
The hospitalization studies indicated that the patient had a 
ventricular tachycardia. The commenter indicated that coders would be 
confused as to which code should be listed as the principal diagnosis.
    CMS' determination based on review of this scenario as described 
was that the heart failure led to the admission and would be the 
principal diagnosis. This case would properly be assigned to DRG 535. 
Furthermore, when two conditions are considered to be equally 
responsible for the admission, either one of the two conditions may be 
selected as the principal diagnosis.
    The commenter also stated that its own study shows CRT-D patients 
have significantly higher charges than do other patients in DRGs 535 
and 536 who receive an implantable defibrillator. This was the case 
whether heart failure was used as a principal or secondary diagnosis.
    A cardiac catheterization is a diagnostic procedure generally 
performed to establish the nature of the patient's cardiac problem and 
determine if implantation of a cardiac defibrillator is appropriate. 
Generally, the cardiac catheterization can be done on an outpatient 
basis. Patients who are admitted with acute myocardial infarction, 
heart failure, or shock and have a cardiac catheterization are 
generally acute patients who require emergency implantation of the 
defibrillator. Thus, there are very high costs associated with these 
patients.
    For the analysis in the proposed rule, we examined the MedPAR file 
for all cases in DRGs 535 and 536 and only cases in DRG 536 in which 
acute myocardial infarction or heart failure was listed as a secondary 
diagnosis. The following chart illustrates the results of our findings:
[GRAPHIC] [TIFF OMITTED] TR11AU04.005

    The data show that cases with a secondary diagnosis of acute 
myocardial infarction or heart failure have average charges 
($94,832.14) closer to the overall average charges for DRG 536 
($89,493.85) where they are currently assigned. Overall charges for DRG 
535 were $110,663.57. We do not believe these data support modifying 
DRG 535 and DRG 536 as requested. Many of the CRT-D patients who are 
admitted for heart failure would be assigned into DRG 535. Furthermore, 
modifying the DRG logic for one specific type of defibrillator (CRT-D) 
is not consistent with our overall policy of grouping similar types of 
patients together in the same DRG. In addition, to modify the DRG logic 
for the small percentage of cases where there might be confusion 
concerning the selection of the principal diagnosis does not seem 
prudent. Therefore, we did not propose a modification to DRG 535 or 536 
for CRT-Ds.
    Comment: Several commenters supported our proposal not to change 
the current DRG structure of DRG 535 and DRG 536 for CRT-D devices. Our 
proposal was in response to a manufacturer that had requested that CRT-
D cases be assigned to DRG 535 when the patient has heart failure as 
either a principal diagnosis or a secondary diagnosis.
    Response: After publication of the May 18, 2004 proposed rule, we 
discussed the issue of coding cases implanted with a CRT-D at the June 
2004 meeting of the American Hospital Association's Editorial Advisory 
Board for Coding Clinical for ICD-9-CM. Discussions between coding 
representatives from the American Hospital Association, the American 
Health Information Management Association, the National Centers for 
Health Statistics, and CMS did not identify diagnosis sequencing 
problems for patients receiving a CRT-D, as was suggested by the 
manufacturer. A number of problems in coding the implantation of these 
devices using the procedure codes were discussed. In addition, we 
learned that physicians are not clearly and consistently documenting 
the types of devices being implanted. This is leading to a number of 
questions from hospitals on how to assign the correct codes for an 
implantable cardiac defibrillator (ICD) versus the newer CRT-D. As a 
result of these further discussions, the Editorial Advisory Board for 
Coding Clinical for ICD-9-CM is developing a series of questions and 
answers to clearly illustrate to hospitals how the various devices, 
leads, and generators are to be correctly coded.
    We appreciate the support of the commenters for maintaining the 
current DRG structure for DRGs 535 and 536 and not modifying them in 
this final rule for one specific type of defibrillator.
    Comment: One commenter, a national hospital organization, opposed 
our recommendation not to alter the logic of DRG 535. The commenter 
believed that resynchronization is not performed during an acute 
exacerbation of congestive heart failure. Rather, the

[[Page 48932]]

commenter indicated, the patient returns at a later date once the 
congestive heart failure becomes more stabilized. The commenter added 
that, at that time, the patient often manifests associated arrhythmias 
that require the resynchronization. The commenter believed that, as a 
result, under the current proposal, this case would possibly not group 
to DRG 535 if the congestive heart failure were not sequenced as the 
principal diagnosis.
    Response: The commenter stated that the hospital might not list 
congestive heart failure as the principal diagnosis in the case 
described. However, if this were a planned second admission for the 
implantation of a CRT-D for congestive heart failure, the hospital 
would assign congestive heart failure as the principal diagnosis. The 
associated arrhythmias would be listed as a secondary diagnosis. This 
case would be assigned to DRG 535. If the admission were equally due to 
both the congestive heart failure and the arrhythmias, the hospital 
could choose either one as the principal diagnosis. Once again, the 
hospital could select congestive heart failure as the principal 
diagnosis and DRG 535 would be assigned. It would not be appropriate to 
change the DRG logic for DRG 535 to capture congestive heart failure as 
either the principal diagnosis or secondary diagnosis for CRT-D 
patients when appropriate coding would lead to the correct DRG 
assignment. Therefore, it would not be appropriate to modify the logic 
for DRGs 535 and 536 for congestive heart failure at this time.
    Comment: Commenters who supported our proposal of maintaining the 
current DRG structure for DRGs 535 and 536 suggested that coders should 
follow the ICD-9-CM Official guidelines for Coding and Reporting 
(available on the following Web site: http://www.cdc.gov/nchs/icd9.htm) 

when sequencing the principal diagnosis for admissions involving 
cardiac resynchronization. The commenters indicated that, if the reason 
for the admission is heart failure, that condition would be sequenced 
as the principal diagnosis. The commenter added that when two 
conditions are equally responsible for the admission, the ICD-9-CM 
Official Guidelines for Coding and Reporting allow either condition to 
be sequenced as the principal diagnosis. The commenters further stated 
that, in that case, the condition resulting in the higher-weighted DRG 
adjustment would likely be sequenced as the principal diagnosis. The 
commenter recommended that CMS continue to analyze the data in DRGS 535 
and 536 and seek additional clinical input regarding the typical 
principal diagnosis for patients being admitted to evaluate the need 
for a CRT-D device. The commenters added that further revisions to 
these DRGs may be warranted in the future.
    Response: We agree with the commenters that coders should follow 
the ICD-9-CM Official Guidelines for Coding and Reporting. We also 
agree that although we are currently maintaining the structure of DRGs 
535 and 536, we will continue to examine data for these procedures in 
future years to ensure that assignment of cases to these DRGs remains 
appropriate.
    Comment. One commenter indicated that its hospital was assigning 
the following codes for heart failure cases where the existing 
automatic cardioverter/defibrillator pulse generator is replaced and 
the pocket in which the device is implanted is revised:
     37.98 Replacement of automatic cardioverter/defibrillator 
pulse generator only.
     37.99 Other operations of heart and pericardium.
    The commenter stated that when the hospital submits a claim with 
the code for the replacement of the generator (code 37.98), the case is 
assigned to DRG 115 (Permanent Cardiac Pacemaker Implant With Acute 
Myocardial Infarction, Heart Failure, or Shock or ACID Lead or 
Generator Procedures). When the hospital submits a claim with codes for 
both the generator replacement (code 37.98) and the pocket revision 
(code 37.99), the case is assigned to DRG 111 (Major Cardiovascular 
Procedures Without CC). The commenter was concerned because DRG 111 has 
a lower relative weight than DRG 115. The commenter believed that DRG 
111 does not adequately reimburse the hospital for the replacement of 
the pulse generator device.
    The commenter requested that we consider modifying the DRG logic 
when both codes are submitted, modify the surgical hierarchy, or 
develop separate codes for revisions and relocations of defibrillator 
generators.
    Response: We are addressing the issue of the surgical hierarchy 
surfaced by the commenter in section II.B.11. of this final rule. We 
have carefully evaluated the other issues raised by the commenter, and 
we concur that assigning procedures such as the revision or relocation 
of defibrillator pockets to a vague code such as code 37.99 does not 
allow these procedures to be clearly identified. We believe that 
grouping disparate procedures such as repositioning of leads, removal 
without replacement of pulse generator, and revision or relocation of 
pockets within one code makes the DRG refinements difficult. We will 
discuss this topic at the October 7-8, 2004 meeting of the ICD-9-CM 
Coordination and Maintenance Committee. We will give consideration to 
creating one or more new codes to more clearly identify these 
procedures. With these more precise codes, we should be able to modify 
the DRG logic to resolve this issue.
    Comment: Several commenters requested that we restructure DRG 515 
(Cardiac Defibrillator Implant without Cardiac Catheterization) by 
splitting it into two DRGs based on the presence of acute myocardial 
infarction (AMI), heart failure, or shock. One commenter pointed out 
that we previously split DRG 514 (Cardiac Defibrillator with Cardiac 
Catheterization) into two DRGs based on these conditions. In FY 2004, 
we created DRGs 535 and 536 (Cardiac Defibrillator Implant with Cardiac 
Catheterization With and Without AMI/Heart Failure/Shock, 
respectively). The commenter commended us for splitting DRG 514 into 
these two new DRGs and asked that we now split DRG 515 in a similar 
manner.
    The commenter stated that there was significant difference in 
hospital charges associated with cases in DRG 515 with and without 
these principal diagnoses. The commenter stated that it was important 
to ensure more appropriate payment for all defibrillator cases and 
better align the DRG payment logic across all pacemaker and 
defibrillator cases based on important differences in hospital resource 
requirements.
    The commenter pointed out that, in the FY 2004 IPPS rule, we 
indicated that we did not believe the number of cases within DRG 515, 
or the differences in charges for cases with and without a principal 
diagnosis of acute myocardial infarction, heart failure, or shock, were 
sufficient to merit the creation of two separate DRGs. The commenter 
stated there was an increase in defibrillator implants assigned to DRG 
515 in FY 2003 based on changes in medical science and practice 
patterns, and speculated that a large number of cases now assigned to 
DRG 515 are for patients with a principal diagnosis of acute myocardial 
infarction, heart failure, or shock. The commenter believed that these 
patients will have significant differences in hospital charges and 
lengths of stay as compared to those cases in DRG 515 without these 
principal diagnoses. In addition, the commenter mentioned that other 
DRGs within MDC 5 are split based on the principal diagnosis or the 
presence of complications or comorbidities. In

[[Page 48933]]

summation, the commenter requested that we split DRG 515 into two 
separate new DRGs based on the principal diagnoses of acute myocardial 
infarction, heart failure, or shock. The commenter believed the split 
is justified based on the large number of cases in DRG 515, the large 
percentage of cases that include a principal diagnosis of acute 
myocardial infarction, heart failure, or shock, and the significantly 
higher charges and length of patient stays associated with these cases.
    Another commenter made a similar request to split DRG 515 into two 
separate new DRGs based on the principal diagnosis of acute myocardial 
infarction, heart failure, or shock. The commenter stated that we had 
split DRG 514 into two DRGs (DRGs 535 and 536), and this split has 
worked well in the facility environment to accurately capture charges 
and assign appropriate DRGs to cases.
    Response: We have performed additional analysis of our FY 2003 
MedPAR claims data for DRG 515 using the March 2004 update of the 
files. We found that 32 percent (4,191) of cases reported for DRG 515 
contained a principal diagnosis of acute myocardial infarction, heart 
failure, or shock. These cases had average charges of $84,688, as 
compared to average charges of $77,554 for all cases in DRG 515. 
Therefore, DRG 515 cases with a principal diagnosis of acute myocardial 
infarction, heart failure, or shock had average charges that were 
$7,134 (9 percent) higher than those for all cases in DRG 515. The data 
also show that patients with a principal diagnosis of acute myocardial 
infarction, heart failure, or shock have average lengths of stay of 
6.056 days compared to 4.73 days for all cases in DRG 515. Therefore, 
cases in DRG 515 with a principal diagnosis of acute myocardial 
infarction, heart failure, or shock have an average length of stay that 
is only 1.326 days longer than that for all cases in DRG 515.
    The data that we included in the May 18, 2004, proposed rule (69 FR 
28208) showed significantly larger differences between DRGs 535 and 536 
in average lengths of stay and charges. DRG 535 had an average length 
of stay of 9.5 days and average charges of $110,663.57. DRG 536 had an 
average length of stay of 5.47 days and average charges of $89,493.85. 
The difference in average charges was $21,169.72.
    As a result of this analysis, we find that the requested split of 
DRG 515 would not result in cases with as significantly different 
lengths of stay or charges as compared to the difference between DRGs 
535 and 536. In addition, our current data show only 4,191 cases that 
would be assigned to a new DRG for Cardiac Defibrillator Implant 
without Cardiac Catheterization with a principal diagnosis of acute 
myocardial infarction, heart failure, or shock. Given the limited 
number of cases in DRG 515 and the relatively small differences between 
average charges and length of stay for the two DRGs suggested by the 
commenter, we have decided that a modification of DRG 515 is not 
warranted at this time. However, we will examine the data in the future 
to determine if changes are warranted.
    In summary, we are not making changes to DRG 535 or DRG 536 for 
CRT-D cases at this time. In addition, DRG 515 will remain unchanged 
for FY 2005. However, we will continue to study data on these DRGs to 
consider whether future DRG refinements are warranted.
c. Combination Cardiac Pacemaker Devices and Lead Codes
    In the May 18, 2004, proposed rule, we discussed a comment we had 
received that recommended that we include additional combination 
procedure codes representing cardiac pacemaker device and lead codes 
under DRG 115 (Permanent Cardiac Pacemaker Implant With Acute 
Myocardial Infarction, Heart Failure, or Shock or ACID Lead or 
Generator Procedures) and DRG 116 (Other Permanent Cardiac Pacemaker 
Implant). DRGs 115 and 116 are assigned when a complete pacemaker unit 
with leads is implanted. Combinations of pacemaker devices and lead 
codes that would lead to the DRG assignment are listed under DRGs 115 
and 116. The commenter recommended that the following pacemaker device 
and lead procedure code combinations be added to these two DRGs:
     00.53 & 37.70
     00.53 & 37.71
     00.53 & 37.72
     00.53 & 37.73
     00.53 & 37.74
     00.53 & 37.76
    These codes are defined as follows:
     00.53, Implantation or replacement of cardiac 
resynchronization pacemaker, pulse generator only [CRT-P]
     37.70, Initial insertion of pacemaker lead [electrode], 
not otherwise specified
     37.71, Initial insertion of transvenous lead [electrode] 
into ventricle
     37.72, Initial insertion of transvenous lead [electrode] 
into atrium and ventricle
     37.73, Initial insertion of transvenous lead [electrode] 
into atrium
     37.74, Initial insertion or replacement of epicardial lead 
[electrode] into epicadium
     37.76, Replacement of transvenous atrial and/or 
ventricular lead(s) [electrode]
    We consulted our medical advisors and they agreed that these 
recommended procedure code combinations also describe pacemaker device 
and lead implantations and should be included under DRGs 115 and 116. 
Therefore, we proposed to add the recommended procedure code 
combinations to the list of procedure code combinations under DRGs 115 
and 116.
    Comment: Several commenters, including those from organizations 
representing hospitals and coders, supported our proposal to add the 
pacemaker device and lead procedure code combinations to DRGs 115 and 
116 as specified above. The commenters agreed that these combinations 
indicate that a complete pacemaker unit, including a pacemaker unit and 
leads, is implanted.
    Response: We appreciate the commenters' support for our proposal.
    In summary, we are adopting, as final without modification, our 
proposal to add the procedure code combinations of pacemaker devices 
and lead procedure codes included above and specified in the proposed 
rule to the list of procedure code combinations under DRGs 115 and 116.
d. Treatment of Venous Bypass Graft [Conduit] with Pharmaceutical 
Substance
    In the May 18, 2004, proposed rule, we included in Table 6B of the 
Addendum a new ICD-9-CM procedure code 00.16 (Pressurized treatment of 
venous bypass graft [conduit] with pharmaceutical substance) that was 
approved, effective on October 1, 2004. We received a number of 
comments on this new code.
    Comment: A number of comments from physicians applauded our 
decision to create new procedure code 00.16. The commenters stated 
that, upon approval by the Food and Drug Administration (FDA) of this 
procedure, the code will be used to recognize the E2F Decoy 
(edifoligide) procedure. This procedure will be performed on patients 
undergoing bypass vein graft procedures if the FDA finds the procedure 
to be safe and effective. The commenters stated that they are currently 
performing this procedure on a number of their patients, and asked that 
Medicare payments that are in addition to that for the cardiac bypass 
procedure be made to offset resource utilization and costs incurred by 
hospitals.
    Response: We appreciate the commenters' support for the creation of

[[Page 48934]]

this procedure code. We proposed to classify this procedure as a non-
O.R. procedure in Table 6B of the Addendum to the proposed rule. The 
``N'' under the O.R. column in Table 6B means that the code will not be 
considered an O.R. procedure and therefore, will not affect the DRG 
assignment. While the commenters suggested that extra payment be made 
for this procedure in addition to that for the cardiac bypass 
procedure, they did not suggest a means to do so. Furthermore, because 
procedure code 00.16 will not begin to be used until October 1, 2004, 
we have no data for this new procedure. Accordingly, in this final 
rule, we are retaining as final the proposed classification of 
procedure code 00.16 as a non-O.R., ICD-9-CM procedure code. Code 00.16 
will not affect the DRG assignment.
4. MDC 6 (Diseases and Disorders of the Digestive System): Artificial 
Anal Sphincter
    In the FY 2003 IPPS final rule (67 FR 50242), we created two new 
codes for procedures involving an artificial anal sphincter, effective 
for discharges occurring on or after October 1, 2002: code 49.75 
(Implantation or revision of artificial anal sphincter) that is used to 
identify cases involving implantation or revision of an artificial anal 
sphincter and code 49.76 (Removal of artificial anal sphincter) that is 
used to identify cases involving the removal of the device. In Table 6B 
of that final rule, we assigned both codes to one of four MDCs, based 
on principal diagnosis, and one of six DRGs within those MDCs. In the 
August 1, 2003, IPPS final rule (68 FR 45372), we discussed the 
assignment of these codes in response to a request we had received to 
consider reassignment of these two codes to different MDCs and DRGs. 
The requester believed that the average charges ($44,000) for these 
codes warranted reassignment. In the August 1, 2003, IPPS final rule, 
we stated that we did not have sufficient MedPAR data available on the 
reporting of codes 49.75 and 49.76 to make a determination on DRG 
reassignment of these codes. We agreed that, if warranted, we would 
give further consideration to the DRG assignments of these codes 
because it is our customary practice to review DRG assignment(s) for 
newly created codes to determine clinical coherence and similar 
resource consumption after we have had the opportunity to collect 
MedPAR data on utilization, average length of stay charges, and 
distribution throughout the system.
    Therefore, we reviewed the FY 2003 MedPAR data for the presence of 
codes 49.75 and 49.76. We then arrayed the results by DRG, count, 
average length of stay, charges, and the presence or absence of a 
secondary diagnosis that could be classified as a CC. We found that 
there were a total of 13 cases in 5 total DRGs with CCs, and 9 cases in 
4 total DRGs without CCs, for a total of 22 cases that reported these 
procedure codes. We had anticipated that the majority of cases would 
have been found in DRGs 157 (Anal and Stomal Procedures With CC) and 
158 (Anal and Stomal Procedures Without CC), but found only 2 cases 
grouped to DRG 157 and 4 cases grouped to DRG 158. Our data showed 
average charges of $22,374 for the cases with CC, and average charges 
of $20,831 for the cases without CC. Average charges for DRG 157 were 
$18,196, while average charges for DRG 158 were $9,348.
    Our medical advisors also reviewed the contents of DRGs 157 and 
158. The consensus was that codes 49.75 and 49.76 are not a clinical 
match to the other procedure codes found in these two DRGs. The other 
procedure codes in DRGs 157 and 158 are for simpler and less invasive 
procedures. In some circumstances, these procedures could potentially 
be performed in an outpatient setting or in a physician's office. Our 
medical advisors determined that clinical coherence was not 
demonstrated and recommended that we move these codes to DRGs 146 
(Rectal Resection With CC) and 147 (Rectal Resection Without CC), as 
these anal sphincter procedures more closely resemble the procedures in 
these DRGs. In addition, the average charges for paired DRG 146 
($33,853) and DRG 147 ($21,747) more closely resemble the actual 
average charges found in the MedPAR data for these cases.
    Even though there were few reports of codes 49.75 and 49.76 in the 
MedPAR data and we did not anticipate a significant increase in 
utilization of these procedures, we proposed that these two codes would 
only be removed from paired DRGs 157 and 158 and reassigned to paired 
DRGs 146 and 147 under MDC 6 (Diseases and Disorders of the Digestive 
System). We also proposed that all other MDC and DRG assignments for 
codes 49.75 and 49.76 would remain the same.
    Comment: Two commenters agreed with our proposal and suggested that 
the recommendation be adopted as a final change. One commenter 
recommended that CMS continue to monitor the cost of these cases for 
future consideration of the creation of a new DRG. This commenter 
stated that CMS has limited reassignment of codes 49.75 and 49.76 to 
only one pair of DRGs. Specifically, these procedures were assigned to 
DRGs 157 and 158 and will be reassigned to DRGs 146 and 147. The 
commenter took issue with this limited correction and urged CMS to 
create a new DRG for ``Complex Anal/Rectal Procedure with Implant''.
    Response: As noted above, codes 49.75 and 49.76 are arrayed in four 
MDCs and six DRGs within those MDCs. To clarify the proposed rule, we 
proposed to move these codes within MDC 6, but we did not propose to 
change any other DRG assignment. With an appropriate principal 
diagnosis, and absent any other surgical procedure that would 
reconfigure the case, these codes will continue to be assigned to the 
other four DRGs in the other three MDCs.
    We point out that this reassignment of cases in MDC 6 will double 
the payment for cases now classified to DRG 146, and will more than 
double the payment for cases now classified to DRG 147 based on the 
increases in the relative weights.
    With regard to the suggestion to create a specific DRG for this 
procedure, we remind the commenter that the DRG structure is a system 
of averages, and is based on groups of patients with similar 
characteristics. It has not been our past practice to create a DRG 
based on one device from one manufacturer. We will continue to monitor 
these two procedure codes and the DRGs to which they are assigned for 
the annual IPPS updates. However, for FY 2005, we are adopting the 
proposal to reassign cases reporting codes 49.75 and 49.76 in MDC 6 to 
DRGs 146 and 147 as final, without further modification.
5. MDC 8 (Diseases and Disorders of the Musculoskeletal System and 
Connective Tissue)
a. 360 Degree Spinal Fusions
    In the May 18, 2004 proposed rule, we discussed a comment we had 
received that suggested procedure code 81.61 (360 Spinal fusion) should 
not be included in DRG 496 (Combined Anterior/Posterior Spinal Fusion). 
The commenter stated that code 81.61 does not represent the same types 
of cases as other codes included in DRG 496. The commenter indicated 
that cases reported with code 81.61 involve making only one incision, 
and then fusing both the anterior and posterior portion of the spine. 
All other cases in DRG 496 involve two separate surgical approaches 
used to reach the site of the spinal fusion. For these other patients, 
an incision is made into the patient, and a fusion is made in part of 
the spine. The patient is then turned over and a separate incision is 
made so that a fusion can be made in another part of

[[Page 48935]]

the spine. The commenter added that these two separate incisions and 
fusions are more time consuming than the single incision used for code 
81.61. The commenter also stated that patients receiving the two 
surgical approaches have a longer recovery period and use more hospital 
resources.
    We examined data in the MedPAR file for cases assigned to DRG 496 
and found the following:
[GRAPHIC] [TIFF OMITTED] TR11AU04.006

    We also examined cases in related DRG 497 (Spinal Fusion Except 
Cervical With CC) and DRG 498 (Spinal Fusion Except Cervical Without 
CC) in which code 81.61 was not reported. The results of our 
examination are summarized in the following table.
[GRAPHIC] [TIFF OMITTED] TR11AU04.007

    These data clearly showed that cases with code 81.61 have 
significantly lower average charges than other cases in DRG 496 that 
have two surgical approaches. Cases with code 81.61 are more closely 
aligned with cases in DRG 497 and DRG 498. Furthermore, including code 
81.61 will have the effect of lowering the relative weights for DRG 496 
in future years. Therefore, we proposed to remove code 81.61 from DRG 
496 and reassign it to DRGs 497 and 498.
    Comment: Several commenters supported our proposal to remove code 
81.61 from DRG 496 and reassign it to DRGs 497 and 498. One commenter 
representing a major hospital organization stated that patients 
receiving two surgical approaches have a longer recovery period and use 
more hospital resources. The commenter believed that there is confusion 
regarding the use of code 81.61 that stems from physicians who do not 
use the term ``360 degree spinal fusion'' in the medical record, and 
hospital coders who need to review the operative report to determine 
which surgeries, in fact, qualify for code 81.61. The commenter agreed 
that code 81.61 should be moved from DRG 496 to DRGs 497 and 498. 
However, the commenter recommended that data for code 81.61 be reviewed 
in the future once coding practices have improved. Another commenter 
representing a national organization of health information managers 
also supported our proposal to remove code 81.61 from DRG 496 and 
reassign it to DRGs 497 and 498. The commenter stated that MedPAR data 
indicate that this procedure is less expensive than other procedures 
classified to DRG 496.
    Response: We agree with the commenters that code 81.61 should be 
removed from DRG 496 and reassigned to DRGs 497 and 498. We also agree 
that the data for code 81.61 should be reviewed in the future to 
determine if additional DRG revisions are warranted.
    Comment: Several commenters opposed our proposal to remove 
procedure code 81.61 from DRG 496 and to reassign it to DRGs 497 and 
498. The commenters believed that CMS' reasoning was flawed in three 
areas: clinical coherence, accurate coding, and the incentive for more 
efficient care.
    First, the commenters believed that CMS did not fully address the 
clinical coherence of the cases, electing instead to make its proposal 
largely on the basis of charge coherence, alone. The commenters further 
believed that the combination of anterior and posterior fusions in a 
single surgery is the most appropriate for defining clinical 
characteristic of all cases currently included in DRG 496. The 
commenters stated that except for the number of incisions, a 360-degree 
(anterior and posterior) fusion is clinically comparable to all other 
anterior and posterior fusions because of the patient and the surgical 
characteristics.
    Second, the commenters expressed concerns that a significant number 
of 360-degree single-incision spinal fusion cases were inaccurately 
coded. The commenters pointed out that the data we used to examine the 
reporting of code 81.61 (which was created on October 1, 2002) 
represented only the first year of the use of the code. The commenters 
suggested that a significant number of 360-degree single-incision 
spinal fusion cases were incorrectly coded as involving a two-incision 
approach. Thus, these cases should have been correctly assigned to DRG 
496, but were mislabeled as involving a two-incision approach. One 
commenter stated that, as a manufacturer, it provides a coding hotline 
for hospitals with questions related to spinal cases. For the period 
January 2003 through April 2004, 20 percent (113 out of 563) of the 
total calls related to accurate coding of this procedure.
    One commenter stated that a high rate of coding errors is not 
surprising in the first year of use, given that code 81.61 just became 
effective for FY 2003, that 360-degree spinal fusion is a complex 
topic, and that misinformation may

[[Page 48936]]

have been given. The commenter recommended that consideration of a 
reclassification be held for at least another year or two to ensure 
that a sufficient volume of more accurate data can be collected and 
analyzed.
    Third, with regard to the issue of DRGs serving as an incentive for 
more efficient care, the commenters believed that CMS proposed the 
reassignment of code 81.61 to avoid lowering the relative weight for 
DRG 496 in the future. They stated that, by contrast, CMS has often 
maintained in the past that the DRG weighting process allows changes in 
the resource intensity of specific types of cases (whether upward or 
downward) to be reflected over time, as technology evolves. The 
commenters indicated that the single-incision method may be less time-
consuming, use fewer hospital resources, and allow patients to enjoy a 
shorter recovery period. The commenters stated that collection and 
analysis of additional and more accurate data may well show this. 
However, the commenters recommended that we leave code 81.61 in DRG 496 
as a financial incentive for providers to perform the lower-resource 
procedure. The commenters believed this would lead to the reduction of 
the relative weight for DRG 496 as more providers performed the less 
expensive procedure (single-incision anterior/posterior fusion). The 
commenters stated that the weighting process in DRG 496 is ideally 
designed to accomplish the goal of having hospitals perform a procedure 
that requires less resources.
    Response: We do not agree with the commenters' suggestions that our 
analysis did not fully address the clinical coherence of the cases or 
that our analysis was based largely on charge coherence alone. As we 
stated in the proposed rule, anterior and posterior fusions of the 
spine using one incision are quite different from those fusions 
involving two incisions of the spine. The patient endures a more 
extensive surgery when incisions to the spine are made using approaches 
from both the front and back of the patient. The surgery and recovery 
time are longer when two incisions are made into the patient. While we 
agree that the charge data support our proposal, we disagree that we 
ignored clinical differences in these two approaches.
    We acknowledge that there have been a number of questions 
concerning the use of code 81.61. This code has been discussed at the 
Editorial Advisory Board on Coding Clinic for ICD-9-CM. Based on some 
of the records sent to the Board, it would appear that some hospitals 
are incorrectly applying this code. The Board is attempting to develop 
additional educational material to include in future issues of Coding 
Clinic for ICD-9-CM.
    However, as we discussed in the proposed rule, cases reported with 
code 81.61 had average charges that are significantly lower than spinal 
fusions using two approaches. Approximately 30 percent (829) of the 
2,706 DRG 496 cases reported code 81.61. The 360-degree spinal fusion 
cases had average charges that were only 68 percent of those for all 
cases in DRG 496. The average charge for all cases in DRG 496 was 
$74,967.33, while the average charge for DRG 496 cases with code 81.61 
was only $50,659.69. There were also significant differences in the 
length of stay. The average length of stay for all cases in DRG 496 was 
8.0 days, while it was only 4.7 days for cases with code 81.61.
    While there may be some confusion in the correct coding of 360 
degree spinal fusions with a single incision, there are significant 
differences in the charges of those reported cases with 360 degree 
spinal fusion, single incision approach. If we were to keep code 81.61 
in DRG 496, the result would be a lowering of the weight for DRG 496 in 
future years. We discussed this issue with our medical advisors who 
agreed that the data and clinical similarities support our proposal to 
remove code 81.61 from DRG 496 and reassign it to DRGs 497 and 498. The 
nature of the surgery and the charges are similar to other cases in 
DRGs 497 and 498.
    We believe that the commenters' argument that leaving code 81.61 in 
DRG 496 would subsequently lead to a lowering of the relative weight 
for DRG 496 because it would increasingly consist of cases involving a 
single incision approach that would have lower charges seems to confirm 
CMS' suggestion that the single incision-approaches are significantly 
less resource intensive as well as less surgically invasive than the 
two-incision approaches. Therefore, we do not believe these cases 
belong in DRG 496 along with the more extensive surgeries.
    Comment: One commenter opposed moving code 81.61 from DRG 496 and 
into DRGs 497 and 498. The commenter stated that the amount of time it 
takes to perform a single incision 360-degree spinal fusion is similar 
to that of performing an anterior and posterior spinal fusion with two 
approaches. The commenter stated that any extra time in completing the 
surgery involves turning the patient over so that the separate approach 
(incision) can be made. The commenter stated that, in his hospital, the 
length of stay for one incision versus two incision approaches to 
spinal fusion does not vary significantly.
    Response: While the commenter's hospital may have similar length of 
stays for patients who have single versus two incision approaches to 
spinal fusion, our national data show a significant difference. As 
stated earlier, the average length of stay for DRG 496 was 8.0 days, 
while that for cases with code 81.61 was 4.7 days. We believe the data 
support this DRG change.
    Therefore, we are adopting as final our proposal to remove code 
81.61 from DRG 496 and reassign it to DRGs 497 and 498. We will examine 
data for cases reporting 81.61 in future years to determine if 
additional DRG modifications are needed.
b. Multiple Level Spinal Fusion
    On October 1, 2003 (68 FR 45596), the following new ICD-9-CM 
procedure codes were created to identify the number of levels of 
vertebra fused during a spinal fusion procedure:
     81.62, Fusion or refusion of 2-3 vertebrae.
     81.63, Fusion or refusion of 4-8 vertebrae.
     81.64, Fusion or refusion of 9 or more vertebrae.
    Prior to the creation of these new codes, we received a comment 
recommending the establishment of new DRGs that would differentiate 
between the number of levels of vertebrae involved in a spinal fusion 
procedure. In the August 1, 2003, final rule, we discussed the creation 
of these new codes and the lack of sufficient MedPAR data with the new 
multiple level spinal fusion codes (68 FR 45369). The commenter had 
conducted an analysis and submitted data to support redefining the 
spinal fusion DRGs. The analysis found that increasing the levels fused 
from 1 to 2 levels to 3 levels or more levels increased the mean 
standardized charges by 38 percent for lumbar/thoracic fusions, and by 
47 percent for cervical fusions.
    The following current spinal fusion DRGs separate cases based on 
whether or not a CC is present: DRG 497 (Spinal Fusion Except Cervical 
With CC) and DRG 498 (Spinal Fusion Except Cervical Without CC); DRG 
519 (Cervical Spinal Fusion With CC) and DRG 520 (Cervical Spinal 
Fusion Without CC). However, the difference in charges associated with 
the current CC split was only slightly greater than the difference 
attributable to the number of levels fused as found by the commenter's 
analysis. In addition, adopting the commenter's recommendation would 
have necessitated adjusting the DRG relative weights using non-MedPAR 
data

[[Page 48937]]

because Medicare claims data with the new ICD-9-CM codes would not have 
been available until the FY 2003 MedPAR file. Therefore, at that time, 
we did not redefine the spinal fusion DRGs to differentiate on the 
basis of the number of levels of vertebrae involved in a spinal fusion 
procedure.
    We did not yet have any reported cases utilizing the new multilevel 
spinal fusion codes in our data. We stated that we would wait until 
sufficient data with the new multilevel spinal fusion codes were 
available before making a final determination on whether multilevel 
spinal fusions should be incorporated into the spinal fusion DRG 
structure. The codes went into effect on October 1, 2003, and we have 
not received any data using these codes. Spinal surgery is an area of 
rapid changes. In addition, we have created a series of new procedure 
codes that describe a new type of spinal surgery, spinal disc 
replacement. (See codes 84.60 through 84.69 in Table 6B in the Addendum 
to this final rule that will go into effect on October 1, 2004.) Our 
medical advisors describe this new surgical procedure as a more 
conservative approach for back pain than the spinal fusion surgical 
procedure. With only limited data concerning multiple level spinal 
fusion and the rapid changes in spinal surgery, we believed it was more 
prudent not to propose the establishment of new DRGs based on the 
number of levels of vertebrae involved in a spinal fusion procedure in 
the May 18, 2004, proposed rule.
    In addition, no other surgical DRG is split based on the number of 
procedures performed. For instance, the same DRG is assigned whether 
one or more angioplasties are performed on a patient's arteries. The 
insertion of multiple stents within an artery does not result in a 
different DRG assignment. Similarly, the excision of neoplasms from 
multiple sites does not lead to a different DRG assignment. To begin 
splitting DRGs based on the number of procedures performed or devices 
inserted could set a new and significant precedent for DRG policy. 
Therefore, in the May 18, 2004, proposed rule, we indicated that while 
we would continue to study this area, we did not propose to redefine 
the spinal fusion DRGs based on the number of levels of vertebrae 
fused.
    Comment: Several commenters supported our proposal not to modify 
the spinal fusion DRGs to differentiate between the number of levels of 
vertebrae involved in a spinal fusion procedure. The commenters agreed 
that we should wait until we received sufficient data with the new 
multilevel spinal fusion codes to propose any new DRG revisions for 
using these codes.
    Response: We agree with the commenters that it would be premature 
to propose DRG revisions to the spinal fusion DRGs based on the new 
multiple level spinal fusion codes. Furthermore, as stated in the 
proposed rule, no other surgical DRG is split based on the number of 
procedures performed. To so do would have the potential of dramatically 
increasing the number of DRGs. Therefore, it would be prudent to wait 
for claims data prior to considering such a departure from the current 
DRG structure.
    Comment: One commenter who supported our recommendation expressed 
concern that our decision was grounded in part on the expectation that 
a ``more conservative'' surgical approach for back pain (that is spinal 
disc replacement) will be available soon. (In the proposed rule, we 
noted that new codes for spinal disc prosthesis procedures, codes 84.60 
through 84.69, will go into effect on October 1, 2004). The commenter 
stated that FDA has not approved some of the spinal disc prostheses. 
The commenter believed that this new technology may not become a 
medically accepted procedure in the clinical community. The commenter 
believed that we were implying that we would defer a decision on 
modification of the spinal fusion DRGs until such time as the FDA 
formally approves spinal disc prosthesis procedures. The commenter 
recommended that the spinal fusion DRGs should not be modified at this 
point; that CMS should wait for data using the multiple level spinal 
fusion codes prior to proposing modifications of the spinal fusion 
DRGs; and that CMS not wait to make any modifications to these DRGs 
based upon FDA approval of spinal disc prostheses.
    Response: We agree with the commenter that we should wait to 
evaluate claims data with the new multilevel spinal fusion codes before 
using these codes to revise the DRG structure. While we mentioned that 
new codes were created for FY 2005 for other types of spinal 
procedures, such as spinal disc prostheses, we did not mean to imply 
that we would defer analysis on multilevel spinal fusion until such 
time as the FDA reviews and approves other specific types of procedures 
and devices. We acknowledge that different types of procedures should 
be considered independently.
    In this final rule, we are maintaining the current DRG structure 
for the spinal fusion DRGs. We will wait for claims data on the new 
codes to become available before we consider proposing future revisions 
to the spinal fusion DRGs.
c. Insertion of Spinal Disc Prostheses and Other Spinal Devices
    In the May 18, 2004, proposed rule, we included in Table 6B of the 
Addendum new codes that were created to capture the insertion of spinal 
disc prostheses and other spinal devices (codes 84.59 through 84.69). 
We proposed to assign these new codes to DRGs 499 and 500 (Back and 
Neck Procedures Except Spinal Fusion with and without CC, respectively) 
within MDC 8. Shortly after publication of the proposed rule, we 
discovered errors of omission in the assignment of these codes within 
the MDCs in Table 6B. These codes should have also included DRG 
assignments within MDC 1, MDC 21, and MDC 24, in addition to the 
specified assignment to MCD 8. We corrected these errors of omission in 
a correction notice published on June 25, 2004 (69 FR 35716). The 
correction notice showed the following additional DRG assignments for 
these codes:
    MDC 1, DRGs 531 and 532 (Spinal Procedures With and Without CC, 
respectively).
    MDC 21, DRGs 442 and 443 (Other Procedure for Injuries With and 
Without CC, respectively).
    MDC 24, DRG 486 (Other Procedures for Multiple Significant Trauma).
    The official ICD-9-CM code conversion table showed code 80.51 
(Excision of intervertebral disc) as the predecessor code for codes 
84.60 through 84.69. There was no predecessor code listed for code 
84.59. Code 80.51 was assigned to DRGs 499 and 500 in MDC 8. It was 
also assigned to DRGs 531 and 532 in MDC 1, DRGs 442 and 443 in MDC 21, 
and DRG 486 in MDC 24.
    By correcting the proposed DRG assignment information for codes 
84.59 and 84.60 through 84.69, we clearly indicated our proposal of 
assigning these codes 84.59 and 84.60 through 84.69 to DRGs 531 and 532 
in MDC 1; DRGs 499 and 500 in MDC 8; DRGs 442 and 443 within MDC 21; 
and DRG 486 in MDC 24.
    Comment: Several commenters that are developing spinal disc 
prosthesis devices described these spinal disc prostheses devices as 
minimally invasive alternatives to spinal fusion. The commenters 
indicated that there is controversy among spine surgeons as to the 
cause, or causes, of back pain. However, they stated that many surgeons 
believe degeneration of the nucleus and annular destruction is a major 
source of pain. The commenters stated that if patients fail 
conservative

[[Page 48938]]

treatment, spinal fusion is currently the primary treatment option. The 
commenters further stated that fusing one or more levels in the spine 
results in increased stress and strain and the potential breakdown at 
adjacent disc levels. In addition, the commenters stated that partial 
and total spinal disc replacement prosthesis devices were designed to 
replace the degenerated nucleus or disc and restore the normal disc 
function and anatomy. They believed these devices have the potential of 
decreasing stress, which is redistributed to adjacent levels of the 
spine when spinal fusions are performed. The commenters indicated that 
fusion surgery patients have poor return to work results, that recovery 
periods are extended, and that the spinal disc prosthesis devices 
reduce this recovery period.
    The commenters objected to the proposed assignment of the new 
spinal disc prosthesis codes (84.60 through 84.69) to DRGs 499 and 500 
in MDC 8. The commenters stated that since total and partial spinal 
disc prostheses will be used for patients who would very likely be 
candidates for spinal fusion, the procedures should be assigned to DRGs 
497 and 498 for those in the lumbar spine and to DRGs 519 and 520 for 
those implanted in the cervical spine. One commenter compared the 
implantation of a total spinal disc prosthesis device in the lumbar 
spine to that of fusion of the lumbar spine with the use of a BAK cage. 
The commenter stated that both use an anterior approach to the surgery, 
and both involve implanting devices in the anterior part of the spine. 
One procedure involves implanting the spinal disc prosthesis; the other 
involves implanting a BAK cage while fusing the spine.
    The commenters stated that the costs of treating these types of 
patients with spinal disc prosthesis devices are also similar to the 
costs for those patients in the spinal fusion DRGs. One commenter 
stated that the operating room time would be similar, with the total 
lumbar disc prosthesis devices taking about 111 minutes and the lumbar 
fusion with a BAK cage taking 114 minutes. The commenter presented 
information to show a patient stay of 3.7 days for the total lumbar 
disc prosthesis procedures versus 4.3 days for the lumbar fusion with 
BAK cages. One commenter stated that the cost of the total disc 
prosthesis is approximately $10,585, compared to $4,800 for a BAK cage 
used in a lumbar fusion.
    Response: Based on advice from our medical advisors, we disagree 
with the suggestion that patients having partial and total spinal disc 
prosthesis procedures are clinically similar to patients assigned to 
the spinal fusion DRGs. To mix these two distinctly different 
approaches to the treatment of back pain would violate the principal of 
clinical cohesiveness of DRGs. DRGs 497, 498, 519, and 520 include only 
procedures that involve fusion of the spine. DRGs 499 and 500 include a 
number of other procedures performed on the spine and explicitly 
exclude spinal fusion procedures. Currently, spinal disc prosthesis 
procedures are assigned to code 80.51 (Excision of intervertebral 
disc). The new, more specific codes (84.60 through 84.69) will go into 
effect on October 1, 2004. As stated earlier, code 80.51 is assigned to 
DRGs 499 and 500 within MDC 8. Our proposal of assigning the new spinal 
disc prosthesis codes to DRGs 499 and 500 would maintain current 
practice based on the assignment of the predecessor code 80.51. Our 
medical advisors also stated that it would be inappropriate to move the 
partial and total spinal disc procedures to the spinal fusion DRGs 
because the implantation of these disc devices do not involve fusion of 
the spine. We do not yet have any charge data on these new types of 
spinal procedures because the codes are being implemented on October 1, 
2004. Thus, it would also be premature to assign these new procedures 
to the fusion DRGs.
    In this final rule, we are assigning the total and partial spinal 
disc procedures and other spinal devices (codes 84.59 and codes 84.60 
through 84.69) to DRGs 499 and 500 within MDC 8 as proposed. We will 
continue to monitor data on these procedures as their use increases to 
determine if future DRG modifications are needed.
d. Kyphoplasty
    In the May 18, 2004, proposed rule, in Table 6B of the Addendum, we 
included new ICD-9-CM codes that go into effect October 1, 2004. Among 
these new codes are codes 81.65 (Vertebroplasty) and 81.66 
(Kyphoplasty). We added these new codes to better differentiate between 
the surgical procedures of vertebroplasty and kyphoplasty. Both 
procedures are currently assigned to code 78.49 (Other repair or 
plastic operation on bone) and are assigned to the DRGs 223 and 234 in 
MDC 8, DRGs 442 and 443 in MDC 21, and DRG 486 in MDC 24.
    In the May 18, 2004, proposed rule, we proposed to assign both new 
codes 81.65 and 81.66 to the same DRGs to which code 78.49 is assigned.
    Comment: Several commenters supported the creation of the new 
procedure codes for kyphoplasty and vertebroplasty. However, some of 
the commenters opposed the assignment of code 81.66 to DRGs 233 and 234 
in MDC 8. The commenters stated that kyphoplasty is a significantly 
more resource intensive procedure than vertebroplasty and requires 
special inflatable bone tamps and bone cement. The commenters further 
stated that while kyphoplasty involves internal fixation of the spinal 
fracture and restoration of vertebral height, vertebroplasty involves 
only fixation. The commenters indicated that kyphoplasty procedures are 
more akin to spinal fusion and should be assigned to DRGs 497 and 498 
(Spinal Fusion Except Cervical With and without CC, respectively) in 
MDC 8. The commenters did not object to the DRG assignments for MDC 21 
or MDC 24 for kyphoplasty, or to the proposed DRG assignments for 
81.65.
    Response: Commenters supported the creation of the new procedure 
codes for kyphoplasty and vertebroplasty. The commenters indicated that 
kyphoplasty is more resource intensive than vertebroplasty and is more 
similar to resources used in a spinal fusion. However, we do not have 
data to support this claim because the new codes will not be 
implemented until October 1, 2004. We believe that it would be 
premature to consider DRG refinements using these new ICD-9-CM 
procedure codes at this time.
    Therefore, we are adopting, as final, our proposed assignment of 
new codes 81.65 and 81.66 to DRGs 223 and 234 in MDC 8, DRGs 442 and 
443 in MDC 21, and DRG 486 in MDC 24, as indicated in Table 6B of the 
Addendum to this final rule. We will take the commenters' 
recommendation into consideration when we conduct our annual reviews of 
MedPAR data.
6. MDC 15 (Newborns and Other Neonates With Conditions Originating in 
the Perinatal Period)
    In the May 18, 2004, proposed rule, we indicated that we continue 
to receive comments that MDC 15 (Newborn and Other Neonates With 
Conditions Originating in the Perinatal Period) does not adequately 
capture care provided for newborns and neonates by hospitals. The 
commenters pointed out that we have not updated the DRGs within MDC 15 
as we have for other parts of the DRG system.
    Our primary focus of updates to the Medicare DRG classification 
system is on changes relating to the Medicare patient population, not 
the pediatric or neonatal patient populations. However, we acknowledge 
the Medicare DRGs are

[[Page 48939]]

sometimes used to classify other patient populations. Over the years, 
we have received comments about aspects of the Medicare newborn DRGs 
that appear problematic, and we have responded to these on an 
individual basis. In the May 9, 2002, IPPS proposed rule (67 FR 31413), 
we proposed extensive changes to multiple DRGs within MDC 15. Because 
of our limited data and experience with newborn cases under Medicare, 
we contacted the National Association of Children's Hospitals and 
Related Institutions (NACHRI) to obtain proposals for possible 
revisions of the DRG categories within MDC 15. We received extensive 
comments opposing these revisions. Therefore, we did not implement the 
proposals.
    We advise those non-Medicare systems that need a more up-to-date 
system to choose from other systems that are currently in use in this 
country, or to develop their own modifications. As previously stated, 
we do not have the data or the expertise to develop more extensive 
newborn and pediatric DRGs. Our mission in maintaining the Medicare 
DRGs is to serve the Medicare population. Therefore, we will make only 
minor corrections of obvious errors to the DRGs within MDC 15. In the 
May 18, 2004, IPPS proposed rule, we indicated that we did not plan to 
conduct a more extensive analysis involving major revisions to these 
DRGs.
    Comment: Commenters, including several national hospital 
associations, supported our proposal not to undertake a major revision 
to MDC 15 at this time, but instead to address specific errors brought 
to our attention by providers and other commenters. One commenter, a 
national organization representing health information managers and 
coders, agreed with our approach to updating MDC 15 without undertaking 
a major revision. The commenter stated it believed a comprehensive 
revision of MDC 15 should not be undertaken without broad input from 
all types of hospitals that provide care for neonates to ensure the 
appropriateness of these DRG revisions across all institutions treating 
newborns. The commenter indicated that, given CMS' limited data and 
experience with newborn cases, it supported CMS' decision not to 
conduct a major overhaul of the newborn DRGs. However, the commenter 
agreed that CMS should address specific, individual requests for 
modifications to the newborn DRGs on a case-by-case basis.
    One commenter who supported our proposal indicated that there are 
challenges to developing DRG classifications systems and applications 
appropriate to children. The commenter acknowledged the practical 
difficulties of CMS assuming a larger role in this area, given the 
difference between the Medicare population and that of newborns and 
children. The commenter stated that there are evolving alternative DRG 
classification systems for children. The commenter agreed that a broad-
based fundamental restructuring of the neonatal DRGs would be a huge 
and complex undertaking and indicated that there are other DRG 
classification systems that are attempting at varying levels of 
sophistication to do this restructuring for the neonatal and pediatric 
patient populations. The commenter supported our approach of responding 
to specific requests for updating MDC 15 on a case-by-case basis.
    Response: We appreciate the commenters' support for our decision to 
perform only limited updates to MDC 15 based on specific requests for 
modification. We will continue to address specific requests for 
modification of the newborn DRGs on an individual basis.
    In the IPPS final rule for FY 2004 (68 FR 45360), we added heart 
failure diagnosis codes 428.20 through 428.43 to the list of secondary 
diagnosis of major problem under DRG 387 (Prematurity With Major 
Problems) and DRG 389 (Full-Term Neonate With Major Problems). We 
received a comment after the August 1, 2003 final rule stating that we 
should add the following list of combination codes, which also include 
heart failure, to the list of major problems under DRGs 387 and 389:
     398.91, Rheumatic heart failure (congestive).
     402.01, Malignant hypertensive heart disease, with heart 
failure.
     402.11, Benign hypertensive heart disease, with heart 
failure.
     402.91, Unspecified hypertensive heart disease, with heart 
failure.
     404.01, Malignant hypertensive heart and renal disease, 
with heart failure.
     404.03, Malignant hypertensive heart and renal disease, 
with heart failure and renal failure.
     404.11, Benign hypertensive heart and renal disease, with 
heart failure.
     404.13, Benign hypertensive heart and renal disease, with 
heart failure and renal failure.
     404.91, Unspecified hypertensive heart and renal disease, 
with heart failure.
     404.93, Unspecified hypertensive heart and renal disease, 
with heart failure and renal failure.
     428.9, Heart failure, unspecified.
    We agree that the codes listed above also include heart failure and 
should also be added to DRGs 387 and 389 as major problems. Therefore, 
in the May 18, 2004, proposed rule, we proposed to add the heart 
failure codes listed above to DRGs 387 and 389 as major problems.
    Comment: Several commenters supported the addition of the 
combination codes, including heart failure, to the list of major 
problems under DRGs 387 and 389 because there are a number of other 
heart failure codes already listed as major problems under DRGs 387 and 
389.
    Response: We appreciate the support of the commenters for our 
proposal.
    In this final rule, we are adopting, as final without modification, 
the proposed revisions to add the specified combination codes to the 
list of major problems under DRGs 387 and 389.
7. MDC 20 (Alcohol/Drug Use and Alcohol/Drug Induced Organic Mental 
Disorders): Drug-Induced Dementia
    In the May 18, 2004, proposed rule, we discussed a request that we 
had received from a commenter that we remove the principal diagnosis 
code 292.82 (Drug-induced dementia) from MDC 20 (Alcohol/Drug Use and 
Alcohol/Drug Induced Organic Mental Disorders) and the following DRGs 
under MDC 20:
     DRG 521 (Alcohol/Drug Abuse or Dependence With CC).
     DRG 522 (Alcohol/Drug Abuse or Dependence With 
Rehabilitation Therapy Without CC).
     DRG 523 (Alcohol/Drug Abuse or Dependence Without 
Rehabilitation Therapy Without CC).
    The commenter indicated that a patient who has a drug-induced 
dementia should not be classified to an alcohol/drug DRG. However, the 
commenter did not propose a new DRG assignment for code 292.82.
    Our medical advisors evaluated the request and determined that the 
most appropriate DRG classification for a patient with drug-induced 
dementia would be within MDC 20. The medical advisors indicated that 
because this mental condition is drug induced, it is appropriately 
classified to DRGs 521 through 523 in MDC 20. Therefore, we did not 
propose a new DRG classification for the principal diagnosis code 
292.82.
    Comment: Several commenters supported our proposal not to modify 
DRGs 521 through 523 by removing code 292.82. One commenter 
representing hospital coders disagreed with our proposal to retain code 
292.82 in DRGs 521 through 523. The commenter stated that DRGs 521 
through 523 are described as alcohol/drug abuse and dependence DRGs. 
The

[[Page 48940]]

commenter further indicated that drug-induced dementia could be caused 
by an adverse effect of a prescribed medication or a poisoning. The 
commenter did not believe that assignment of drug-induced dementia to 
DRGs 521 through 523 was appropriate if the drug-induced dementia is 
related to an adverse effect or poisoning due to a prescribed drug. The 
commenter recommended that admissions for drug-induced dementia be 
classified to DRGs 521 through 523 only if there is a secondary 
diagnosis indicating alcohol/drug abuse or dependence.
    The commenter further recommended that drug-induced dementia that 
is due to the adverse effect of drugs be classified to the same DRGs as 
other types of dementia, such as DRG 429 (Organic Disturbances and 
Mental Retardation). The commenter stated that when drug-induced 
dementia is caused by a poisoning, either accidental or intentional, 
the appropriate poisoning code would be sequenced as the principal 
diagnosis and, therefore, these cases would likely already be assigned 
to DRGs 449 and 450 (Poisoning and Toxic Effects of Drugs, Age Greater 
Than 17, With and Without CC, respectively) and DRG 451 (Poisoning and 
Toxic Effects of Drugs, Age 0-17). The commenter suggested that these 
DRG assignments would be the appropriate DRG assignments for drug-
induced dementia due to a poisoning.
    Response: We have considered the issues raised by the commenters 
relating to the DRG assignment for code 292.82 and the suggested 
alternatives for DRG assignment based on sequencing of the principal 
diagnosis and reporting of additional secondary diagnoses. We 
acknowledge that patients do develop drug-induced dementia from drugs 
that are prescribed as well as from drugs that are not prescribed. 
However, we still believe that dementia developed as a result of use of 
a drug is appropriately assigned to DRGs 521 through 523, as mentioned 
by the commenters who supported the current assignment. We also agree 
that if the drug-induced dementia is caused by a poisoning, either 
accidental or intentional, the appropriate poisoning code should be 
sequenced as the principal diagnosis. As the commenter stated, these 
cases would be assigned to DRGs 449 through 451.
    We will continue to evaluate the DRG assignment for this code 
during the next year and further consider the alternative DRG 
structures suggested by the commenters, if warranted. We will also 
further examine the use of secondary diagnoses as a means of better 
classifying patients with drug-induced dementia and consider 
alternative DRG assignments such as those mentioned by the commenters. 
We also encourage hospitals to examine the coding for these types of 
cases to determine if there are any coding or sequencing errors.
    We are adopting as final our proposal to maintain the current 
structure of DRGs 521 through 523. However, we will continue to examine 
the issue to determine whether any changes to the structure of these 
DRGs are warranted.
8. MDC 22 (Burns): Burn Patients on Mechanical Ventilation
    In the May 18, 2004, proposed rule (69 FR 28211), we discussed 
concerns that had been raised by hospitals treating burn patients that 
the current DRG payment for burn patients on mechanical ventilation is 
not adequate. The DRG assignment for these cases depends on whether the 
hospital performed the tracheostomy or the tracheostomy was performed 
prior to transfer to the hospital. If the hospital does not actually 
perform the tracheostomy, the case is assigned to one of the burn DRGs 
in MDC 22 (Burns). If the hospital performs a tracheostomy, the case is 
assigned to Pre-MDC DRG 482 (Tracheostomy for Face, Mouth, and Neck 
Diagnoses) or DRG 483 (Tracheostomy With Mechanical Ventilation 96+ 
Hours or Principal Diagnosis Except Face, Mouth and Neck Diagnoses).
    In the August 1, 2002, final rule, we modified DRGs 482 and 483 to 
recognize code 96.72 (Continuous mechanical ventilation for 96+ hours) 
for the first time in the DRG assignment (67 FR 49996). The 
modification was partially in response to concerns that hospitals could 
omit diagnosis codes indicating face, mouth, or neck diagnoses in order 
to have cases assigned to DRG 483 rather than the much lower paying DRG 
482 (the payment for DRG 483 is more than four times greater than the 
DRG 482 payment weight). In addition, we noted that many patients 
assigned to DRG 483 did not have code 96.72 recorded. We believed this 
was due, in part, to the limited number of procedure codes (six) that 
can be submitted on the current billing form and the fact that code 
96.72 did not affect the DRG assignment prior to FY 2003. The 
modification was the first attempt to refine DRGs 482 and 483 so that 
patients who receive long-term mechanical ventilation for more than 96 
hours are differentiated from those who receive mechanical ventilation 
for less than 96 hours. The modification was intended to ensure that 
patients who have a tracheostomy and continuous mechanical ventilation 
greater than 96 hours (code 96.72) would be assigned to DRG 483. By 
making the GROUPER recognize long-term mechanical ventilation and 
assigning those patients to the higher weighted DRG 483, we encouraged 
hospitals to be more aware of the importance of reporting code 96.72 
and to increase reporting of code 96.72 when, in fact, patients had 
been on the mechanical ventilator for greater than 96 hours. We stated 
in the August 1, 2002 final rule that, once we received more accurate 
data, we would give consideration to further modifying DRGs 482 and 483 
based on the presence of code 96.72.
    As we indicated in the May 18, 2004, proposed rule, to assess the 
DRG payments for burn patients on mechanical ventilation, we analyzed 
FY 2003 MedPAR data for burn cases in the following DRGs to determine 
the frequency for which these burn cases were treated with continuous 
mechanical ventilation for 96 or more consecutive hours (code 96.72):
     DRG 483 (Tracheostomy With Mechanical Ventilation 96+ 
Hours or Principal Diagnosis Except Face, Mouth, and Neck Diagnoses).
     DRG 504 (Extensive 3rd Degree Burns With Skin Graft).
     DRG 505 (Extensive 3rd Degree Burns Without Skin Graft).
     DRG 506 (Full Thickness Burn With Skin Graft or Inhalation 
Injury With CC or Significant Trauma)
     DRG 507 (Full Thickness Burn With Skin Graft or Inhalation 
Injury Without CC or Significant Trauma)
     DRG 508 (Full Thickness Burn Without Skin Graft or 
Inhalation Injury With CC or Significant Trauma)
     DRG 509 (Full Thickness Burn Without Skin Graft or 
Inhalation Injury Without CC or Significant Trauma)
     DRG 510 (Nonextensive Burns With CC or Significant Trauma)
     DRG 511 (Nonextensive Burns Without CC or Significant 
Trauma)
    The following chart summarizes those findings:

[[Page 48941]]

[GRAPHIC] [TIFF OMITTED] TR11AU04.008

    We found 120 cases that reported code 96.72 within the 3,394 burn 
DRG cases (DRGs 504 through 511). Cases reporting code 96.72 have 
significantly longer average lengths of stay and average charges. The 
majority (54) of these cases that reported code 96.72 were in DRG 506. 
The cases with code 96.72 reported had average charges approximately 
1.5 times higher than other cases in DRG 506 without code 96.72.
    We noted that there were 21 cases that reported code 96.72 within 
DRG 510. Since the 21 patients were on continuous mechanical 
ventilation for 96 consecutive hours or more, it seems surprising that 
the principal diagnosis was listed as one of the nonextensive burn 
codes included in DRG 510. A closer review of these cases shows some 
questionable coding and reporting of information. It would appear that 
hospitals did not always correctly select the principal diagnosis (the 
reason after study that led to the hospital admission). For instance, 
one admission was for a second-degree burn of the ear. This patient was 
on a ventilator for over 96 hours. It would appear that the reason for 
the admission was a diagnosis other than the burn of the ear. Other 
cases where the patient received long-term mechanical ventilation 
included those with a principal diagnosis of first degree burn of the 
face, second degree burn of the nose, second degree burn of the lip, 
and an unspecified burn of the foot. These four cases reported average 
charges ranging from $48,551 to $186,824 and had lengths of stay 
ranging from 8 to 36 days.
    The impact of long-term mechanical ventilation is quite clear on 
burn cases as was shown by the data above. Therefore, in the May 18, 
2004, proposed rule, we proposed to modify the burn DRGs 504 through 
509 under MDC 22 to recognize this impact. We also proposed to modify 
DRG 504 and DRG 505 so that code 96.72 will be assigned to these DRGs 
when there is a principal or secondary diagnosis of extensive third 
degree burns or full thickness burns (those cases currently assigned to 
DRGs 504 through 509). In other words, when cases currently in DRGs 506 
through 509 also have code 96.72 reported, they would now be assigned 
to DRGs 504 or 505. We also proposed to modify the titles of DRGs 504 
and 505 to reflect the proposed changes in reporting code 96.72 as 
follows:

[[Page 48942]]

     Proposed DRG 504, (Extensive Burns or Full Thickness Burns 
With Mechanical Ventilation 96+ Hours With Skin Graft)
     Proposed DRG 505, (Extensive Burns or Full Thickness Burns 
With Mechanical Ventilation 96+ Hours Without Skin Graft)
    Cases currently assigned to DRGs 504 and 505 that do not entail 96+ 
hours of mechanical ventilation will continue to be assigned to DRGs 
504 and 505 because they would have extensive burns, as required by the 
DRG logic.
    We did not propose to include DRG 510 and DRG 511 within this 
revised DRG logic. Cases currently assigned to DRG 510 or DRG 511 that 
also report code 96.72 would not be reassigned to DRGs 504 and 505. We 
recommended that hospitals examine cases that are assigned to DRG 510 
or DRG 511 and that have code 96.72 to determine if there are possible 
coding problems or other issues. As stated earlier, in examining 
reported cases within DRG 510, we noted several cases with code 96.72 
that appear to have an incorrect principal diagnosis. It would appear 
that the principal diagnosis may more appropriately be related to an 
inhalation injury, if the injury was present at the time of admission.
    We solicited comments on our proposal to move cases reporting code 
96.72 from DRGs 506 through 509 and assign them to DRGs 504 and 505. We 
also solicited comments on our proposal not to include DRGs 510 and 511 
in this proposed revision.
    Comment: Several commenters supported our recommended changes for 
the burn DRGs 504 through 509 under MDC 22. The commenters agreed that 
utilizing long-term mechanical ventilation of 96 or more hours (code 
96.72) would assist in identifying the more expensive burn patients. 
One commenter stated that the proposed DRG changes would be greatly 
beneficial to burn center hospitals and to patients who have suffered 
burn injuries. The commenters supported the proposal to move cases 
reporting code 96.72 that are currently assigned to DRGs 506 through 
509 into DRGs 504 and 505. The commenter also agreed with our proposal 
that cases assigned to DRGs 510 and 511 that also report code 96.72 
should not be reassigned to DRGs 504 and 505, because the data cited 
appeared to indicate incorrect principal diagnoses were reported in 
these cases. The commenters also recommended that consideration be 
given to further refinements of DRGs 504 and 505. The commenters 
recommended that in the future CMS consider further DRG splits for 
cases in DRGs 504 and 505 that have extensive third degree burns with 
an inhalation injury and 96+ hours of mechanical ventilation or perhaps 
creating a new DRG specifically for these patients.
    Response: We appreciate the commenters' support of our proposal. As 
we indicated in the May 18, 2004, proposed rule and in our discussion 
of the reporting of code 96.72 in the August 1, 2002, IPPS final rule 
(67 FR 49996), we did not have data on cases of reported burns among 
patients who receive mechanical ventilation until the FY 2003 MedPAR 
data became available. In the FY 2003 IPPS final rule, we had asked 
hospitals to examine their coding and reporting practices and to begin 
reporting code 96.72 when burn patients were on long-term mechanical 
ventilation. Hospitals have now increased their reporting of code 96.72 
among burn cases when patients were on long-term mechanical 
ventilation. With these improved data, in the proposed rule, we were 
able to identify the impact that mechanical ventilation had on the 
treatment of burn patients.
    In the proposed rule, we discussed our concern that hospitals may 
have a sequencing problem for some reported cases of minor burns in 
which the patient was on long-term mechanical ventilation. We suggested 
that some of these patients may have been admitted to the hospital for 
an inhalation injury as opposed to a minor burn. The American Hospital 
Association (AHA) has reviewed our data and shares our concern. The AHA 
has informed us that it is drafting instructional material that will 
appear in Coding Clinic for ICD-9-CM to assist hospitals in sequencing 
the principal diagnosis for burn cases in which the patients have an 
inhalation injury and a minor skin burn.
    We will continue to analyze cases assigned to the burn DRGs to 
determine if additional DRG refinements, such as the alternative 
suggestions mentioned by the commenters, are necessary.
    Comment: Another commenter representing hospital coders expressed 
its support of the proposed restructuring of the burn DRGs to account 
for the use of mechanical ventilation. The commenter shared our concern 
about possible errors in the sequencing of diagnoses on claims 
resulting in a nonextensive burn being reported as the principal 
diagnosis instead of the more serious inhalation or respiratory 
condition that was the actual reason for the inpatient admission. The 
commenter asked that we encourage hospitals to review admissions 
assigned to DRG 510 or 511 that have a code for mechanical ventilation 
(codes 96.70 through 96.72) assigned in order to identify any coding 
errors. The commenter recommended that hospitals identify cases in 
which poor medical record documentation resulted in miscoding of the 
reason for the inpatient admission or mechanical ventilation for burn 
patients. The commenter further recommended that hospitals use these 
cases as the basis for physician education to improve documentation 
practices.
    Response: We appreciate the commenter's support of the proposed DRG 
changes for burn patients on mechanical ventilation. As we indicated in 
the proposed rule, we agree with the commenters' suggestion that 
hospitals should review their medical records for cases assigned to DRG 
510 or 511 that had a code for mechanical ventilation to determine if 
there are coding errors. We agree that it is important for hospitals to 
have good medical record documentation in order to code accurately.
    After analysis of the public comments received, we are adopting, as 
final, our proposed changes to the burn DRGs. In summary, we are 
modifying DRGs 504 and 505 so that cases in which there is a principal 
diagnosis of extensive third degree burns or full thickness burns with 
code 96.72 reported are assigned to these two DRGs, rather than to DRGs 
506 through 509. We are also changing the title of DRG 504 to 
``Extensive Burns or Full Thickness Burns With Mechanical Ventilation 
96+ Hours With Skin Graft'' and the title of DRG 505 to ``Extensive 
Burns or Full Thickness Burns With Mechanical Ventilation 96+ Hours 
Without Skin Graft''. We will continue to follow these DRGs to 
determine if additional changes are needed.
9. Pre-MDC: Tracheostomy
    In the August 1, 2002, IPPS final rule (67 FR 49996), for FY 2003, 
we modified DRG 482 (Tracheostomy for Face, Mouth, and Neck Diagnoses) 
and DRG 483 (Tracheostomy With Mechanical Ventilation 96+ Hours or 
Principal Diagnosis Except Face, Mouth, and Neck Diagnoses) to 
recognize procedure code 96.72 (Continuous mechanical ventilation 96+ 
hours) in the DRG 483 assignment. As discussed above and in the 
proposed rule, we were concerned about an underreporting of code 96.72 
and wanted to encourage increased reporting of this code.
    In the May 18, 2004, proposed rule, we indicated that we had 
examined cases in the MedPAR file in which code 96.72 was reported 
within DRGs 482 and 483. The following chart illustrates the average 
charges and lengths of stays for cases within DRGs 482 and 483 with and 
without code 96.72 reported:

[[Page 48943]]

[GRAPHIC] [TIFF OMITTED] TR11AU04.009

    Of the 3,557 cases reported in DRG 482, only 22 cases reported code 
96.72. These 22 cases did not have a tracheostomy performed. All 22 
cases reported code 30.4 (Laryngectomy), which also leads to an 
assignment of DRG 482. It would appear that the long-term mechanical 
ventilation was performed through an endotracheal tube instead of 
through a tracheostomy. While the average charges for DRG 482 cases 
with code 96.72 reported were significantly higher than the average 
charges for other cases in the DRG, we did not believe that the very 
limited number of cases (22) warranted a proposed DRG modification. 
Therefore, we did not propose any modification for DRG 482. In the May 
18, 2004, IPPS proposed rule, we indicated that we will continue to 
monitor cases assigned to this DRG.
    We did not receive any comments on our proposal not to modify DRG 
482 and, therefore, are not making any changes to the DRG in this final 
rule.
    In the proposed rule we stated that in DRG 483, 19,669 cases were 
reported with code 96.72. However, we noted that the data were counter-
intuitive. While one would expect to find higher average charges for 
cases reported with code 96.72, the opposite is the case. Cases in DRG 
483 reported with code 96.72 had average charges that were $40,623 
lower than those not reported with code 96.72. Clearly, the presence or 
absence of code 96.72 does not explain differences in charges for 
patients within DRG 483.
    As stated earlier, we are concerned that hospitals may not always 
report code 96.72 because of space limitations. The electronic billing 
system limits the number of procedure codes that can be reported to six 
codes. We then looked at whether or not another major O.R. procedure 
was performed in addition to a tracheostomy. The DRG 483 logic requires 
that all patients assigned to DRG 483 have a tracheostomy. We examined 
cases in DRG 483 in the MedPAR file and discovered that those patients 
in DRG 483 who had a major procedure performed in addition to the 
tracheostomy had higher charges. A major procedure is a procedure whose 
code is included on the list that would be assigned to DRG 468 
(Extensive O.R. Procedure Unrelated to Principal Diagnosis), except for 
tracheostomy codes 31.21 and 31.29. Currently, this additional O.R. 
procedure does not affect the DRG assignment for cases assigned to DRG 
483. The following chart reflects our findings.
[GRAPHIC] [TIFF OMITTED] TR11AU04.010

    We found that cases of patients assigned to DRG 483 who had a major 
procedure (in addition to the required tracheostomy) had average 
charges that were $87,023 higher than the average charges for cases 
without a major O.R. procedure and had an average length of stay of 5 
days more than those without a major O.R. procedure. We found that the 
performance of an additional major O.R. procedure helps to identify the 
more expensive patients within DRG 483.
    Therefore, as a result of our findings, in the May 18, 2004, 
proposed rule, we proposed to modify DRG 483 by dividing these cases 
into two new DRGs depending on whether or not there is a major O.R. 
procedure reported (in addition to the tracheostomy). We proposed to 
delete DRG 483 and create two new DRGs as follows:
     Proposed new DRG 541 (Tracheostomy With Mechanical 
Ventilation 96+ Hours or Principal Diagnosis Except Face, Mouth, and 
Neck Diagnoses With Major O.R. Procedure)
     Proposed new DRG 542 (Tracheostomy With Mechanical 
Ventilation 96+ Hours or Principal Diagnosis Except Face, Mouth and 
Neck Diagnoses Without Major O.R. Procedure)
    We solicited comments on our proposal to delete DRG 483 and replace 
it with two proposed new DRGs by splitting the assignment of cases on 
the basis of the performance of a major O.R. procedure (in addition to 
the tracheostomy).
    Comment: Some commenters supported our proposed changes to DRG 483. 
One commenter stated that, based on the data presented by CMS, the 
proposal appears to be a reasonable approach to distinguish the more 
expensive cases in DRG 483. The commenter also stated that hospitals 
are not always reporting code 96.72 due to space limitations (that is, 
the electronic billing system limits the number of procedures that can 
be reported to six procedure codes). The commenter stated that patients 
in this patient population (undergoing procedures with procedure code 
96.72) may have several significant

[[Page 48944]]

O.R. procedures that may be sequenced before code 96.72, resulting in 
code 96.72 not appearing on the claim.
    Response: We appreciate the commenters' support of our proposed DRG 
revision as a reasonable approach to distinguish the more expensive 
cases from the less expensive cases in DRG 483. We continue to 
encourage hospitals to report code 96.72 for patients on mechanical 
ventilation for 96+ hours.
    Comment: Some commenters opposed our DRG change because of issues 
surrounding our proposed inclusion of DRG 483 as a DRG that would 
qualify for payment as a post-acute care transfer case.
    Response: We are responding to the specific comments received 
regarding the proposed inclusion of DRG 483 under the postacute care 
transfer discussion in section IV.A. of the preamble of this final 
rule. The commenters did not provide other specific objections to the 
proposed deletion of DRG 483 and the proposed creation of new DRGs 541 
and 542.
    Comment: Several commenters requested clarification of what 
procedures would be classified as major O.R. procedures in relationship 
to our proposed changes to DRG 483.
    Response: As we stated in the May 18, 2004 proposed rule, a major 
O.R. procedure is a procedure whose code is included on the list that 
would be assigned to DRG 468, except for tracheostomy codes 31.21 and 
31.29. These are the procedure codes listed as O.R. procedures in 
Appendix E of the Diagnosis Related Groups Definitions Manual. The 
reporting of a major procedure with a procedure code from Appendix E, 
along with an unrelated principal diagnosis, results in a case being 
assigned to DRG 468. Major O.R. procedures do not include prostatic or 
nonextensive procedures, or both, which are assigned to DRGs 476 and 
477.
    Currently, the reporting of an additional major O.R. procedure code 
does not affect the DRG assignment for cases assigned to DRG 483. In 
the proposed rule, we proposed to modify this logic by deleting DRG 483 
and creating two new DRGs 541 and 452 that are split on the basis of 
the performance of a major O.R. procedure (in addition to tracheostomy 
codes 31.21 and 31.29).
    Comment: Several commenters agreed that the CMS data support the 
subdivision of DRG 483 based on the presence of an additional major 
O.R. procedure. They agreed that this approach helps to identify the 
more expensive patients within DRG 483. One commenter stated that the 
proposed modifications were valuable. Another commenter stated that the 
proposed DRG revisions will better reflect the costs of furnishing care 
to these two categories of patients.
    Response: We agree with the commenters that subdividing the cases 
assigned to DRG 483 based on the presence of an additional major O.R. 
procedure helps to identify the more expensive patients. We also agree 
that the proposed new DRGs should lead to more equitable payment for 
the more expensive tracheostomy cases. Therefore, we are proceeding 
with finalizing our proposal of deleting DRG 483 and replacing it with 
DRGs 541 and 542.
    Comment: One commenter expressed concern regarding the proposed 
creation of a new DRG for mechanical ventilation as a pre-MDC for all 
patients undergoing more than 96 hours of mechanical ventilation. The 
commenter suggested that we delete DRG 475 (Respiratory System 
Diagnoses with Ventilator Support) from MDC 4 and move all of these 
cases reporting code 96.72 to a new DRG for mechanical ventilation in 
the pre-MDC section.
    Response: Patients undergoing more than 96 hours of mechanical 
ventilation are captured through code 96.72. Currently, patients with a 
respiratory system diagnosis listed in MDC 4 who receive mechanical 
ventilation are assigned to DRG 475. Cases are assigned to DRG 475 if 
one of the following procedure codes is reported:
     96.70, Continuous mechanical ventilation of unspecified 
duration.
     96.71, Continuous mechanical ventilation for less than 96 
consecutive hours.
     96.72, Continuous mechanical ventilation for 96 
consecutive hours or more.
    In the August 1, 2002, final rule (67 FR 49996), we discussed the 
reporting of code 96.72. We pointed out the importance of hospitals 
accurately reporting the use of long-term mechanical ventilation (code 
96.72). We stated in the August 1, 2002, final rule that, once we 
received more accurate data, we would give consideration to further 
modifying DRGs 482 and 483 based on the presence of code 96.72. As 
discussed previously, in this final rule, we are modifying DRG 483 to 
differentiate between patients with and without other major O.R. 
procedures (in addition to the tracheostomy). We are also modifying the 
burn DRGs to better classify those patients on long-term mechanical 
ventilation.
    As stated in the May 4, 2001, proposed rule (66 FR 22646): 
``Central to the success of the Medicare inpatient hospital prospective 
payment system is that DRGs have remained a clinical description of why 
the patient required hospitalization.'' Thus, the central 
classification criteria for DRG assignment has been the reason the 
patient was admitted (that is, the principal diagnosis for medical 
patients and the procedures performed for surgical patients). For a 
medical patient admitted for respiratory disease, the use of mechanical 
ventilation was used as a classification criteria because the 
mechanical ventilation was directly associated with the reason for 
hospital admission. The one exception to this rule is for patients who 
received a tracheostomy for long-term mechanical ventilation. These are 
catastrophic patients who, in general, have serious disease in multiple 
organ systems. Tracheostomies are performed on patients when it is 
anticipated that the patients will remain on mechanical ventilation for 
an extended period. The tracheostomy patients with long-term mechanical 
ventilation were all assigned to the same DRG regardless of their 
reason for admission. As we discussed previously, we are subdividing 
the patients assigned to DRG 483 into two new DRG 541 and 542 based on 
the presence of an additional major O.R. procedure.
    We believe it would not be appropriate to classify mechanical 
ventilation patients who do not receive a tracheostomy in the same 
manner as long-term mechanical ventilation patients who receive a 
tracheostomy. The patients who do not receive a tracheostomy tend to 
require mechanical ventilation for shorter periods and do not use the 
level of resources required by tracheostomy patients.
    The reason for admission for patients with short-term mechanical 
ventilation can vary greatly and include degenerative nervous system 
diseases, short-term acute disease, trauma, and terminal care. Further, 
the resource requirements for patients on short-term mechanical 
ventilation vary greatly, depending on the patient's reason for 
admission. We believe it is more appropriate to classify patients with 
short-term mechanical ventilation based on their reason for admission 
and to provide additional payments for patients with extreme resource 
use through outlier payments. Therefore, we are not accepting the 
commenter's request that we delete DRG 475 and create a new DRG in the 
Pre-MDC section for mechanical ventilation. We will maintain DRG 475 as 
it is currently configured.
    In summary, in this final rule, we are deleting DRG 483 and 
establishing the

[[Page 48945]]

following new DRGs 541 and 542 as replacements:
     DRG 541 (Tracheostomy With Mechanical Ventilation 96+ 
Hours or Principal Diagnosis Except Face, Mouth, and Neck Diagnoses 
With Major O.R. Procedure)
     DRG 542 (Tracheostomy With Mechanical Ventilation 96+ 
Hours or Principal Diagnosis Except Face, Mouth, and Neck Diagnoses 
Without Major O.R. Procedure)
10. Medicare Code Editor (MCE) Changes
    As explained under section II.B.1. of this preamble, the Medicare 
Code Editor (MCE) is a software program that detects and reports errors 
in the coding of Medicare claims data. In the May 18, 2004, IPPS 
proposed rule (69 FR 28213), we proposed to make changes to three of 
the edits in the MCE.
    a. Edit 11 (Noncovered Procedures) in the MCE contains codes that 
describe procedures for which Medicare does not provide reimbursement. 
In the proposed rule, we stated that we had received a request to 
remove procedure codes relating to stem cell transplants from Edit 11 
to conform the MCE edit to our published coverage decisions in the 
Medicare Coverage Issues Manual. Chapter 13.5 of the Program Integrity 
Manual (PIM) states that contractor discretion exists to cover 
diagnoses for which coverage is not explicitly precluded by a national 
coverage decision. Specifically this section states: that ``a local 
medical review policy (LMRP)'' must be clear, concise, properly 
formatted and not restrict or conflict with NCDs or coverage provisions 
in interpretive manuals. If an NCD or coverage provision in an 
interpretive manual states that a given item is `covered for diagnoses/
conditions A, B, and C,' contractors may not use that as a basis to 
develop LMRP to cover only ``diagnosis/conditions A, B, C''. When an 
NCD or coverage provision in an interpretive manual does not exclude 
coverage for other diagnoses/conditions, contractors must allow for 
individual consideration unless the LMRP supports automatic denial for 
some or all of those other diagnoses/conditions.''
    The national coverage decision on stem cell transplantation 
provides for coverage of certain diagnoses and excludes coverage for 
other diagnoses. However, the vast majority of diagnoses are not 
mentioned as either covered or noncovered. In accordance with the 
above-cited provision of the PIM, contractors must allow for individual 
consideration of these diagnoses. Thus, they are not appropriate for 
inclusion in the edit for noncovered procedures.
    In the proposed rule, we indicated that we agreed that we need to 
make conforming changes relating to stem cell transplants. Therefore, 
we proposed the following restructure of Edit 11:
    This list contains ICD-9-CM procedure codes identified as 
``Noncovered Procedures'' that are always considered noncovered 
procedures:
     11.71, Keratomileusis
     11.72, Keratophakia
     11.75, Radial keratotomy
     11.76, Epikeratophakia
     36.32, Other transmyocardial revascularization
     37.35, Partial ventriculectomy
     37.52, Implantation of total replacement heart system
     37.53, Replacement or repair of thoracic unit of total 
replacement heart system
     37.54, Replacement or repair of other implantable 
component of total replacement heart system
     39.28, Extracranial-intracranial (EC-IC) vascular bypass
     44.93, Insertion of gastric bubble (balloon)
     50.51, Auxiliary liver transplant
     52.83, Heterotransplant of pancreas
     57.96, Implantation of electronic bladder stimulator
     57.97, Replacement of electronic bladder stimulator
     63.70, Male sterilization procedure, not otherwise 
specified
     63.71, Ligation of vas deferens
     63.72, Ligation of spermatic cord
     63.73, Vasectomy
     64.5, Operations for sex transformation, not elsewhere 
classified
     66.21, Bilateral endoscopic ligation and crushing of 
fallopian tubes
     66.22, Bilateral endoscopic ligation and division of 
fallopian tubes
     66.29, Other bilateral endoscopic destruction or occlusion 
of fallopian tubes
     66.31, Other bilateral ligation and crushing of fallopian 
tubes
     66.32, Other bilateral ligation and division of fallopian 
tubes
     66.39, Other bilateral destruction or occlusion of 
fallopian tubes
     98.52, Extracorporeal shockwave lithotripsy [ESWL] of the 
gallbladder and/or bile duct
     98.59, Extracorporeal shockwave lithotripsy of other sites
    The following list contains ICD-9-CM procedure codes identified as 
``Noncovered Procedures'' only when any of the following diagnoses are 
present as either a principal or secondary diagnosis.
Procedure List
     41.01, Autologous bone marrow transplant without purging
     41.04, Autologous hematopoietic stem cell transplant 
without purging
     41.07, Autologous hematopoietic stem cell transplant with 
purging
     41.09, Autologous bone marrow transplant with purging
Principal or Secondary Diagnosis List
     204.00, Acute lymphoid leukemia, without mention of 
remission
     205.00, Acute myeloid leukemia, without mention of 
remission
     206.00, Acute monocytic leukemia, without mention of 
remission
     207.00, Acute erythremia and erythroleukemia, without 
mention of remission
     208.00, Acute leukemia of unspecified cell type, without 
mention of remission
     205.10, Acute myeloid leukemia, in remission
     205.11, Chronic myeloid leukemia, in remission
    The following list contains ICD-9-CM procedure codes identified as 
``Noncovered Procedures'' only when any of the following diagnoses are 
present as either a principal or secondary diagnosis.
Procedure List
     41.02, Allogeneic bone marrow transplant with purging
     41.03, Allogeneic bone marrow transplant without purging
     41.05, Allogeneic hematopoietic stem cell transplant 
without purging
     41.08, Allogeneic hematopoietic stem cell transplant with 
purging
Principal or Secondary Diagnosis List
     203.00, Multiple myeloma, without mention of remission
     203.01, Multiple myeloma, in remissionThe following list 
contains ICD-9-CM procedure codes identified as ``Non-Covered 
Procedures'' except when there is at least one principal or secondary 
diagnosis code present from both list 1 and list 2.
Procedure List
     52.80, Pancreatic transplant, not otherwise specified
     52.82, Homotransplant of pancreas
Diagnosis List 1:
     250.00, Diabetes mellitus without mention of complication, 
type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, not stated as uncontrolled
     250.01, Diabetes mellitus without mention of complication, 
type I [insulin dependent type] [IDDM] [juvenile type], not stated as 
uncontrolled

[[Page 48946]]

     250.02, Diabetes mellitus without mention of complication, 
type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, uncontrolled
     250.03, Diabetes mellitus without mention of complication, 
type I [insulin dependent type] [IDDM type] [juvenile type], 
uncontrolled
     250.10, Diabetes with ketoacidosis, type II [non-insulin 
dependent type] [NIDDM type] [adult-onset type] or unspecified type, 
not stated as uncontrolled
     250.11, Diabetes with ketoacidosis, type I [insulin 
dependent type] [IDDM] [juvenile type], not stated as uncontrolled
     250.12, Diabetes with ketoacidosis, type II [non-insulin 
dependent type] [NIDDM type] [adult-onset type] or unspecified type, 
uncontrolled
     250.13, Diabetes with ketoacidosis, type I [insulin 
dependent type] [IDDM type] [juvenile type], uncontrolled
     250.20, Diabetes with hyperosmolarity, type II [non-
insulin dependent type] [NIDDM type] [adult-onset type] or unspecified 
type, not stated as uncontrolled
     250.21, Diabetes with hyperosmolarity, type I [insulin 
dependent type] [IDDM] [juvenile type], not stated as uncontrolled
     250.22, Diabetes with hyperosmolarity, type II [non-
insulin dependent type] [NIDDM type] [adult-onset type] or unspecified 
type, uncontrolled
     250.23, Diabetes with hyperosmolarity, type I [insulin 
dependent type] [IDDM] [juvenile type], uncontrolled
     250.30, Diabetes with other coma, type II [non-insulin 
dependent type] [NIDDM type] [adult-onset type] or unspecified type, 
not stated as uncontrolled
     250.31, Diabetes with other coma, type I [insulin 
dependent type] [IDDM] [juvenile type], not stated as uncontrolled
     250.32, Diabetes with other coma, type II [non-insulin 
dependent type] [NIDDM type] [adult-onset type] or unspecified type, 
uncontrolled
     250.33, Diabetes with other coma, type I [insulin 
dependent type] [IDDM] [juvenile type], uncontrolled, type I [insulin 
dependent type] [IDDM type] [juvenile type], uncontrolled
     250.40, Diabetes with renal manifestation, type II [non-
insulin dependent type] [NIDDM type] [adult-onset type] or unspecified 
type, not stated as uncontrolled
     250.41, Diabetes with renal manifestation, type I [insulin 
dependent type] [IDDM] [juvenile type], not stated as uncontrolled
     250.42, Diabetes with renal manifestation, type II [non-
insulin dependent type] [NIDDM type] [adult-onset type] or unspecified 
type, uncontrolled
     250.43, Diabetes with renal manifestation, type I [insulin 
dependent type] [IDDM type] [juvenile type], uncontrolled
     250.50, Diabetes with ophthalmic manifestations, type II 
[non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, not stated as uncontrolled
     250.51, Diabetes with ophthalmic manifestations, type I 
[insulin dependent type] [IDDM] [juvenile type], not stated as 
uncontrolled
     250.52, Diabetes with ophthalmic manifestations, type II 
[non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, uncontrolled
     250.53, Diabetes with ophthalmic manifestations, type I 
[insulin dependent type] [IDDM type] [juvenile type], uncontrolled
     250.60, Diabetes with neurological manifestations, type II 
[non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, not stated as uncontrolled
     250.61, Diabetes with neurological manifestations, type I 
[insulin dependent type] [IDDM] [juvenile type], not stated as 
uncontrolled
     250.62, Diabetes with neurological manifestations, type II 
[non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, uncontrolled
     250.63, Diabetes with neurological manifestations, type I 
[insulin dependent type] [IDDM type] [juvenile type], uncontrolled
     250.70, Diabetes with peripheral circulatory disorders, 
type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, not stated as uncontrolled
     250.71, Diabetes with peripheral circulatory disorders 
type I [insulin dependent type] [IDDM] [juvenile type], not stated as 
uncontrolled
     250.72, Diabetes with peripheral circulatory disorders, 
type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, uncontrolled
     250.73, Diabetes with peripheral circulatory disorders, 
type I [insulin dependent type] [IDDM type] [juvenile type], 
uncontrolled
     250.80, Diabetes with other specified manifestations, type 
II [non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, not stated as uncontrolled
     250.81, Diabetes with other specified manifestations, type 
I [insulin dependent type] [IDDM] [juvenile type], not stated as 
uncontrolled
     250.82, Diabetes with other specified manifestations, type 
II [non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, uncontrolled
     250.83, Diabetes with other specified manifestations, type 
I [insulin dependent type] [IDDM] [juvenile type], uncontrolled
     250.90, Diabetes with unspecified complication, type II 
[non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, not stated as uncontrolled
     250.91, Diabetes with unspecified complication, type I 
[insulin dependent type] [IDDM] [juvenile type], not stated as 
uncontrolled
     250.92, Diabetes with unspecified complication, type II 
[non-insulin dependent type] [NIDDM type] [adult-onset type] or 
unspecified type, uncontrolled
     250.93, Diabetes with unspecified complication, type I 
[insulin dependent type] [IDDM] [juvenile type], uncontrolled

    Note: The proposed rule contained inadvertent typographical 
errors in the above list on four diabetes codes at 250.50 through 
250.53. These errors have been corrected in this list in the final 
rule.

Diagnosis List 2
     403.01, Malignant hypertensive renal disease, with renal 
failure
     403.11, Benign hypertensive renal disease, with renal 
failure
     403.91, Unspecified hypertensive renal disease, with renal 
failure
     404.02, Malignant hypertensive heart and renal disease, 
with renal failure
     404.03, Malignant hypertensive heart and renal disease, 
with heart failure and renal failure
     404.12, Benign hypertensive heart and renal disease, with 
renal failure
     404.13, Benign hypertensive heart and renal disease, with 
heart failure and renal failure
     404.92, Unspecified hypertensive heart and renal disease, 
with renal failure
     404.93, Unspecified hypertensive heart and renal disease, 
with heart failure and renal failure
     585, Chronic renal failure
     V42.0, Organ or tissue replaced by transplant, kidney
     V43.89, Organ or tissue replaced by other means, other

[[Page 48947]]

    We received one comment in support of our proposal to restructure 
Edit 11 in the MCE. Therefore, we are adopting the proposal as final.
    In addition, it has come to our attention that two of the new codes 
created for use for discharges effective October 1, 2004, should also 
be included on Edit 11 in order to conform to current coverage policy. 
These changes were not included in the proposed rule. However, the 
addition of these codes is not a change in CMS policy. Rather, it is 
simply a procedural change that is necessary to effectuate CMS' 
existing coverage policy and to facilitate the appropriate payment (or 
non-payment) of claims reporting these codes. Therefore, we are making 
the following additional changes to the MCE:
     In the ``Non-Covered Procedures'' section of Edit 11, we 
are adding code 00.62 (Percutaneous angioplasty or atherectomy of 
intracranial vessel(s)) to the list of procedure codes that are always 
considered noncovered procedures.
     ICD-9-CM O.R. procedure code 00.61 (Percutaneous 
angioplasty or atherectomy of precerebral (extracranial vessel(s)) is 
identified as a ``Non-Covered Procedure'' except when the following 
non-O.R. procedure and secondary diagnosis are also present:
    Non-O.R. Procedure: 00.63 (Percutaneous insertion of carotid artery 
stent(s); and
    Secondary Diagnosis: V70.7 (Examination of participant in clinical 
trial).
    We are making these changes in Version 22.0 of the MCE software 
program.
    b. Edit 6 (Manifestations Not Allowed As Principal Diagnosis) in 
the MCE contains codes that describe the manifestation of an underlying 
disease, not the disease itself, and therefore, should not be used as a 
principal diagnosis. The following codes describe manifestations of an 
underlying disease; they should not be used as a principal diagnosis 
according to ICD-9-CM coding convention. Therefore, in the May 18, 
2004, proposed rule, we proposed to add the following diagnosis codes 
to Edit 6:
     289.52, Splenic sequestration
     517.3, Acute chest syndrome (inadvertently erroneously 
cited as 571.3 in the May 18, 2004 proposed rule)
     785.52, Septic shock
    Coding conventions in the ICD-9-CM Diagnostic Tabular List specify 
that etiologic conditions be coded first.
    We received two comments in support of our proposal to add three 
diagnosis codes to Edit 6 of the MCE. However, both commenters pointed 
out a typographical error in one of the citations of the diagnosis 
codes. Code 571.3 should have read 517.3.
    We are adopting, as final, our proposed additions of the diagnosis 
codes to Edit 6, with the correction of the one code number cited.
    c. Edit 9 (Unacceptable Principal Diagnoses) contains codes ``that 
describe a circumstance which influences an individual's health status 
but is not a current illness of injury; therefore, these codes are 
considered unacceptable as a principal diagnosis.'' (This definition 
can be found on page 1094 of the DRG Definitions Manual, Version 21.0). 
Last year, we became aware that two codes should be removed from this 
list, as they can be legitimate causes for inpatient admission. 
However, we were made aware of this too late in the process to make a 
change to this edit prior to FY 2004. In the May 18, 2004, IPPS 
proposed rule (69 FR 28197), we indicated that we will now be able to 
make the necessary system changes before the start of FY 2005. 
Therefore, we proposed to remove the following codes from Edit 9:
     V53.01, Adjustment of cerebral ventricular (communicating) 
shunt
     V53.02, Adjustment of neuropacemaker (brain) (peripheral 
nerve) (spinal cord)
    We received one comment in support of our proposed removal of codes 
V53.01 and V53.02 from Edit 9 in the MCE. Therefore, we are adopting, 
as final, our proposed removal of the two codes from Edit 9.
11. Surgical Hierarchies
    Some inpatient stays entail multiple surgical procedures, each one 
of which, occurring by itself, could result in assignment of the case 
to a different DRG within the MDC to which the principal diagnosis is 
assigned. Therefore, it is necessary to have a decision rule within the 
GROUPER by which these cases are assigned to a single DRG. The surgical 
hierarchy, an ordering of surgical classes from most resource-intensive 
to least resource-intensive, performs that function. Application of 
this hierarchy ensures that cases involving multiple surgical 
procedures are assigned to the DRG associated with the most resource-
intensive surgical class.
    Because the relative resource intensity of surgical classes can 
shift as a function of DRG reclassification and recalibrations, we 
reviewed the surgical hierarchy of each MDC, as we have for previous 
reclassifications and recalibrations, to determine if the ordering of 
classes coincides with the intensity of resource utilization.
    A surgical class can be composed of one or more DRGs. For example, 
in MDC 11, the surgical class ``kidney transplant'' consists of a 
single DRG (DRG 302) and the class ``kidney, ureter and major bladder 
procedures'' consists of three DRGs (DRGs 303, 304, and 305). 
Consequently, in many cases, the surgical hierarchy has an impact on 
more than one DRG. The methodology for determining the most resource-
intensive surgical class involves weighting the average resources for 
each DRG by frequency to determine the weighted average resources for 
each surgical class. For example, assume surgical class A includes DRGs 
1 and 2 and surgical class B includes DRGs 3, 4, and 5. Assume also 
that the average charge of DRG 1 is higher than that of DRG 3, but the 
average charges of DRGs 4 and 5 are higher than the average charge of 
DRG 2. To determine whether surgical class A should be higher or lower 
than surgical class B in the surgical hierarchy, we would weight the 
average charge of each DRG in the class by frequency (that is, by the 
number of cases in the DRG) to determine average resource consumption 
for the surgical class. The surgical classes would then be ordered from 
the class with the highest average resource utilization to that with 
the lowest, with the exception of ``other O.R. procedures'' as 
discussed below.
    This methodology may occasionally result in assignment of a case 
involving multiple procedures to the lower-weighted DRG (in the 
highest, most resource-intensive surgical class) of the available 
alternatives. However, given that the logic underlying the surgical 
hierarchy provides that the GROUPER search for the procedure in the 
most resource-intensive surgical class, this result is unavoidable.
    We note that, notwithstanding the foregoing discussion, there are a 
few instances when a surgical class with a lower average charge is 
ordered above a surgical class with a higher average charge. For 
example, the ``other O.R. procedures'' surgical class is uniformly 
ordered last in the surgical hierarchy of each MDC in which it occurs, 
regardless of the fact that the average charge for the DRG or DRGs in 
that surgical class may be higher than that for other surgical classes 
in the MDC. The ``other O.R. procedures'' class is a group of 
procedures that are only infrequently related to the diagnoses in the 
MDC, but are still occasionally performed on patients in the MDC with 
these diagnoses. Therefore, assignment to

[[Page 48948]]

these surgical classes should only occur if no other surgical class 
more closely related to the diagnoses in the MDC is appropriate.
    A second example occurs when the difference between the average 
charges for two surgical classes is very small. We have found that 
small differences generally do not warrant reordering of the hierarchy 
because, as a result of reassigning cases on the basis of the hierarchy 
change, the average charges are likely to shift such that the higher-
ordered surgical class has a lower average charge than the class 
ordered below it.
    Based on the preliminary recalibration of the DRGs, in the May 18, 
2004 proposed rule, we proposed modifications of the surgical hierarchy 
as set forth below.
    We proposed to revise the surgical hierarchy for the pre-MDC DRGs 
and MDC 8 (Diseases and Disorders of the Musculoskeletal System and 
Connective Tissue).
    In the pre-MDC DRGs, we proposed to reorder DRG 541 (Tracheostomy 
With Mechanical Ventilation 96 + Hours or Principal Diagnosis Except 
Face, Mouth, and Neck Diagnoses With Major O.R. Procedure) and DRG 542 
(Tracheostomy With Mechanical Ventilation 96+ Hours or Principal 
Diagnosis Except Face, Mouth, and Neck Diagnoses Without Major O.R. 
Procedure) above DRG 480 (Liver Transplant).
    In MDC 8, we proposed to--
     Reorder DRG 496 (Combined Anterior/Posterior Spinal 
Fusion), DRG 497 (Spinal Fusion Except Cervical With CC), and DRG 498 
(Spinal Fusion Except Cervical Without CC) above DRG 471 (Bilateral or 
Multiple Major Joint Procedures of the Lower Extremity).
     Reorder DRG 519 (Cervical Spinal Fusion With CC) and DRG 
520 (Cervical Spinal Fusion Without CC) above DRG 216 (Biopsies of the 
Musculoskeletal System and Connective Tissue).
     Reorder DRG 213 (Amputation for the Musculoskeletal System 
and Connective Tissue Disorders) above DRG 210 (Hip and Femur 
Procedures Except Major Joint Age> 17 With CC), DRG 211 (Hip and Femur 
Procedures Except Major Joint Age> 17 Without CC), and DRG 212 (Hip and 
Femur Procedures Except Major Joint Age 0-17).
     Reorder DRG 499 (Back and Neck Procedures Except Spinal 
Fusion With CC) and DRG 500 (Back and Neck Procedures Except Spinal 
Fusion Without CC) above DRG 218 (Lower Extremity and Humerus 
Procedures Except Hip, Foot, and Femur Age> 17 With CC), DRG 219 (Lower 
Extremity and Humerus Procedures Except Hip, Foot, and Femor Age> 17 
Without CC), and DRG 220 (Lower Extremity and Humerus Procedures Except 
Hip, Foot, and Femur Age 0-17).
    In the proposed rule, we were unable to test the effects of the 
proposed revisions to the surgical hierarchy and to reflect these 
changes in the proposed relative weights because the revised GROUPER 
software was unavailable at the time the proposed rule was completed. 
Rather, we simulated most major classification changes to approximate 
the placement of cases under the proposed reclassification, and then 
determined the average charge for each DRG. These average charges 
served as our best estimate of relative resource used for each surgical 
class. We have now tested the proposed surgical hierarchy changes after 
the revised GROUPER was received and are reflecting the final changes 
in the DRG relative weights in this final rule. Further, as discussed 
in section II.C. of this preamble, the final recalibrated weights are 
somewhat different from the proposed weights because they are based on 
more complete data.
    We have tested the proposed revisions using the March 2004 update 
of the FY 2003 MedPAR file and the revised GROUPER software and have 
found that the revisions are supported by the data, and no additional 
changes are indicated except those discussed below pertaining to the 
implementation of new DRG 543 (Craniotomy with Implantation of 
Chemotherapeutic Agent or Acute Complex Central Nervous System 
Principal Diagnosis). (For a complete description of this change see 
the discussion under ``Other Issues'' in section II.B.16 of this 
preamble.) Due to the implementation of DRG 543, we also are reordering 
the following DRGs in MDC 1 (Disease and Disorders of the Nervous 
System): DRG 543 above DRGs 1 (Craniotomy Age > 17 With CC) and 2 
(Craniotomy Age> 17 Without CC). Therefore, we are adopting these 
changes as final.
    Comment: One commenter requested a change in the surgical hierarchy 
for a case where procedure code 37.99 (Other operations on heart and 
pericardium) and code 37.98 (Replacement of an automatic cardioverter/
defibrillator pulse generator only) is reported during the same 
admission. This case is assigned to either DRG 110 (Major 
Cardiovascular Procedures With CC) or DRG 111 (Major Cardiovascular 
Procedures Without CC). The commenter requested that this case be 
reassigned to DRG 115 (Permanent Cardiac Pacemaker Implant with AMI, 
Heart Failure, or Shock or AICD Lead or Generator Procedure) because it 
has a higher DRG weight than DRG 110 or DRG 111.
    Response: The surgical hierarchy places a patient with multiple 
procedures in the most resource intensive class of DRGs, but not 
necessarily in the most resource intensive DRG. In the scenario 
described by the commenter, there are two surgical classes, one 
including DRGs 110 and 111 and the other including DRG 115 and DRG 116 
(Other Permanent Cardiac Pacemaker Implant). The average charges for 
the class containing DRGs 110 and 111 are approximately $16,604 more 
than for the class containing DRGs 115 and 116. As a result, the class 
containing DRGs 110 and 111 is ordered higher in the surgical group 
than the class containing DRGs 115 and 116. As a result, the case is 
assigned to either DRG 110 or DRG 111.
12. Refinement of Complications and Comorbidities (CC) List
    In the September 1, 1987 final notice (52 FR 33143) concerning 
changes to the DRG classification system, we modified the GROUPER logic 
so that certain diagnoses included on the standard list of CCs would 
not be considered valid CCs in combination with a particular principal 
diagnosis. We created the CC Exclusions List for the following reasons: 
(1) To preclude coding of CCs for closely related conditions; (2) to 
preclude duplicative or inconsistent coding from being treated as CCs; 
and (3) to ensure that cases are appropriately classified between the 
complicated and uncomplicated DRGs in a pair. We developed this list of 
diagnoses, using physician panels, to include those diagnoses that, 
when present as a secondary condition, would be considered a 
substantial complication or comorbidity. In previous years, we have 
made changes to the list of CCs, either by adding new CCs or deleting 
CCs already on the list. In the May 18, 2004, proposed rule, we did not 
propose to delete any of the diagnosis codes on the CC list.
    Comment: One commenter requested that ICD-9-CM codes 996.64 
(Infection due to indwelling urinary catheter) and 599.0 (Urinary tract 
infection) be removed from the CC List so that hospitals are not 
rewarded with higher payment when they allow patients to develop 
urinary tract infections. The commenter pointed out that these 
conditions are often avoidable complications of hospitalization, and 
that hospitals allow these infections to occur in order to receive 
higher payments from Medicare.

[[Page 48949]]

    Response: We do not agree with the assertion that hospitals allow 
urinary tract infections to occur in Medicare patients in order to 
receive higher payment rates. While it is true that some urinary tract 
infections are preventable through the use of improved sterile 
technique, reduced indwelling catheter duration, more appropriate use 
of broad spectrum antibiotics and improved patient mobilization, among 
others, we do not believe there is a direct causal link between 
substandard hospital care and the presence of urinary tract infection 
in general.
    Particularly in the elderly Medicare population, urinary tract 
infections occur in diverse clinical scenarios that lead to 
colonization and ultimately overt clinical infection within the urinary 
tract. General debilitation, various acute illnesses, immobility, 
impaired host defense mechanisms, dehydration and the post-surgical 
state are but a few of the situations in which urinary tract infections 
may occur, and which do in fact require higher resource utilization 
when they occur. Therefore, we are not removing codes 996.64 and 599.0 
from the CC List.
    In this final rule, as we proposed, we are not deleting any of the 
diagnosis codes on the CC list for FY 2005.
    In the May 19, 1987, proposed notice (52 FR 18877) and the 
September 1, 1987, final notice (52 FR 33154), we explained that the 
excluded secondary diagnoses were established using the following five 
principles:
     Chronic and acute manifestations of the same condition 
should not be considered CCs for one another.
     Specific and nonspecific (that is, not otherwise specified 
(NOS)) diagnosis codes for the same condition should not be considered 
CCs for one another.
     Codes for the same condition that cannot coexist, such as 
partial/total, unilateral/bilateral, obstructed/unobstructed, and 
benign/malignant, should not be considered CCs for one another.
     Codes for the same condition in anatomically proximal 
sites should not be considered CCs for one another.
     Closely related conditions should not be considered CCs 
for one another.
    The creation of the CC Exclusions List was a major project 
involving hundreds of codes. We have continued to review the remaining 
CCs to identify additional exclusions and to remove diagnoses from the 
master list that have been shown not to meet the definition of a CC.\1\
---------------------------------------------------------------------------

    \1\ See the September 30, 1988 final rule (53 FR 38485) for the 
revision made for the discharges occurring in FY 1989; the September 
1, 1989 final rule (54 FR 36552) for the FY 1990 revision; the 
September 4, 1990 final rule (55 FR 36126) for the FY 1991 revision; 
the August 30, 1991 final rule (56 FR 43209) for the FY 1992 
revision; the September 1, 1992 final rule (57 FR 39753) for the FY 
1993 revision; the September 1, 1993 final rule (58 FR 46278) for 
the FY 1994 revisions; the September 1, 1994 final rule (59 FR 
45334) for the FY 1995 revisions; the September 1, 1995 final rule 
(60 FR 45782) for the FY 1996 revisions; the August 30, 1996 final 
rule (61 FR 46171) for the FY 1997 revisions; the August 29, 1997 
final rule (62 FR 45966) for the FY 1998 revisions; the July 31, 
1998 final rule (63 FR 40954) for the FY 1999 revisions, the August 
1, 2000 final rule (65 FR 47064) for the FY 2001 revisions; the 
August 1, 2001 final rule (66 FR 39851) for the FY 2002 revisions; 
the August 1, 2002 final rule (67 FR 49998) for the FY 2003 
revisions; and the August 1, 2003 final rule (68 FR 45364) for the 
FY 2004 revisions.) In the July 30, 1999 final rule (64 FR 41490), 
we did not modify the CC Exclusions List for FY 2000 because we did 
not make any changes to the ICD-9-CM codes for FY 2000.
---------------------------------------------------------------------------

    In the May 18, 2004, proposed rule, we proposed a limited revision 
of the CC Exclusions List to take into account the proposed changes 
that will be made in the ICD-9-CM diagnosis coding system effective 
October 1, 2004. (See section II.B.15. of this preamble for a 
discussion of ICD-9-CM changes.) We proposed these changes in 
accordance with the principles established when we created the CC 
Exclusions List in 1987.
    We received no comments on the proposed changes. Therefore, we will 
adopt the CC Exclusions List as proposed.
    Tables 6G and 6H in the Addendum to this final rule contain the 
revisions to the CC Exclusions List that will be effective for 
discharges occurring on or after October 1, 2004. Each table shows the 
principal diagnoses with changes to the excluded CCs. Each of these 
principal diagnoses is shown with an asterisk, and the additions or 
deletions to the CC Exclusions List are provided in an indented column 
immediately following the affected principal diagnosis.
    CCs that are added to the list are in Table 6G--Additions to the CC 
Exclusions List. Beginning with discharges on or after October 1, 2004, 
the indented diagnoses will not be recognized by the GROUPER as valid 
CCs for the asterisked principal diagnosis.
    CCs that are deleted from the list are in Table 6H--Deletions from 
the CC Exclusions List. Beginning with discharges on or after October 
1, 2004, the indented diagnoses will be recognized by the GROUPER as 
valid CCs for the asterisked principal diagnosis.
    Copies of the original CC Exclusions List applicable to FY 1988 can 
be obtained from the National Technical Information Service (NTIS) of 
the Department of Commerce. It is available in hard copy for $152.50 
plus shipping and handling. A request for the FY 1988 CC Exclusions 
List (which should include the identification accession number (PB) 88-
133970) should be made to the following address: National Technical 
Information Service, United States Department of Commerce, 5285 Port 
Royal Road, Springfield, VA 22161; or by calling (800) 553-6847.
    Users should be aware of the fact that all revisions to the CC 
Exclusions List (FYs 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 
1997, 1998, 1999, 2001, 2002, 2003, and 2004) and those in Tables 6G 
and 6H of this final rule for FY 2005 must be incorporated into the 
list purchased from NTIS in order to obtain the CC Exclusions List 
applicable for discharges occurring on or after October 1, 2004. (Note: 
There was no CC Exclusions List in FY 2000 because we did not make 
changes to the ICD-9-CM codes for FY 2000.)
    Alternatively, the complete documentation of the GROUPER logic, 
including the current CC Exclusions List, is available from 3M/Health 
Information Systems (HIS), which, under contract with CMS, is 
responsible for updating and maintaining the GROUPER program. The 
current DRG Definitions Manual, Version 21.0, is available for $225.00, 
which includes $15.00 for shipping and handling. Version 22.0 of this 
manual, which includes the final FY 2005 DRG changes, is available for 
$225.00. These manuals may be obtained by writing 3M/HIS at the 
following address: 100 Barnes Road, Wallingford, CT 06492; or by 
calling (203) 949-0303. Please specify the revision or revisions 
requested.
13. Review of Procedure Codes in DRGs 468, 476, and 477
    Each year, we review cases assigned to DRG 468 (Extensive O.R. 
Procedure Unrelated to Principal Diagnosis), DRG 476 (Prostatic O.R. 
Procedure Unrelated to Principal Diagnosis), and DRG 477 (Nonextensive 
O.R. Procedure Unrelated to Principal Diagnosis) to determine whether 
it would be appropriate to change the procedures assigned among these 
DRGs.
    DRGs 468, 476, and 477 are reserved for those cases in which none 
of the O.R. procedures performed are related to the principal 
diagnosis. These DRGs are intended to capture atypical cases, that is, 
those cases not occurring with sufficient frequency to represent a 
distinct, recognizable clinical group. DRG 476 is assigned to those 
discharges in which one or more of the following

[[Page 48950]]

prostatic procedures are performed and are unrelated to the principal 
diagnosis:
     60.0, Incision of prostate
     60.12, Open biopsy of prostate
     60.15, Biopsy of periprostatic tissue
     60.18, Other diagnostic procedures on prostate and 
periprostatic tissue
     60.21, Transurethral prostatectomy
     60.29, Other transurethral prostatectomy
     60.61, Local excision of lesion of prostate
     60.69, Prostatectomy, not elsewhere classified
     60.81, Incision of periprostatic tissue
     60.82, Excision of periprostatic tissue
     60.93, Repair of prostate
     60.94, Control of (postoperative) hemorrhage of prostate
     60.95, Transurethral balloon dilation of the prostatic 
urethra
     60.96, Transurethral destruction of prostate tissue by 
microwave thermotherapy
     60.97, Other transurethral destruction of prostate tissue 
by other thermotherapy
     60.99, Other operations on prostate

    All remaining O.R. procedures are assigned to DRGs 468 and 477, 
with DRG 477 assigned to those discharges in which the only procedures 
performed are nonextensive procedures that are unrelated to the 
principal diagnosis.\2\
---------------------------------------------------------------------------

    \2\ In the August 1, 2003 final rule (68 FR 45365) we moved 
several procedures from DRG 468 to DRGs 476 and 477 because the 
procedures are nonextensive. The original list of the ICD-9-CM 
procedure codes for the procedures we consider nonextensive 
procedures, if performed with an unrelated principal diagnosis, was 
published in Table 6C in section IV. of the Addendum to the 
September 30, 1988 final rule (53 FR 38591). As part of the final 
rules published on September 4, 1990 (55 FR 36135), August 30, 1991 
(56 FR 43212), September 1, 1992 (57 FR 23625), September 1, 1993 
(58 FR 46279), September 1, 1994 (59 FR 45336), September 1, 1995 
(60 FR 45783), August 30, 1996 (61 FR 46173), and August 29, 1997 
(62 FR 45981), we moved several other procedures from DRG 468 to DRG 
477, and some procedures from DRG 477 to DRG 468. No procedures were 
moved in FY 1999, as noted in the July 31, 1998 final rule (63 FR 
40962); in FY 2000, as noted in the July 30, 1999 final rule (64 FR 
41496); in FY 2001, as noted in the August 1, 2000 final rule (65 FR 
47064); or in FY 2002, as noted in the August 1, 2001 final rule (66 
FR 39852). In the August 1, 2002 final rule (67 FR 49999), we did 
not move any procedures from DRG 477. However, we did move 
procedures codes from DRG 468 and placed them in more clinically 
coherent DRGs.
---------------------------------------------------------------------------

a. Moving Procedure Codes from DRG 468 or DRG 477 to MDCs
    We annually conduct a review of procedures producing assignment to 
DRG 468 or DRG 477 on the basis of volume, by procedure, to see if it 
would be appropriate to move procedure codes out of these DRGs into one 
of the surgical DRGs for the MDC into which the principal diagnosis 
falls. The data are arrayed two ways for comparison purposes. We look 
at a frequency count of each major operative procedure code. We also 
compare procedures across MDCs by volume of procedure codes within each 
MDC.
    We identify those procedures occurring in conjunction with certain 
principal diagnoses with sufficient frequency to justify adding them to 
one of the surgical DRGs for the MDC in which the diagnosis falls. 
Based on this year's review, we did not identify any procedures in DRG 
477 that should be removed. Therefore, in the May 18, 2004 proposed 
rule, we did not propose to move any procedures from DRG 477 to one of 
the surgical DRGs in this final rule.
    We did not receive any comments on our proposal not to move any 
procedures from DRG 477 to one of the surgical DRGs and, therefore, are 
adopting our proposal as final.
b. Reassignment of Procedures among DRGs 468, 476, and 477
    We also annually review the list of ICD-9-CM procedures that, when 
in combination with their principal diagnosis code, result in 
assignment to DRGs 468, 476, and 477, to ascertain if any of those 
procedures should be reassigned from one of these three DRGs to another 
of the three DRGs based on average charges and the length of stay. We 
look at the data for trends such as shifts in treatment practice or 
reporting practice that would make the resulting DRG assignment 
illogical. If we find these shifts, we would propose to move cases to 
keep the DRGs clinically similar or to provide payment for the cases in 
a similar manner. Generally, we move only those procedures for which we 
have an adequate number of discharges to analyze the data. Based on a 
comment we received in response to last year's proposed rule (68 FR 
45366), in the May 18, 2004 proposed rule, we proposed to move 
procedure code 51.23 (Laparoscopic cholecystectomy) from DRG 468 
(Extensive O.R. Procedure Unrelated to Principal Diagnosis) into DRG 
477 (Nonextensive O.R. Procedure Unrelated to Principal Diagnosis).
    The commenter suggested that a laparoscopic procedure was probably 
not an extensive O.R. procedure; it was more likely a nonextensive O.R. 
procedure. We indicated that we agreed and, therefore, proposed this 
change. In addition, we proposed to add several new procedure codes to 
DRGs 476 and 477. These procedures are also listed on Table 6B--New 
Procedure Codes in the Addendum to this final rule. However, DRGs 476 
and 477 are not limited to one MDC, so the new codes are also included 
here for nonextensive cases in which the procedures are unrelated to 
the principal diagnosis:
     44.67, Laparoscopic procedures for creation of 
esophagogastric sphincteric competence
     44.68, Laparoscopic gastroplasty
     44.95, Laparoscopic gastric restrictive procedure
     44.96, Laparoscopic revision of gastric restrictive 
procedure
     44.97, Laparoscopic removal of gastric restrictive 
device(s)
     44.98, Laparoscopic adjustment of size of adjustable 
gastric restrictive device
    In DRG 476, the above codes are to be added to the section ``With 
or Without Operating Room Procedures'' in the GROUPER logic.
    We did not propose to move any procedure codes from DRG 476 to DRGs 
468 or 477, or from DRG 477 to DRGs 468 or 476.
    We did not receive any comments on this proposal and, therefore, 
are adopting it as final.
c. Adding Diagnosis or Procedure Codes to MDCs
    Based on our review this year, we did not propose to add any 
diagnosis codes to MDCs. We did not receive any comments on this 
proposal. Therefore, we are adopting our proposal as final and are 
making no changes to MDCs other than those specified in other portions 
of this section II. of the preamble of this final rule.
14. Pancreatic Islet Cell Transplantation in Clinical Trials
    Section 733(a) of Public Law 108-173 directs the Secretary, acting 
through the National Institute of Diabetes and Digestive and Kidney 
Disorders (NIDDKD) to conduct a clinical investigation of pancreatic 
islet cell transplantation that includes Medicare beneficiaries. 
Section 733(b) of Public Law 108-173 provides for Medicare payments, 
beginning no earlier than October 1, 2004, for the routine costs as 
well as the costs of the transplantation and appropriate related items 
and services for Medicare beneficiaries who are participating in a 
clinical trial as if such transplantation were covered under Medicare 
Part A or Part B. Routine costs are defined as reasonable and necessary 
routine patient care costs (as defined in the CMS Coverage Issues 
Manual, Section 30-1) including immunosuppressive drugs and other 
followup care. Section 733(c)(2) of Public Law 108-173 defines 
transplantation and appropriate related

[[Page 48951]]

items and services as items and services related to the acquisition and 
delivery of the pancreatic islet cell transplantation, notwithstanding 
any national noncoverage determination contained in the CMS Coverage 
Issues Manual.
    As we indicated in the May 18, 2004, proposed rule, while the DRG 
payment will cover the transplant injection and the subsequent hospital 
stay, we considered establishing an add-on payment to the DRG payment 
amount to reimburse the acquisition costs associated with islet cell 
procurement (69 FR 28218). Historically, organ acquisition costs have 
been reimbursed as a cost pass-through. However, islet cell transplants 
are not exactly the same as solid organ transplants. While solid 
pancreata are procured, islet cells are not transplanted in the solid 
organ state as are other types of organs. Rather, the pancreata are 
procured by an organ procurement organization (OPO) and are then sent 
to an islet cell resource center that extracts the islet cells from the 
pancreata and sends the cells on to the transplant center. Because the 
procurement and processing system for islet cell transplants is not the 
same as for solid organ transplants, we proposed not paying for these 
costs as a pass-through. With the anticipated small number of 
beneficiaries in the clinical trial and the Medicare program's 
unfamiliarity with the isolation process, we believed it would be most 
appropriate at this time to have a set payment rate for acquisition 
costs, rather than attempting a case-by-case determination of the 
reasonableness of these costs in each institution. We note there is 
precedent to exclude acquisition costs from the pass-through payment 
process. For example, stem cell transplants and corneal transplants do 
not have acquisition costs reimbursed as a cost pass-through payment.
    We proposed that the add-on payment would be a single amount that 
includes pre-transplant tests and services, pancreas procurement, and 
islet isolation services. In addition, we proposed to use an add-on as 
opposed to increasing the DRG amount because the DRGs at issue are also 
applied in cases involving a variety of other procedures that do not 
include the costly islet cell acquisition required for this procedure. 
Thus, including these costs in the DRGs would have the potential of 
skewing the weights for all other DRGs. We solicited comments on 
whether an add-on payment amount is the appropriate way to reimburse 
islet cell acquisition costs, or whether another methodology may be 
more appropriate.
    In addition, while we had some data available regarding the cost of 
pancreas procurement, in the proposed rule we specifically asked for 
any other data that supported the costs of acquisition and the costs of 
isolation cell resource centers. We stated that, because of 
insufficient data, we were unable to publish a proposed acquisition 
amount in the FY 2005 proposed rule. However, we indicated that, after 
analyzing data submitted during the comment period, other data acquired 
by CMS, and any suggested changes from the methodology proposed, the 
final organ acquisition payment amount would be announced in the FY 
2005 IPPS final rule.
    Pancreatic islet cell transplantation during the clinical trial 
will be performed to decrease or eliminate the need for insulin in 
patients with Type I diabetes. Patients with Type II islet diabetes are 
not included in this trial. Islet cells are acquired from a cadaveric 
pancreas donor (islet allotransplantation).
    As described in II.B.1. of this preamble, ICD-9-CM diagnosis and 
procedure codes are used to determine DRG assignments. In 1996, CMS 
(then HCFA) created codes for islet cell transplantation:
     52.84, Autotransplantation of cells of islets of 
Langerhans.
     52.85, Allotransplantation of cells of islets of 
Langerhans.
    The Medicare GROUPER does not consider codes 52.84 and 52.85 as 
O.R. procedures and, therefore, these codes do not move the case from a 
medical DRG into a surgical DRG unless another procedure is performed. 
Based on the circumstances noted above under which pancreatic islet 
cell transplantation would be performed, we identified the three most 
logical DRGs to which we believe cases should be assigned. If a patient 
has Type I diabetes mellitus with ESRD and a pancreatectomy is 
performed, the case would group to DRG 468 (Extensive O.R. Procedure 
Unrelated to Principal Diagnosis). If a patient has Type I diabetes 
mellitus with ESRD and is also receiving a kidney transplant 
(simultaneous kidney and islet transplantation), the case would group 
to DRG 302 (Kidney Transplant). If a patient has Type I diabetes 
mellitus with ESRD and a history of a kidney transplant and then has 
the islet cells inserted via an open approach, the case would group to 
DRG 315 (Other Kidney and Urinary Tract O.R. Procedures). We note that 
this third scenario reflects incorrect coding practice. However, in 
this final rule we are modifying the structure of DRG 315 so that 
patients receiving infusions of islet cells without any other surgical 
intervention will be appropriately assigned to this DRG.
    As each case is assigned to a DRG based on all of the ICD-9-CM 
codes reported, cases could also be assigned to DRGs other than those 
mentioned above. In fact, as indicated in the proposed rule, our review 
of FY 2003 MedPAR data revealed that codes 52.84 and 52.85 were present 
in only four cases, and that each case was assigned to a different DRG. 
We found one case each in DRG 18 (Cranial and Peripheral Nerve 
Disorders With CC), DRG 192 (Pancreas, Liver, and Shunt Procedures 
Without CC), DRG 207 (Disorders of the Biliary Tract With CC), and DRG 
302 (Kidney Transplant). As the GROUPER software program does not 
recognize codes for islet cell transplantation as O.R. procedure codes, 
the presence of these codes did not modify the DRG assignment in these 
four cases.
    We were reluctant to propose assigning the islet cell codes to one 
specific DRG, as the islet cell infusion will have different 
indications depending on the merits of each case, as is shown from the 
MedPAR data mentioned above. In addition, we do not currently have 
accurate cost data or charges for patients in this type of clinical 
trial, which makes it difficult to determine an appropriate DRG weight. 
As a result, assignment of cases to a specific DRG might have the 
consequence of either overpaying or underpaying the cases. We believe 
that both of these consequences are unacceptable. Therefore, we did not 
propose that cases involved in the clinical trial be assigned to one 
specific DRG for payment purposes. As we believe that these cases will 
have been assigned to DRGs 302, 315, and 468, we proposed to establish 
an add-on payment for cases in these three DRGs containing procedure 
codes 52.84 or 52.85. As stated earlier, we were not able to establish 
the amount of this add-on until we had determined procurement costs for 
the islet cells. We solicited information from transplant centers and 
organ procurement organizations on costs for these types of 
transplantations.
    Comment: Several commenters noted that the assignment of DRG 315, 
as currently constructed, to patients participating in the clinical 
trial does not reflect appropriate coding practice, as a laparotomy 
code for hepatic vessel catheterization should not be recorded.
    Response: The commenters are correct in their assessment. 
Therefore, we are modifying the structure of DRG 315 so that patients 
receiving infusions of islet cells without any other surgical

[[Page 48952]]

intervention will appropriately be assigned to DRG 315. We are aware 
that patients will often require more than one admission for islet cell 
transplantation. We are making this modification in order to recognize 
the surgical aspects of islet cell transplantation in the absence of 
any other surgical procedure.
    The logic for DRG 315 is modified as follows:
O.R. Procedures
    This list remains the same as V21.0 of the GROUPER.
    or
Non-O.R. Procedures
    52.84, Autotransplantation of cells of islets of Langerhans
    52.85, Allotransplantation of cells of islets of Langerhans
    or
Principal Diagnosis
    This list remains the same as V21.0 of GROUPER.
    and
Non-O.R. Procedure
    This list remains the same as V21.0 of GROUPER.
    Comment: One commenter stated that it was not clinically 
appropriate to categorize islet cell transplants into DRG 315, as these 
transplants do not involve either the kidney or the urinary tract 
directly. Rather, the islet cells are transplanted into the patient's 
liver. The commenter indicated that islet transplants have no relevance 
to the genito-urinary system, but rather to the 
hepatopancreaticobiliary system. Therefore, the commenter believed that 
the proposed classification to DRG 315 is clinically inappropriate.
    Response: DRGs are diagnosis related groups. Each surgical DRG is 
comprised of procedure codes in combination with a principal diagnosis 
that causes the case to be assigned to a particular major diagnostic 
category (MDC). Because there are so many procedures in most DRGs, it 
is impossible to capture the purpose of all procedures in the title.
    Comment: Some commenters suggested that the most appropriate 
resolution is to create a new DRG for islet transplants performed 
alone. The commenters mentioned that solid organ transplants are 
classified into their own DRGs, and that this precedent should be 
continued.
    Response: DRGs are created based on the need of the program to 
identify clinical coherence and resource consumption. Ideally, both 
components will be part of the decision making process in DRG creation. 
In this case, we have no substantial data upon which to determine an 
appropriate relative weight for the resources that will be utilized in 
all islet cell transplant cases. In addition, there may be different 
scenarios in which patients are transfused with islet cells. These 
cases could include patients receiving a kidney transplant during the 
same admission, or cases in which the islet cells comprise the only 
procedure during the admission. As cases will be varied in this 
clinical trial, we prefer to have MedPAR data and case histories prior 
to creating specific new DRGs for these cases.
    Comment: Some commenters believed that the most closely related DRG 
from a clinical as well as resource perspective is DRG 513 (Pancreas 
Transplant). The commenters noted that the diagnoses are the same for 
islet and pancreas transplants, and that the patient populations 
involved in these two procedures are virtually identical in terms of 
comorbidities and the nature of their primary disease. In addition, the 
technical aspects of islet transplants are of a surgical nature, 
whether performed in an operating room or in the interventional 
radiology suite. One commenter noted that pancreas transplants are in 
reality just another method of transplanting the insulin producing 
islet cells since the other functions of the pancreas are superfluous.
    Response: While the patient populations requiring intervention are 
similar, we do not believe that one can equate an operation of the 
magnitude of a pancreas transplant with a less intensive islet cell 
transplantation in which the portal vein is accessed and islet cells 
infused through a catheter. It is only because the technical aspects of 
islet transplants are of a surgical nature that we have modified 
surgical DRG 315 to reflect the transfusion of islet cells.
    Comment: One commenter suggested that the most appropriate DRG for 
simultaneous kidney and islet cell transplantation would be DRG 512 
(Simultaneous Pancreas/Kidney Transplant), as the resource allocation 
and patient population involved in both types of admissions are 
comparable. The commenter noted that so few of these combination 
procedures have been performed that no assumption can be projected 
based on the experience to date.
    Response: We do not agree that an islet cell transplantation is the 
equivalent of a pancreas transplantation. Cases involving simultaneous 
kidney and islet cell transplantation will group to DRG 302, and will 
receive an add-on payment for the infusion of the islet cells.
    Comment: Some commenters believed CMS should pay for islet 
acquisition services as a cost pass-through. Several of these 
commenters stated that they found insufficient justification to pay for 
islet cell transplants through an add-on when pancreata used for solid 
organ transplantation are paid as a cost pass-through. These commenters 
stated that the costs of procuring a pancreas used for solid organ 
transplantation are the same as procuring a pancreas for islet cell 
transplantation. One commenter agreed that payment through an add-on is 
the best approach.
    Response: We continue to believe that reimbursing acquisition costs 
as an add-on to the DRG is an appropriate reimbursement mechanism. 
However, we have decided that reimbursing pancreata procured for islet 
cells as an add-on while the acquisition of all other organs are 
reimbursed as a cost pass-through may be premature at this time. 
Accordingly, we will pay for organ acquisition costs as a cost pass-
through. Costs associated with the procurement of the pancreata will be 
included in the islet acquisition costs center of the transplant center 
cost report. We will continue to study the appropriateness of paying 
for pancreata used for islets as an add-on in the future. Islet 
isolation will be paid as an add-on as proposed. We discuss this add-on 
below.
    Comment: Some commenters were concerned that pre-transplant costs 
would not be appropriately reflected in the proposed add-on 
methodology. These commenters recommended that the pre-transplant costs 
be paid as a cost-pass through.
    Response: After additional analysis, we agree that it may be 
difficult to ensure an appropriate payment amount for pre-transplant 
costs in an add-on methodology. Therefore, pre-transplant costs will be 
handled in the same manner as they are for all other solid organ 
transplantation and will be included in the islet acquisition cost 
center of the cost report. Pre-transplant costs will not be included as 
an add-on to the DRG payment.
    Comment: Some commenters believed that islet isolation services 
should be paid on a cost pass-through rather than as an add-on. One 
commenter mentioned that islet centers have differing arrangements with 
transplant centers on how the isolation is performed. The commenters 
added that these same centers have differing processes in isolating the 
islet cells. Some commenters also indicated that there are 
inconsistencies in the isolation center data provided to CMS for use in

[[Page 48953]]

developing the add-on payment and expressed concerns about the validity 
of these data.
    Response: We continue to believe that paying for islet isolation 
services as an add-on amount to the DRG is appropriate in the context 
of this clinical trial. We derived the isolation add-on amount through 
analysis of direct costs data submitted by 10 of the prominent 
isolation centers in the country. These centers may well have differing 
arrangements and differing processes, but despite these differences, 
the costs and components of costs showed reasonable similarities. The 
differences were also notable, but we were able to adjust for these 
differences. In addition to including direct costs, we added 
actuarially-derived overhead amounts that are used in the hospital 
payment methodology and provided a 20-percent capital adjustment for 
building and equipment and a market basket adjustment to take the 
payment amount to a FY 2005 funding level. Historically, capital costs 
are approximately 10 percent of the total hospital costs. However, we 
recognize that the isolation centers are equipment intensive, and to 
account for that equipment, we are doubling that rate so that capital 
costs are 20 percent of the total isolation payment. We believe that 20 
percent is sufficient to account for capital at the isolation centers. 
In future years, we would like to obtain capital costs amortized on a 
per isolation basis. The varying processes and arrangements are all 
included in our computation, and $18,848 will be paid as the islet 
isolation add-on to the DRG payment.
    Comment: One commenter wanted to be sure that costs of transporting 
islet cells to and from the islet isolation center are included in the 
add-on payment.
    Response: Shipping costs from the OPO to the islet isolation center 
are included in procurement costs. The islet isolation centers did not 
provide data on shipping to the transplant centers; however, we have 
included an actuarially based overhead amount that we believe is 
sufficient to cover these costs.
    Comment: Some commenters noted that more than one infusion of islet 
cells is typically required to establish insulin independence and 
believed that this argued in favor of payment on a cost pass-through 
basis rather than as an add-on amount.
    Response: We recognize that normally two or more infusions are 
required for islet transplants. We also understand that it is extremely 
rare for two infusions to be performed at the same time. Accordingly, 
we have constructed our payment mechanism to pay one DRG for the 
infusion and one islet isolation add-on amount per discharge under most 
circumstances for allograft islet cell transplants. However, in those 
rare instances in which two infusions occur during the same hospital 
stay, two add-on payments for isolation of the islet cells can be made 
along with the single DRG payment. The cost associated with the 
procurement of two pancreata will be paid as an acquisition cost on a 
reasonable cost basis. We will issue billing instructions on this issue
    Comment: Some commenters asked for guidance on the appropriate 
methodology for OPOs to use in identifying costs incurred in procuring 
pancreata for islet cell transplantation. Some OPOs have indicated that 
they currently are providing pancreata for islet cell transplantation 
but do not receive their full standard acquisition charge (SAC) for the 
organ.
    Response: In some cases, OPOs have been billing pancreata for islet 
cell transplant at a lower tissue rate. This is an improper billing 
method. The quality and resources required to procure the organ are 
identical, and a full charge should be made. Organs that are determined 
to be nonviable can be billed at a lesser research rate .
    Comment: One commenter indicated that the costs included in 
pancreas acquisition at OPOs vary, making an add-on payment 
impractical.
    Response: As mentioned above, we will continue paying acquisition 
costs as a cost pass-through. However, all OPOs should have included in 
their costs direct donor hospital charges, surgeon retrieval fee, 
registry fees, donor testing, and transportation. These costs should 
not be shifted to another organization.
    Comment: One commenter noted that it was unclear how physicians' 
services involved in the oversight of the isolation process would to be 
paid since it does not appear that there is an existing CPT code for 
these services.
    Response: The commenter is correct that there is no CPT code for 
the physician's oversight services at the isolation center. CPT codes 
are for direct patient care services; the services at the isolation 
center do not meet that level of patient participation. In a similar 
vein, the medical directors at OPOs do not bill for their services 
using a CPT code. Rather, they are paid by the OPO both for organ 
retrieval and medical director services. We have included physician 
costs in the salary portion of the isolation portion of the add-on 
amount.
    Comment: One commenter believed that the costs associated with the 
isolation portion of the add-on amount should be between $30,000 and 
$40,000. This commenter further explained that isolation centers incur 
cost and time to develop improvements to the islet isolation technology 
and pointed out the startup costs associated with an FDA approved 
isolation center.
    Response: As noted earlier, we have calculated the islet isolation 
portion of the add-on amount as $18,848. We suspect that the $30,000 to 
$40,000 estimate referenced by the commenter included costs 
attributable to research and other services, which are not considered 
to be routine and reasonably necessary for patient care.
    Comment: One commenter suggested two levels of add-on payments to 
account for the difference in expenses for autograft versus allograft 
islet cells transplants. While the proposed add-on methodology included 
the cost of pre-transplant tests and services, organ procurement and 
islet isolation services, autograft transplants have no associated 
organ procurement costs, as the islet cells are taken from the 
patient's own pancreas. Autograft transplants still require pre-
transplant services and the actual islet isolation procedure itself.
    Response: Our original understanding was that autograft transplants 
would not be included in the NIH study. After review of the legislation 
and accompanying Conference Report and consultation with NIH, we 
believe that an autograft should not occur in this trial. However, in 
the unlikely event that an autograft islet cell transplant is performed 
as part of the study on a Medicare beneficiary, we will provide an 
autograft add-on amount that includes payment for isolation but not for 
organ procurement. No acquisition cost of the pancreas will be provided 
because the cost of removal of the organ is included in the DRG payment 
for the native pancreatectomy procedure itself. The isolation add-on 
amount will be $18,848 for an autograft islet cell transplant.
    In this rule we are finalizing our proposed payment methodology for 
acquisition costs associated with procuring pancreata for islet cells 
with modification. We will pay for the organ acquisition costs as a 
cost pass-through rather than as an add-on payment to the DRG as 
proposed. In addition, we are finalizing our proposal to pay for islet 
isolation services as an add-on.
15. Changes to the ICD-9-CM Coding System
    As described in section II.B.1. of this preamble, the ICD-9-CM is a 
coding system used for the reporting of diagnoses and procedures 
performed on

[[Page 48954]]

a patient. In September 1985, the ICD-9-CM Coordination and Maintenance 
Committee was formed. This is a Federal interdepartmental committee, 
co-chaired by the National Center for Health Statistics (NCHS) and CMS, 
charged with maintaining and updating the ICD-9-CM system. The 
Committee is jointly responsible for approving coding changes, and 
developing errata, addenda, and other modifications to the ICD-9-CM to 
reflect newly developed procedures and technologies and newly 
identified diseases. The Committee is also responsible for promoting 
the use of Federal and non-Federal educational programs and other 
communication techniques with a view toward standardizing coding 
applications and upgrading the quality of the classification system.
    The Official Version of the ICD-9-CM contains the list of valid 
diagnosis and procedure codes. (The Official Version of the ICD-9-CM is 
available from the Government Printing Office on CD-ROM for $25.00 by 
calling (202) 512-1800.) The Official Version of the ICD-9-CM is no 
longer available in printed manual form from the Federal Government; it 
is only available on CD-ROM. Users who need a paper version are 
referred to one of the many products available from publishing houses.
    The NCHS has lead responsibility for the ICD-9-CM diagnosis codes 
included in the Tabular List and Alphabetic Index for Diseases, while 
CMS has lead responsibility for the ICD-9-CM procedure codes included 
in the Tabular List and Alphabetic Index for Procedures.
    The Committee encourages participation in the above process by 
health-related organizations. In this regard, the Committee holds 
public meetings for discussion of educational issues and proposed 
coding changes. These meetings provide an opportunity for 
representatives of recognized organizations in the coding field, such 
as the American Health Information Management Association (AHIMA), the 
American Hospital Association (AHA), and various physician specialty 
groups, as well as individual physicians, medical record 
administrators, health information management professionals, and other 
members of the public, to contribute ideas on coding matters. After 
considering the opinions expressed at the public meetings and in 
writing, the Committee formulates recommendations, which then must be 
approved by the agencies.
    The Committee presented proposals for coding changes for 
implementation in FY 2005 at public meetings held on April 3, 2003, 
December 4-5, 2003, and April 1-2, 2004, and finalized the coding 
changes after consideration of comments received at the meetings and in 
writing by January 12, 2004. Those coding changes are announced in 
Tables 6A through 6F of the Addendum to this rule. Copies of the 
minutes of the procedure codes discussions at the Committee's 2003 
meetings can be obtained from the CMS Web site: http://www.cms.gov/paymentsystems/icd9/.
 The minutes of the diagnoses codes discussions at 

the 2003 meetings are found at: http://www.cdc.gov/nchs/icd9.htm. Paper 

copies of these minutes are no longer available and the mailing list 
has been discontinued.
    For a report of procedure topics discussed at the April 1-2, 2004, 
meeting, see the Summary Report at: http://www.cms.hhs.gov/paymentsystems/icd9/.
 For a report of the diagnosis topics discussed at 

the April 1-2, 2004 meeting, see the Summary Report at: http://www.cdc.gov/nchs/icd9.htm
.

    We encourage commenters to address suggestions on coding issues 
involving diagnosis codes to: Donna Pickett, Co-Chairperson, ICD-9-CM 
Coordination and Maintenance Committee, NCHS, Room 2404, 3311 Toledo 
Road, Hyattsville, MD 20782. Comments may be sent by e-mail to: 
dfp4@cdc.gov.
    Questions and comments concerning the procedure codes should be 
addressed to: Patricia E. Brooks, Co-Chairperson, ICD-9-CM Coordination 
and Maintenance Committee, CMS, Center for Medicare Management, 
Hospital and Ambulatory Policy Group, Division of Acute Care, C4-08-06, 
7500 Security Boulevard, Baltimore, MD 21244-1850. Comments may be sent 
by e-mail to: Patricia.Brooks1@cms.hhs.gov.
    The ICD-9-CM code changes that have been approved will become 
effective October 1, 2004. The new ICD-9-CM codes are listed, along 
with their DRG classifications, in Tables 6A and 6B (New Diagnosis 
Codes and New Procedure Codes, respectively) in the Addendum to this 
final rule. As we stated above, the code numbers and their titles were 
presented for public comment at the ICD-9-CM Coordination and 
Maintenance Committee meetings. Both oral and written comments were 
considered before the codes were approved. In the May 18, 2004, 
proposed rule, we only solicited comments on the proposed 
classification of these new codes.
    For codes that have been replaced by new or expanded codes, the 
corresponding new or expanded diagnosis codes are included in Table 6A. 
New procedure codes are shown in Table 6B. Diagnosis codes that have 
been replaced by expanded codes or other codes or have been deleted are 
in Table 6C (Invalid Diagnosis Codes). These invalid diagnosis codes 
will not be recognized by the GROUPER beginning with discharges 
occurring on or after October 1, 2004. Table 6D usually contains 
invalid procedure codes, however, for FY 2005, there are no invalid 
procedure codes. Revisions to diagnosis code titles are in Table 6E 
(Revised Diagnosis Code Titles), which also includes the DRG 
assignments for these revised codes. Table 6F includes revised 
procedure code titles for FY 2005.
    The first of the 2004 public meetings was held on April 1-2, 2004. 
In the September 7, 2001, final rule implementing the IPPS new 
technology add-on payments (66 FR 46906), we indicated we would attempt 
to include proposals for procedure codes that would describe new 
technology discussed and approved at the April meeting as part of the 
code revisions effective the following October.
    Section 503(a) of Public Law 108-173 includes a requirement for 
updating ICD-9-CM codes twice a year instead of the current process of 
annual updates on October 1 of each year. This requirement is included 
as part of the amendments to the Act relating to recognition of new 
technology under the IPPS. Section 503(a) amended section 1886(d)(5)(K) 
of the Act by adding a new clause (vii) which states that the 
``Secretary shall provide for the addition of new diagnosis and 
procedure codes in April 1 of each year, but the addition of such codes 
shall not require the Secretary to adjust the payment (or diagnosis-
related group classification) * * * until the fiscal year that begins 
after such date.'' Because this new statutory requirement will have a 
significant impact on health care providers, coding staff, publishers, 
system maintainers, software systems, among others, in the May 18, 
2004, proposed rule, we solicited comments on our proposals described 
below to implement this requirement. This new requirement will improve 
the recognition of new technologies under the IPPS system by providing 
information on these new technologies at an earlier date. Under the 
proposal, data would be available 6 months earlier than would be 
possible with updates occurring only once a year on October 1. Many 
coding changes apply to longstanding medical issues.
    While the new requirement states that the Secretary shall not 
adjust the payment of the DRG classification for the April 1 new codes, 
the Department

[[Page 48955]]

will have to update its DRG software and other systems in order to 
recognize and accept the new codes. We will also have to publicize the 
code changes and the need for a mid-year systems update by providers to 
capture the new codes. Hospitals will have to obtain the new code books 
and encoder updates, and make other system changes in order to capture 
and report the new codes. We indicated that we are aware of the 
additional burden this will have on health care providers.
    The ICD-9-CM Coordination and Maintenance Committee has held its 
meetings in April and December of each year in order to update the 
codes and the applicable payment and reporting systems by October 1 of 
each year. Items are placed on the agenda for the ICD-9-CM Coordination 
and Maintenance Committee meeting if the request is received at least 2 
months prior to the meeting. This requirement allows time for staff to 
review and research the coding issues and prepare material for 
discussion at the meeting. It also allows time for the topic to be 
publicized in meeting announcements in the Federal Register as well as 
on the CMS website. The public decides whether or not to attend the 
meeting based on the topics listed on the agenda. In order to provide 
an update on April 1, it became clear that a December Committee meeting 
would not provide time to finalize and publicize these code revisions. 
Final decisions on code title revisions are currently made by March 1 
so that these titles can be included in the IPPS proposed rule. A 
complete addendum describing details of all changes to ICD-9-CM, both 
tabular and index, are publicized on CMS and NCHS web pages in May of 
each year. Publishers of coding books and software use this information 
to modify their products that are used by health care providers. This 
5-month time period has proved to be necessary for hospitals and other 
providers to update their systems.
    A discussion of this timeline and the need for changes are included 
in the December 4-5, 2003 ICD-9-CM Coordination and Maintenance 
Committee minutes. The public provided comment that additional time 
would be needed to update hospital systems and obtain new code books 
and coding software. There was considerable concern expressed about the 
impact this new update would have on providers. Therefore, we have 
rescheduled the second Committee meeting for 2004 for October 7-8, 
2004. Those who wish to have a coding issue discussed at the October 
Committee meeting will be required to submit their request by August 7, 
2004. The Department will continue this process to accommodate all 
requesters who submit appropriate requests in a timely manner.
    In the May 18, 2004 proposed rule, we proposed to implement section 
503(a) by developing a mechanism for approving, in time for the April 
update, diagnoses and procedure code revisions needed to describe new 
technologies and medical services for purposes of the new technology 
add-on payment process. We also proposed the following process for 
making these determinations. Topics considered during the October ICD-
9-CM Coordination and Maintenance Committee meeting would be considered 
for an April 1 update if a strong and convincing case is made by the 
requester at the Committee's public meeting. The request must identify 
the reason why a new code is needed in April for purposes of the new 
technology process. The participants at the meeting and those reviewing 
the Committee meeting summary report would be provided the opportunity 
to comment on this expedited request. All other topics would be 
considered for the October 1 update. Participants at the Committee 
meeting would be encouraged to comment on all such requests.
    We stated that we believe that this proposal captures the intent of 
section 503(a). This requirement was included in the provision revising 
the standards and process for recognizing new technology under the 
IPPS. In addition, the need for approval of new codes outside the 
existing cycle (October 1) arises most frequently and most acutely 
where the new codes will capture new technologies that are (or will be) 
under consideration for new technology add-on payments. Thus, we 
believe this provision was intended to expedite data collection through 
the assignment of new ICD-9-CM codes for new technologies seeking 
higher payments. We indicated that our proposal was designed to carry 
out that intention, while minimizing the additional administrative 
costs associated with mid-year changes to the ICD-9-CM codes.
    Comment: Several comments expressed concerns about the impact the 
April 1 ICD-9-CM coding update will have on providers. While the 
commenters acknowledged the requirement was mandated by section 503(a) 
of Public Law 108-173, the commenters urged CMS to carefully consider 
the number of these mid-year coding updates. The commenters stated that 
these changes will have a significant impact on providers' systems. One 
commenter representing a large hospital organization recommended that 
codes being considered for the April 1 update be limited only to new 
technologies that present a strong and convincing case for new 
technology add-on payment. The commenter recommended that the annual 
April 1 update be limited to as few codes as possible for the following 
reasons:
     The addition of a significant number of new codes outside 
the traditional October 1 implementation will result in doubling the 
costs associated with the purchase of new code books and updating 
encoder software programs, requiring hospitals to purchase new code 
books twice a year. The commenter stated that at least one publisher 
has already announced that two editions of the code books will be 
published every year.
     Many health plans, including Medicare, require a 
significant lead-time to incorporate new codes into their systems. The 
commenter expressed concern that some payers will not be able to 
support a large number of codes being implemented outside the 
traditional October 1 update.
     A considerable amount of education and coder training 
takes place every year with the introduction of new and updated codes. 
Introducing a large number of new codes on a twice-yearly basis, rather 
than annually, will increase this burden.
    The commenter urged that the new codes be released with a 5-month 
lead-time as is the case now for ICD-9-CM updates. Currently the public 
is notified in May of the same year for ICD-9-CM codes being 
implemented on October 1. The commenter requested that the public be 
notified by November of codes that will be implemented on April 1.
    The commenter pointed out that, by tradition, new ICD-9-CM codes 
have been published in the Federal Register, as part of the annual IPPS 
proposed rule. The commenter urged CMS to develop a process for the 
wide dissemination of new and modified ICD-9-CM codes for April 1 
implementation. The commenter requested that this process be published 
in the IPPS final rule to inform users of the process.
    These comments were supported by organizations representing State 
hospitals and coding specialists. The commenters agreed with CMS' 
proposal to use the public meetings of the ICD-9-CM Coordination and 
Maintenance Committee to consider requests for an April 1 
implementation date for a new ICD-9-CM code. The commenters agreed that 
these updates should primarily focus on new technology

[[Page 48956]]

issues. When an individual or organization requests implementation of 
an ICD-9-CM code on April 1, the commenters agreed that the requestor 
should make a strong and convincing case as to why a new code is needed 
in April for purposes of the new technology process.
    Response: We agree that section 503(a) of Public Law 108-173 
requires that ICD-9-CM codes needed to capture new technology must be 
implemented on April 1 and October 1 of each year. We also agree that 
the April updates will be disruptive to current provider systems. Any 
April updates must be carefully considered and evaluated in order to 
capture new technology in an expedited manner. Those commenters who 
request an April implementation of a new ICD-9-CM code must make a 
strong and convincing case at the ICD-9-CM Coordination and Maintenance 
Committee as to why a new code is needed in April for purposes of the 
new technology process. The public will be provided an opportunity to 
discuss this request. Comments regarding the publication and 
dissemination of codes to be implemented on April 1 are discussed 
below.
    Comment: One commenter called the twice a year updates of ICD-9-CM 
an important step forward in allowing new products to enter the market 
more quickly and receive adequate payment sooner. The commenter 
expressed some concerns about CMS' proposed approach to these updates. 
The commenter stated that, by using the April updates for new 
technology, we would not have a true twice yearly coding update, but 
rather an opportunity for only a small group of services or 
technologies to receive more prompt coding updates. The commenter 
stated that the April update should be an open opportunity for any 
coding updates to be considered.
    Response: We agree with the commenter that the process for 
discussing updates to ICD-9-CM should be an open process. This has been 
the practice of the ICD-9-CM Coordination and Maintenance Committee 
since it was established in 1985. As previously stated, we will provide 
the opportunity for a requestor to make a clear and convincing case for 
the need to update specific ICD-9-CM codes in April. The public will be 
provided an opportunity to discuss the merits of any codes under 
consideration for the April updates.
    Comment: Several commenters requested details on how the public 
will be notified of the April ICD-9-CM code updates. They requested 
clarification as to whether the current publication processes will be 
used. One commenter representing a national organization of codes and 
health information managers urged CMS to provide information on April 1 
code updates at least 4 months prior to implementation. Other 
commenters representing hospital organizations urged CMS to provide 
updates 5 months ahead of implementation, or by November of the prior 
year.
    Response: Current addendum and code title information is published 
on the CMS Web page at: http://www.cms.hhs.gov/paymentsystems /icd9. 

Summary tables showing new, revised, and deleted code titles are also 
posted on the following CMS Web page: http://www.cms.hhs.gov/medlearn/ 

icd9code.asp. Information on ICD-9-CM diagnosis codes can be found at: 
http://www.cdc.gov/nchs/icd9.htm. Information on new, revised, and 

deleted ICD-9-CM codes is also provided to the AHA for publication in 
the Coding Clinic for ICD-9-CM. AHA also distributes information to 
publishers and software vendors.
    CMS also sends copies of all ICD-9-CM coding changes to its 
contractors for use in updating their systems and providing education 
to providers.
    We agree that these same means of disseminating information on new, 
revised, and deleted ICD-9-CM codes should be used to notify providers, 
publishers, software vendors, contractors, and others of changes to the 
ICD-9-CM codes that will be implemented in April. We will continue to 
provide the information in this manner.
    Currently, code titles are also published in the IPPS proposed and 
final rules. The code titles are adopted as part of the ICD-9-CM 
Coordination and Maintenance Committee process. The code titles are not 
subject to comment in the proposed or final rules. We will continue to 
publish the October code updates in this manner within the IPPS 
proposed and final rules. However, we do not publish a mid-year IPPS 
rule, so the April 1 code updates will not be published in a mid-year 
IPPS rule. We will assign the new procedure code to the same DRG in 
which its predecessor code was assigned so there will be no DRG impact 
as far as DRG assignment. This mapping was specified by Public Law 108-
173. Any proposed coding updates will be available through the websites 
indicated above and through the Coding Clinic for ICD-9-CM. Publishers 
and software vendors currently obtain code changes through these 
sources in order to update their code books and software systems. We 
will strive to have the April 1 updates available through these 
websites 5 months prior to implementation (that is, early November of 
the previous year), as is the case for the October 1 updates. Code book 
publishers are evaluating how they will provide any code updates to 
their subscribers. Some publishers may decide to publish mid-year book 
updates. Others may decide to sell an addendum that lists the changes 
to the October 1 code book. Coding personnel should contact publishers 
to determine how they will update their books. CMS and its contractors 
will also consider developing provider education articles concerning 
this change to the effective date of certain ICD-9-CM codes.
    Comment: Commenters requested clarification as to whether the April 
1 updates would be limited to procedure codes. The commenters supported 
our proposed approach for implementing the new legislative requirement 
to update ICD-9-CM codes twice a year. Specifically, they agreed that 
limiting the implementation of new codes on April 1 to those for which 
a strong and convincing case is made for an expedited implementation is 
the best approach and will reduce the additional administrative costs 
associated with twice-yearly updates to the coding system. The 
commenters acknowledged that the section of 503(a) of Public Law 108-
173 that includes the requirement for updating ICD-9-CM codes twice a 
year is primarily related to the recognition of new technology under 
the IPPS, but the language in the legislation does not limit the 
requirement to procedure codes. The commenters stated that CMS' 
proposed approach requires the requestor of a code proposal to identify 
the reason why a new code is needed on April 1 for purposes of the new 
technology process. One commenter stated that this requirement seems to 
preclude diagnosis code updates. Another commenter requested 
clarification in the final rule as to whether new diagnosis codes are 
intended to be included in the April 1 update.
    Response: We agree that section 503(a) of Pub. L. 108-173 did not 
limit ICD-9-CM code updates to procedure codes. The legislation covered 
all of ICD-9-CM, which includes both diagnoses and procedures codes. 
Therefore, consideration will be given to updates to both the diagnosis 
and procedure parts of ICD-9-CM on April 1 if a strong and convincing 
case can be made that either a diagnosis or procedure code is necessary 
to capture a new technology. We acknowledge that it may be necessary to 
recognize a new disease, such as SARS, on April 1 so that a new 
technology directed toward the disease can be more easily

[[Page 48957]]

identified. We anticipate that most, if not all, requests for April 1 
ICD-9-CM code updates will apply to procedure codes, as the commenters 
have stated. While it is unlikely that there will be many such disease 
code requests for an April 1 update, we will not restrict any such 
requests for consideration.
    Comment: Commenters representing national and state hospital 
associations as well as other organizations suggested that providing 
twice-yearly updates to the ICD-9-CM is only a temporary solution to 
meeting the coding needs of providers who may need to report new 
technology. The organizations stated that a more permanent and long-
term-solution would be the implementation of ICD-10-CM and ICD-10-PCS 
as quickly as possible. Several other commenters recommended moving 
forward with the implementation of ICD-10 as quickly as possible. One 
commenter urged DHHS to adopt and implement ICD-10-CM and ICD-10-PCS as 
quickly as possible in the United States. The commenter further stated 
that the sooner the health care industry and CMS begin to use and 
collect data more closely representing actual diagnosis and procedures, 
the better the picture of our health services and healthcare services 
will be; reimbursement will be more accurate; and there will be less 
administrative burden on health care providers and on CMS. One 
commenter asked that the regulatory process for implementing ICD-10 be 
started by the end of 2004. Another commenter stated that ICD-9-CM is 
becoming increasingly difficult to update and progress should be made 
on implementing ICD-10.
    Response: We acknowledge that there are some concerns with the ICD-
9-CM code set. The National Committee on Vital and Health Statistics 
(NCVHS) has recommended that DHHS, under its HIPAA responsibilities, 
prepare a notice of proposed rulemaking regarding the proposed adoption 
of ICD-10 as a HIPAA standard to replace ICD-9-CM. We are assessing the 
NCVHS recommendations.
    DHHS has been actively working on the development of new coding 
systems to replace the ICD-9-CM. In December 1990, the NCVHS issued a 
report noting that, while the ICD-9-CM classification system had been 
responsive to changing technologies and identifying new diseases, there 
was concern that the ICD classification might be stressed to a point 
where the quality of the system would soon be compromised. The ICD-10-
CM (for diagnoses) and the ICD-10-PCS (for procedures) were developed 
in response to these concerns. These efforts have become increasingly 
important because of the growing number of problems with the ICD-9-CM, 
which was implemented 25 years ago.
16. Other Issues
a. Craniotomy Procedures
    As discussed in the August 1, 2003, IPPS final rule (68 FR 45353), 
for FY 2004 we conducted an analysis of the charges for various 
procedures and diagnoses within DRG 1 (Craniotomy Age > 17 With CC) and 
DRG 2 (Craniotomy Age > 17 Without CC) to determine whether further 
changes to these DRGs were warranted. Based on our analysis and 
consideration of public comments received on our May 19, 2003, IPPS 
proposed rule (68 FR 27161), in the August 1, 2003, IPPS final rule, we 
created three new DRGs: DRG 528 (Intracranial Vascular Procedures With 
a Principal Diagnosis of Hemorrhage) for patients with an intracranial 
vascular procedure and an intracranial hemorrhage; and DRGs 529 
(Ventricular Shunt Procedures With CC) and 530 (Ventricular Shunt 
Procedures Without CC) for patients with only a vascular shunt 
procedure.
    In the May 18, 2004, proposed rule, we indicated that we had 
received further comments (discussed below) regarding the composition 
of DRGs 1 and 2 that relate to the appropriate DRG assignment of 
unruptured cerebral aneurysm cases and cases involving implantation of 
GLIADEL[reg] chemotherapy wafers. We had also received comments on 
possible revisions to DRG 3 (Craniotomy Age 0-17).
(1) Unruptured Cerebral Aneurysms
    In the August 1, 2003, final rule (68 FR 45354), in response to a 
comment that suggested we create a companion DRG to DRG 528 for 
intracranial vascular procedures for unruptured cerebral aneurysms, we 
evaluated cases in the MedPAR file involving unruptured cerebral 
aneurysm and determined that the average charges for unruptured 
cerebral aneurysm cases were consistent with the variation of charges 
found in DRGs 1 and 2. Therefore, we did not propose a change in the 
DRG classification. We indicated that we would continue to monitor 
cases involving unruptured cerebral aneurysms.
    In the May 18, 2004, proposed rule, we discussed our examination of 
cases in the FY 2003 MedPAR file that reported unruptured cerebral 
aneurysms. We found 657 unruptured aneurysm cases assigned to DRG 1 and 
481 unruptured cerebral aneurysm cases assigned to DRG 2. The average 
charges for these unruptured cerebral aneurysm cases in DRG 1 ($50,879) 
are slightly lower than the overall charges for all cases in that DRG 
($51,300). For unruptured cerebral aneurysm cases assigned to DRG 2, we 
found the average charges of approximately $29,524 are consistent with 
the overall average charges of that DRG of approximately $28,416.
    Based on the results of our analysis, we indicated that we still do 
not believe a proposal to modify the DRG assignment of unruptured 
cerebral aneurysm cases is warranted.
    We received one comment on this issue from an organization 
representing hospitals. The commenter agreed that no change is 
warranted for the DRG assignment of unruptured aneurysm cases at this 
time.
(2) GLIADEL[reg] Chemotherapy Wafers
    In the August 1, 2003 final rule (68 FR 45354), we stated that we 
had received comments requesting a change to the DRG assignment of 
cases involving implantation of GLIADEL[reg] chemotherapy wafers to 
treat brain tumors. One of the commenters had offered two options: (1) 
create a new DRG for cases involving implantation of GLIADEL[reg] 
chemotherapy wafers; and (2) reassign these cases to DRG 484 
(Craniotomy for Multiple Significant Trauma).
    At that time, we had analyzed data in the March 2003 update of the 
FY 2003 MedPAR file and found a total of 61 cases in which procedure 
code 00.10 (Implantation of a chemotherapy agent) was reported for 
cases assigned to DRGs 1 and 2. There were 38 cases assigned to DRG 1 
and 23 cases assigned to DRG 2. The GROUPER logic for these DRGs 
assigns cases with CCs to DRG 1 and those without CCs to DRG 2. 
Consistent with the GROUPER logic for these DRGs, we had found that the 
average standardized charges in DRGs 1 and 2 were approximately $64,864 
and $42,624, respectively. However, while the estimated average charges 
for GLIADEL[reg] wafer cases of $50,394 may have been higher than the 
average standardized charges for DRG 2, they were within the normal 
variation of overall charges within each DRG. In addition, the volume 
of cases in these two DRGs was too small to warrant the establishment 
of a separate new DRG for this technology. Therefore, we stated that we 
wanted to review a full year of data and take the time to consider 
alternative options that might appear warranted before proposing a 
change.
    In the May 18, 2004, proposed rule, we discussed our examination of 
more

[[Page 48958]]

complete MedPAR data (December 2003 update for FY 2003) on cases 
reporting GLIADEL[reg] chemotherapy wafers. We found a total of 127 
cases in which procedure code 00.10 was reported for cases assigned to 
DRGs 1 and 2. There were 80 cases assigned to DRG 1 and 47 cases 
assigned to DRG 2. The average charges for these cases in DRGs 1 and 2 
were approximately $61,866 and $47,189, respectively. The average 
charges for these cases were higher than the overall charges of DRGs 1 
and 2 of approximately $51,300 and $28,416, respectively. Although the 
average charges for the GLIADEL[reg] wafer cases within these DRGs are 
higher than the average charges of all cases in these DRGs, they remain 
within the range of average charges for other procedures included in 
these DRGs. The majority of the GLIADEL[reg] wafer cases are assigned 
to the second highest weighted DRG in MDC 1 behind DRG 528 
(Intracranial Vascular Procedure With a Principal Diagnosis of 
Hemorrhage) in which the weights were derived from average charges of 
approximately $113,884. In DRG 1, there are 10 procedures that have 
higher average charges than the GLIADEL[reg] wafer cases. However, in 
DRG 2, the charges associated with GLIADEL[reg] wafer cases are the 
highest of the procedures included within the DRG.
    DRGs are based on the principal diagnosis, secondary diagnosis, and 
procedures performed on the patient. DRGs are not generally created to 
recognize the presence or absence of specific technologies for each 
patient. In the past, we have made one exception to this rule. The 
exception was the creation of two new DRGs for drug-eluting stents: DRG 
526 (Percutaneous Cardiovascular Procedure With Drug-Eluting Stent With 
Acute Myocardial Infarction) and DRG 527 (Percutaneous Cardiovascular 
Procedure With Drug-Eluting Stent Without Acute Myocardial Infarction) 
(67 FR 50003). We took this unprecedented approach in response to the 
unique circumstances surrounding the potential breakthrough nature of 
this technology. We currently have 59,613 drug-eluting stent cases 
annually, far more cases than the volume for GLIADEL[reg] wafers. We 
believe that the volume of GLIADEL[reg] wafer cases remains too small 
to warrant the taking of the exceptional step of establishing a 
separate new DRG for this technology.
    Commenters also have proposed the reassignment of GLIADEL[reg] 
wafer cases to other existing DRGs, such as DRG 484 (Craniotomy for 
Multiple Significant Trauma), DRG 528 (Intracranial Vascular Procedures 
With Principal Diagnosis of Hemorrhage), DRG 492 (Chemotherapy With 
Acute Leukemia as a Secondary Diagnosis or With Use of a High Dose 
Chemotherapeutic Agent), or DRG 481 (Bone Marrow Transplant). In the 
proposed rule, we stated that we had examined these alternatives, and 
had come to the conclusion that none of these alternatives meets the 
standard of clinical coherence under the DRG system. For example, 
reconfiguring DRG 484 to include GLIADEL[reg] wafer cases would not 
produce a clinically coherent DRG because DRG 484 contains cases where 
craniotomy is performed in the setting of multiple significant trauma. 
Similarly, assigning GLIADEL[reg] wafer cases to DRG 528 would not 
produce a clinically coherent DRG because DRG 528 contains cases where 
craniotomy is performed as part of a vascular procedure with a primary 
diagnosis of hemorrhage, as in the case of a ruptured aneurysm. DRG 492 
is clinically inappropriate because it contains cases of acute leukemia 
treated with chemotherapy, and DRG 481 is clinically inappropriate 
because it contains cases involving bone marrow transplant. None of 
these DRGs contains cases of glioblastoma multiforme or other primary 
brain tumors. Therefore, in the May 18, 2004 proposed rule, we did not 
propose to adopt any of these changes.
    As discussed in the May 18, 2004 proposed rule, we also considered 
several other approaches to reassigning GLIADEL[reg] wafer cases in a 
manner that is appropriate both in terms of clinical coherence and 
resource use. For example, we considered the creation of a new DRG that 
includes GLIADEL[reg] wafer cases along with other types of local 
therapy for intracerebral malignant disease. Specifically, we 
considered the creation of a new DRG that includes GLIADEL[reg] wafers 
and a Gliasite Radiation Therapy System, a relatively new form of 
intracavitary brachytherapy. Such a DRG would be clinically coherent 
because it would contain cases of malignant brain tumors treated with 
local therapy. However, our analysis of existing FY 2003 MedPAR data 
suggested that such a DRG would probably not provide enhanced 
reimbursement for the GLIADEL[reg] wafer cases, and that, in fact, 
decreased reimbursement for GLIADEL[reg] wafer cases is a more likely 
result. Therefore, we did not propose a specific change. However, we 
stated that we would continue to monitor our data to determine whether 
a change is warranted in the future.
    We recognize that the implantation of chemotherapeutically active 
wafers for local therapy of malignant brain tumors represents a 
significant medical technology that currently offers clinical benefits 
to patients and holds out the promise of future innovation in the 
treatment of these brain tumors.
    In our proposed rule (69 FR 28221), we invited comments and 
suggestions regarding the appropriate DRG assignment for this 
technology.
    Comment: One comment agreed with the current DRG assignment of DRG 
1 or 2 for GLIADEL[reg] cases.
    Response: We appreciate the commenter's support for the current DRG 
assignment for these cases.
    Comment: Four commenters supported the reassignment of Gliadel[reg] 
cases to DRG 528 (Intracranial Vascular Procedure With a Principal 
Diagnosis of Hemorrhage). The commenters stated that the average cost 
of a patient receiving Gliadel[reg] chemotherapy wafer treatment is 
consistent with the average DRG 528 payments to providers. The 
commenters also believed that treatment using the Gliadel[reg] wafer is 
clinically consistent with the treatment under procedures currently 
assigned to DRG 528.
    Response: As we stated in the May 18, 2004 proposed rule (69 FR 
28222), we do not believe that the GLIADEL[reg] cases meet the clinical 
coherence criteria for inclusion in DRG 528. DRG 528 includes 
hemorrhage or ruptured cerebral aneursym cases. While the surgical 
approach may be similar to GLIADEL[reg], cases assigned to DRG 528 
involve patients who have an acute condition with a high severity of 
illness and a significantly higher rate of mortality during surgery 
than GLIADEL[reg] cases (20.6 percent for DRG 528 cases compared to 
3.15 for GLIADEL[reg] cases). In addition, the average charges for 
cases in DRG 528, approximately $97,540, are significantly higher than 
the average charges for GLIADEL[reg] cases in DRG 1, approximately 
$61,866. Thus, we do not believe that GLIADEL[reg] cases and those 
assigned to DRG 528 are clinically coherent and similar in resource 
use. We continue to believe that reassigning GLIADEL[reg] cases to DRG 
528 is inappropriate and would result in overpayment for GLIADEL[reg] 
cases.
    Comment: One commenter suggested that we reassign GLIADEL[reg] 
cases to DRG 528 for FY 2005 and eventually create a DRG for 
intracerebral therapies. The commenter proposed a new DRG that would 
include implantation of a chemotherapeutic agent and seven new drugs 
that are currently in FDA Phase II and III clinical trials and are 
expected to receive FDA approval in 2 to 5 years. According to the 
commenter, the new drugs are also indicated for glioblastoma multiforme 
and the mode of therapy is

[[Page 48959]]

chemotherapy, radiotherapy, or brachytherapy.
    Response: As we discussed above, we do not believe assignment to 
DRG 528 is appropriate. We review DRG assignments every year and will 
determine the appropriate assignment of the new technologies when it is 
appropriate to do so.
    Comment: Many commenters encouraged CMS to reassign Gliadel[reg] 
chemotherapy wafer treatment to a new or higher paying DRG. The 
commenters believed that higher payment would ensure access to life-
extending treatment for patients suffering from malignant brain tumors. 
These commenters offered no specific recommendations on reassignment of 
these cases to other DRGs.
    Response: In this final rule, we are creating a new DRG that would 
include implantation of chemotherapeutic agent (procedure code 00.10) 
cases or cases in which an acute complex central nervous system 
diagnosis was reported as the principal diagnosis. An example of an 
acute complex diagnosis is an intracranial abscess. GLIADEL[reg] 
chemotherapy wafer cases would be reassigned to this new DRG.
    Although we did not propose this specific solution to the issue of 
payment for GLIADEL[reg] in the proposed rule, we indicated that we 
would continue to consider appropriate changes to the DRG assignment of 
cases involving GLIADEL[reg]. Furthermore, we believe that the creation 
of a new DRG for cases involving implantation of a chemotherapeutic 
agent or cases with an acute complex central nervous system diagnosis 
as the principal diagnosis ensures that GLIADEL[reg] cases are assigned 
to a DRG that is clinically coherent and reflects the resources used to 
treat these cases and appropriately addresses the concerns of those 
commenters who raised questions regarding the DRG assignment for these 
cases.
    The new DRG 543 (Craniotomy with Implantation of Chemotherapeutic 
Agent or Acute Complex Central Nervous System Principal Diagnosis) is 
being placed in MDC 1. It was created from existing DRGs 1 and 2 
(Craniotomy Age >17 With and Without CC, respectively) by removing 
three types of patients based on their principal diagnosis. Therefore, 
new DRG 543 will contain patients who undergo a craniotomy procedure 
with a principal diagnosis belonging to one of the following three 
categories:
    1. Patients with a major central nervous system infection, such as 
bacterial meningitis, encephalitis, or an intracranial abscess.
    2. Patients with a subarachnoid hemorrhage, intracranial 
hemorrhage, or an acute stroke.
    3. Patients with central nervous system trauma resulting in brain 
laceration or brain injury associated with an open head wound.
    In addition, new DRG 543 will include cases involving treatment 
using chemotherapeutic agents and devices implanted in the brain, such 
as implantable chemotherapeutic wafers.
    The cases remaining in DRGs 1 and 2 will be the following types of 
patients:
    1. Patients with chronic central nervous system conditions such as 
malignancies, degenerative conditions, and cerebrovascular disease 
without acute infarct.
    2. Patients with subdural hematoma not associated with an open head 
wound.
    3. Patients with lesser degrees of central nervous system trauma, 
such as skull fracture or other injury but without brain laceration.
    Patients in new DRG 543 would, on average, consume more resources 
because they require greater pre-operative and post-operative care, and 
in many cases require more complicated operative procedures. The FY 
2003 MedPAR data for the new DRG includes 5,413 cases with overall 
average charges of approximately $63,409. These charges are similar to 
the current average charges for Gliadel[reg] cases in DRG 1 of 
approximately $61,866.
    For FY 2005, we will be implementing new DRG 543 with the following 
logic:
     Craniotomy procedure from DRGs 1 and 2 and procedure code 
00.10, Implantation of chemotherapeutic agent; or
     Craniotomy procedure from DRGs 1 and 2 and principal 
diagnosis of acute complex central nervous system listed below.

[[Page 48960]]

[GRAPHIC] [TIFF OMITTED] TR11AU04.011


[[Page 48961]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.012


[[Page 48962]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.013


[[Page 48963]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.014


[[Page 48964]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.015



[[Continued on page 48965]]


From the Federal Register Online via GPO Access [wais.access.gpo.gov]
]                         
 
[[pp. 48965-49014]] Medicare Program; Changes to the Hospital Inpatient Prospective 
Payment Systems and Fiscal Year 2005 Rates

[[Continued from page 48964]]

[[Page 48965]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.016


[[Page 48966]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.017


[[Page 48967]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.018


[[Page 48968]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.019


[[Page 48969]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.020


[[Page 48970]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.021


[[Page 48971]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.022

BILLING CODE 4121-01-C
(3) DRG 3 (Craniotomy Age 0-17)
    In the May 18, 2004, proposed rule, we addressed a comment we had 
received stating concern that DRG 3 has not been reviewed, while DRGs 1 
and 2 have had some revisions. The commenter believed that, 
particularly with the removal of major trauma cases, age distinctions 
may no longer be significant for craniotomies and the other 
intracranial procedures classified in DRGs 1 through 3. The commenter 
stated that it may be more consistent, from both a clinical and 
resource perspective, to simply eliminate DRG 3 and redistribute the 
pediatric and juvenile cases to DRGs 1 and 2 based on the procedures 
performed and the complications or comorbidities present, instead. We 
stated that this analysis would require supplemental data from non-
MedPAR sources.
    We noted in the proposed rule that the primary focus of updates to 
the Medicare DRG classification system is on changes relating to the 
Medicare patient population, not the pediatric patient population. In 
the FY 2003 data, there were only two cases assigned to DRG 3. 
Therefore, we did not believe a proposal to address the commenter's 
request was warranted. We indicated that we are aware that the Medicare 
DRGs are sometimes used to classify other patient populations. We 
advised those non-Medicare systems that need a more up-to-date system 
to consider choosing from other systems that are currently in use in 
this country, or developing their own modifications.
    Comment: One commenter agreed that there does not appear to be a 
need to address DRG 3 at this time. However, the commenter noted that 
other payers, such as many Medicaid payers, reimburse based on DRG 
groupings and requested that we consider those payers when addressing 
proposed changes to the DRG system in the future.
    Response: For this final rule, we will not be making any changes to 
DRG 3. Decisions about the use of DRGs in Medicaid are made by the 
states. As we stated previously, the primary focus of our updates to 
the Medicare DRG classification system is on changes relating to the 
Medicare patient population.
b. Coronary Stent Procedures
    In the May 18, 2004, proposed rule, we addressed recommendations 
that we had received from several industry representatives about the 
DRG assignments for coronary artery stents. These representatives 
expressed concern about whether the reimbursement for stents is 
adequate, especially for insertion of multiple stents. They also 
expressed concern about whether the current DRG structure represents 
the most clinically coherent classification of stent cases.
    We received two comprehensive recommendations for refinement and 
restructuring of the current coronary stent DRGs. The current DRG 
structure incorporates stent cases into the following two pairs of 
DRGs, depending on whether bare metal or drug-eluting stents are used 
and whether acute myocardial infarction (AMI) is present:
     DRG 516 (Percutaneous Cardiovascular Procedures With AMI)
     DRG 517 (Percutaneous Cardiovascular Procedures With 
Nondrug-Eluting Stent Without AMI)
     DRG 526 (Percutaneous Cardiovascular Procedures With Drug-
Eluting Stent With AMI)
     DRG 527 (Percutaneous Cardiovascular Procedures With Drug-
Eluting Stent Without AMI)
    One of the recommendations involved restructuring these DRGs to 
create two additional stent DRGs that are closely patterned after these 
existing pairs and that would reflect insertion of multiple stents with 
and without AMI. The manufacturer recommended incorporating either 
stenting code 36.06 (Insertion of nondrug-eluting coronary artery 
stent(s)) or code 36.07 (Insertion of drug-eluting coronary artery 
stent(s)) when they are reported along with code 36.05 (Multiple vessel 
percutaneous transluminal coronary angioplasty [PTCA] or coronary 
atherectomy performed during the same operation, with or without 
mention of thrombolytic agent). The manufacturer expressed concern that 
hospitals are steering patients toward coronary artery bypass graft 
surgery in place of stenting in order to avoid significant financial 
losses due to what it considered the inadequate reimbursement for 
inserting multiple stents.
    We appreciated receiving the manufacturer's recommendation, and 
agree that the DRG classification of cases involving coronary stents 
must be clinically coherent and provide for adequate reimbursement, 
including

[[Page 48972]]

adequate reimbursement of cases requiring multiple stents. We also 
agree that the recommendation has some merits and deserves further 
study. However, as stated in the proposed rule, we believed that it was 
premature to act on this recommendation for two reasons. One reason is 
that the current coding structure for coronary artery stents cannot 
distinguish cases in which multiple stents are inserted from cases in 
which only a single stent is inserted. Current codes are able to 
identify performance of PTCA in more than one vessel by use of code 
36.05. However, while this code indicates that PTCA was performed in 
more than one vessel, its use does not reflect the exact number of 
procedures performed or the exact number of vessels treated. Similarly, 
when codes 36.06 and 36.07 are used, they document the insertion of at 
least one stent. However, these stenting codes do not identify how many 
stents were inserted in a procedure, nor distinguish insertion of a 
single stent from insertion of multiple stents. Even the use of one of 
the stenting codes in conjunction with multiple-PTCA code 36.05 does 
not distinguish insertion of a single stent from insertion of multiple 
stents. The use of code 36.05 in conjunction with code 36.06 or code 
36.07 indicates only performance of PTCA in more than one vessel, along 
with insertion of at least one stent. The precise numbers of PTCA-
treated vessels, the number of vessels into which stents were inserted, 
and the total number of stents inserted in all treated vessels cannot 
be determined. Therefore, the capabilities of the current coding 
structure do not permit the distinction between single vessel stenting 
and multiple vessel stenting that would be required under the 
recommended restructuring of the stenting DRGs.
    In addition, because the FDA approved drug-eluting stents for use 
in April 2003, the distinct DRGs for drug-eluting stents have only been 
effective for payment for a little over a year. The MedPAR file thus 
does not contain a full year of data with which to conduct the 
requisite analysis to evaluate the adequacy of the current structure of 
four stenting DRGs. In the proposed rule, we indicated that we would 
consider this recommendation as we evaluate the current DRG structure 
once adequate data on the current stenting DRGs become available. We 
also stated in the proposed rule that we believe it is still premature 
to undertake such a thorough restructuring of the stent DRGs.
    The second recommendation was that we transform the current 
structure of stenting DRGs into two new pairs of DRGs, reclassifying 
stenting cases according to whether bare metal or drug-eluting stents 
are used (as with the present DRGs) and whether the cases are 
``complex'' or ``noncomplex.'' The manufacturer indicated that complex 
cases are those that include certain comorbid conditions or procedural 
factors such as hypertensive renal failure, diabetes, AMI, and 
multivessel PCI. The manufacturer further indicated that this structure 
would provide an improvement in both clinical and resource coherence 
over the current structure that classifies cases according to the type 
of stent inserted and the presence or absence of AMI alone, without 
considering other complicating conditions. Specifically, the 
manufacturer recommended replacing the current structure with the 
following four DRGs:
     Recommended restructured DRG 516 (Complex percutaneous 
cardiovascular procedures with nondrug-eluting stents)
     Recommended restructured DRG 517 (Noncomplex percutaneous 
cardiovascular procedures with nondrug-eluting stents)
     Recommended restructured DRG 526 (Complex percutaneous 
cardiovascular procedures with drug-eluting stents)
     Recommended restructured DRG 527 (Noncomplex percutaneous 
cardiovascular procedures with drug-eluting stents)
    The manufacturer presented an analysis based on FY 2002 MedPAR 
data, in which it evaluated charges and lengths of stay for cases with 
expected high resource use, and reclassified cases into the recommended 
new structure of paired ``complex'' and ``noncomplex'' DRGs. The 
analysis shows some evidence of clinical and resource coherence in the 
recommended DRG structure. However, as we stated in the proposed rule, 
the analysis does not yet provide a convincing case for adopting the 
recommended restructure. First, the analysis does not reveal 
significant gains in resource coherence compared to existing DRGs for 
stenting cases. Second, the analysis is limited in assessing the 
feasibility of using the recommended DRG restructure versus the current 
DRG structure for classification of stent cases. Because the 
manufacturer used FY 2002 MedPAR data in its analysis, it was not able 
to compare the resource coherence of the recommended structure with the 
current structure of four DRGs, but only with the two DRGs that 
preceded the approval of drug-eluting stents. While the manufacturer 
asserted that ``similar results would be expected'' from a comparison 
between its recommended DRG restructure and the current DRG structure, 
we do not believe that it is advisable to undertake a critical DRG 
restructuring without examining the recommendation against actual 
experience under the current structure. As we stated in the proposed 
rule, we believe that this recommendation may have merit, and we will 
conduct a full analysis of the recommendation in comparison to the 
other recommendation for DRG revision and to the current DRG structure 
once adequate data become available.
    The drug-eluting stents had not yet been FDA approved when we 
calculated the relative weights for DRGs 526 and 527 for the FY 2003 
IPPS final rule. Therefore, in the absence of MedPAR data, we based our 
FY 2003 relative weight calculations on prices in countries where drug-
eluting stents were already being used. A full discussion of this 
process can be found in the FY 2004 IPPS final rule (68 FR 45370). For 
computation of the proposed relative weights for FY 2005 in the May 18, 
2004 proposed rule, we used the December update of FY 2003 MedPAR data. 
(As stated in the June 25, 2004 correction notice (69 FR 35921), there 
have been a total of approximately 11,084 cases in DRG 526, and 48,097 
cases in DRG 527, with adjustments made for transfers to other 
facilities.) For computation of the final FY 2005 relative weights, we 
are using the March FY 2004 update of the FY 2003 MedPAR data file for 
cases in these two DRGs. No foreign data have been used to compute the 
relative weights for DRGs 526 and 527 in FY 2005.
    We received a number of comments concerning coronary stents, both 
bare and drug-eluting in response to the May 18, 2004, proposed rule. 
As noted above, we had discussed two external recommendations for 
refinement or restructuring of the current coronary stent DRGs (69 FR 
28222). At that time, we indicated that we believed that arguments for 
change might have merit. However, as there was not an adequate database 
upon which to structure a DRG revision, and because the two proposals 
were so dissimilar, we indicated that we would continue to monitor the 
coronary stent DRGs and would review the DRG structure once adequate 
data became available. We will continue to review the data carefully 
and will assess whether a revised DRG structure is appropriate when we 
have more than 11 months of data experience. The FDA approved the drug-
eluting stent for use in April 2003. Therefore, our MedPAR payment data 
collection began at that time.

[[Page 48973]]

    Comment: Two commenters supported the complex vs. noncomplex case-
mix DRG pairs option. The commenters suggested that the complexities be 
based on diagnoses of congestive heart failure, cerebral vascular 
disease, renal failure, AMI, and the presence of a multiple vessel 
procedure. (We believe that the commenter intended the latter 
complexity to be the presence of code 36.05 (Multiple vessel 
percutaneous transluminal coronary angioplasty [PTCA] or coronary 
atherectomy performed during the same operation, with or without 
mention of thrombolytic agent) in the same inpatient episode.)
    Response: We take this opportunity to clarify that we did not offer 
a choice between two options in the proposed rule. We discussed the two 
options that had been suggested to us. However, we determined that it 
was premature to undertake a thorough restructuring of the four current 
stent DRGs, both because the recommendations differed so completely 
from each other and because we lacked data of adequate historical 
duration with which to make a comprehensive analysis.
    We note that FDA is in the process of determining the efficacy of 
drug-eluting stents in high-risk patient clinical trials, and acute 
myocardial infarction (AMI) has been identified as one of the high-risk 
triggers. We do not believe it is appropriate to further use high-risk 
triggers such as AMI to structure the stent DRGs until FDA's work is 
complete.
    Comment: One commenter recommended restructuring of the four 
existing stent DRGs (DRG 516, 517, 526, and 527) by complex and 
noncomplex components. Specifically, the commenter suggested replacing 
the existing DRG structure that distinguishes between ``with and 
without AMI'' and the presence of bare or drug-eluting stents with a 
structure distinguishing between ``with and without complexity.'' In 
performing its analysis, the commenter reviewed charges within each of 
the four stent DRGs and then stratified the cases into groups with and 
without the following comorbidities or procedural characteristics: a 
principal diagnosis of AMI, or any secondary diagnosis of congestive 
heart failure, renal failure, cerebrovascular disease, or cases 
including code 36.05, reflecting multiple vessel procedure. The 
commenter classified cases with the above characteristics as 
``complex'' and cases without these characteristics as ``noncomplex.''
    The commenter included the following table for comparison purposes:
    [GRAPHIC] [TIFF OMITTED] TR11AU04.023
    
    The commenter's conclusion was that a diagnosis of AMI, by itself, 
was not an accurate reflection of the most resource-intensive 
procedures associated with coronary stenting.
    Response: We appreciate the considerable thought and study that 
went into the analysis that was submitted. However, in reviewing the 
comparison, we identified the similarities of the mean charges between 
the current DRGs and the proposed complex DRGs, and the fact that in 
every single comparison, the mean charges go down in the complex DRGs. 
For example, according to the table, current DRG 516 has mean charges 
of $41,788, while the proposed complex revision of DRG 516 has mean 
charges of $41,762. This is a decrease of $26. Also, current DRG 526 
has mean charges of $51,746, while the proposed complex revision of DRG 
526 has mean charges of $51,054. This is a decrease of $692. These 
results indicate to us that the current DRG structure is accurate in 
terms of resource consumption.
    In addition, we note that under the commenter's proposal, the 
number of cases in the complex DRG categories, while the number of 
noncomplex cases decreases. There would be a shift in the number of 
cases per DRG, but each case would have lower average charges per case, 
which would reduce the relative weight of all four DRGs. We are 
hesitant to adopt this approach, given the comments and concerns that 
reimbursement for stenting procedures is already under funded.
    Comment: One commenter supported our proposal to maintain temporary 
DRGS 526 and 527.
    Response: We appreciate the commenter's support of these temporary 
DRGs. In the FY 2003 IPPS final rule (67 FR 50004), we stated that we 
expect that when claims data are available that reflect the use of 
drug-eluting stents, we would combine drug-eluting stents cases with 
other stent cases in DRGs 516 and 517. A change of that nature would be 
subject to an analysis of the claims data to determine whether these 
data reflect a significant reduction in the use of bare stents, due to 
the overwhelming industry acceptance of the more efficacious drug-
eluting stent. At this time, with only 11 months of claims data, we 
believe that changes to these DRG pairs would be premature. We will 
continue our analysis and monitor the data for these cases.
    Comment: One commenter expressed concern that the relative weights

[[Page 48974]]

published in Table 5 of the Addendum to the proposed rule (69 FR 28642) 
were inadequate to cover the costs of procedures involving this 
technology and might provide financial incentives for hospitals to use 
less effective technologies (such as bare metal stents) or more 
invasive coronary artery bypass graft (CABG) procedures for Medicare 
beneficiaries.
    Response: We note that the relative weights listed in Table 5 of 
the proposed rule are based on MedPAR hospital charge data as of the 
December 2003 update of the files, which were not as complete for FY 
2003 as the data are now. The relative weights in this final rule are 
based on the March FY 2004 update of the FY 2003 MedPAR file, and 
reflect a more comprehensive picture of hospital charges. The final 
weight for DRG 516 is 2.6457, for DRG 517 is 2.1106, for DRG 526 is 
2.9741, and for DRG 527 is 2.3282.
    We also point out that the DRG base rate computed using relative 
weights is only part of the formula used to determine what each 
hospital is paid for each case. Additional payment is made to each 
hospital based on its unique structure, including indirect medical 
education, area wage levels, disproportionate share adjustment, and any 
applicable cost-of-living adjustments in Alaska and Hawaii. Hospitals 
may also receive outlier payments for certain cases involving 
extraordinary high costs.
    We are concerned by the comment regarding the provision of CABG 
procedures when less appropriate to the patient than drug-eluting 
therapy. One commenter believed the conversion from CABG to drug-
eluting stent therapy has already begun and cited MedPAR data to prove 
its point. These data show that during the first quarter of full drug-
eluting stent availability (July, August, and September 2003), Medicare 
CABG discharges declined 9.3 percent from the same quarter in the 
previous year. The commenter also noted a corresponding increase in 
stenting procedures.
    In addition, it has come to our attention that there may be some 
coding errors that are contributing to an erroneous data and 
reimbursement case-mix profile for hospitals. Specifically, it has been 
suggested that some hospitals may be reluctant to include a code for 
vessel angioplasty in conjunction with stent placement. Apparently some 
hospital staff have expressed concerns that a ``true'' angioplasty is 
not being performed, and that they will therefore be censured by 
regulatory agencies for erroneous coding. Therefore, these hospitals 
have instructed their coding staff not to include a code describing 
angioplasty of a vessel and only to include a code for insertion of a 
stent or stents.
    This action is not proper. The AHA publication, Coding Clinic for 
ICD-9-CM, Fourth Quarter, 1996, specifically instructs that a code for 
angioplasty, by any technique, be used when an angioplasty is performed 
in the placement of a stent or stents (page 63). Therefore, the correct 
coding for insertion of coronary stent(s) requires two codes. One code 
describes the angioplasty: 36.01 (Single vessel percutaneous 
transluminal coronary angioplasty [PTCA] or coronary atherectomy 
without mention of thrombolytic agent); 36.02 (Single vessel 
percutaneous transluminal coronary angioplasty [PTCA] or coronary 
atherectomy with mention of thrombolytic agent); or 36.03 (Open chest 
coronary artery angioplasty, or 36.05. The second code describes which 
stent was inserted: either 36.06 (Insertion of non drug-eluting 
coronary artery stent(s)) or 36.07 (Insertion of drug-eluting coronary 
artery stent(s)). Failure to record the angioplasty procedure will 
result in assignment of the case to the medical DRG instead of the 
correct surgical DRG. This erroneous coding action will have an impact 
on many levels. It will result in incorrect data in the database, which 
in turn will result in an erroneous base upon which future DRG relative 
weights are calculated. In addition, in the short term, it will result 
in reduced revenue to the hospitals because of the incorrect DRG 
assignment for all cases in which incorrect coding occurs.
    Comment: One commenter indicated that there is a disincentive for 
the insertion of multiple drug-eluting stents placed during the same 
inpatient admission. This commenter indicated that there might be 
pressures on physicians to bring patients back for an additional stent 
procedure on a subsequent admission. Another commenter suggested that, 
as an interim approach, code 36.05 be used as a trigger for DRG 
assignment to a newly created DRG, or act as a trigger for an add-on 
payment for each stent. The commenter's justification for this 
suggestion was that, because current medical practice indicates that 
over 85 percent of balloon angioplasties currently involve a concurrent 
insertion of a stent, code 36.05 could serve as a good surrogate code 
until such time as new codes are created and available for use.
    Response: One of the suggestions received that we discussed in the 
proposed rule recommended that two new DRGs be created based on 
multiple-vessel procedures with drug-eluting stent(s) and the presence 
or absence of an AMI. The suggester's argument was that the presence of 
code 36.05, which shows treatment of multiple vessels, also indicates 
that more than one stent was inserted. We considered this assertion in 
the proposed rule because we recognize that current ICD-9-CM codes do 
not adequately describe the insertion of more than one stent. However, 
as we discussed in the proposed rule, we believe that the presence of 
code 36.05 only indicates that more than one vessel was surgically 
treated. It does not indicate that more than one stent was placed in 
all cases. We reiterate that no conclusions can be drawn regarding the 
number of stents inserted based upon the number of vessels treated. 
Therefore, we are not prepared to make DRG adjustments based on the 
commenter's assertion. In addition, we are not prepared to assume that 
the presence of code 36.05 is solely responsible for any higher charges 
associated with these cases.
    We do believe that there is a need to further identify the 
insertion of multiple stents and will work with industry 
representatives to conceptualize the most appropriate ICD-9-CM 
procedure code or codes to capture this data. The topic of a new code 
or codes for multiple stent insertion will be addressed at the October 
7, 2004 ICD-9-CM Coordination and Maintenance Committee meeting at CMS' 
headquarters in Baltimore, MD.
    Comment: One commenter expressed concern about the implication of 
maintaining separate and distinct DRGs for drug-eluting stents and 
encouraged CMS to consider fully the impact on less expensive 
technologies, such as intravascular brachytherapy (IVBT). IVBT is the 
use of vascular radiation delivered inside an artery to reduce the 
incidence of restenosis. The commenter noted that the DRG system should 
not create financial incentives to use drug-eluting stents when the 
clinical outcomes and costs of other treatments are similar or better 
in the appropriate patient populations.
    Response: As we have stated above in response to other comments, in 
the absence of more complete data and without thorough evaluation, we 
are reluctant to undertake any restructuring of these four DRGs (516, 
517, 526, and 527) for FY 2005. Therefore, these DRGs will continue to 
be structured as they currently are. In the upcoming fiscal year, as in 
the past, we will be closely monitoring our own data, outside data, and 
any FDA decision on the efficacy of stent placement in a high-risk AMI 
population. We will also consider

[[Page 48975]]

alternative therapies, such as IVBT, as part of that process.
c. Severe Sepsis
    In the May 18, 2004, proposed rule, we addressed a comment we had 
received that recommended a separate DRG be assigned to the diagnosis 
of severe sepsis. Patients admitted with sepsis currently are assigned 
to DRG 416 (Septicemia Age > 17) and DRG 417 (Septicemia Age 0-17) in 
MDC 18 (Infectious and Parasitic Diseases, Systemic or Unspecified 
Sites). The commenter contended that the costs of caring for patients 
with severe sepsis exceed those costs associated with other types of 
sepsis. Therefore, the commenter indicated, severe sepsis should be 
given a separate, unique DRG. Furthermore, the commenter requested that 
all cases in which severe sepsis is present on admission, as well as 
those cases in which it develops after admission (which are currently 
classified elsewhere) be included in this new DRG. The commenter 
suggested using various coexisting conditions and their corresponding 
ICD-9-CM codes (for example, respiratory failure or hypotension and 
renal failure) to identify patients with severe sepsis. The conditions 
suggested do not describe a clinically coherent set of patients that 
have severe sepsis. Using this list of conditions would erroneously 
identify patients as having severe sepsis.
    We acknowledge the high costs of caring for seriously ill patients 
with sepsis. However, we do not find, from a clinical perspective, that 
a subset of patients with severe sepsis exists to the degree that a 
separate DRG classification is justified. Sepsis in all forms is quite 
common across many DRGs in the Medicare population. In addition, we do 
not believe that the commenter's suggested defining criteria for severe 
sepsis are specific, accurate, or unique enough to warrant a new DRG 
classification. Therefore, in the May 18, 2004, proposed rule, we did 
not propose any change to the current DRG structure for sepsis.
    Comment: Several commenters agreed with our proposal not to create 
a new DRG for severe sepsis. Some of the commenters mentioned coding 
problems that exist with new codes 995.90 through 995.94 that were 
created to capture Systemic Inflammatory Response Syndrome (SIRS). The 
commenters acknowledged that the codes were specifically created to 
capture severe sepsis. However, they indicated that there has been much 
confusion among coders in their use. The commenters mentioned coding 
notes included in the ICD-9-CM book that appear to be contradictory. 
The commenters agreed that it was not appropriate to modify the DRGs at 
this time, given the uncertainty about the use of the SIRS codes and 
the accuracy of the reported data.
    One commenter recommended continued monitoring of the population 
with severe sepsis in the future. Another commenter supported our 
proposal not to create a new DRG for severe sepsis, given the data and 
information provided.
    Response: We agree with the commenters that there has been 
confusion in the correct use of the SIRS codes based on use of the ICD-
9-CM code book. The related section of the ICD-9-CM code book is being 
revised on October 1, 2004, to help resolve this confusion. Additional 
coding instructions are also being developed on the correct use of 
these codes. These instructions will be published in the American 
Hospital Association's Coding Clinic for ICD-9-CM. These actions should 
lead to more consistency in identifying and reporting cases of severe 
sepsis. Once this information is available, CMS will review the data to 
determine any needed modifications to the DRG to better capture severe 
sepsis. We agree with the commenters that we should not create a new 
DRG for severe sepsis based on the currently available data, and that 
we should continue to monitor the population with severe sepsis in 
order to better characterize resource utilization in these patients.
    Comment: One commenter expressed disagreement with our decision not 
to modify the DRGs to capture severe sepsis. The commenter asserted 
that using the accepted definition of severe sepsis--``a systemic 
inflammatory response to infection associated with acute organ 
dysfunction''--was adequate to identify patients for the purpose of 
creating new DRGs. The commenter also asserted that severe sepsis is 
common, deadly, and costly; that it involves extensive use of intensive 
care unit resources; and that it is inadequately represented by the use 
of ICD-9-CM procedure code 00.11(Infusion of diotrecogin alfa 
(activated)).
    Response: We agree with the commenter that severe sepsis is a 
common, deadly, and costly clinical entity. We also acknowledge that 
the current coding for all forms of sepsis is problematic. We believe 
that the creation of code 00.17 (Infusion of vasopressor agent), which 
goes into effect on October 1, 2004, in combination with code 00.11 and 
the SIRS codes 995.90 through 995.94, will help to better identify 
patients with severe sepsis. We also note, as mentioned above, that 
improved and modified coding instructions and guidelines will be 
available in October 2004. However, we continue to believe that a 
separate DRG for severe sepsis is not appropriate at this time based on 
the available data. We believe that the defining criteria for severe 
sepsis, using the currently available ICD-9-CM codes, are not specific, 
accurate, or unique enough to warrant a new DRG classification. 
However, we anticipate receiving data using the new and modified codes 
and instructions and will consider this issue again in the future.
    Comment: One commenter disagreed with our decision not to create a 
new DRG for severe sepsis. The commenter urged CMS to ``recognize 
severe sepsis as a clinically coherent condition associated with high 
mortality and a patient population displaying similar characteristics 
in terms of outcome and costs incurred for treatment, which thereby 
deserves its own DRG.'' The commenter asserted that the current DRG for 
sepsis uses the clinically obsolete term ``septicemia.'' The commenter 
also stated that severe sepsis cases now classify to 339 different 
DRGs; however, these DRGs do not distinguish between cases with and 
without severe sepsis. The commenter believed that payment for cases in 
which severe sepsis occurs is inadequate and urged us to work closely 
with the Critical Care Work Group in the development of a new DRG.
    Response: We agree with the commenter that severe sepsis cases fall 
into a wide spectrum of DRGs, and therein lies the problem. The ICD-9-
CM coding system has lacked the requisite specificity and accuracy 
needed to identify patients with severe sepsis. While new codes were 
created specifically for this purpose (codes 995.90 through 995.94), 
coders have had difficulty in consistently using the codes. We have 
worked closely with the Centers for Disease Control and Prevention to 
make refinements to the coding notes and instructions so that these 
codes can be more consistently applied. These revised notes and 
instructions will go into effect on October 1, 2004. We believe that 
when more consistent data are submitted, we will have the necessary 
information to propose further refinements in the DRGs to better 
capture severe sepsis. As mentioned before, CMS will closely monitor 
the classification of patients with severe sepsis in the near future, 
particularly with regard to the use of other codes commonly reported 
for patients with severe sepsis such as new

[[Page 48976]]

code 00.17 (Infusion of vasopressor agent) and code 00.11 (Infusion of 
diotrecogin alfa (activated)). We will also work closely with the 
American Hospital Association and the American Health Information 
Management Association on their efforts to provide education to coders 
in the correct use of the severe sepsis codes (SIRS codes 995.90 
through 995.94).
    Comment: One commenter believed that CMS was shortsighted in its 
failure to create a new DRG for severe sepsis. The commenter also noted 
that severe sepsis is a widespread and deadly disease that has been 
defined since 1992, and that severe sepsis cases currently classify 
into 339 DRGs. The commenter asserted that grouping these cases 
together in at least one DRG would enhance hospitals and practitioners' 
ability to understand the disease and its treatment as well as to 
evaluate the costs of care. This commenter further asserted that only a 
small proportion of patients with severe sepsis and organ dysfunction 
are assigned to DRG 416 (Septicemia Age >17) and DRG 417 (Septicemia 
Age 0-17), and that a large number of surgical cases with severe sepsis 
are ignored. The commenter also noted that cases of severe sepsis that 
develop after admission typically are classified in other DRGs.
    This commenter mentioned the set of proposed criteria put forth by 
another commenter to define severe sepsis (``a systemic inflammatory 
response syndrome associated with organ dysfunction, hypoperfusion, or 
hypotension'') and asserted that this definition has been widely 
accepted within the international clinical community, that it is 
encompassed by code 995.92 (Systemic inflammatory response syndrome due 
to infectious process with organ dysfunction), and that it should be 
used to identify patients for classification to a new DRG.
    Response: As mentioned earlier, we recognize that severe sepsis is 
a widespread and deadly disease that accompanies a wide spectrum of 
other diagnoses. We also recognize that it frequently develops after 
admission, and that it is a frequent complication of surgical cases. In 
addition, we recognize that current coding practices are problematic, 
and we look forward to better refining our ability to identify patients 
with severe sepsis by using codes 00.11 and 00.17 and the SIRS series 
of codes. We look forward to working with groups represented by the 
commenters in the future to optimize the DRG system to best serve this 
important Medicare patient population.
d. Implantable Cardiac Defibrillators
    There is a range of implantable cardiac defibrillators (ICDs) 
available on the market from extremely complex devices with multiple 
leads, settings, and functions to simpler models with a single lead and 
simpler functions. ICDs deliver electrical shocks to the heart to 
eliminate the life-threatening abnormal rhythms such as ventricular 
fibrillation or ventricular tachycardia.
    As indicated in the May 18, 2004, proposed rule, we received a 
coverage request to expand the indications for implantable 
defibrillators to include the population studied in the Sudden Cardiac 
Death in Heart Failure Trial (SCD-HeFT) sponsored by the National 
Institutes of Health. SCD-HeFT treated heart failure patients with 
conventional therapy and randomized them to one of three additional 
treatment strategies: (1) Placebo; (2) amiodarone (drug therapy); or 
(3) single lead implantable defibrillator. The SCD-HeFT investigators 
presented results at the American College of Cardiology annual meeting 
that the basic single-lead implantable defibrillator is effective for 
saving lives in a population at low-moderate risk for sudden cardiac 
death. As part of CMS' coverage decisions, we are considering whether 
to restrict the use of complex defibrillators to patients for whom they 
are medically necessary, that is, the population at low-moderate risk 
for sudden cardiac death.
    Given the potential increase of implantable defibrillator use in 
our population, in the May 18, 2004, proposed rule, we solicited input 
on how to encourage physicians to use the simpler, less costly device 
when advanced devices are not medically preferred. We also solicited 
input on the appropriate measures within the payment systems to 
accommodate payment for classes of defibrillators with very different 
costs. Ideally, we would like not only to align payments with relative 
costs, but also to align the incentives within the payment system with 
medically appropriate uses of different technologies.
    We believe that, within the PPS for inpatient hospital operating 
costs, there are several ways to deal with the expanding use of 
simpler, lower cost defibrillators. One possibility is to maintain the 
current DRG configuration, under which complex, expensive devices and 
simpler, less costly devices would remain within the same DRGs and 
receive the same payment rates. This approach would encourage use of 
the simpler devices, which would receive relatively higher 
reimbursement because their lower charges would be averaged in with the 
higher charges for the more complex devices in setting the DRG weights. 
However, it could lead to complaints that the program is underpaying 
for the more complex, expensive devices as the lower charges for 
simpler, less expensive devices begin to affect (lower) the DRG 
weights.
    Another approach would be to recognize the cost differences between 
various classes of defibrillators by establishing separate DRGs for 
basic single-lead implantable defibrillators as opposed to more 
complex, expensive models. This approach would prevent payments for the 
use of more expensive defibrillators (where medically necessary) from 
being diluted by the effect of the lower charges for basic single-lead 
implantable defibrillators on the weights within common DRGs. However, 
this policy would arguably provide less incentive for use of the lower 
cost devices: the weights for the DRGs containing the less expensive 
devices would be driven solely by their relatively lower charges, 
without being lifted by the higher charges for the more expensive 
models. This approach might also be criticized for departing from the 
averaging principle within the DRG system by basing too much on the 
cost differential alone in reconfiguring these DRGs.
    We solicited comments on these and other approaches to paying for 
defibrillators under the IPPS. We discuss an application for new 
technology add-on payments for a Cardiac Resynchronization Therapy with 
Defibrillator (CRT-D) in section II.E.4.c. of this final rule. We 
discuss comments regarding payments for these devices in that section.
e. Intestinal Transplantation
    Even though we did not address the issue of DRG payment for 
intestinal transplantation in the May 18, 2004, proposed rule, we 
received a comment from an institution that performs intestinal 
transplantation.
    Comment: The commenter expressed concern that the current payment 
policy utilizes a relatively low weight DRG that imposes a significant 
financial burden on health care providers. The commenter requested a 
new DRG for each of three main types of intestinal transplantation: 
isolated intestine, liver plus intestine, and multivisceral (liver, 
stomach, duodenum, pancreas, and small bowel).
    Due to the small patient population associated with these 
transplantations, the commenter suggested that CMS lower the number of 
cases required to create a new DRG. In addition, the commenter 
suggested that CMS utilize

[[Page 48977]]

data on non-Medicare patients and the pediatric population to 
supplement current MedPAR data.
    Response: We have been monitoring intestinal transplantation cases 
since October 2000, when Medicare issued a national coverage decision 
for this transplant, to determine whether it may be appropriate to 
establish a new DRG. An ICD-9-CM procedure code 46.97 (Transplant of 
intestine) was created in October 1, 2000, to uniquely capture isolated 
intestinal transplantation. Acquisition cost centers were established 
for intestines and multivisceral organs to be paid on a reasonable cost 
basis. Based on our past annual reviews, we did not find a sufficient 
number of cases to warrant the creation of a new DRG. The commenter 
provided some rationale for the absence of cases, including the time 
lag between the actual transplant date and the submission of the bill 
and the limited patient population involved.
    If an intestinal transplantation alone is performed on a patient 
with a principal diagnosis in MDC 6 (Diseases and Disorders of the 
Digestive System), the case would be assigned to either DRG 148 (Major 
Small & Large Bowel Procedures With CC) or DRG 149 (Major Small & Large 
Bowel Procedures Without CC). If an intestinal transplantation was 
performed and the patient required a tracheostomy, the case would be 
assigned to DRG 483 (Tracheostomy With Mechanical Ventilation 96+ Hours 
or Principal Diagnosis Except Face, Mouth & Neck Diagnosis). In cases 
where multiple surgical procedures are performed, the case is assigned 
to the DRG associated with the most resource-intensive surgical class. 
If an intestinal and liver transplantation were performed 
simultaneously, the case would be assigned to DRG 480 (Liver 
Transplant). It is not uncommon that a liver transplant would be 
performed with an intestinal transplant. If a multivisceral 
transplantation is performed, the case is also assigned to DRG 480.
    Based on our review of the FY 2003 MedPAR data, we identified six 
cases with procedure code 46.97 all performed at one facility. We are 
concerned that only one facility's data is contained in the MedPAR file 
when there are five Medicare-approved intestinal transplant centers. Of 
the six cases, three cases were assigned to DRG 148, with total charges 
ranging from $839,802 to $903,518 and an average length of stay of 36 
days. Two cases were assigned to DRG 483. One case was assigned to DRG 
154 (Stomach, Esophageal, & Duodenal Procedures Age >17 With CC) 
because, in addition to the intestinal transplantation, there was 
another operation on the stomach. The total charge for the one case in 
DRG 154 was $1,105,627, with a length of stay of 32 days.
    We are open to receiving non-MedPAR data but would limit the data 
to Medicare patients, rather than using non-Medicare data as suggested 
by the commenter. We believe that, if we received data from the five 
approved intestinal transplant centers regarding all Medicare patients 
receiving intestinal transplantations during the fiscal year, the 
minimum requirement of cases may be met. When we receive sufficient 
data, we will again consider a separate intestinal transplant DRG.
    We agree that payment for isolated intestinal transplant is too low 
in DRGs 148 and 149. The average payments for DRGs 148 and 149 are 
approximately $15,314 and $6,567, respectively. As mentioned earlier, 
it is not uncommon for an intestinal transplant to be performed in 
conjunction with transplants of other organs, such as the liver. As a 
matter of fact, intestinal transplants are assigned to DRG 480 now 
since these patients frequently have both an intestinal transplant and 
a liver transplant. Therefore, DRG 480 already contains cases with 
intestinal transplants. Therefore, we would not be disrupting the 
clinical cohesiveness of DRG 480 by adding intestinal transplant.
    Furthermore, intestinal transplantation has become a definitive 
treatment for patients with short gut syndrome and intestinal diseases 
who no longer can be maintained on total parenteral nutrition (TPN). 
Liver failure may be induced by TPN. The average charges for DRG 480 
are approximately $157,129. While the total charges for intestinal 
transplantation are higher than the average charges for DRG 480, we 
believe that DRG 480 is a better assignment of these cases.
    Given this practice, we are moving intestinal transplantation cases 
out of DRGs 148 and 149 and into DRG 480 (Liver Transplant), effective 
FY 2005. ICD-9-CM procedure code 46.97 will be assigned to pre-MDC, DRG 
480. The title for DRG 480 will change to ``Liver Transplant and/or 
Intestinal Transplant''. The result of this reassignment would move 
intestinal transplant cases from a weight of 3.3871 in DRG 148 and 
1.4352 in DRG 149 to a weight of 9.8696. We are aware that, with this 
change, the three main types of intestinal transplantation; isolated 
intestine, liver plus intestine, and multivisceral, will be assigned to 
DRG 480. We will continue to monitor intestinal transplantation to 
determine appropriate assignment of these cases.
f. Cochlear Implants
    Even though we did not specifically address issues relating to the 
DRG payment for cochlear implants in the May 18, 2004, proposed rule, 
we received public comments on this area.
    Comment: One commenter expressed concern about the low 
reimbursement for cochlear implants. Cochlear implants are currently 
assigned to DRG 49 (Major Head and Neck Procedures). The commenter 
stated that cochlear implants represent the only procedure in DRG 49 
involving implantation of a high cost medical device. It was stated 
that the acquisition cost alone represent 85 percent of the total cost 
of the procedure. The commenter noted that although CMS has 
acknowledged the disparity between payment and cost and vowed to 
further evaluate possible reclassification options for cochlear 
implants, nothing has been done to mitigate this payment shortfall.
    Response: Although cochlear implants was not addressed in our May 
18, 2004 proposed rule, we have continued to monitor these cases. In 
our analysis of the FY 2003 MedPAR file, we found 120 cochlear implant 
cases with average charges of approximately $44,366. There were a total 
of 1,602 cases assigned to DRG 49 with average charges of approximately 
$24,971. Cochlear implant cases represent more than 7 percent of the 
total cases in DRG 49.
    We have been unable to identify an alternative DRG assignment for 
these cases. As we discussed in the August 1, 2003, final rule (68 FR 
45367), we continue to believe that assignment of cochlear implant 
cases to DRG 482 (Tracheostomy for Face, Mouth and Neck Diagnoses) is 
inappropriate. A tracheostomy must be performed in order for the case 
to be assigned to this DRG. We remain reluctant to create a new DRG for 
specific, low-volume procedures. Doing so would create a proliferation 
of DRGs and a loss of some of the efficiency incentives inherent in the 
current system.
g. Artificial Hearts
    Comment: One commenter requested that newly created procedure codes 
37.52 (Implantation of total replacement heart system), 37.53 
(Replacement or repair of thoracic unit of total replacement heart 
system), and 37.54 (Replacement or repair of other implantable 
component of total replacement heart system) be assigned to DRG 103 
instead of DRG 525.

[[Page 48978]]

    Response: Codes 37.52, 37.53, and 37.54 are not new codes. They 
were created for the October 1, 2003 ICD-9-CM update. In the proposed 
rule, CMS discussed the restructuring of DRG 525 (69 FR 28208) and 
further listed the codes that were included in that DRG. Codes 37.52, 
37.53, and 37.54 are part of that list. We did not propose the addition 
of codes 37.52, 37.53, or 37.54 to DRG 525 for FY 2005. These codes 
were assigned to DRG 525 upon their formation, as it is our practice to 
assign all codes to DRGs when they are created. We take this 
opportunity to note that Medicare does not cover the use of an 
artificial heart as a permanent replacement for a human heart or as a 
temporary life-support system until a human heart becomes available for 
transplant. Therefore, we believe that a DRG reassignment would be 
inappropriate at this time. No DRG assignment changes will be made to 
codes 37.52, 37.53, or 37.54 for FY 2005.
h. Left Atrial Appendage Devices: DRG Assignment for New Code 37.90
    The issue of the DRG assignment of new code 37.90 (Insertion of 
left atrial appendage device) was not presented as a topic in the May 
18, 2004, proposed rule. At the April 1, 2004, ICD-9-CM Coordination 
and Maintenance Committee meeting, we discussed these devices. A new 
code was created for use in upcoming clinical trials and was fast-
tracked so that the code could be used beginning October 1, 2004, for 
discharges for FY 2005. The new code is listed in Table 6B of the 
Addendum (69 FR 28672 in the proposed rule). Table 6B represents a 
listing of approved final new codes. The codes themselves are not 
subject to comment but their assignment regarding placement as an O.R. 
procedure and the MDC and DRG placement are open to comment. As 
discussed elsewhere in this preamble, the announcement of the adoption 
of the codes as final in the IPPS proposed rule is included in the ICD-
9-CM Coordination and Maintenance Committee meeting process.
    Background: Atrial fibrillation is a common heart rhythm disorder 
that can lead to cardiovascular blood clot formation leading to 
increased risk of stroke. According to product literature, nearly all 
strokes are from embolic clots arising in the left atrial appendage of 
the heart; an appendage for which there is no useful function. Standard 
therapy uses anticoagulation drugs. However, these drugs may be 
contraindicated in certain patients and may cause complications such as 
bleeding. The underlying concept behind the left atrial appendage 
device is to block off the left atrial appendage so that blood clots 
formed therein cannot travel to other sites in the vascular system. The 
device is implanted using a percutaneous catheter procedure under 
fluoroscopy through the femoral vein. Implantation is performed in a 
hospital catheterization laboratory using standard transseptal 
technique, with the patient generally under local anesthesia. The 
procedure takes approximately one hour, and most patients stay 
overnight in the hospital.
    We received several comments concerning the proposal to assign new 
code 37.90 to DRG 518 (Percutaneous Cardiovascular Procedure Without 
Coronary Artery Stent or AMI).
    Comment: All of the commenters discussed the surgical technique 
required for insertion of the device and cited the risk and complexity 
of the procedure, especially due to the transseptal catheterization 
required. The commenters noted that because comparatively simple 
procedures are already grouped to DRG 518, DRG 518 does not reflect the 
resources used in this procedure. The commenters suggested that 
insertion of a left atrial appendage device more closely resembles the 
insertion of an atrial septal defect occluder.
    Response: Insertion of an atrial septal defect occluder would be 
coded to the 35.xx series of ICD-9-CM procedure codes. DRG 108 includes 
code 35.52 (Repair of atrial septal defect with prosthesis, closed 
technique) which may be similar to insertion of the left atrial 
appendage device. Codes in the 35.xx series are assigned to DRG 108 
(Other Cardiothoracic Procedures). We reviewed the MedPAR data and 
found the following:
[GRAPHIC] [TIFF OMITTED] TR11AU04.024

    Because code 37.90 was created for use beginning on October 1, 
2004, we have no data history regarding its utilization. However, given 
that the atrial appendage device is percutaneously inserted, and that 
most of the procedures in DRG 108 are open chest procedures, we do not 
believe that DRG 108 is the most appropriate clinical placement for new 
code 37.90. In addition, review of the data in the table above shows a 
large variance between the hospital charges and length of stay between 
DRG 518 and DRG 108. According to one manufacturer, the projected 
length of stay for insertion of an atrial appendage is overnight for 
observation purposes. The many open chest procedures in DRG 108, some 
requiring the use of cardiopulmonary bypass, would also seem to 
indicate that DRG 108 is not the best choice for clinical coherence. We 
are disinclined to assign this new code to such a resource intensive 
DRG without appropriate data to reinforce and justify such a decision. 
Therefore, we are maintaining the assignment of code 37.90 to DRG 518 
in this final rule.
    Review of code 35.52 (Repair of atrial septal defect with 
prosthesis, closed technique) in the table above shows a decided 
similarity to the cases found in DRG 518. We will analyze the placement 
of code 35.52 as part of next year's proposed rule. We will analyze 
these cases for both clinical coherence and charge data as part of the 
process of identifying the most appropriate DRG assignment for code 
35.52.
i. Carotid Artery Stents
DRG Assignment for New Codes
    At the April 1, 2004, ICD-9-CM Coordination and Maintenance 
Committee meeting, we discussed creation of a new code or codes to 
identify carotid artery stenting, along with a concomitant percutaneous 
angioplasty or atherectomy (PTA) code for delivery of the stent(s). 
This subject was addressed in response to the need to identify carotid 
artery stenting for use

[[Page 48979]]

in clinical trials in the upcoming fiscal year. Public comment 
confirmed the need for specific codes for this procedure. 
Implementation of the code was fast-tracked so that the code could be 
used beginning October 1, 2004, for discharges in FY 2005 for patients 
who are enrolled in an FDA-approved clinical trial and are using on-
label FDA approved stents and embolic protection devices.
    The newly created codes 00.61 (Percutaneous angioplasty or 
atherectomy of precerebral (extracranial vessel(s)) and 00.63 
(Percutaneous insertion of carotid artery stent(s)) were published in 
Table 6B, New Procedure Codes in the proposed rule (69 FR 28671). Table 
6B in the proposed rule represents final codes and the codes themselves 
were not subject to comment, as the notice and comments are part of the 
ICD-9-CM Coordination and Maintenance Committee process. However, their 
assignment regarding placement as an OR procedure, as well as MDC and 
DRG placement, were open to public comment.
    New code 00.61 was assigned to four MDCs and seven DRGs. The most 
likely scenario will have cases being assigned to MDC 1 (Diseases and 
Disorders of the Nervous System in DRGs 533 (Extracranial Procedures 
With CC) and 534 (Extracranial Procedures Without CC). Cases could also 
be assigned to MDC 5 (Diseases and Disorders of the Circulatory 
System), MDC 21 (Injuries, Poisoning, and Toxic Effects of Drugs), and 
MDC 24 (Multiple Significant Trauma). The less likely DRG assignments 
can be reviewed in Table 6B in the Addendum to this final rule.
    Background: Stroke is the third leading cause of death in the 
United States and the leading cause of serious, long-term disability. 
Approximately 70 percent of all strokes occur in people age 65 and 
older. The carotid artery is located in the neck and is the principal 
artery supplying the head and neck with blood. Accumulation of plaque 
in the carotid artery can lead to stroke either by decreasing the blood 
flow to the brain or by having plaque break free and lodge in the brain 
or in other arteries to the head. The PTA procedure involves inflating 
a balloon-like device in the narrowed section of the carotid artery to 
reopen the vessel. A carotid stent is then placed in the artery to 
prevent the vessel from closing and to prevent pieces of plaque from 
entering the bloodstream.
    Effective July 1, 2001, Medicare covers PTA of the carotid artery 
concurrent with carotid stent placement when furnished in accordance 
with the FDA-approved protocols governing Category B Investigational 
Device Exemption (IDE) clinical trials. PTA of the carotid artery, when 
provided solely for the purpose of carotid artery dilation concurrent 
with carotid stent placement, is considered to be a reasonable and 
necessary service only when provided in the context of such clinical 
trials, and therefore is considered a covered service for the purposes 
of these trials. Performance of PTA in the carotid artery when used to 
treat obstructive lesions outside of approved protocols governing 
Category B IDE clinical trials remains a noncovered service.
    We received several comments concerning the proposed assignment of 
new code 00.61 to MDC 1, DRG 533 and DRG 534.
    Comment: All commenters suggested that instead of code 00.61 
grouping to both DRGs 533 and 534, the cases should only be assigned to 
DRG 533. Commenters have suggested that the patients in Category B IDE 
clinical trials will not have the kinds of CCs that would assure 
assignment to DRG 533. Commenters cited other complications such as 
bilateral occlusion, certain anatomical conditions such as a 
``surgically hostile neck,'' and complex diseases, as complications in 
their cases. However, most of the CCs cited by the commenters are not 
able to be captured using current ICD-9-CM codes, and therefore would 
not contribute to the assignment of these cases to DRG 533.
    All of the commenters stated that the payment for DRG 534 is 
inadequate, but did not furnish data regarding the cost of the stent(s) 
and the embolic protection devices, possibly because these devices are 
still in the trial stage and no hospital costs have yet been 
established. Two commenters stated that they knew of reports that a 
number of sites in one of the clinical trials have indicated a 
reluctance to enroll patients due to the low level of payment under DRG 
534. One commenter reviewed cases in the FY 2002 MedPAR data file and 
noted that the cases are primarily clinical trial cases that do not 
include a charge for the carotid stent and embolic protection device. 
Therefore, the commenter added, the reported hospital charges 
significantly understate the charges that would be associated with the 
carotid stenting procedure in a nonclinical trial setting.
    Response: As we have created code 00.61 for use beginning October 
1, 2004, we have no data history regarding its utilization.
    In FY 2003, any carotid stenting procedures performed would have 
been assigned to DRG 5. Insertion of a carotid stent or stents was a 
procedure for which there was no specific coverage decision. In 
addition, the ICD-9-CM codes describing insertion of a stent were 
nonspecific, and the codes used to describe that procedure also applied 
to many other procedures for which there was a coverage decision. The 
commenter is correct that any cases in our data may have been performed 
within the setting of a clinical trial. In FY 2004, we restructured DRG 
5, splitting all those cases into DRGs 533 and 534, and ordered the 
DRGs based on the presence or absence of CCs. When we reviewed the 
available MedPAR data, we used the following proxy: Principal diagnosis 
code 433.10 (Occlusion and stenosis of carotid artery, without mention 
of cerebral infarction), and procedure codes 39.50 (Angioplasty or 
atherectomy of noncoronary vessel), plus code 39.90 (Insertion of 
nondrug-eluting, noncoronary artery stent(s)). The following table 
shows the results of our review:

[[Page 48980]]

[GRAPHIC] [TIFF OMITTED] TR11AU04.025

    When we evaluated the data in the above table, we found relative 
weights have increased for DRG 533 over the past two reporting periods 
compared to the cases in DRG 5. In addition, we found that, although 
the hospital charges had increased between reporting years 2002 and 
2003, the charges were within the mean and .75 standard deviation. As 
the DRG system is one of averages, we are reassured that this payment 
structure is appropriate.
    The FDA has not given final approval to the safety and efficacy of 
carotid PTA with stenting as clinical trials are still ongoing. CMS has 
not yet approved this procedure and device under Medicare, outside of 
the clinical trial setting. To reiterate, specific codes were recently 
created and have not yet been put into use in hospitals. We believe 
that the data that we have reviewed in DRGs 5, 533, and 534 are 
reasonably correct regarding hospital charges for this procedure. We 
believe that adjusting the IPPS system for a specific device that has 
not been used outside the clinical trial setting, without 
substantiating data, obviates the intent of the diagnosis-related 
groups. Therefore, we believe the assignment of code 00.61 to DRGs 533 
and 534 as proposed is appropriate at this time. We will continue to 
monitor DRGs 533 and 534 and procedure codes 00.61 in combination with 
00.63 in upcoming annual DRG reviews.
    At the April 1, 2004, ICD-9-CM Coordination and Maintenance 
Committee Meeting, we also created procedure codes 00.62 (Percutaneous 
angioplasty or atherectomy of intracranial vessel(s), 00.64 
(Percutaneous insertion of other precerebral (extracranial) artery 
stent(s), and 00.65 (Percutaneous insertion of intracranial vascular 
stent(s). We assigned procedure code 00.62 to the same MDCs and DRGs as 
code 00.61, mimicking the DRG assignment for predecessor codes.
    Comment: One commenter encouraged CMS to assign intracranial 
angioplasty cases containing procedure code 00.62 to DRGs 1 and 2 
instead of DRGs 533 and 534. The commenter believed that DRGs 1 and 2 
better reflect the grouping logic for clinical homogeneity and resource 
utilization.
    Response: When new ICD-9-CM codes are created, they are 
automatically assigned to an MDC and a DRG(s). We generally assign new 
codes to the predecessor DRGs until we have compelling MedPAR data that 
indicate otherwise. In the case of code 00.62, the point is moot. 
Medicare does not cover PTA of intracranial vessels, and we are not 
aware of any clinical trials during the upcoming fiscal year. We refer 
readers to the discussion of changes to Edit 11 (Non-Covered 
Procedures) of the Medicare Code Editor under section II.B.10. of this 
preamble. Therefore, in the absence of compelling evidence, we are not 
making any changes to the MDC or DRG assignments of code 00.62.
    In addition, it has come to our attention that there may be some 
coding errors that are contributing to an erroneous reimbursement case-
mix profile for hospitals. Specifically, it has been suggested that 
some hospitals may be reluctant to include a code for vessel 
angioplasty in conjunction with stent placement. Apparently, some 
hospital staff have expressed concerns that a ``true'' angioplasty is 
not being performed, and that, therefore, they will be censured by 
regulatory agencies for erroneous coding. As a result, these hospitals 
have instructed their coding staff not to include a code describing 
angioplasty of a vessel, and to only include a code for insertion of a 
stent or stents.
    This is incorrect. The AHA publication Coding Clinic for ICD-9-CM 
specifically instructs that a code for angioplasty, by any technique, 
is performed in the placement of a stent or stents (Fourth Quarter, 
1996, page 63). Therefore, the correct coding for insertion of coronary 
stent(s) requires two codes. One code describes the angioplasty with 
00.61, and the second code describes the stent insertion with code 
00.63. To fail to record the angioplasty procedure will result in 
assignment of the case to the medical DRG instead of the correct 
surgical DRG. This erroneous coding action will have an impact on many 
levels. It will result in incorrect data in the database, which in turn 
will result in an erroneous base upon which future DRG relative weights 
are calculated. In addition, in the short term, it will result in 
reduced revenue to the hospital because of the incorrect DRG assignment 
for all cases in which this occurs. To reiterate, the correct procedure 
coding for insertion of a carotid stent combines codes 00.61 and 00.63.

[[Page 48981]]

j. Acute Intermittent Porphyria
    In the May 18, 2004 IPPS proposed rule, we did not present as an 
issue the DRG assignment of the code used for acute intermittent 
porphyria. However, we did receive one comment concerning this 
condition.
    Comment: One commenter requested that we give consideration to 
assignment of a DRG to an orphan biologic intended to treat acute 
intermittent porphyria. This condition is a rare metabolic disorder 
affecting fewer than 1,000 persons in the United States. The drug 
manufacturer was concerned that Medicare hospitalization payments do 
not accurately reflect the cost of the treatment. The condition is 
coded to Code 277.1 (Disorders of porphyrin metabolism) and is assigned 
to DRG 299 (Inborn Errors of Metabolism).
    Response: The DRG assignment of code 277.1 was not an issue that 
was addressed in the May 18, 2004 proposed rule. We will take this 
comment into consideration in the future as we conduct analysis of the 
MedPAR data for next year's proposed rule.

C. Recalibration of DRG Weights

    As we proposed, in this final rule, we used the same basic 
methodology for the FY 2005 recalibration as we did for FY 2004 (August 
1, 2003 IPPS final rule (68 FR 45373)). That is, we have recalibrated 
the DRG weights based on charge data for Medicare discharges using the 
most current charge information available (the FY 2003 MedPAR file).
    The MedPAR file is based on fully coded diagnostic and procedure 
data for all Medicare inpatient hospital bills. The FY 2003 MedPAR data 
used in this final rule include discharges occurring between October 1, 
2002, and September 30, 2003, based on bills received by CMS through 
March 31, 2004, from all hospitals subject to the IPPS and short-term 
acute care hospitals in Maryland (which are under a waiver from the 
IPPS under section 1814(b)(3) of the Act). The FY 2003 MedPAR file 
includes data for approximately 11,740,557 Medicare discharges. 
Discharges for Medicare beneficiaries enrolled in a Medicare+Choice 
managed care plan are excluded from this analysis. The data excludes 
CAHs, including hospitals that subsequently became CAHs after the 
period from which the data were taken.
    The methodology used to calculate the DRG relative weights from the 
FY 2003 MedPAR file is as follows:
     To the extent possible, all the claims were regrouped 
using the DRG classification revisions discussed in section II.B. of 
this preamble.
     The transplant cases that were used to establish the 
relative weight for heart and heart-lung, liver, and lung transplants 
(DRGs 103, 480, and 495) were limited to those Medicare-approved 
transplant centers that have cases in the FY 2001 MedPAR file. 
(Medicare coverage for heart, heart-lung, liver, and lung transplants 
is limited to those facilities that have received approval from CMS as 
transplant centers.)
     Organ acquisition costs for kidney, heart, heart-lung, 
liver, lung, pancreas, and intestinal (or multivisceral organs) 
transplants continue to be paid on a reasonable cost basis. Because 
these acquisition costs are paid separately from the prospective 
payment rate, it is necessary to subtract the acquisition charges from 
the total charges on each transplant bill that showed acquisition 
charges before computing the average charge for the DRG and before 
eliminating statistical outliers.
     Charges were standardized to remove the effects of 
differences in area wage levels, indirect medical education and 
disproportionate share payments, and, for hospitals in Alaska and 
Hawaii, the applicable cost-of-living adjustment.
     The average standardized charge per DRG was calculated by 
summing the standardized charges for all cases in the DRG and dividing 
that amount by the number of cases classified in the DRG. A transfer 
case is counted as a fraction of a case based on the ratio of its 
transfer payment under the per diem payment methodology to the full DRG 
payment for nontransfer cases. That is, a transfer case receiving 
payment under the transfer methodology equal to half of what the case 
would receive as a nontransfer would be counted as 0.5 of a total case.
     Statistical outliers were eliminated by removing all cases 
that are beyond 3.0 standard deviations from the mean of the log 
distribution of both the charges per case and the charges per day for 
each DRG.
     The average charge for each DRG was then recomputed 
(excluding the statistical outliers) and divided by the national 
average standardized charge per case to determine the relative weight.
    The new weights are normalized by an adjustment factor of 1.46795 
so that the average case weight after recalibration is equal to the 
average case weight before recalibration. This adjustment is intended 
to ensure that recalibration by itself neither increases nor decreases 
total payments under the IPPS.
    When we recalibrated the DRG weights for previous years, we set a 
threshold of 10 cases as the minimum number of cases required to 
compute a reasonable weight. We used that same case threshold in 
recalibrating the final DRG weights for FY 2005. Using the FY 2003 
MedPAR data set, there are 41 DRGs that contain fewer than 10 cases. We 
computed the weights for these low-volume DRGs by adjusting the FY 2004 
weights of these DRGs by the percentage change in the average weight of 
the cases in the other DRGs.
    Section 1886(d)(4)(C)(iii) of the Act requires that, beginning with 
FY 1991, reclassification and recalibration changes be made in a manner 
that assures that the aggregate payments are neither greater than nor 
less than the aggregate payments that would have been made without the 
changes. Although normalization is intended to achieve this effect, 
equating the average case weight after recalibration to the average 
case weight before recalibration does not necessarily achieve budget 
neutrality with respect to aggregate payments to hospitals because 
payments to hospitals are affected by factors other than average case 
weight. Therefore, as we have done in past years and as discussed in 
section II.A.4.a. of the Addendum to this final rule, we are making a 
budget neutrality adjustment to ensure that the requirement of section 
1886(d)(4)(C)(iii) of the Act is met.
    Comment: Two commenters addressed the proposed DRG weights for 
three DRGs. One commenter was appreciative of the increased proposed 
DRG weight for DRG 36 (Retinal Procedures). The current DRG weight is 
0.6298 and the proposed weight was 0.6766. Another commenter expressed 
concern that the proposed weights for DRGs 535 (Cardiac Defibrillator 
Implant With Cardiac Catheterization With AMI, Heart Failure, or Shock) 
and DRG 536 (Cardiac Defibrillator Implant With Cardiac Catheterization 
Without AMI, Heart Failure or Shock) believes this would not cover the 
cost of the Cardiac Resynchronization Therapy Defibrillator (CRT-D), 
much less the procedure and nursing care costs associated with these 
procedures. The commenter believed that the DRG weight data are 
problematic because they are based on hospital charges. The commenter 
stated that hospitals do not like to mark up the cost of an item at 
$34,000. The commenter inquired whether CMS has evaluated the cost of 
the CRT-Ds from the claims which was calculated using the cost-to-
charge ratio compared to outside data on the cost of the CRT-Ds.
    Response: In the process of recalibration of the DRG weights, we

[[Page 48982]]

consider the most recent charge data available. Both high and low cost 
technologies are absorbed gradually into the data that are used to 
determine the DRG weight.

D. LTC-DRG Reclassifications and Relative Weights for LTCHs for FY 2005

1. Background
    In the June 6, 2003, LTCH PPS final rule (68 FR 34122), we changed 
the LTCH PPS annual payment rate update cycle to be effective July 1 
through June 30 instead of October 1 through September 30. In addition, 
because the patient classification system utilized under the LTCH PPS 
is based directly on the DRGs used under the IPPS for acute care 
hospitals, in that same final rule, we explained that the annual update 
of the long-term care diagnosis-related group (LTC-DRG) classifications 
and relative weights will continue to remain linked to the annual 
reclassification and recalibration of the CMS-DRGs used under the IPPS.
    The annual update to the IPPS DRGs is based on the annual revisions 
to the ICD-9-CM codes and is effective each October 1. In the health 
care industry, annual changes to the ICD-9-CM codes are effective for 
discharges occurring on or after October 1 each year. The use of the 
ICD-9-CM coding system is also compliant with the requirements of the 
Health Insurance Portability and Accountability Act (HIPAA), Public Law 
104-191, under 45 CFR parts 160 and 162. Therefore, the manual and 
electronic versions of the GROUPER software, which are based on the 
ICD-9-CM codes, are also revised annually and effective for discharges 
occurring on or after October 1 each year. Because the LTC-DRGs are 
based on the patient classification system used under the IPPS (CMS-
DRGs), which is updated annually and effective for discharges occurring 
on or after October 1 through September 30 each year, in the May 7, 
2004, LTCH PPS final rule (69 FR 25674), we specified that we will 
continue to update the LTC-DRG classifications and relative weights to 
be effective for discharges occurring on or after October 1 through 
September 30 each year. Furthermore, we stated that we will publish the 
annual update of the LTC-DRGs in the proposed and final rules for the 
IPPS.
    In the May 18, 2004, IPPS proposed rule (69 FR 28225), we proposed 
revisions to the LTC-DRG classifications and relative weights. We are 
finalizing them in this IPPS final rule, to be effective October 1, 
2004, through September 30, 2005, using the latest available data. The 
final LTC-DRGs and relative weights for FY 2005 in this final rule are 
based on the IPPS DRGs (GROUPER Version 22.0) discussed in section II. 
of this final rule.
    Comment: One commenter questioned whether the rate update cycle for 
the LTCH PPS will revert from a July 1 through June 30 cycle to the 
Federal fiscal year cycle (October 1 through September 30) since we 
proposed to update the LTC-DRGs effective for discharges on or after 
October 1, 2004.
    Response: In the June 6, 2003 LTCH PPS final rule (68 FR 34122), we 
changed the LTCH PPS annual payment rate update cycle to be effective 
July 1 through June 30 instead of October 1 through September 30. As we 
discussed in that same LTCH PPS final rule and as we discussed in the 
May 18, 2004, IPPS proposed rule (69 FR 28225), because the patient 
classification system utilized under the LTCH PPS is based directly on 
the DRGs used under the IPPS for acute care hospitals, the annual 
update of the LTC-DRG classifications and relative weights will 
continue to remain linked to the annual reclassification and 
recalibration of the CMS-DRGs used under the IPPS.
    The most recent annual LTCH PPS payment rate update and policy 
changes for the 2005 LTCH PPS rate year (July 1, 2004 through June 30, 
2004) was published in the Federal Register on May 7, 2004 (69 FR 25674 
through 25749). In that same LTCH PPS final rule, we established rate 
updates and policy changes that were effective for discharges occurring 
on or after July 1, 2004, including an update to the standard Federal 
LTCH PPS rate, the LTCH PPS wage index and the LTCH PPS outlier 
threshold. However, because the LTC-DRGS are linked to the IPPS DRGs, 
the LTC-DRG classifications and relative weights established in the 
August 1, 2003, final rule (68 FR 45374), which were effective 
beginning in Federal FY 2004, remain in effect through September 30, 
2004. The updated LTC-DRG classifications and relative weights 
established for FY 2005 shown in Table 11 of this final rule will be 
effective for LTCH discharges on or after October 1, 2004 and before 
September 30, 2005. As we stated in the June 6, 2003 LTCH PPS final 
rule, the rate update cycle for the LTCH PPS will continue to remain on 
a July 1 through June 30 cycle while the annual update to the LTC-DRG 
classifications and relative weights will remain on a Federal fiscal 
year cycle (October 1 through September 30). Accordingly, the updated 
LTCH PPS Federal rate ($36,833.69) and other payment factors (such as 
the outlier threshold and wage index values) effective July 1, 2004 
(see May 7, 2004, (69 FR 25674)), are applied in conjunction with the 
LTC-DRGs and relative weights established in the August 1, 2003, IPPS 
final rule (68 FR 45374) that are in effect through September 30, 2004, 
for LTCH discharges occurring from July 1, 2004 through September 30, 
2004. However, beginning with discharges occurring on or after October 
1, 2004, the LTC-DRGs and relative weights established in this final 
rule will be applied in conjunction with the LTCH PPS Federal rate 
($36,833.69) and other payment factors (such as the outlier threshold 
and wage index values) effective July 1, 2004, as established in the 
May 7, 2004 LTCH PPS final rule (69 FR 25674), for discharges occurring 
through June 30, 2005.
2. Changes in the LTC-DRG Classifications
a. Background
    Section 123 of Public Law 106-113 specifically requires that the 
PPS for LTCHs be a per discharge system with a DRG-based patient 
classification system reflecting the differences in patient resources 
and costs in LTCHs while maintaining budget neutrality. Section 
307(b)(1) of Public Law 106-554 modified the requirements of section 
123 of Public Law 106-113 by specifically requiring that the Secretary 
examine ``the feasibility and the impact of basing payment under such a 
system [the LTCH PPS] on the use of existing (or refined) hospital 
diagnosis-related groups (DRGs) that have been modified to account for 
different resource use of long-term care hospital patients as well as 
the use of the most recently available hospital discharge data.''
    In accordance with section 307(b)(1) of Public Law 106-554 and 
Sec.  412.515 of our existing regulations, the LTCH PPS uses 
information from LTCH patient records to classify patient cases into 
distinct LTC-DRGs based on clinical characteristics and expected 
resource needs. The LTC-DRGs used as the patient classification 
component of the LTCH PPS correspond to the DRGs under the IPPS for 
acute care hospitals. Thus, as we proposed in the May 18, 2004, IPPS 
proposed rule, we will use the IPPS GROUPER Version 22.0 for FY 2005 to 
process LTCH PPS claims in this final rule. The changes to the IPPS DRG 
classification system for FY 2005 (GROUPER Version 22.0) are discussed 
in section II.B. of this preamble.
    Under the LTCH PPS, we determine relative weights for each of the 
CMS DRGs to account for the difference in resource use by patients 
exhibiting the case complexity and multiple medical

[[Page 48983]]

problems characteristic of LTCH patients. In a departure from the IPPS, 
as we discussed in the August 30, 2002, final rule (67 FR 55985), which 
implemented the LTCH PPS, and the August 1, 2003, IPPS final rule (68 
FR 45374), we use low-volume quintiles in determining the LTC-DRG 
weights for LTC-DRGs with less than 25 LTCH cases, since LTCHs do not 
typically treat the full range of diagnoses as do acute care hospitals. 
Specifically, we group those low-volume LTC-DRGs (LTC-DRGs with fewer 
than 25 cases) into 5 quintiles based on average charge per discharge. 
(A listing of the composition of low-volume quintiles for the FY 2004 
LTC-DRGs (based on FY 2002 MedPAR data) appears in section II.D.3. of 
the August 1, 2003 IPPS final rule (68 FR 45377 through 45380).) We 
also adjust for cases in which the stay at the LTCH is less than or 
equal to five-sixths of the geometric average length of stay; that is, 
short-stay outlier cases (Sec.  412.529), as discussed below in section 
II.D.4. of this preamble.
b. Patient Classifications Into DRGs
    Generally, under the LTCH PPS, Medicare payment is made at a 
predetermined specific rate for each discharge; that is, payment varies 
by the LTC-DRG to which a beneficiary's stay is assigned. Similar to 
case classification for acute care hospitals under the IPPS (see 
section II.B. of this preamble), cases are classified into LTC-DRGs for 
payment under the LTCH PPS based on the principal diagnosis, up to 
eight additional diagnoses, and up to six procedures performed during 
the stay, as well as age, sex, and discharge status of the patient. The 
diagnosis and procedure information is reported by the hospital using 
codes from the ICD-9-CM.
    As discussed in section II.B. of this preamble, the CMS DRGs are 
organized into 25 major diagnostic categories (MDCs), most of which are 
based on a particular organ system of the body; the remainder involve 
multiple organ systems (such as MDC 22, Burns). Accordingly, the 
principal diagnosis determines MDC assignment. Within most MDCs, cases 
are then divided into surgical DRGs and medical DRGs. Some surgical and 
medical DRGs are further differentiated based on the presence or 
absence of CCs. (See section II.B. of this preamble for further 
discussion of surgical DRGs and medical DRGs.)
    Because the assignment of a case to a particular LTC-DRG will help 
determine the amount that is paid for the case, it is important that 
the coding is accurate. As used under the IPPS, classifications and 
terminology used under the LTCH PPS are consistent with the ICD-9-CM 
and the Uniform Hospital Discharge Data Set (UHDDS), as recommended to 
the Secretary by the National Committee on Vital and Health Statistics 
(``Uniform Hospital Discharge Data: Minimum Data Set, National Center 
for Health Statistics, April 1980'') and as revised in 1984 by the 
Health Information Policy Council (HIPC) of the U.S. Department of 
Health and Human Services. We wish to point out again that the ICD-9-CM 
coding terminology and the definitions of principal and other diagnoses 
of the UHDDS are consistent with the requirements of the Administrative 
Simplification Act of 1996 of the HIPAA (45 CFR parts 160 and 162).
    The emphasis on the need for proper coding cannot be overstated. 
Inappropriate coding of cases can adversely affect the uniformity of 
cases in each LTC-DRG and produce inappropriate weighting factors at 
recalibration and result in inappropriate payments under the LTCH PPS. 
LTCHs are to follow the same coding guidelines used by the acute care 
hospitals to ensure accuracy and consistency in coding practices. There 
will be only one LTC-DRG assigned per long-term care hospitalization; 
it will be assigned at the discharge. Therefore, it is mandatory that 
the coders continue to report the same principal diagnosis on all 
claims and include all diagnostic codes that coexist at the time of 
admission, that are subsequently developed, or that affect the 
treatment received. Similarly, all procedures performed during that 
stay are to be reported on each claim.
    Upon the discharge of the patient from a LTCH, the LTCH must assign 
appropriate diagnosis and procedure codes from the ICD-9-CM. As of 
October 16, 2002, a LTCH that was required to comply with the HIPAA 
Administrative Simplification Standards and that had not obtained an 
extension in compliance with the Administrative Compliance Act (Pub. L. 
107-105) is obligated to comply with the standards at 45 CFR 162.1002 
and 45 CFR 162.1102. Completed claim forms are to be submitted to the 
LTCH's Medicare fiscal intermediary. Medicare fiscal intermediaries 
enter the clinical and demographic information into their claims 
processing systems and subject this information to a series of 
automated screening processes called the Medicare Code Editor (MCE). 
These screens are designed to identify cases that require further 
review before assignment into an LTC-DRG can be made.
    After screening through the MCE, each LTCH claim will be classified 
into the appropriate LTC-DRG by the Medicare LTCH GROUPER. The LTCH 
GROUPER is specialized computer software based on the same GROUPER used 
under the IPPS. After the LTC-DRG is assigned, the Medicare fiscal 
intermediary determines the prospective payment by using the Medicare 
LTCH PPS PRICER program, which accounts for LTCH hospital-specific 
adjustments. As provided for under the IPPS, we provide an opportunity 
for the LTCH to review the LTC-DRG assignments made by the fiscal 
intermediary and to submit additional information within a specified 
timeframe (Sec.  412.513(c)).
    The GROUPER is used both to classify past cases in order to measure 
relative hospital resource consumption to establish the LTC-DRG weights 
and to classify current cases for purposes of determining payment. The 
records for all Medicare hospital inpatient discharges are maintained 
in the MedPAR file. The data in this file are used to evaluate possible 
DRG classification changes and to recalibrate the DRG weights during 
our annual update (as discussed in section II. of this preamble). The 
LTC-DRG relative weights are based on data for the population of LTCH 
discharges, reflecting the fact that LTCH patients represent a 
different patient mix than patients in short-term acute care hospitals.
3. Development of the FY 2005 LTC-DRG Relative Weights
a. General Overview of Development of the LTC-DRG Relative Weights
    As we stated in the August 30, 2002, LTCH PPS final rule (67 FR 
55981), one of the primary goals for the implementation of the LTCH PPS 
is to pay each LTCH an appropriate amount for the efficient delivery of 
care to Medicare patients. The system must be able to account 
adequately for each LTCH's case-mix in order to ensure both fair 
distribution of Medicare payments and access to adequate care for those 
Medicare patients whose care is more costly. To accomplish these goals, 
we adjust the LTCH PPS standard Federal prospective payment system rate 
by the applicable LTC-DRG relative weight in determining payment to 
LTCHs for each case.
    Under the LTCH PPS, relative weights for each LTC-DRG are a primary 
element used to account for the variations in cost per discharge and 
resource utilization among the payment groups (Sec.  412.515). To 
ensure that Medicare patients classified to each LTC-DRG have access to 
an appropriate level of services and to encourage efficiency, we 
calculate a relative weight

[[Page 48984]]

for each LTC-DRG that represents the resources needed by an average 
inpatient LTCH case in that LTC-DRG. For example, cases in an LTC-DRG 
with a relative weight of 2 will, on average, cost twice as much as 
cases in an LTC-DRG with a weight of 1.
b. Data
    To calculate the LTC-DRG relative weights for FY 2005 in this final 
rule, we obtained total Medicare allowable charges from FY 2003 
Medicare hospital bill data from the March 2004 update of the MedPAR 
file, and we used Version 22.0 of the CMS GROUPER for IPPS, as 
discussed in section II.B. of this preamble, to classify cases. 
Consistent with the methodology under the IPPS, we recalculated the FY 
2005 LTC-DRG relative weights based on the best available data for this 
final rule.
    As we discussed in the May 18, 2004 proposed rule (69 FR 28227), we 
have excluded the data from LTCHs that are all-inclusive rate providers 
and LTCHs that are reimbursed in accordance with demonstration projects 
authorized under section 402(a) of Public Law 90-248 (42 U.S.C. 1395b-
1) or section 222(a) of Public Law 92-603 (42 U.S.C. 1395b-1). 
Therefore, in the development of the FY 2005 LTC-DRG relative weights, 
we have excluded the data of the 22 all-inclusive rate providers and 
the 3 LTCHs that are paid in accordance with demonstration projects 
that had claims in the FY 2003 MedPAR file.
    In the August 1, 2003, final rule (68 FR 45367), we discussed 
coding inaccuracies that were found in claims data for a large chain of 
LTCHs in the FY 2002 MedPAR file used to determine the LTC-DRG relative 
weights for FY 2004. Specifically, the principal diagnosis was not 
reported correctly on many of those LTCHs' claims, which resulted in 
those claims being incorrectly assigned to an LTC-DRG. As we explained 
in the same final rule, we were able to determine the correct diagnoses 
and procedure codes for the claims that contained the coding errors, 
and we used them to group each LTCH case to the appropriate LTC-DRG for 
determining the LTC-DRG relative weights for FY 2004. In addition, we 
stated that since the LTCH PPS was implemented for cost reporting 
periods beginning on or after October 1, 2002 (FY 2003), we believe 
that this problem will be self-correcting as LTCHs submit more 
completely coded data in the future.
    As we discussed in the May 7, 2004, LTCH PPS final rule (69 FR 
25674), an analysis of LTCH claims data from the September 2003 update 
of the FY 2003 MedPAR file contained coding errors. Specifically, a 
large hospital chain of LTCHs continued to consistently code diagnoses 
inaccurately on the claims it submitted, and these coding errors were 
reflected in the September 2003 update of the FY 2003 MedPAR file. Upon 
discovering the coding errors, we notified the large chain of LTCHs 
whose claims contained the coding inaccuracies to request that they 
resubmit those claims with the correct diagnoses codes by December 31, 
2003, so that those corrected claims would be contained in the December 
2003 update of the FY 2003 MedPAR file. As we discussed in that same 
final rule, it appears that those claims were submitted timely with the 
correct diagnoses codes. Therefore, it was not necessary to correct the 
FY 2003 MedPAR data for the development of the rates and factors 
established in the May 7, 2004, LTCH PPS final rule. Accordingly, in 
the May 18, 2004, IPPS proposed rule, we used LTCH claims data from the 
December 2003 update of the FY 2003 MedPAR file for the determination 
of the proposed FY 2005 LTC-DRG relative weights. For this final rule, 
we used the latest available LTCH claims data from the March 2004 
update of the FY 2003 MedPAR file.
c. Hospital-Specific Relative Value Methodology
    By nature LTCHs often specialize in certain areas, such as 
ventilator-dependent patients and rehabilitation and wound care. Some 
case types (DRGs) may be treated, to a large extent, in hospitals that 
have, from a perspective of charges, relatively high (or low) charges. 
This nonarbitrary distribution of cases with relatively high (or low) 
charges in specific LTC-DRGs has the potential to inappropriately 
distort the measure of average charges. To account for the fact that 
cases may not be randomly distributed across LTCHs, we use a hospital-
specific relative value method to calculate the LTC-DRG relative 
weights instead of the methodology used to determine the DRG relative 
weights under the IPPS described above in section II.C. of this 
preamble. We believe this method will remove this hospital-specific 
source of bias in measuring LTCH average charges. Specifically, we 
reduce the impact of the variation in charges across providers on any 
particular LTC-DRG relative weight by converting each LTCH's charge for 
a case to a relative value based on that LTCH's average charge.
    Under the hospital-specific relative value method, we standardize 
charges for each LTCH by converting its charges for each case to 
hospital-specific relative charge values and then adjusting those 
values for the LTCH's case-mix. The adjustment for case-mix is needed 
to rescale the hospital-specific relative charge values (which, by 
definition, averages 1.0 for each LTCH). The average relative weight 
for a LTCH is its case-mix, so it is reasonable to scale each LTCH's 
average relative charge value by its case-mix. In this way, each LTCH's 
relative charge value is adjusted by its case-mix to an average that 
reflects the complexity of the cases it treats relative to the 
complexity of the cases treated by all other LTCHs (the average case-
mix of all LTCHs).
    In accordance with the methodology established under Sec.  412.523, 
we standardize charges for each case by first dividing the adjusted 
charge for the case (adjusted for short-stay outliers under Sec.  
412.529 as described in section II.D.4. (step 3) of this preamble) by 
the average adjusted charge for all cases at the LTCH in which the case 
was treated. Short-stay outliers under Sec.  412.529 are cases with a 
length of stay that is less than or equal to five-sixths the average 
length of stay of the LTC-DRG. The average adjusted charge reflects the 
average intensity of the health care services delivered by a particular 
LTCH and the average cost level of that LTCH. The resulting ratio is 
multiplied by that LTCH's case-mix index to determine the standardized 
charge for the case.
    Multiplying by the LTCH's case-mix index accounts for the fact that 
the same relative charges are given greater weight in a LTCH with 
higher average costs than they would at a LTCH with low average costs 
which is needed to adjust each LTCH's relative charge value to reflect 
its case-mix relative to the average case-mix for all LTCHs. Because we 
standardize charges in this manner, we count charges for a Medicare 
patient at a LTCH with high average charges as less resource intensive 
than they would be at a LTCH with low average charges. For example, a 
$10,000 charge for a case in a LTCH with an average adjusted charge of 
$17,500 reflects a higher level of relative resource use than a $10,000 
charge for a case in a LTCH with the same case-mix, but an average 
adjusted charge of $35,000. We believe that the adjusted charge of an 
individual case more accurately reflects actual resource use for an 
individual LTCH because the variation in charges due to systematic 
differences in the markup of charges among LTCHs is taken into account.
    Comment: MedPAC supported the use of the hospital-specific relative 
value methodology for determining the LTC-DRG relative weights, stating 
that ``[t]his method eliminates distortions in

[[Page 48985]]

weights due to systematic differences among hospitals in the level of 
costs per case and in charge markups.'' The Commission believed that we 
should explore the use of this methodology for the DRG relative weights 
used under the IPPS.
    Response: We appreciate MedPAC's support of the use of the 
hospital-specific relative value methodology for determining the LTC-
DRG relative weights. As we discuss above, because by nature LTCHs 
often specialize in certain types of care, we believe it is important 
to remove any hospital-specific source of bias in measuring LTCHs' 
average charges. Therefore, we have continued to use of the hospital-
specific relative value methodology for determining the final FY 2005 
LTC-DRG relative weights shown in Table 11 of this final rule.
    As discussed above, we believe that the LTCHs' charge data are 
particularly vunerable to having a hospital-specific source of bias 
when measuring LTCHs' average charges because of the small number of 
LTCHs (approximately 300 hospitals with approximately 100,00 discharges 
annually) and the relatively high degree of specialization of many 
LTCHs. There are over 4,000 short-term acute care hospitals paid under 
the IPPS, with approximately 11.9 million discharges annually, that 
generally treat a wide range of conditions, rather than specializing in 
one or two types of conditions. Therefore, although we agree with the 
Commission that the hospital-specific relative value methodology 
eliminates distortions in relative weights due to systematic 
differences among hospitals' charges, we do not believe that it is 
necessary to use the hospital-specific relative value methodology under 
the IPPS since short-term acute care hospitals' charge data is not as 
susceptible to having a hospital-specific source of bias when measuring 
average charges.
    Furthermore, as we discussed in the August 1, 2000, IPPS final rule 
(65 FR 47103), in 1995 the MedPAC's predecessor, the Prospective 
Payment Assessment Commission, made a similar recommendation to adopt 
the hospital-specific relative value methodology under the IPPS. In the 
June 2, 1995, proposed rule (60 FR 29246), we agreed with the 
Commission's judgment that basing the IPPS DRG weights on standardized 
charges results in weights that are somewhat distorted as measures of 
the relative costliness of treating a typical case in each DRG, and 
that the hospital-specific relative value method of setting weights may 
reduce or eliminate distortions present in the current system. However, 
in our discussion on DRG refinements under the IPPS in the same rule 
(60 FR 29209), we reiterated our position published in the final rule 
on September 1, 1992 (57 FR 39761), that we would not propose to make 
significant changes to the DRG classification system under the IPPS, 
unless we are able to either improve our ability to predict coding 
changes by validating in advance the impact that potential DRG changes 
may have on coding behavior, or to make methodological changes to 
prevent building the inflationary effects of the coding changes into 
future program payments. Without further evaluation, we do not believe 
it would be appropriate to change the methodology for determining the 
DRG relative weights under the IPPS at this time. The development of 
the FY 2005 DRG relative weights used under the IPPS for short-term 
acute care hospitals is discussed in section II.C. of this preamble.
d. Low-Volume LTC-DRGs
    In order to account for LTC-DRGs with low-volume (that is, with 
fewer than 25 LTCH cases), in accordance with the methodology discussed 
in the August 30, 2002, LTCH PPS final rule (67 FR 55984) and in the 
May 18, 2004, IPPS proposed rule (69 FR 28228), we group those low-
volume LTC-DRGs into one of five categories (quintiles) based on 
average charges, for the purposes of determining relative weights. For 
this final rule, using LTCH cases from the March 2004 update of the FY 
2003 MedPAR file, we identified 172 LTC-DRGs that contained between 1 
and 24 cases. This list of LTC-DRGs was then divided into one of the 5 
low-volume quintiles, each containing a minimum of 34 LTC-DRGs (172/5 = 
34 with 2 LTC-DRGs as the remainder). For FY 2005, as we described in 
the May 18, 2004 IPPS proposed rule, we are making an assignment to a 
specific low-volume quintile by sorting the low-volume LTC-DRGs in 
ascending order by average charge. For this final rule, this results in 
an assignment to a specific low volume quintile of the sorted 172 low-
volume LTC-DRGs by ascending order by average charge. Since the number 
of LTC-DRGs with less than 25 LTCH cases is not evenly divisible by 
five, the average charge of the low-volume LTC-DRG was used to 
determine which low-volume quintile received the additional LTC-DRG. 
After sorting the 172 low-volume LTC-DRGs in ascending order, we 
grouped the first fifth (34) of low-volume LTC-DRGs with the lowest 
average charge would be grouped into Quintile 1. The highest average 
charge cases are grouped into Quintile 5. Since the average charge of 
the 103rd LTC-DRG in the sorted list is closer to the previous LTC-
DRG's average charge (assigned to Quintile 3) than to the average 
charge of the 104th LTC-DRG in the sorted list (to be assigned to 
Quintile 4), we placed it into Quintile 3. This process was repeated 
through the remaining low-volume LTC-DRGs so that 3 low-volume 
quintiles contain 34 LTC-DRGs and 2 low-volume quintiles contain 35 
LTC-DRGs.
    In order to determine the relative weights for the LTC-DRGs with 
low volume for FY 2005, in accordance with the methodology described in 
the August 30, 2002 LTCH PPS final rule (67 FR 55984) and cited in the 
May 18, 2004 IPPS proposed rule, we used the five low-volume quintiles 
described above. The composition of each of the five low-volume 
quintiles shown below in Table 1 is used in determining the LTC-DRG 
relative weights for FY 2005. We determine a relative weight and 
(geometric) average length of stay for each of the five low-volume 
quintiles using the formula that we apply to the regular LTC-DRGs (25 
or more cases), as described below in section II.D.4. of this preamble. 
We assign the same relative weight and average length of stay to each 
of the LTC-DRGs that make up that low-volume quintile. We note that, as 
this system is dynamic, it is possible that the number and specific 
type of LTC-DRGs with a low volume of LTCH cases will vary in the 
future. We use the best available claims data in the MedPAR file to 
identify low-volume LTC-DRGs and to calculate the relative weights 
based on our methodology.
BILLING CODE 4121-01-P

[[Page 48986]]

[GRAPHIC] [TIFF OMITTED] TR11AU04.026


[[Page 48987]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.027


[[Page 48988]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.028


[[Page 48989]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.029

BILLING CODE 4121-01-C
4. Steps for Determining the FY 2005 LTC-DRG Relative Weights
    As we noted previously, the FY 2005 LTC-DRG relative weights are 
determined in accordance with the methodology described in the August 
1, 2003 IPPS final rule (68 FR 45367) and cited in the May 18, 2004 
IPPS proposed rule (69 FR 28231). In summary, LTCH cases must be 
grouped in the appropriate LTC-DRG, while taking into account the low-
volume LTC-DRGs as described above, before the FY 2005 LTC-DRG relative 
weights can be determined. After grouping the cases in the appropriate 
LTC-DRG, we calculate the relative weights for FY 2005 in this final 
rule by first removing statistical outliers and cases with a length of 
stay of 7 days or less. Next, we adjust the number of cases in each 
LTC-DRG for the effect of short-stay outlier cases under Sec.  412.529. 
The short-stay adjusted discharges and corresponding charges are used 
to calculate ``relative adjusted weights'' in each LTC-DRG using the 
hospital-specific relative value method described above.
    Below we discuss in detail the steps for calculating the FY 2005 
LTC-DRG relative weights.
    Step 1--Remove statistical outliers.
    The first step in the calculation of the FY 2005 LTC-DRG relative 
weights is to remove statistical outlier cases. We define statistical 
outliers as cases that are outside of 3.0 standard deviations from the 
mean of the log distribution of both charges per case and the charges 
per day for each LTC-DRG. These statistical outliers are removed prior 
to calculating the relative weights. We believe that they may represent 
aberrations in the data that distort the measure of average resource 
use. Including those LTCH cases in the calculation of the relative 
weights could result in an inaccurate relative weight that does not 
truly reflect relative resource use among the LTC-DRGs.
    Step 2--Remove cases with a length of stay of 7 days or less.
    The FY 2005 LTC-DRG relative weights reflect the average of 
resources used on representative cases of a specific type. Generally, 
cases with a length of stay 7 days or less do not belong in a LTCH 
because these stays do

[[Page 48990]]

not fully receive or benefit from treatment that is typical in a LTCH 
stay, and full resources are often not used in the earlier stages of 
admission to a LTCH. If we were to include stays of 7 days or less in 
the computation of the FY 2005 LTC-DRG relative weights, the value of 
many relative weights would decrease and, therefore, payments would 
decrease to a level that may no longer be appropriate.
    We do not believe that it would be appropriate to compromise the 
integrity of the payment determination for those LTCH cases that 
actually benefit from and receive a full course of treatment at a LTCH, 
in order to include data from these very short-stays. Thus, in 
determining the FY 2005 LTC-DRG relative weights, we remove LTCH cases 
with a length of stay of 7 days or less.
    Comment: One commenter believes that it is inappropriate to exclude 
cases with a length of stay of 7 days or less from the calculation of 
the proposed LTC-DRG relative weights since it is not uncommon for very 
resource intensive patients to expire within the first 7 days of the 
stay. The commenter also suggested that we consider creating a separate 
LTC-DRG for LTCH patients that expire within the first 7 days of the 
stay.
    Response: While we understand the commenters concerns, as we 
discussed in the August 30, 2002, final rule (67 FR 55989) which 
implemented the LTCH PPS, in calculating the LTC-DRG relative weights, 
we exclude cases with a length of stay of 7 days or less because we 
believe that, generally, cases with a length of stay of 7 days or less 
do not belong in a LTCH. In general, LTCHs are defined by statute as 
hospitals having an average length of stay of greater than 25 days. 
LTCHs typically furnish extended medical and rehabilitative care for 
patients who are clinically complex and have multiple or chronic 
conditions. Generally, LTCH cases with very short lengths of stay (that 
is, 7 days or less) are discharged from the LTCH before the patient 
receives a full course of treatment, and therefore do not use the same 
amount or type of resources as typical LTCH ``inlier'' cases (that is, 
cases in which Medicare covered days exceed five-sixths of the 
geometric average length of stay for the LTC-DRG and the patient is 
discharged prior to receiving a LTCH PPS high cost outlier payment). We 
believe that the length of stay of an ``inlier'' case is indicative of 
a LTCH patient receiving a full course of treatment because such cases 
include cases with stays that received a full LTC-DRG payment, which 
represents the average resources used for that DRG (that is, the case 
does not receive an adjusted short-stay outlier payment or a high-cost 
outlier payment). LTCH discharges with very short lengths of stay (that 
is, 7 days or less) often occur when it is determined, following 
admission to a LTCH, that the beneficiary would receive more 
appropriate care at another setting. Other circumstances that result in 
cases with very short stays (that is, 7 days or less) would involve 
patients who were either discharged to their home or who expired within 
the first 7 days of being admitted to an LTCH. Because LTCH cases with 
very short lengths of stay (that is, 7 days or less) do not use the 
same amount or type of resources as typical LTCH inlier cases, our 
simulations indicate that including these cases would significantly 
bias payments against LTCH inlier cases to a point where LTCH inlier 
cases would be underpaid.
    As we also discussed in the August 30, 2002, LTCH PPS final rule 
(65 FR 55989), the LTC-DRG relative weights reflect the average 
resources used on representative cases of a specific type. Stays of 7 
days or less generally do not fully receive or benefit from treatment 
that is typical in a LTCH stay because the patient is discharged prior 
to receiving a full course of treatment that a LTCH inlier patient 
would receive. In addition, full resources are often not used in the 
earlier stages of an admission to a LTCH because the patient is often 
medically unstable, and initial efforts are focused on stabilizing the 
patient before beginning treatment of the patient's additional 
complications and comorbidities. If we did include stays of 7 days or 
less in the calculation of the LTC-DRG relative weights, the value of 
many relative weights would decrease for cases that do, in fact, 
receive a full course of treatment, and, therefore, LTCH inlier 
payments could decrease to a level that would not be appropriate (that 
is, provide sufficient payment). We continue to believe that it is not 
appropriate to compromise the integrity of the payment amounts for LTCH 
inlier cases that actually benefit from and receive a full course of 
treatment at a LTCH in order to include data from cases with stays of 7 
days or less. Therefore, we disagree with the commenter that cases with 
lengths of stay of 7 days or less should be included in the calculation 
of the LTC-DRG relative weights. Accordingly, in this final rule, in 
calculating the FY 2005 LTC-DRG relative weights, as we proposed, we 
have removed cases with a length of stay of 7 days or less.
    With regard to the commenter's suggestion that we create a separate 
LTC-DRG for patients who expire, as we also discussed in the August 30, 
2002, LTCH PPS final rule (67 FR 56002), we do not believe that a 
separate LTC-DRG for patients who expire is necessary. We continue to 
believe that the short-stay outlier policy at Sec.  412.529 adequately 
addresses payments for patients who expire August 30, 2002, LTCH PPS 
final rule (65 FR 56006), because a case with a length of stay up to 
and including five-sixths of the average length of stay of the LTC-DRG 
is paid under the short-stay outlier policy regardless of whether or 
not the patient expires. Under the short-stay outlier policy (Sec.  
412.529), generally a case is paid the least of 120 percent of the 
estimated cost of the case, 120 percent of the LTC-DRG specific per 
diem amount, or the full LTC-DRG payment.
    We continue to believe that adjusted payments under the short-stay 
outlier policy for cases that expire generally compensate for any 
increased costs associated with treating a severely ill patient who 
dies, including those who expire within 7 days of being admitted to a 
LTCH. We note that one of the principles underlying prospective payment 
is that it is a system of payments based on average costs that assumes 
that some patient stays will consume more resources than the typical 
stay, while other patients will demand fewer resources. Thus, an 
efficiently operated hospital should be able to deliver care to its 
Medicare patients for an overall cost that is at or below the amount 
paid under the LTCH PPS. We continue to believe the LTCH PPS payment 
adequately address payments for patients who expire, and therefore, we 
are not adopting the commenter's suggestion to create a separate LTC-
DRG for LTCH patients that expire within the first 7 days of the stay. 
Accordingly, in establishing the final FY 2005 LTC-DRG relative 
weights, we continue to exclude cases with a length of stay of 7 days 
or less and we continue to include the total charges of cases with a 
length of stay of 8 days or more, including patients who expire, in the 
LTC-DRG to which the case is assigned based on version 22.0 of the 
GROUPER.
    Step 3--Adjust charges for the effects of short-stay outliers.
    The third step in the calculation of the FY 2005 LTC-DRG relative 
weights is to adjust each LTCH's charges per discharge for short-stay 
outlier cases (that is, a patient with a length of stay that is less 
than or equal to five-sixths the average length of stay of the LTC-
DRG).
    We make this adjustment by counting a short-stay outlier as a 
fraction of a discharge based on the ratio of the

[[Page 48991]]

length of stay of the case to the average length of stay for the LTC-
DRG for nonshort-stay outlier cases. This has the effect of 
proportionately reducing the impact of the lower charges for the short-
stay outlier cases in calculating the average charge for the LTC-DRG. 
This process produces the same result as if the actual charges per 
discharge of a short-stay outlier case were adjusted to what they would 
have been had the patient's length of stay been equal to the average 
length of stay of the LTC-DRG.
    As we explained in the May 18, 2004 proposed rule (69 FR 28231), 
counting short-stay outlier cases as full discharges with no adjustment 
in determining the LTC-DRG relative weights would lower the LTC-DRG 
relative weight for affected LTC-DRGs because the relatively lower 
charges of the short-stay outlier cases would bring down the average 
charge for all cases within an LTC-DRG. This would result in an 
``underpayment'' to nonshort-stay outlier cases and an ``overpayment'' 
to short-stay outlier cases. Therefore, in this final rule, we adjust 
for short-stay outlier cases under Sec.  412.529 in this manner because 
it results in more appropriate payments for all LTCH cases.
    Step 4--Calculate the FY 2005 LTC-DRG relative weights on an 
iterative basis.
    The process of calculating the LTC-DRG relative weights using the 
hospital specific relative value methodology is iterative. First, for 
each LTCH case, we calculate a hospital-specific relative charge value 
by dividing the short-stay outlier adjusted charge per discharge (see 
step 3) of the LTCH case (after removing the statistical outliers (see 
step 1)) and LTCH cases with a length of stay of 7 days or less (see 
step 2) by the average charge per discharge for the LTCH in which the 
case occurred. The resulting ratio is then multiplied by the LTCH's 
case-mix index to produce an adjusted hospital-specific relative charge 
value for the case. An initial case-mix index value of 1.0 is used for 
each LTCH.
    For each LTC-DRG, the FY 2005 LTC-DRG relative weight is calculated 
by dividing the average of the adjusted hospital-specific relative 
charge values (from above) for the LTC-DRG by the overall average 
hospital-specific relative charge value across all cases for all LTCHs. 
Using these recalculated LTC-DRG relative weights, each LTCH's average 
relative weight for all of its cases (case-mix) is calculated by 
dividing the sum of all the LTCH's LTC-DRG relative weights by its 
total number of cases. The LTCHs' hospital-specific relative charge 
values above are multiplied by these hospital specific case-mix 
indexes. These hospital-specific case-mix adjusted relative charge 
values are then used to calculate a new set of LTC-DRG relative weights 
across all LTCHs. In this final rule, this iterative process is 
continued until there is convergence between the weights produced at 
adjacent steps, for example, when the maximum difference is less than 
0.0001.
    Step 5--Adjust the FY 2005 LTC-DRG relative weights to account for 
nonmonotonically increasing relative weights.
    As explained in section II.B. of this preamble, the FY 2005 CMS 
DRGs, which the FY 2005 LTC-DRGs are based, contain ``pairs'' that are 
differentiated based on the presence or absence of CCs. The LTC-DRGs 
with CCs are defined by certain secondary diagnoses not related to or 
inherently a part of the disease process identified by the principal 
diagnosis, but the presence of additional diagnoses does not 
automatically generate a CC. As we discussed in the May 18, 2004 IPPS 
proposed rule (69 FR 28232), the value of monotonically increasing 
relative weights rises as the resource use increases (for example, from 
uncomplicated to more complicated). The presence of CCs in an LTC-DRG 
means that cases classified into a ``without CC'' LTC-DRG are expected 
to have lower resource use (and lower costs). In other words, resource 
use (and costs) are expected to decrease across ``with CC''/``without 
CC'' pairs of LTC-DRGs.
    For a case to be assigned to a LTC-DRG with CCs, more coded 
information is called for (that is, at least one relevant secondary 
diagnosis), than for a case to be assigned to an LTC-DRG ``without 
CCs'' (which is based on only one principal diagnosis and no relevant 
secondary diagnoses). Currently, the LTCH claims data include both 
accurately coded cases without complications and cases that have 
complications (and cost more), but were not coded completely. Both 
types of cases are grouped to an LTC-DRG ``without CCs'' because only 
one principal diagnosis was coded. Since the LTCH PPS was only 
implemented for cost reporting periods beginning on or after October 1, 
2002 (FY 2003) and LTCHs were previously paid under cost-based 
reimbursement, which is not based on patient diagnoses, coding by LTCHs 
for these cases may not have been as detailed as possible.
    Thus, in developing the FY 2003 LTC-DRG relative weights for the 
LTCH PPS based on FY 2001 claims data, as we discussed in the August 
30, 2002 LTCH PPS final rule (67 FR 55990), we found on occasion that 
the data suggested that cases classified to the LTC-DRG ``with CCs'' of 
a ``with CC''/``without CC'' pair had a lower average charge than the 
corresponding LTC-DRG ``without CCs.'' Similarly, based on FY 2003 
claims data, we also found on occasion that the data suggested that 
cases classified to the LTC-DRG ``with CCs'' of a ``with CC''/without 
CC'' pair have a lower average charge than the corresponding LTC-DRG 
``without CCs'' for FY 2005.
    We believe this anomaly may be due to coding that may not have 
fully reflected all comorbidities that were present. Specifically, 
LTCHs may have failed to code relevant secondary diagnoses, which 
resulted in cases that actually had CCs being classified into a 
``without CC'' LTC-DRG. It would not be appropriate to pay a lower 
amount for the ``with CC'' LTC-DRG. Therefore, in this final rule, we 
grouped both the cases ``with CCs'' and ``without CCs'' together for 
the purpose of calculating the FY 2005 LTC-DRG relative weights in this 
final rule. As we stated in the August 30, 2002 LTCH PPS final rule (67 
FR 55990), we will continue to employ this methodology to account for 
nonmonotonically increasing relative weights until we have adequate 
data to calculate appropriate separate weights for these anomalous LTC-
DRG pairs. We expect that, as was the case when we first implemented 
the IPPS, this problem will be self-correcting, as LTCHs submit more 
completely coded data in the future.
    There are three types of ``with CC'' and ``without CC'' pairs that 
could be nonmonotonic, that is, where the ``without CC'' LTC-DRG would 
have a higher average charge than the ``with CC'' LTC-DRG. For this 
final rule, using the LTCH cases in the March 2004 update of the FY 
2003 MedPAR file, we identified two of the three types of nonmonotonic 
LTC-DRG pairs.
    The first category of nonmonotonically increasing relative weights 
for FY 2005 LTC-DRG pairs ``with and without CCs'' contains 2 pairs of 
LTC-DRGs in which both the LTC-DRG ``with CCs'' and the LTC-DRG 
``without CCs'' had 25 or more LTCH cases and, therefore, did not fall 
into one of the 5 low-volume quintiles. For those nonmonotonic LTC-DRG 
pairs, as discussed in the May 18, 2004, proposed rule, we combine the 
LTCH cases and compute a new relative weight based on the case-weighted 
average of the combined LTCH cases of the LTC-DRGs. The case-weighted 
average charge is determined by dividing the total charges for all LTCH

[[Page 48992]]

cases by the total number of LTCH cases for the combined LTC-DRG. This 
new relative weight is then assigned to both of the LTC-DRGs in the 
pair. In this final rule, for FY 2005, LTC-DRGs 144 and 145 and LTC-
DRGs 444 and 445 are in this category.
    The second category of nonmonotonically increasing relative weights 
for LTC-DRG pairs with and without CCs consists of zero pairs of LTC-
DRGs that has fewer than 25 cases, and each LTC-DRG is grouped to 
different low-volume quintiles in which the ``without CC'' LTC-DRG is 
in a higher-weighted low-volume quintile than the ``with CC'' LTC-DRG. 
For those pairs, as we discussed in the May 18, 2004, proposed rule (69 
FR 28232), we combine the LTCH cases and determine the case-weighted 
average charge for all LTCH cases. The case-weighted average charge is 
determined by dividing the total charges for all LTCH cases by the 
total number of LTCH cases for the combined LTC-DRG. Based on the case-
weighted average LTCH charge, we determine which low-volume quintile 
the ``combined LTC-DRG'' is grouped. Both LTC-DRGs in the pair are then 
grouped into the same low-volume quintile, and thus have the same 
relative weight. In this final rule, for FY 2005, there are no LTC-DRGs 
that fall into this category.
    The third category of nonmonotonically increasing relative weights 
for LTC-DRG pairs with and without CCs consists of 10 pairs of LTC-DRGs 
where one of the LTC-DRGs has fewer than 25 LTCH cases and is grouped 
to a low-volume quintile and the other LTC-DRG has 25 or more LTCH 
cases and has its own LTC-DRG relative weight, and the LTC-DRG 
``without CCs'' has the higher relative weight. As discussed in the May 
18, 2004 proposed rule (69 FR 28232), we remove the low-volume LTC-DRG 
from the low-volume quintile and combine it with the other LTC-DRG for 
the computation of a new relative weight for each of these LTC-DRGs. 
This new relative weight is assigned to both LTC-DRGs, so they each 
have the same relative weight. In this final rule, for FY 2005, the 
following LTC-DRGs are in this category: LTC-DRGs 85 and 86; LTC-DRGs 
101 and 102; LTC-DRGs 141 and 142; LTC-DRGs 170 and 171; LTC-DRGs 172 
and 173; LTC-DRGs 175 and 175; LTC-DRGs 300 and 301; LTC-DRGs 318 and 
319; LTC-DRGs 442 and 443; and LTC-DRGs 521, 522 and 523 (We note, 3 
LTC-DRGs make up this non-monotonic ``pair'' of DRGs because the 
``without CCs'' DRG is further divided into two DRGs based on the 
presence or absence of rehabilitation therapy, so that there is one DRG 
in this non-monotonic ``pair'' with CCs and two DRGs in this non-
monotonic ``pair'' without CCs).
    Step 6--Determine an FY 2005 LTC-DRG relative weight for LTC-DRGs 
with no LTCH cases.
    As we stated above, we determine the relative weight for each LTC-
DRG using charges reported in the March 2004 update of the FY 2003 
MedPAR file. Of the 520 LTC-DRGs for FY 2005, we identified 171 LTC-
DRGs for which there were no LTCH cases in the database. That is, based 
on data from the FY 2003 MedPAR file used in this final rule, no 
patients who would have been classified to those LTC-DRGs were treated 
in LTCHs during FY 2003 and, therefore, no charge data were reported 
for those LTC-DRGs. Thus, in the process of determining the LTC-DRG 
relative weights, we are unable to determine weights for these 171 LTC-
DRGs using the methodology described in steps 1 through 5 above. 
However, because patients with a number of the diagnoses under these 
LTC-DRGs may be treated at LTCHs beginning in FY 2005, we assign 
relative weights to each of the 171 ``no volume'' LTC-DRGs based on 
clinical similarity and relative costliness to one of the remaining 349 
(520 - 171 = 349) LTC-DRGs for which we are able to determine relative 
weights, based on FY 2003 claims data.
    As there are currently no LTCH cases in these ``no volume'' LTC-
DRGs, as we discussed in the May 18, 2004 proposed rule (69 FR 28233), 
we determine relative weights for the 171 LTC-DRGs with no LTCH cases 
in the FY 2003 MedPAR file used in this final rule by grouping them to 
the appropriate low-volume quintile. This methodology is consistent 
with our methodology used in determining relative weights to account 
for the low-volume LTC-DRGs described above.
    Our methodology for determining relative weights for the ``no 
volume'' LTC-DRGs is as follows: We crosswalk the no volume LTC-DRGs by 
matching them to other similar LTC-DRGs for which there were LTCH cases 
in the FY 2003 MedPAR file based on clinical similarity and intensity 
of use of resources as determined by care provided during the period of 
time surrounding surgery, surgical approach (if applicable), length of 
time of surgical procedure, post-operative care, and length of stay. We 
assign the relative weight for the applicable low-volume quintile to 
the no volume LTC-DRG if the LTC-DRG to which it is crosswalked is 
grouped to one of the low-volume quintiles. If the LTC-DRG to which the 
no volume LTC-DRG is crosswalked is not one of the LTC-DRGs to be 
grouped to one of the low-volume quintiles, we compare the relative 
weight of the LTC-DRG to which the no volume LTC-DRG is crosswalked to 
the relative weights of each of the five quintiles and we assign the no 
volume LTC-DRG the relative weight of the low-volume quintile with the 
closest weight. For this final rule, a list of the no volume FY 2005 
LTC-DRGs and the FY 2005 LTC-DRG to which it is crosswalked in order to 
determine the appropriate low-volume quintile for the assignment of a 
relative weight for FY 2005 is shown below in Table 2.
BILLING CODE 4121-01-P

[[Page 48993]]

[GRAPHIC] [TIFF OMITTED] TR11AU04.030


[[Page 48994]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.031


[[Page 48995]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.032


[[Page 48996]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.033


[[Page 48997]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.034


[[Page 48998]]


[GRAPHIC] [TIFF OMITTED] TR11AU04.035

BILLING CODE 4121-01-C
    To illustrate this methodology for determining the relative weights 
for the 171 LTC-DRGs with no LTCH cases, we are providing the following 
examples, which refer to the no volume LTC-DRGs crosswalk information 
for FY 2005 provided above in Table 2:


[[Page 48999]]


    Example 1: There were no cases in the FY 2003 MedPAR file used 
for this final rule for LTC-DRG 163 (Hernia Procedures Age 0-17). 
Since the procedure is similar in resource use and the length and 
complexity of the procedures and the length of stay are similar, we 
determined that LTC-DRG 178 (Uncomplicated Peptic Ulcer Without CC), 
which is assigned to low-volume quintile 1 for the purpose of 
determining the FY 2005 relative weights, would display similar 
clinical and resource use. Therefore, we assign the same relative 
weight of LTC-DRG 178 of 0.4586 (Quintile 1) for FY 2005 (Table 11 
in the Addendum to this final rule) to LTC-DRG 163.
    Example 2: There were no LTCH cases in the FY 2003 MedPAR file 
used in this final rule for LTC-DRG 91 (Simple Pneumonia and 
Pleurisy Age 0-17). Since the severity of illness in patients with 
bronchitis and asthma is similar in patients regardless of age, we 
determined that LTC-DRG 90 (Simple Pneumonia and Pleurisy Age >17 
Without CC) would display similar clinical and resource use 
characteristics and have a similar length of stay to LTC-DRG 91. 
There were over 25 cases in LTC-DRG 90. Therefore, it would not be 
assigned to a low-volume quintile for the purpose of determining the 
LTC-DRG relative weights. However, under our established 
methodology, LTC-DRG 91, with no LTCH cases, would need to be 
grouped to a low-volume quintile. We identified that the low-volume 
quintile with the closest weight to LTC-DRG 90 (0.7494; see Table 11 
in the Addendum to this final rule) would be low-volume quintile 2 
(0.8508; see Table 11 in the Addendum to this final rule). 
Therefore, we assign LTC-DRG 91 a relative weight of 0. 8508 for FY 
2005.

    Furthermore, we are providing LTC-DRG relative weights of 0.0000 
for heart, kidney, liver, lung, pancreas, and simultaneous pancreas/
kidney transplants (LTC-DRGs 103, 302, 480, 495, 512, and 513, 
respectively) for FY 2005 because Medicare will only cover these 
procedures if they are performed at a hospital that has been certified 
for the specific procedures by Medicare and presently no LTCH has been 
so certified.
    Based on our research, we found that most LTCHs only perform minor 
surgeries, such as minor small and large bowel procedures, to the 
extent any surgeries are performed at all. Given the extensive criteria 
that must be met to become certified as a transplant center for 
Medicare, we believe it is unlikely that any LTCHs would become 
certified as a transplant center. In fact, in the nearly 20 years since 
the implementation of the IPPS, there has never been a LTCH that even 
expressed an interest in becoming a transplant center.
    However, if in the future a LTCH applies for certification as a 
Medicare-approved transplant center, we believe that the application 
and approval procedure would allow sufficient time for us to determine 
appropriate weights for the LTC-DRGs affected. At the present time, we 
are only including these six transplant LTC-DRGs in the GROUPER program 
for administrative purposes. Because we use the same GROUPER program 
for LTCHs as is used under the IPPS, removing these LTC-DRGs would be 
administratively burdensome.
    Again, we note that as this system is dynamic, it is entirely 
possible that the number of LTC-DRGs with a zero volume of LTCH cases 
based on the system will vary in the future. We used the best most 
recent available claims data in the MedPAR file to identify zero volume 
LTC-DRGs and to determine the relative weights in this final rule.
    Table 11 in the Addendum to this final rule lists the LTC-DRGs and 
their respective relative weights, geometric mean length of stay, and 
five-sixths of the geometric mean length of stay (to assist in the 
determination of short-stay outlier payments under Sec.  412.529) for 
FY 2005.
    Comment: A few commenters believe that the budget neutrality 
requirement found in section 123 of the Public Law 106-113 requires CMS 
to adjust the LTC-DRG relative weights to ensure that total payments to 
LTCHs are budget neutral for the proposed changes to the LTC-DRG 
classifications and relative weights. Alternatively, the commenters 
suggested that we make an adjustment to the LTCH PPS Federal rate to 
account for the estimated $55 million reduction in LTCH PPS payments 
which resulted from the proposed changes in the LTC-DRG classifications 
and relative weights.
    Response: In the May 18, 2004 proposed rule (69 FR 28806), we 
estimated a $55 million aggregate decrease in LTCH PPS payments as a 
result of the proposed changes in the LTC-DRG relative weights and 
proposed version 22.0 GROUPER for FY 2005. We note that we incorrectly 
estimated the impact of the change in the proposed LTC-DRGs for FY 2005 
in the proposed rule because we failed to account for the change in DRG 
classifications and the change in the geometric average length of stay 
for each LTC-DRG. As discussed in section VII.B. of Appendix A to this 
final rule, we are estimating that the impact of the change in LTC-DRGs 
for FY 2005 (including changes in the DRG classifications, relative 
weights and geometric average lent of stay) will result in 
approximately a $14.9 million decrease in LTCH PPS payments. In that 
same proposed rule, we explained that we found that based on an 
analysis of the LTCH claims in the FY 2003 MedPAR files, the average 
LTC-DRG relative weight across all LTC-DRGs has increased due to an 
increase in the number of cases being assigned to higher weighted LTC-
DRGs. As a result, including cases with relatively lower charges into 
LTC-DRGs that have a relatively higher relative weight in the GROUPER 
version 21.0 (FY 2004) decreases the average relative weight in the 
proposed GROUPER version 22.0 (FY 2005).
    As we discussed in the August 30, 2002 LTCH PPS final rule (67 FR 
55960), which implemented the LTCH PPS, section 123 of Public Law 106-
113 requires that the LTCH PPS, among other things, shall include an 
adequate patient classification system that is based on DRGs and that 
reflects the differences in patient resource use and costs, and shall 
maintain budget neutrality. With respect to budget neutrality, we 
interpreted section 123(a)(1) of Public Law 106-113 to require that 
total payments under the LTCH PPS during FY 2003 will be projected to 
equal estimated payments that would have been made for LTCHs' operating 
and capital-related inpatient hospital costs had the LTCH PPS not have 
been implemented. Consistent with this requirement, under Sec.  
412.523(d)(2) an adjustment is made in determining the standard Federal 
rate for FY 2003 so that aggregate payments under the LTCH PPS are 
estimated to equal the amount that would have been paid to LTCHs under 
the reasonable cost-based (TEFRA) payment system if the LTCH PPS were 
not implemented. Therefore, in that same final rule (67 FR 56027 
through 56037), in order to maintain budget neutrality, we adjusted the 
LTCH PPS Federal rate for FY 2003 so that aggregate payments under the 
LTCH PPS are estimated to equal the amount that would have been paid to 
LTCHs under the reasonable cost-based (TERFA) payment system had the 
LTCH PPS had not been implemented.
    In addition, when we implemented the LTCH PPS in the August 30, 
2002 LTCH PPS final rule, we provided subpart O of the regulations at 
42 CFR, including Sec.  412.517, for an annual adjustment to the LTC-
DRG classifications and weighting factors to reflect changes in 
treatment patterns, technology, number of discharges, and other factors 
affecting the relative use of hospital resources. We do not believe 
that section 123 of the Pub. L. 106-113 requires that the annual update 
to the LTC-DRG classifications and relative weights maintain budget 
neutrality. We believe we have satisfied the budget neutrality 
requirement of section 123 of

[[Page 49000]]

the Pub. L. 106-113 by establishing the LTCH PPS Federal rate for FY 
2003 under Sec.  412.523(d)(2) so that aggregate payment under the LTCH 
PPS are projected equal to estimated aggregate payments under the 
reasonable cost-based payment system if the LTCH PPS were not 
implemented. Therefore, we disagree with the commenters that an 
adjustment to the FY 2005 LTC-DRG relative weights or to the LTCH PPS 
Federal rate is required as a result of the annual update to the LTC-
DRGs under Sec.  412.517 for FY 2005. Accordingly, we have updated the 
LTC-DRG classifications and relative weights for FY 2005 (as shown in 
Table 11 of Addendum to this final rule) without an adjustment for 
budget neutrality. We note that this is our policy regardless of 
whether the annual update to the LTC-DRG classifications and relative 
weights results in higher or lower estimated aggregate payments. For 
instance we estimate that the annual update to the LTC-DRG 
classifications and relative weights from FY 2003 to FY 2004 resulted 
in an estimated increase in LTCH PPS payments, yet the update to the 
LTC-DRGs in the August 1, 2003 final rule for FY 2004 were not adjusted 
to maintain budget neutrality. In either case, at this time we do not 
make an adjustment to maintain budget neutrality for the effects of 
changes in the LTC-DRG classifications and relative weights. 
Accordingly, in developing the FY 2005 LTC-DRGs and relative weights 
shown in Table 11 of this final rule, we have not applied an adjustment 
for budget neutrality nor are we adjusting the 2005 LTCH PPS rate year 
Federal rate established in the May 7, 2004, LTCH PPS final rule (69 FR 
25674) to account for the estimated change in LTCH PPS payments which 
result from the annual update to the LTC-DRG classifications and 
relative weights for FY 2005.
    The commenter raises the issue that it may be appropriate for 
certain aspects of the LTCH PPS to maintain budget neutrality when they 
are updated annually as they are in other PPSs, such as the annual 
update to the DRGs and wage index. Under section 123 of Public Law 106-
113 and section 307 of Publicl Law 106-554, the Secretary generally has 
broad authority in developing the LTCH PPS, including whether and how 
to make adjustments to LTCH PPS payments. Specifically, section 
307(b)(1) of Public Law 106-554 provides that ``the Secretary shall 
examine and may provide for appropriate adjustments to the long-term 
hospital payment system, including adjustments to DRG weights, area 
wage adjustments, geographic classification, outliers, updates, and a 
disproportionate share adjustment [* * *].'' We will consider whether 
it is appropriate for use to propose a future revision to the LTCH PPS 
regulations at subpart O of 42 CFR to maintain budget neutrality in the 
annual update of some aspects of the LTCH PPS under our broad 
discretionary authority under the statute to provide ``appropriate 
adjustments to the long-term hospital payment system.'' Any changes to 
the LTCH PPS regulations would be made in accordance with 
Administrative Procedures Act guidelines.
5. Out of Scope Comments Relating to the LTCH PPS Payment Rates
    Comment: A few commenters submitted comments that addressed aspects 
of the existing LTCH PPS, including the standard Federal rate and 
outlier methodology, which are not relevant to the LTCH policy 
proposals set forth in the May 18, 2004 IPPS proposed rule.
    Response: Because those comments pertain to specific aspects of the 
existing LTCH PPS rather than to any specific proposed changes to the 
LTCH PPS presented in the May 18, 2004 IPPS proposed rule, we are 
unable to respond to those comments at this time. Rather, we believe it 
is more appropriate to address those issues in the annual LTCH PPS 
proposed and final rules, and we will consider the issues raised in 
those comments in the context of future rulemaking for the LTCH PPS.

E. Add-On Payments for New Services and Technologies

1. Background
    Sections 1886(d)(5)(K) and (L) of the Act establish a process of 
identifying and ensuring adequate payment for new medical services and 
technologies under the IPPS. Section 1886(d)(5)(K)(vi) of the Act 
specifies that a medical service or technology will be considered new 
if it meets criteria established by the Secretary after notice and 
opportunity for public comment. Section 1886(d)(5)(K)(ii)(I) of the Act 
specifies that the process must apply to a new medical service or 
technology if, ``based on the estimated costs incurred with respect to 
discharges involving such service or technology, the DRG prospective 
payment rate otherwise applicable to such discharges under this 
subsection is inadequate.''
    The regulations implementing this provision establish three 
criteria for special treatment. First, Sec.  412.87(b)(2) defines when 
a specific medical service or technology will be considered new for 
purposes of new medical service or technology add-on payments. The 
statutory provision contemplated the special payment treatment for new 
medical services or technologies until such time as data are available 
to reflect the cost of the technology in the DRG weights through 
recalibration. There is a lag of 2 to 3 years from the point a new 
medical service or technology is first introduced on the market and 
when data reflecting the use of the medical service or technology are 
used to calculate the DRG weights. For example, data from discharges 
occurring during FY 2003 are used to calculate the FY 2005 DRG weights 
in this final rule. Section 412.87(b)(2) provides that a ``medical 
service or technology may be considered new within 2 or 3 years after 
the point at which data begin to become available reflecting the ICD-9-
CM code assigned to the new medical service or technology (depending on 
when a new code is assigned and data on the new medical service or 
technology become available for DRG recalibration). After CMS has 
recalibrated the DRGs, based on available data, to reflect the costs of 
an otherwise new medical service or technology, the medical service or 
technology will no longer be considered `new' under the criterion for 
this section.''
    In the May 18, 2004, proposed rule (69 FR 28237), we stated that 
the 2-year to 3-year period of newness for a technology or medical 
service would ordinarily begin with FDA approval, unless there was some 
documented delay in bringing the product onto the market after that 
approval (for instance, component production or drug production had 
been postponed until FDA approval due to shelf life concerns or 
manufacturing issues). After the DRGs have been recalibrated to reflect 
the costs of an otherwise new medical service or technology, the 
special add-on payment for new medical services or technology ceases 
(Sec.  412.87(b)(2)). For example, an approved new technology that 
received FDA approval in October 2003 and entered the market at that 
time may be eligible to receive add-on payments as a new technology 
until FY 2006 (discharges occurring before October 1, 2005), when data 
reflecting the costs of the technology would be used to recalibrate the 
DRG weights. Because the FY 2006 DRG weights will be calculated using 
FY 2004 MedPAR data, the costs of such a new technology would likely be 
reflected in the FY 2006 DRG weights.
    Section 412.87(b)(3) further provides that, to receive special 
payment treatment, new medical services or technologies must be 
inadequately paid otherwise under the DRG system. To

[[Page 49001]]

assess whether technologies would be inadequately paid under the DRGs, 
we establish thresholds to evaluate applicants for new technology add-
on payments. In the August 1, 2003, final rule (68 FR 45385), we 
established the threshold at the geometric mean standardized charge for 
all cases in the DRG plus 75 percent of 1 standard deviation above the 
geometric mean standardized charge (based on the logarithmic values of 
the charges and transformed back to charges) for all cases in the DRG 
to which the new medical service or technology is assigned (or the 
case-weighted average of all relevant DRGs, if the new medical service 
or technology occurs in many different DRGs). Table 10 in the Addendum 
to the August 1, 2003, final rule (68 FR 45648) listed the qualifying 
threshold by DRG, based on the discharge data that we used to calculate 
the FY 2004 DRG weights.
    However, section 503(b)(1) of Public Law 108-173 amended section 
1886(d)(5)(K)(ii)(I) of the Act to provide for ``applying a threshold * 
* * that is the lesser of 75 percent of the standardized amount 
(increased to reflect the difference between cost and charges) or 75 
percent of one standard deviation for the diagnosis-related group 
involved.'' The provisions of section 503(b)(1) apply to classification 
for fiscal years beginning with FY 2005. We updated Table 10 from the 
October 6, 2003, Federal Register correction document, which contains 
the thresholds that we used to evaluate applications for new service or 
technology add-on payments for FY 2005, using the section 503(b)(1) 
measures stated above, and posted these new thresholds on our Web site 
at: http://www.cms.hhs.gov/providers/hipps/newtech.asp. In the May 18, 

2004, proposed rule, we included preliminary thresholds for evaluating 
applicants for new technology add-on payments for FY 2006. Table 10 of 
this final rule contains the final thresholds that will be used to 
evaluate applicants for new technology add-on payments for FY 2006. 
(Refer to section IV.D. of this preamble for a discussion of a revision 
of the regulations to incorporate the change made by section 503(b)(1) 
of Public Law 108-173.)
    Section 412.87(b)(1) of our existing regulations provides that a 
new technology is an appropriate candidate for an additional payment 
when it represents an advance in medical technology that substantially 
improves, relative to technologies previously available, the diagnosis 
or treatment of Medicare beneficiaries. For example, a new technology 
represents a substantial clinical improvement when it reduces 
mortality, decreases the number of hospitalizations or physician visits 
or reduces recovery time compared to the technologies previously 
available. (See the September 7, 2001 final rule (66 FR 46902) for a 
complete discussion of this criterion.)
    The new medical service or technology add-on payment policy 
provides additional payments for cases with high costs involving 
eligible new medical services or technologies while preserving some of 
the incentives under the average-based payment system. The payment 
mechanism is based on the cost to hospitals for the new medical service 
or technology. Under Sec.  412.88, Medicare pays a marginal cost factor 
of 50 percent for the costs of a new medical service or technology in 
excess of the full DRG payment. If the actual costs of a new medical 
service or technology case exceed the DRG payment by more than the 50-
percent marginal cost factor of the new medical service or technology, 
Medicare payment is limited to the DRG payment plus 50 percent of the 
estimated costs of the new technology.
    The report language accompanying section 533 of Public Law 106-554 
indicated Congressional intent that the Secretary implement the new 
mechanism on a budget neutral basis (H.R. Conf. Rep. No. 106-1033, 
106th Cong., 2nd Sess. at 897 (2000)). Section 1886(d)(4)(C)(iii) of 
the Act requires that the adjustments to annual DRG classifications and 
relative weights must be made in a manner that ensures that aggregate 
payments to hospitals are not affected. Therefore, in the past, we 
accounted for projected payments under the new medical service and 
technology provision during the upcoming fiscal year at the same time 
we estimated the payment effect of changes to the DRG classifications 
and recalibration. The impact of additional payments under this 
provision was then included in the budget neutrality factor, which was 
applied to the standardized amounts and the hospital-specific amounts.
    Section 503(d)(2) of Public Law 108-173 amended section 
1886(d)(5)(K)(ii)(III) of the Act to provide that there shall be no 
reduction or adjustment in aggregate payments under the IPPS due to 
add-on payments for new medical services and technologies. Therefore, 
add-on payments for new medical services or technologies for FY 2005 
and later years will not be budget neutral. We discuss the regulation 
change necessary to implement this provision in section IV.H. of this 
final rule.
    Applicants for add-on payments for new medical services or 
technologies for FY 2006 must submit a formal request, including a full 
description of the clinical applications of the medical service or 
technology and the results of any clinical evaluations demonstrating 
that the new medical service or technology represents a substantial 
clinical improvement, along with a significant sample of data to 
demonstrate the medical service or technology meets the high-cost 
threshold, no later than early October 2004. Applicants must submit a 
complete database no later than mid-December 2004. Complete application 
information, along with final deadlines for submitting a full 
application, will be available at our Web site after publication of 
this FY 2005 final rule at: http://www.cms.hhs.gov/providers/hipps/default.asp.
 To allow interested parties to identify the new medical 

services or technologies under review before the publication of the 
proposed rule for FY 2006, the Web site will also list the tracking 
forms completed by each applicant.
2. Other Provisions of Section 503 of Public Law 108-173
    Section 503(b)(2) of Public Law 108-173 amended section 
1886(d)(5)(K) of the Act by adding a new clause (viii) to provide for a 
mechanism for public input before publication of a notice of proposed 
rulemaking regarding whether a medical service or technology represents 
a substantial improvement or advancement. The revised process for 
evaluating new medical service and technology applications requires the 
Secretary to--
     Provide, before publication of a proposed rule, for public 
input regarding whether a new service or technology represents an 
advance in medical technology that substantially improves the diagnosis 
or treatment of Medicare beneficiaries.
     Make public and periodically update a list of the services 
and technologies for which an application for add-on payments is 
pending.
     Accept comments, recommendations, and data from the public 
regarding whether a service or technology represents a substantial 
improvement.
     Provide, before publication of a proposed rule, for a 
meeting at which organizations representing hospitals, physicians, 
manufacturers, and any other interested party may present comments, 
recommendations, and data regarding whether a new service or technology 
represents a substantial

[[Page 49002]]

clinical improvement to the clinical staff of CMS.
    In order to satisfy the requirements of this last provision, we 
published a notice in the Federal Register on February 27, 2004, and 
held a town meeting at the CMS Headquarters Office in Baltimore, MD, on 
March 15, 2004. In the announcement notice for the meeting, we stated 
that the opinions and alternatives provided during the meeting would 
assist us in our evaluations of applications by allowing public 
discussions of the substantial clinical improvement criteria for each 
of the FY 2005 new medical service and technology add-on payment 
applications before the publication of the FY 2005 IPPS proposed rule.
    Approximately 70 participants registered and attended in person, 
while additional participants listened over an open telephone line. The 
participants focused on presenting data on the substantial clinical 
improvement aspect of their products, as well as the need for 
additional payments to ensure access to Medicare beneficiaries. In 
addition, we also received many written comments regarding the 
substantial clinical improvement criterion for the applicants. As 
indicated in the May 18, 2004, proposed rule, we considered these 
comments in our evaluation of each new application for FY 2005 in the 
proposed rule. In the proposed rule, we summarized these comments or, 
if applicable, indicated that no comments were received, at the end of 
the discussion of the individual applications.
    Section 503(c) of Public Law 108-173 amended section 1886(d)(5)(K) 
of the Act by adding a new clause (ix) requiring that before 
establishing any add-on payment for a new medical service or 
technology, that the Secretary shall seek to identify one or more DRGs 
associated with the new technology, based on similar clinical or 
anatomical characteristics and the costs of the technology and assign 
the new technology into a DRG where the average costs of care most 
closely approximate the costs of care using the new technology. No add-
on payment shall be made with respect to such a new technology.
    At the time an application is submitted, the DRGs associated with 
the new technology are identified. We only determine that a new 
technology add-on payment is appropriate when the reimbursement under 
these DRGs is not adequate for this new technology. The criterion for 
this determination is the cost threshold, which we discuss below. We 
discuss the assignments of several new technologies within the DRG 
payment system in section II.B. of this final rule. The comment 
regarding the DRG assignment of the treatment for AIP is addressed in 
section II.B.16.i. of this final rule.
    Comment: We received several letters from commenters stating that 
we should address the inequities in the DRG system with respect to 
several drugs and technologies that appeared to go unnoticed by us, 
according to the commenters. Specifically, payments for the treatment 
of acute intermittent porphyria (AIP) were brought to our attention. We 
received additional comments from physicians and a company concerning 
new procedure code 00.16 (Pressurized treatment of venous bypass graft 
(conduit) with pharmaceutical substance). The commenters requested that 
we evaluate potential reimbursement scenarios for these new procedures.
    Response: We discuss the method for applying for consideration for 
the new technology add-on payment in section II.E.1. of this preamble. 
The Medicare program pays for thousands of medical services, drugs and 
technologies and may not necessarily be aware of all new technologies 
that come to the market. We have implemented the new technology add-on 
payment provision by providing a process by which applicants can 
present these technologies to us for add-on payment consideration. 
Commenters should also consider the application process for obtaining 
new ICD-9-CM codes to further aid in obtaining specifically identifying 
procedure codes in an effort to seek new technology add-on payments. We 
discuss the DRG assignment of procedure code 00.16 in section 
II.B.16.c. of this final rule. The comment regarding the DRG assignment 
of the treatment for AIP is addressed in section II.B.16.i. of this 
final rule.
    Comment: Some commenters objected to the application of the newness 
criterion in the proposed rule. These commenters asserted that CMS's 
description of the criterion requiring a technology to be new was 
inconsistent with the statute and the September 7, 2001 final rule. 
Specifically, the commenters maintained that defining the period of new 
as during the 2-year to 3-year period after FDA market approval would 
``represent a significant shift, retroactively changing the conditions 
under which companies have been developing innovative technologies and 
filing new technology applications.'' These commenters further stated 
that this makes the regulatory process unpredictable, ``potentially 
having an adverse effect on patient access to breakthrough medical 
technologies.'' The commenters urged us to ``reaffirm'' our September 
7, 2001, policy and reevaluate the applications that CMS proposed to 
deny on the newness issue.
    Response: The intent of section 1886(d)(5)(K) of the Act and 
regulations under Sec.  412.87(b)(2) is to pay for new medical services 
and technologies for the first 2 to 3 years that a product comes on the 
market, during the period when the costs of the new technology are not 
yet fully reflected in the DRG weights. Generally, we use the FDA 
approval as the indicator of the time when a technology begins to 
become available on the market and data reflecting the costs of the 
technology begin to become available for recalibration of the DRGs. In 
some specific circumstances, we have recognized a date later than the 
FDA approval as the appropriate starting point for the 2-year to 3-year 
period. For example, we have recognized a later date where an applicant 
could prove a delay in actual availability of a product after FDA 
approval. The costs of the new medical service or technology, once paid 
for by Medicare for this 2-year to 3-year period, are accounted for in 
the MedPAR data that are used to recalibrate the DRG weights on an 
annual basis. Therefore, it is appropriate to limit the add-on payment 
window for those technologies that have passed this 2-to 3-year 
timeframe.
    We disagree that our statement of the policy in the proposed rule 
is inconsistent with policy that was implemented in previous rules. In 
the first year that new technology applications were considered in the 
IPPS (that is, during calendar year 2002), we discussed several 
applications and determined whether they could be considered new on the 
basis of when FDA approval was granted to the technologies. Again in 
our August 1, 2003 final rule for FY 2004, we denied applicants on the 
basis that the technologies had gained FDA approval prior to FY 2001; 
and thus, were not eligible for new technology add-on payments. In 
these instances, we employed the actual date of FDA market approval, 
not the date a separate ICD-9-CM code became available, since data 
reflecting the costs associated with those technologies had already 
been included in the DRG weights prior to the adoption of a separate 
ICD-9-CM code.
    Using the ICD-9-CM code alone is not an appropriate test of newness 
because technologies that are new to the market are automatically 
placed into the closest ICD-9-CM category when they first come on the 
market, unless the

[[Page 49003]]

manufacturer requests the assignment of a new ICD-9-CM code because 
existing codes do not adequately reflect or describe the medical 
service or device. The services and technologies that have been placed 
into existing ICD-9-CM codes have been paid for using those 
descriptors. Therefore, while it may be impossible to actually identify 
when a particular product was used because there is no unique code to 
identify it amongst other products in the category, the product is 
nonetheless used and paid for. In addition, hospital charges reflect 
the services provided to patients receiving the new service or device 
whether or not a specific code is assigned. Therefore, data containing 
payments for these new technologies are already in our MedPAR database 
and when DRG recalibration occurs these costs are accounted for. 
Furthermore, assignment of new codes can occur for many reasons other 
than the introduction of new procedures and technologies. For example, 
new codes can simply reflect more refined and discriminating 
descriptions of existing procedures and technologies.
    If we were strictly to use the ICD-9-CM coding system for the 
purposes of identifying what technologies are new, there would be an 
incentive for nearly every product, service and surgical technique to 
apply for a new, unique ICD-9-CM code. The ICD-9-CM system could not 
absorb all these potential new codes. It would also be inappropriate to 
pay more, in the form of new technology add-on payments, for most of 
the codes, as the technology may have been in use prior to the 
assignment of the new code for several years, or several decades in 
some cases. For example, there is currently no procedural distinction 
between a patient receiving a kidney transplant from a living or 
cadaver donor. It is conceivable that this kidney transplant could be 
broken out into several procedures, identifying the source of the 
kidney (from living/deceased, relative/stranger, etc.), and each would 
be a ``new'' procedure if we were to adopt the commenters' approach. 
These procedures have been in use for up to half a century; and 
therefore, clearly should not qualify as a new medical service or 
technology simply because a new ICD-9-CM code has been assigned. 
Another example that further exemplifies the limitations of this ICD-9-
CM-based approach is the esophageal permanent tube, which is a stent 
implanted in a patient who cannot be medically treated and is unable to 
swallow. If we create a new code, and use it to determine if the 
esophageal permanent tube should qualify for new technology payment 
under the commenters' approach, the technology could qualify as new, 
although the procedure has been used for the last 20 years.
    We also note that our existing interpretation does not hamper the 
ability of patients to receive technologies that do not qualify for new 
technology add-on payments. The IPPS will continue to pay for existing 
and new medical services and technologies through the regular payment 
mechanism established by the DRG payment methodology. Therefore, 
patient access to these technologies is not adversely affected by this 
interpretation, and this interpretation is not inconsistent with the 
framework used to review new technology applications in previous years.
    Comment: One commenter stated, ``we believe that the 2-to 3-year 
clock should not start until a technology receives final approval by 
the Food and Drug Administration.'' The commenter also submitted an 
additional comment that stated that the ``date of ICD-9 code assignment 
should start the add-on payment eligibility time clock, not the date of 
FDA approval.''
    Response: We note that the commenter's comments were somewhat 
contradictory on the issue of newness. The timeframe that a new 
technology can be eligible to receive new technology add-on payments 
begins when data become available. Section 412.87(b)(2) clearly states 
that ``a medical service or technology may be considered new within the 
2 to 3 year after the point at which data begins to become available 
reflecting the ICD-9-CM code assigned to the new service or technology 
(depending on when a new code is assigned and data on the new service 
or technology become available for DRG recalibration).'' Section 
412.87(b)(2) also states ``***[a]fter CMS has recalibrated the DRGs, 
based on available data, to reflect the costs of an otherwise new 
medical service or technology, the medical service or technology will 
no longer be considered `new' under the criterion of this section.'' 
Therefore, regardless of whether a technology can be individually 
identified by a separate ICD-9-CM code, if the costs of the technology 
are included in the charge data, and the DRGs have been recalibrated 
using that data, then the device can no longer be considered new for 
the purposes of this provision.
    Comment: A commenter suggested that CMS adopt a different strategy 
for defining the newness criterion. The commenter believes that the 
decision of whether a technology is new should involve consideration of 
both the FDA approval date and the date of issuance of an ICD-9-CM 
code. The commenter explained that if an ICD-9-CM code is issued within 
12 months of FDA approval, the 2-to 3-year period of a technology being 
considered new should begin from the date of issuance of the ICD-9-CM 
code. If a code is issued more than 12 months after FDA approval, the 
2-to 3-year period should begin from the FDA approval date. The 
commenter noted that adoption of this interpretation would strike a 
balance between the FDA approval date and the procedure code effective 
date and is consistent with the preamble of the September 7, 2001 
Federal Register (66 FR 46914) and the text of the regulation (42 CFR 
412.87(b)(2)).
    Response: We note that the time period does not necessarily start 
with the approval date for the medical service or technology and does 
not necessarily start with the issuance of a distinct code. Instead, it 
begins with availability of the product on the market, which is when 
data become available. We have consistently applied this standard, and 
believe that it is most consistent with the purpose of new technology 
add-on payments.
    Comment: MedPAC recommended that we use a different approach to DRG 
recalibration. In these instances, MedPAC recommends that we exclude 
those cases involving a new technology from our DRG recalibration 
method. Doing so ``would avoid overpaying for the technology by 
including its costs in the base payment while also providing an add-on 
payment'' during the overlapping 2-to 3-year period in question. MedPAC 
further stipulates that this approach ``should be used for all cases 
where the new technology can be tracked'' with an ICD-9-CM code or 
where cases can be identified by other characteristics in our MedPAR 
data. They also stressed the importance of maintaining a conservative 
approach when CMS evaluates technologies for add-on payments. In 
addition, they noted that paying indiscriminately for too many 
technologies ``can be seen as unbundling of the DRG system'' which 
would threaten the ``incentives for hospitals to be efficient and weigh 
the benefits of new technologies against their costs.'' Moreover, they 
noted that section 503(b)(1) of Public Law 108-173 changed the cost 
criteria by lowering the threshold to qualify for add-on payments. As 
such, MedPAC believes that the number of technologies that could 
potentially be eligible to qualify will likely increase expenditures to 
the program since these payments are no longer budget neutral.

[[Page 49004]]

    Response: We appreciate MedPAC's recommendations and will consider 
its suggestion regarding excluding the costs of cases involving new 
technologies from DRG recalibration calculations in the future. We also 
believe that we have consistently applied an appropriately high 
standard of clinical improvement to restrict these types of payments to 
relatively few technologies that are truly new. We will continue to 
apply this high standard in our review of applications for new 
technology add-on payments in the future.
    Comment: A commenter noted that if ``CMS believes that it erred in 
developing the payment period policy published in the September 7, 2001 
final rule, then it should propose a policy change applying to all 
applications for new technology add-on payments.'' The commenter also 
stated, that ``the implementation of such a policy change should affect 
only the applications received thereafter, and should not apply to any 
applications currently under consideration.''
    Response: We believe that the commenter, the manufacturer of InFUSE 
TM Bone Graft, wanted to ensure that if we made a change in 
the policy, that change would be done through notice and comment 
rulemaking and that the change would not be applied retroactively to 
applicants that are currently under consideration. However, we note 
that we have not made any changes to the policies implemented in the 
September 7, 2001 final rule.
    Comment: Several commenters urged us to be as clear as possible in 
implementing section 503 of Public Law 108-173. The commenters stated 
that transparency is necessary, particularly for ``small companies 
doing a disproportionate amount of the medical device research and 
development.'' Many commenters urged us to clearly state and adopt an 
approach to the provision so there is ``a clear path to follow and a 
reliable set of requirements to meet.'' Several commenters also noted 
that, despite how we have been applying the definition of new, many of 
the companies that have applied or could apply for new technology add-
on payments do not neatly fall into a standard definition because 
different manufacturers follow different pathways. These commenters 
stated, ``many device manufacturers, especially small device 
entrepreneurs, lack the nationwide marketing, distribution, and 
reputation of the larger companies in the industry. These small 
companies are most affected by the so-called 'payment lag' during which 
new products are under-reimbursed.***'' In addition, commenters stated, 
despite or because of these problems of distribution, the rates of 
adoption and utilization of new products should be accounted for before 
we decide technologies are no longer new. In addition, commenters call 
for CMS to ``clarify what the bar is for a device to represent a 
substantial [clinical] improvement.'' Commenters stated that 
determinations of what represents a substantial clinical improvement 
have been largely subjective, but that, ``for future generations of 
add-on applicants, an elaborated definition would be helpful.''
    Response: As stated previously, we have used as our uniform 
standard, the date of FDA approval in combination with market 
availability to evaluate new technology applications. We also note that 
in our evaluation of previous new technology applications, we have 
stated whether or not the applicants have met the substantial clinical 
improvement criterion as part of the basis for our approval or 
disapproval of the application. We follow the guidelines, as listed in 
the September 7, 2001 final rule, to make these determinations as they 
apply to improving the quality of care for the elderly Medicare 
population. However, as discussed in response to several of the other 
comments, we may need to consider revising our policies in the future 
to make the process more streamlined as more technologies apply for the 
new technology add-on payments. We will also consider the commenter's 
views concerning the payment lag for new products as we continue to 
develop policy in this area. However, at this time we believe that the 
2-to 3-years timeframe remains an appropriate standard for determining 
when the costs of new technologies have been incorporated into the DRG 
weights.
    Comment: Several commenters urged CMS to adopt a uniform standard 
for reviewing new technology add-on payment applications that is 
consistent between both the IPPS and the OPPS. Additionally, one 
commenter believes that CMS is inconsistent in its use of external data 
for verifying or amending payment rates. The commenter recommended that 
CMS should acknowledge that different types of data are appropriate for 
different uses such as revisions to APCs in the outpatient setting and 
adjustment of DRG relative weights in the inpatient setting. The 
commenter added that data requirements for determining eligibility for 
a new technology add-on payment should not be the same as for adjusting 
DRG relative weights. The commenter also recommended that external data 
provided for DRG assignments or payments for new technologies may be 
appropriately proprietary in these cases and the commenter believes CMS 
should release such data in a summary format agreed to by the companies 
and should not make the data available for public inspection without 
the companies' consent. The commenter also suggested that CMS should 
not require identification of a hospital by its Medicare provider 
number in cases where there may be a confidentiality agreement between 
the manufacturer or data vendor and the hospital submitting the data. 
The commenter recommended that CMS use pseudo-identifiers as an 
alternative to actual provider numbers. The commenter also proposed 
that CMS allow the use of external data from recent timeframes without 
corresponding MedPAR data, particularly for procedures involving new 
technologies and codes. The commenter explained that external data from 
private vendors has only a 60-90 day time lag compared to MedPAR, which 
has a lengthier time lag. The commenter further recommended that when 
determining the price of a drug or device CMS should accept the 
disclosure of discounts and rebates at the estimated aggregate level 
since the company may not know the final price paid by the hospital for 
a given product. Finally, the commenter recommended that CMS should 
request that medical technology companies offer the HCPCS codes and 
ICD-9-CM codes that seem most clinically appropriate to the procedure 
since this information would be most helpful to CMS and allow companies 
to target their resources in providing external data. Another commenter 
expressed that companies will not make the best data available ``unless 
CMS agrees to hold it confidential.''
    Another commenter encouraged CMS to expand its acceptance of 
external data in order to ease the process of establishing adequate 
initial inpatient payment for new technology procedures at or as close 
as possible to the time of FDA approval. The commenter also urged CMS 
to accept external data as part of the recalibration of the DRG 
weights. The commenter also recommended that CMS apply reasonable 
standards that take into account the limited amount of data that may be 
available for new technologies and the difficulties involved in 
collecting such data in determining whether external data provides an 
acceptable basis for making a new DRG assignment or adjustment of the 
DRG weights.
    One commenter, a company that gathers data on hospital services, 
noted

[[Page 49005]]

that its data could be used to project national trends and establish 
Medicare policies. The commenter also noted that there are instances 
where its data are more detailed than MedPAR. The commenter believes 
CMS should work with the industry to develop criteria for making use of 
external data. The commenter was also concerned about the difficulty of 
obtaining MedPAR data. The commenter explained that CMS no longer makes 
available quarterly updates to the MedPAR and that the MedPAR data used 
to develop the FY 2005 proposed rule were not made available in a 
timely manner.
    Response: We note that we have followed many of these examples when 
reviewing previous technologies. In the case of Xigris([reg]), we 
worked very closely with the applicant to review the applicant's data 
in order to identify a cohort of cases that would be appropriate 
candidates to receive the new drug. For FY 2005, we have also worked 
very closely with the applicants to help them identify what data 
requirements needed to be met and to help them to determine the best 
strategies to meet these requirements. We note, however, that 
applicants should weigh the advantages of submitting additional data in 
support of an application for new technology add-on payments with the 
need to preserve the confidentiality of certain proprietary data. We 
thank the commenters for their other comments and recommendations 
regarding accepting non-MedPAR data. We intend to take these comments 
into consideration and review the feasibility of adopting one or more 
of these approaches at some time in the future. Because we did not make 
any proposals regarding the use of external data in the May 18, 2004 
proposed rule, we are not making any changes at this time. However, we 
will consider the comments in developing future proposals.
    We also note that we offer two annual updates of the MedPAR data 
used for determining the rates in FY 2005. One update is based on the 
data used for the proposed rule. This update is usually issued in May. 
The second update is based on the data used in the final rule and is 
usually issued in September. Information on purchasing the MedPAR data 
used in determining the rates for FY 2005 can be found on our Web site 
at http://www.cms.hhs.gov/data/order/default.asp. Finally, we note, 

that in the interests of providing the most accurate and complete data 
files and due to time and work constraints, we are no longer able to 
issue quarterly updates of the MedPAR to the public.
    Comment: Commenters in general contended that they ``cannot meet 
the public's demands to adopt new technologies * * * because their 
ability to access capital is deteriorating''. Commenters stated that 
since very few new technologies have qualified for this add-on payment, 
hospitals continue to underutilize and potentially limit use of 
clinically important new technologies in the absence of these higher 
payments. Commenters again urged CMS to increase the payment for new 
technology add-on payments from 50 percent of the cost of the device to 
80 percent of the costs. They stated that to do so would be in line 
with the Conference Committee Agreement accompanying Public Law 108-173 
which states, ``the Secretary should consider increasing the percent of 
payment associated with the add-on payments up to the marginal rate 
used for the inpatient outlier.'' (108 Cong., 2d Sess., 212(2003)). 
Commenters further stated that CMS ``apparently believes that this 
outlier payment level strikes the appropriate balance between ensuring 
that providers are not unduly at financial risk for expensive cases * * 
*'', yet has offered no explanation for why this payment level would 
not be appropriate for the new technology add-on payment as well.
    Response: We note that we have made substantial changes to the 
application threshold in the last year, reducing the cost threshold to 
qualify for new technology add-on payments twice. In addition, we have 
eliminated the budget neutrality provision, thus increasing the total 
moneys spent to pay for deserving, new technologies. While the 
conference report to the MMA recommended that the Secretary should 
consider changing the payment factor, we will not make such a change 
this year. Rather, we will analyze the impacts of the other MMA 
changes, especially the reduction in the cost threshold and the 
elimination of the budget neutrality of the add-on payments, before we 
consider making changes in the payment percentage. We will continue to 
consider the conference report's recommendation and will determine 
whether to proceed with a change in the light of our continuing 
analysis.
    Comment: Commenters urged CMS to adopt an approach to the public 
meetings required by the MMA in a manner that is similar to the ICD-9 
Coordination and Maintenance Committee meetings. Commenters noted that 
a specific agenda and preliminary opinions are released to the public 
prior to these meetings and urged CMS to present preliminary opinions 
on substantial clinical improvement prior to the public meeting on this 
topic.
    Response: We have traditionally not provided our opinion on 
substantial clinical improvement of applicants for new technology add-
on payments until the final rule. We note that if all the criteria are 
met prior to the publication of the proposed rule, we would prefer to 
make our preliminary determinations available at that time. However, to 
date we have not been able to make a sound determination regarding 
substantial clinical improvement until after the publication of the 
proposed rule.
    Section 503(b)(2) of Public Law 108-173 requires CMS to consider 
public comments regarding whether an applicant for new technology 
payments meets the substantial clinical improvement criterion. Comments 
must be received and considered prior to the publication of the 
proposed rule for the annual IPPS update. This requirement, which was 
implemented for the first time through the new technology town hall 
meeting held in March of this year, and the subsequent comment period 
is further evidence that we do take the issue of substantial clinical 
improvement into account prior to the publication of the proposed rule. 
However, the MMA provision does not require the type of procedure 
recommended by the commenter, but merely the opportunity for 
presentation of comments, recommendations, and data to CMS.
    We designed the town hall-styled meeting this spring to provide a 
forum for public comment on the applicants. This format appeared to be 
received well by most of the attendees. We accepted comments and topics 
from attendees and presenters at the meeting, as well as accepting 
comments on substantial clinical improvement of the applicants after 
the meeting. If presenters would like a more detailed agenda to be 
published prior to the rule, we welcome them to register to attend the 
annual meeting and provide the information requested in the Federal 
Register notice announcing the meeting (this includes personal 
information for registration purposes as well as topics to be presented 
at the meeting). If we have this information well in advance of the 
meeting, the agenda will reflect all issues that have been raised 
regarding the assessment of the substantial clinical improvement 
criterion for each applicant. We welcome further input on how to better 
incorporate input prior to the announcement of the next town hall 
meeting on this topic.
    In the May 18, 2004 proposed rule (69 FR 28236), we also evaluated 
whether new technology add-on payments will

[[Page 49006]]

continue in FY 2005 for the two technologies that currently receive 
such payments. In accordance with section 503(e)(2) of Public Law 108-
173, we also reconsidered one application for new technology add-on 
payments that was denied last year. Finally, we presented our 
evaluations of 10 new applications for add-on payments in FY 2005.
3. FY 2005 Status of Technology Approved for FY 2004 Add-On Payments
a. Drotrecogin Alfa (Activated)--Xigris[reg]
    Xigris[reg], a biotechnology product that is a recombinant version 
of naturally occurring Activated Protein C (APC), was approved by the 
FDA on November 21, 2001. In the August 1, 2002, IPPS final rule (67 FR 
50013), we determined that cases involving the administration of 
Xigris[reg], (as identified by the presence of code 00.11 (Infusion of 
drotrecogin alfa (activated)) were eligible for additional payments in 
FY 2003. (The August 1, 2002, final rule contains a detailed discussion 
of this technology.)
    In the August 1, 2003, final IPPS rule (68 FR 45387), we indicated 
that, for FY 2004, we would continue to make add-on payments for cases 
involving the administration of Xigris[reg] as identified by the 
presence of code 00.11. This was because we determined that Xigris[reg] 
was still within the 2-year to 3-year period before the costs of this 
new technology would be reflected in the DRG weights.
    Xigris[reg] became available on the market at the time of its FDA 
licensure on November 21, 2001. Early in FY 2005, Xigris[reg] will be 
beyond the 2-year to 3-year period during which a technology can be 
considered new. Therefore, in the May 18, 2004 proposed rule, we 
proposed that Xigris[reg] would not continue to receive new technology 
add-on payments in FY 2005. During the period of 2 years and 8 months 
since it came onto the market, Xigris[reg] has been used frequently in 
the appropriate DRGs. For FY 2005, we analyzed the number of cases 
involving this technology in the FY 2003 MedPAR file. We found 4,243 
cases that received Xigris[reg], the majority of which fell 
appropriately into DRGs 415, 416, 475, and 483, with by far the most 
cases in DRG 416 (Septicemia Age >17). Accordingly, the costs of 
Xigris[reg] are now well represented in those DRGs. Therefore, we 
proposed that FY 2004 would be the final year for Xigris[reg] to 
receive add-on payments.
    Prior to the publication of the May 18, 2004, proposed rule, we 
received no public comments regarding the continuation of add-on 
payments for Xigris[reg]. During the 60-day comment period for the 
proposed rule, we received 3 comments on this application.
    Comment: The manufacturer submitted comments that were highly 
critical of CMS' proposal to discontinue add-on payments for 
Xigris[reg]. The commenter brought up several points, which it 
believes, show that CMS is in violation of the statutory provisions. 
First, the manufacturer expressed opposition to the proposal to 
terminate the new technology add-on payments. It agreed that it was 
important to consider when a product comes on the market, but stated, 
``[w]hether a technology is `new' is not salient in determining whether 
a third year of add-on payments should continue.'' It stated that the 
costs of the drug had not been adequately accounted for as required by 
statute and that the period during which it was eligible to receive 
add-on payments should continue another year, until 3 full years of 
add-on payments had been made. It stated, that ``the fact that costs of 
a new technology or service may be included in the Medicare hospital 
discharge database (MedPAR) starting at the time an item or service is 
introduced into the marketplace is irrelevant. What matters is the 
ability to examine 2 years of cost data for cases coded as having used 
the new technology or service.'' Further, it argued, ``these cost data 
cannot be identified and collected until the ICD code is assigned and 
used in the coding of cases.'' It also stated that, since this 3-year 
maximum period had not yet ended, the costs of the cases could not have 
adequately been accounted for in our DRG recalibration using only data 
from FY 2003. It further stated that we should wait to remove them from 
add-on payment status until data from the FY 2004 MedPAR are available 
to recalibrate the DRGs. The manufacturer also stated that ``the point 
of the legislative changes was to improve the old way of doing business 
* * *. It is unfortunate that CMS proposes to take the path of least 
resistance because it is the Medicare beneficiaries who will ultimately 
suffer.''
    Another commenter stated that our proposal to deny additional add-
on payments in FY 2005 will deny Medicare beneficiaries the access to 
Xigris[reg]. An additional commenter noted that, particularly because 
CMS was unable to implement the systems changes necessary to pay the 
new technology add-on payment for Xigris[reg] until 8 months after the 
new code and higher payment were allowed, many hospitals were unclear 
as to the significance of correctly coding the new ICD-9-CM code 
identifying Xigris[reg], and therefore, the data for the first year of 
add-on payments do not adequately reflect the actual use of the drug.
    Response: As stated previously, when we determine the newness 
criterion for new technology add-on applications, we use the date of 
FDA approval to determine that data including the technology are being 
incorporated into DRG recalibration, except in those rare cases where 
evidence can be presented that demonstrates that the product could not 
be marketed immediately after FDA approval. We have used this method of 
determining newness since we began reviewing new technology 
applications. While there was no clearly distinguishable code assigned 
to Xigris[reg] prior to the implementation of the new ICD-9-CM code 
00.11 on October 1, 2002, treatment with Xigris[reg] was identified 
prior to that time by procedure code 99.19. While this may not suit the 
applicant in terms of the ability to track specific cases that involved 
the use of Xigris[reg], the drug was being used for more than 10 months 
prior to the assignment of code 00.11 and the costs associated with the 
drug were, therefore, clearly included in the FY 2003 MedPAR update. 
Additionally, we note that the manufacturer itself was able to identify 
patients that would or could use Xigris(r), as discussed in the May 9, 
2002 proposed rule. There we stated, ``Lilly also submitted detailed 
ICD-9-CM diagnosis and procedure codes for a subset of * * * patients 
with billing data. * * *'' (67 FR 31428). Because the manufacturer was 
able to identify a subset of patients without billing data at that 
time, we have met the criteria set forth by the manufacturer itself in 
being able to identify ``2 years of cost data for cases coded as having 
used the new technology. * * *'' The data we have captured since 
including the data used for the FY 2003 proposed rule analysis, have 
adequately accounted for costs associated with these cases. Including 
the 2 subsequent years during which Xigris[reg] was eligible to receive 
new technology add-on payments, this makes a total of 3 years of data 
that CMS has used to incorporate the costs associated with the drug 
into the weights of the DRGs into which these cases fall.
    In the FY 2004 annual update, we estimated that there would be 
3,000 cases involving Xigris[reg] in the relevant DRGs and we note that 
there are now 4,313 cases involving the drug in the March update of the 
FY 2003 MedPAR. We have conducted an analysis of the FY 2002 MedPAR to 
determine the frequency of these cases in the DRGs in

[[Page 49007]]

which Xigris[reg] has been used. We have identified 593 cases using 
procedure code 99.19 in these 5 DRGs, which is significantly lower than 
the most recent 2 years of data. Additionally, we recognize that this 
code included other drugs and that not all 593 cases reporting this 
code in these 5 DRGs necessarily involved Xigris[reg]. However, this 
low number of cases is consistent with what we would expect, given that 
the initial ICD-9-CM code did not drive DRG placement or payments. It 
is also consistent with the reasoning behind our of approval 
Xigris[reg] for new technology add-on payments, since it was clearly a 
new technology that provided great potential benefit to Medicare 
beneficiaries and met the other criteria as defined by the statute. It 
is also reasonable to expect that, once the new ICD-9-CM code went into 
effect, with a payment incentive to encourage its rapid adoption and 
use, the number of cases including this code rose dramatically. While 
the figure of 593 cases using procedure code 99.19 in the relevant 
cases in FY 2002 is not very high, we note that in the August 1, 2002 
final rule we stated that, based on the sales figures from the company 
at that time, there was already ``$35 million in sales reported by 
Lilly through February 2002 (since the drug was approved in November 
2001). (At $6,800 per patient, $35 million in sales equates to just 
over 5,000 cases for the first 4 months since FDA approval.)'' (67 FR 
50015). Therefore, we are confident that we have adequate data 
reflecting the use of Xigris[reg] over the past 3 years. If we were to 
continue add-on payments beyond FY 2004, the technology would be beyond 
its 2-3 year maximum as allowed by the statute. We have used these data 
to recalibrate the DRGs into which these cases most frequently fall, so 
the costs of the technology have already been accounted for in those 
DRG weights. Similarly, although we regret that systems changes delayed 
the processing of add-on payments for Xigris[reg] in FY 2003, hospitals 
received add-on payments for all cases reporting the ICD-9-CM code for 
Xigris[reg]. Furthermore, the costs of the new technology are 
nonetheless represented in the 2003 MedPAR data, whether hospitals used 
the new ICD-9-CM code for Xigris[reg] (00.11) or the earlier procedure 
code (99.19). We do not agree with the assertion that Medicare 
beneficiaries will no longer have access to this important drug once 
the new technology add-on payments associated with it are terminated. 
To the contrary, we will continue to pay for the drug through DRG 
payment, and as noted above, the costs associated with the drug have 
been included in the weights of the relevant DRGs through the DRG 
recalibration.
    Comment: The manufacturer also noted that section 
1886(d)(5)(K)(ii)(IV) of the Act requires, ``that discharges involving 
such a service or technology that occur after the close of the period 
[of add-on payments] will be classified within a new or existing 
diagnosis-related group with a weighting factor * * * that is derived 
from the cost data collected with respect to discharges occurring 
during such period.'' The commenter argues that there is no room for 
interpretation of the statute and that, since the average costs of 
cases involving the technology are very high, they should be assigned 
either to a new DRG or remapped to higher-weighted DRGs to reflect the 
cost of the cases. Another commenter asked that, if CMS refused to 
continue add-on payments for the entirety of FY 2005, such payments 
should be ``maintained at least until the agency has analyzed the 
available data and has classified cases in which Xigris[reg] is 
administered into an appropriate DRG.''
    Response: We do not agree with the implications the commenter draws 
from the statutory language. We have assigned cases involving the use 
of Xigris[reg] to clinically coherent DRGs, and the weights of these 
DRGs have been recalibrated to reflect the costs of these technology. 
We have also analyzed the costs of these cases and determined that, 
although the average standardized charge for these cases is higher than 
the average charges for the DRGs into which the cases involving 
Xigris[reg] fall, there appears to be no justification to warrant 
creation of a new DRG or re-assignment of cases involving Xigris[reg] 
into higher-weighted DRGs. We do not believe that it is necessary to 
assign cases involving Xigris[reg] to a separate unique DRG, as 
requested by the manufacturer, in order to satisfy the statutory 
requirement. Indeed, we note that the commenter's own comment stated, 
``Xigris[reg] is administered to only a small proportion of the severe 
sepsis population and is not representative of the comprehensive 
incidence of the disease.'' Therefore, by the manufacturer's own 
statements, we cannot use cases involving the code for Xigris[reg] as 
the standard by which to assign severe sepsis cases. We discuss the DRG 
assignment of Xigris[reg] in section II B.16.c. of this final rule.
    Comment: One national hospital association agreed with our proposal 
to discontinue add-on payments for this technology. The commenter noted 
that the termination of the add-on payments falls outside the timeframe 
in which a technology is new for add-on payment purposes. The 
association strongly encouraged CMS to continue monitoring the use of 
Xigris[reg] and associated conditions of severe sepsis to determine if 
future revisions to the current DRGs will be necessary. Another 
commenter urged us to continue to monitor the use and diffusion of all 
new technologies that qualify or have previously qualified for this 
provision. Commenters urged CMS to require that all hospitals continue 
to code for the use of the new technologies, even after the period of 
add-on payment for the technologies has ended, thus ensuring adequate 
tracking of diffusion of the new technologies as they continue to be 
used.
    Response: We appreciate the commenter's support for our decision to 
remove this technology from add-on payment status. We note that we 
review new technology add-on payment recipients annually to determine 
whether they continue to meet the criteria to receive add-on payments. 
In the case of Xigris[reg], this review led us to find that it no 
longer meets the newness criterion. While we encourage hospitals to 
continue to code for the drug, even though there is no longer a payment 
incentive to do so, we cannot require hospitals to code for the use of 
the drug.
    We are finalizing our proposal to remove Xigris[reg] from new 
technology status and will no longer pay new technology add-on payments 
for this technology, starting October 1, 2004. The manufacturer also 
asked us to consider creating a DRG specifically for severe sepsis. We 
discuss this request in section II.B.16.c. of the preamble to this 
final rule.
b. InFUSETM (Bone Morphogenetic Proteins (BMPs) for Spinal 
Fusions)
    InFUSETM was approved by FDA for use on July 2, 2002, 
and became available on the market immediately thereafter. In the 
August 1, 2003 IPPS final rule (68 FR 45388), we approved 
InFUSETM for add-on payments under Sec.  412.88, effective 
for FY 2004. This approval was on the basis of using 
InFUSETM for single-level, lumbar spinal fusion, consistent 
with the FDA's approval and the data presented to us by the applicant. 
Therefore, we limited the add-on payment to cases using this technology 
for anterior lumbar fusions in DRGs 497 (Spinal Fusion Except Cervical 
With CC) and 498 (Spinal Fusion Except Cervical Without CC). Cases 
involving InFUSETM that are eligible for the new technology 
add-on payment are identified by assignment to DRGs 497 and 498 as a 
lumbar spinal fusion, with the combination of ICD-9-

[[Page 49008]]

CM procedure codes 84.51 (Insertion of interbody spinal fusion device) 
and 84.52 (Insertion of recombinant bone morphogenetic protein).
    Because InFUSETM was approved by the FDA for use on July 
2, 2003, it is still within the 2-year to 3-year period during which a 
technology can be considered new under the regulations. Therefore, in 
the May 18, 2004 proposed rule, we proposed to continue add-on payments 
for FY 2005 for cases receiving InFUSETM for spinal fusions 
in DRGs 497 (Spinal Fusion Except Cervical With CC) and 498 (Spinal 
Fusion Except Cervical Without CC). We also proposed to continue 
limiting the add-on payment for cases receiving InFUSETM, to 
those cases identified by the presence of procedure codes 84.51 and 
84.52. However, we proposed to eliminate add-on payment for the 
interbody fusion device that is used in combination with this 
recombinant human bone morphogenetic protein (rhBMP) product (procedure 
code 84.52). We note that currently add-on payments for 
InFUSETM include costs for the interbody fusion device (the 
LT Cage, identified by procedure code 84.51), used in the spinal fusion 
procedure with the InFUSETM product. Because this device is 
not a new technology, but in fact has been in use for 9 years for 
spinal fusions, we believe that it is inappropriate to pay for this 
device in conjunction with the genuinely new rhBMP technology. 
Therefore, we proposed no longer to pay for the interbody fusion device 
as bundled in the current maximum add-on payment amount of $4,450 for 
cases that qualify for additional payment. The proposal would reduce 
the add-on payment to account for no longer including the costs of the 
LT Cage in computing the add-on payment amount. This would reduce the 
cost of this new technology by $4,990, which results in a total cost of 
$3,910 for InFUSETM. Therefore, we proposed a maximum add-on 
amount of $1,955 for cases that qualify for additional payment. 
Although we proposed to eliminate payment for the LT Cage, we would 
still require the presence of procedure code 84.51 (in combination with 
procedure code 84.52) when making new technology add-on payments for 
InFUSETM. This is due to the fact that the LT Cage is still 
required by the FDA when InFUSETM is used for single level 
spinal fusions.
    Prior to the publication of the May 18, 2004 proposed rule, we 
received public comments in accordance with section 503(b)(2) of Public 
Law 108-173 regarding the continuation of add-on payments for this 
technology. Commenters expressed support for the continuation of new 
technology add-on payments for this technology in FY 2005.
    We are finalizing that proposal in this final rule.
    We received the following comments in response to the May 18, 2004 
proposed rule.
    Comment: Several commenters supported our proposal to no longer pay 
for the LT Cage as a bundled add-on payment with InFUSETM. 
They noted that it was not appropriate to pay for the LT Cage as part 
of the InFUSETM add-on since the technology has been 
available for several years.
    Response: When we initially reviewed the application, the applicant 
indicated to us that the FDA approval was for a pre-packaged product 
that included the LT Cage, the InFUSETM biotechnology 
product, and an absorbable collagen sponge to carry the rhBMP. While 
the FDA label required the product to be used with the LT Cage, we were 
initially under the impression that these devices were provided to 
hospitals in the same package. It later was brought to our attention 
that the product was not marketed this way and that in fact the rhBMP 
product is supplied to hospitals in several different sized ``kits'' 
that have differing amounts of InFUSETM in them, and that 
the LT Cage is purchased separately. As such, it is not only easy to 
see why the add-on payment should be unbundled, but also easy to do so.
    Comment: Some commenters, including the manufacturer, were opposed 
to our proposal to discontinue bundled payment for InFUSETM 
in combination with the LT Cage. They argue that to remove the payment 
for the LT Cage would result in even further restricting the use of 
this much needed technology that eliminates a painful second surgery 
and extensive blood loss for the patients who must otherwise undergo 
spinal fusions via conventional, autogeneous bone-harvesting methods. 
Other commenters were very concerned that the lower add-on payment 
amount would result in hospitals using cages other than the FDA-
approved LT Cage with this technology. These commenters stated that to 
encourage this off-label use by not continuing the higher payments is 
contrary to our statement in last year's final rule requiring that a 
product qualify for add-on payments based upon usage consistent with 
its FDA labeling.
    Response: In this clear case where a new technology is being used 
in conjunction with an old technology, we do not believe it is 
appropriate to continue to pay an add-on payment for the old device, as 
this device has already been in use for 9 years and has been accounted 
for in DRG payments. We are finalizing our proposal to approve 
InFUSETM for spinal fusion for an additional year of new 
technology add-on payments, through the end of FY 2005. We note that in 
order to receive new technology add-on payment for InFUSETM, 
we are continuing to require both the procedure code for 
InFUSETM (84.52) and the code for the LT Cage (84.51) due to 
the FDA label that requires the LT Cage to be used in conjunction with 
the InFUSETM product. While the procedure code for the LT 
Cage (84.51) does include other brands and types of cages for spinal 
fusion, we expect that doctors will maintain the best clinical standard 
for their patients and will continue to use the LT Cage with the 
InFUSETM product. We are therefore finalizing our proposal 
to unbundle the new technology add-on payments for this device for FY 
2005 by removing payment for the LT Cage from the add-on payment for 
cases involving InFUSETM. We are also finalizing the maximum 
add-on payment amount of $1955 for cases that are eligible to receive 
the add-on payment.
    Comment: Other commenters were pleased about our proposal to 
discontinue bundled payments that include the LT Cage for spinal 
fusions because this bundled payment precluded payment for similar 
technologies that are used in spinal fusion surgery but that do not 
require use of the LT Cage. One commenter noted that another BMP 
product was just awarded FDA approval for spinal fusion involving 
posterolateral approach. This commenter requested that the other 
devices of this nature be included in any approval of rhBMPs for new 
technology add-on payments or an unfair economic advantage would be 
created.
    Response: As we discussed in the September 7, 2001, final rule (66 
FR 46915), an approval of a new technology for special payment should 
extend to all technologies that are substantially similar. Otherwise, 
our payment policy would bestow an advantage to the first applicant to 
receive approval for a particular new technology. The new product, 
called OP-1 Putty, manufactured by Stryker Biotech, utilizes a similar 
mechanism to promote natural bone growth by using a closely related 
bone morphogenetic protein called rhBMP-7 (InFUSETM is 
rhBMP-2). Because the OP-1 Putty is now available on the market (it 
received FDA approval for spinal fusions in May of this year) for 
similar spinal fusion procedures and also eliminates the need

[[Page 49009]]

for the autograft bone surgery, we are extending new technology add-on 
payments to this technology as well, for FY 2005. Because the new 
product does not require the LT Cage to be used simultaneously, we are 
requiring that providers use different codes when the different 
products are used.
    Cases using InFUSETM should be identified by the 
combination of procedure codes 84.51 and 84.52, as described above and 
as required in the previous year of new technology add-on payments for 
this technology. For cases using the OP-1 Putty, the procedure code 
84.52 (Insertion of recombinant bone morphogenetic protein) must be 
coded in combination with procedure codes identifying posterolateral 
spinal fusions, as is consistent with the FDA approval for this device. 
Therefore, procedure code 84.52 must be coded with any of the following 
procedure codes: 81.08 (Lumbar/lumbosac fusion posterior technique), 
81.38 (refusion of lumbar posterior approach), 81.05 (Dorsal and 
dorsolumbar fusion, posterior technique), or 81.35 (Refusion of dorsal 
and dorsolumbar spine, posterior technique) in order to receive add-on 
payments under this provision. Both of these devices have FDA approval 
that is consistent with cases that would be assigned to DRGs 497 or 
498. Because Stryker Biotech did not submit a new technology add-on 
payment application, we were unable to do a complete analysis of the 
cost of the device. However, we have been able to determine that the 
costs associated with the OP-1 Implant are similar to those associated 
with InFUSETM. Therefore, we believe that the same payment 
amount for new technology add-on payments is appropriate for both 
devices. Accordingly, cases containing one of the above combinations of 
procedure codes and that fall into DRGs 497 or 498 will be eligible to 
receive the add-on payment, with a maximum of $1,955 for FY 2005.
4. Reevaluation of FY 2004 Applications That Were Not Approved
    Section 503(e)(2) of Public Law 108-173 requires us to reconsider 
all applications for new medical service or technology add-on payments 
that were denied for FY 2004. We received two applications for new 
technologies to be designated eligible for add-on payments for new 
technology for FY 2004. We approved InFUSETM for use in 
spinal fusions for new technology add-on payments in FY 2004. We denied 
the application for new technology add-on payments for the GLIADEL 
[reg] wafer.
GLIADEL [reg] Wafer
    Gliablastoma Multiforme (GBM) is a very aggressive primary brain 
tumor. Standard care for patients diagnosed with GBM includes surgical 
resection followed by radiation and, in some cases, systemic 
chemotherapy. According to the manufacturer, the GLIADEL[supreg] wafer 
is indicated for use at the time of surgery in order to prolong 
survival in patients with GBM. Implanted directly into the cavity that 
is created when a brain tumor is surgically removed, the 
GLIADEL[supreg] wafer delivers chemotherapy directly to the site where 
the tumor is most likely to recur.
    The FDA gave initial approval for the GLIADEL[supreg] wafer on 
September 23, 1996, for use as an adjunct to surgery to prolong 
survival in patients with recurrent GBM for whom surgical resection is 
indicated. In 2003, Guilford Pharmaceuticals submitted an application 
for approval of the GLIADEL[supreg] wafer for add-on payments and 
stated that the technology should still be considered new for FY 2004, 
despite its approval by the FDA on September 23, 1996. The manufacturer 
stated that the technology was still new because it had not been 
possible to specifically identify cases involving use of the 
GLIADEL[supreg] wafer in the MedPAR data prior to the adoption of a new 
ICD-9-CM code 00.10 (Implantation of a chemotherapeutic agent) on 
October 1, 2002. However, as discussed in the September 7, 2001 final 
rule (66 FR 46914), the determination concerning whether a technology 
meets this criterion depends on the date of its availability for use in 
the Medicare population rather than the date a specific code may be 
assigned. A technology can be considered new for 2 or 3 years after 
data reflecting the costs of the technology begin to become available. 
Data on the costs of this technology began to become available in 
September 1996. As a result, the costs of this technology are currently 
reflected in the DRG weights. As discussed in the final rule for FY 
2004 (68 FR 45391), on February 26, 2003, the FDA approved the 
GLIADEL[supreg] wafer for use in newly diagnosed patients with high-
grade malignant glioma as an adjunct to surgery and radiation. However, 
our understanding is that many newly diagnosed patients were already 
receiving this therapy. To the extent that this is true, the charges 
associated with this use of the GLIADEL[supreg] wafer were also 
reflected in the DRG relative weights. Therefore, the GLIADEL[supreg] 
wafer did not meet this criterion for FY 2004.
    Section 503(e)(2) of Public Law 108-173 required us to reconsider 
this application, but did not revise the criterion for determining 
whether a medical service or technology is new. As stated above, the 
FDA originally approved the GLIADEL[supreg] wafer on September 23, 
1996. Therefore, this technology is beyond the period in which it can 
be considered new. Accordingly, in the May 18, 2004, proposed rule, we 
proposed to deny this application for new technology add-on payments 
for FY 2005.
    Prior to the publication of the May 18, 2004, proposed rule, we 
received no public comments regarding our reconsideration of this 
application for add-on payments. During the 60-day comment period for 
the May 18, 2004, proposed rule, we received the following public 
comments regarding our reconsideration of the application.
    Comment: One commenter stated, ``[a]s a country that prides itself 
on being a leader in cancer research, it is disheartening that patients 
must battle to gain access to the benefits that this research has 
provided.''
    Response: We continue to pay for technologies that do not meet the 
criteria to receive new technology add-on payments through the regular 
payment mechanism established by the DRG payment methodology. 
Therefore, patient access to these technologies should not be adversely 
affected by a determination that a technology does not qualify to 
receive add-on payments.
    Comment: One commenter believes that the GLIADEL[supreg] 
chemotherapy wafer merits a separate DRG, which the applicant contends 
would be similar to our treatment of the establishment of new DRGs for 
drug-eluting stents. The commenter acknowledges that DRGs are ``not 
normally created to recognize the presence or absence of new 
technology.'' Nevertheless, the commenter argues that CMS' recognition 
of the ``unique circumstances surrounding the potential breakthrough 
nature'' of drug-eluting stents should also be applied to 
GLIADEL[supreg] wafer.
    Response: Guilford asked us to consider reclassifying this device 
into another DRG. We discuss issues relating to the DRG assignment of 
the GLIADEL[supreg] wafer in section II.B.16.c. of this final rule. In 
that discussion, we announce our decision to create a new DRG 543 
(Craniotomy with implantation of chemotherapeutic agent or acute 
complex central nervous system principle diagnosis) to which Gliadel 
cases will be assigned. The cases assigned to this new DRG have similar 
resource utilization and comparable charges to cases involving the 
GLIADEL[supreg] wafer. As a result, we

[[Page 49010]]

believe this DRG assignment will result in appropriate payments for 
these cases. In this rule we are finalizing our denial of new 
technology add-on payments for this technology.
5. FY 2005 Applicants for New Technology Add-On Payments
a. InFUSETM Bone Graft (Bone Morphogenetic Proteins (BMPs) 
for Tibia Fractures)
    Bone Morphogenetic Proteins (BMPs) have been shown to have the 
capacity to induce new bone formation and, therefore, to enhance 
healing. Using recombinant techniques, some BMPs (referred to as 
rhBMPs) can be produced in large quantities. This has cleared the way 
for their potential use in a variety of clinical applications such as 
in delayed unions and nonunions of fractured bones and spinal fusions. 
One such product, rhBMP-2, is developed for use instead of a bone graft 
with spinal fusions.
    Medtronic Sofamor Danek submitted an application for the 
InFUSETM Bone Graft for use in tibia fractures for approval 
as a new technology eligible for add-on payments in FY 2005. Medtronic 
submitted a similar application for new technology add-on payments in 
FY 2004 for InFUSETM Bone Graft/LT-CAGETM Lumbar 
Tapered Fusion Device. As discussed above, we approved this application 
for FY 2004, and will continue to make new technology payments for FY 
2005 for InFUSETM when used in spinal fusions (refer to 
section III.E.3.b. of this preamble).
    In cases of open tibia fractures, InFUSETM is applied 
using an absorbable collagen sponge, which is then applied to the 
fractured bone in order to promote new bone formation. The manufacturer 
contends that this use is severely limited due to the greatly increased 
costs for treating these cases with InFUSETM at the time of 
wound debridement and closure. The manufacturer has conducted a 
clinical trial and FDA approval for the use of InFUSETM for 
open tibia fractures was awarded on April 30, 2004. The application for 
add-on payments for the use of InFUSETM for open tibia 
fractures proposes that such payment would encourage the use of 
InFUSETM for treatment of these fractures of grade II or 
higher (up to and including grade III, which often must be amputated 
due to the severity of injury). The additional payment, according to 
the applicant, would encourage more hospitals to use the technology at 
the time of initial wound closure and would result in reduced rates of 
infection and nonunion currently associated with the treatment of these 
injuries.
    The manufacturer submitted data on 315 cases using 
InFUSETM for open tibia fractures in the FY 2002 MedPAR 
file, as identified by procedure code 79.36 (Reduction, fracture, open, 
internal fixation, tibia and fibula) and diagnosis codes of either 
823.30 (Fracture of tibia alone, shaft, open) or 823.32 (Fracture of 
fibula and tibia, shaft, open). The applicant also noted that the 
patients in their clinical trials as well as patients that would be 
likely candidates to receive InFUSETM for tibia fractures 
would include those cases that had malunion of their fractures 
(diagnosis code 733.81) or nonunion of fractures (diagnosis code 
733.82). The applicant also submitted data for a hospital sample that 
included 63 cases using the same identifying codes. Based on the data 
submitted by the applicant, InFUSETM would be used in four 
different DRGs: 217 (Wound Debridement and Skin Graft Except Hand, for 
Musculoskeletal and Connective Tissue Disorders), 218 and 219 (Lower 
Extremity and Humerus Procedures Except Hip, Foot, Femur Age > 17, With 
and Without CCs, respectively) and 486 (Other O.R. Procedures for 
Multiple Significant Trauma). The analysis performed by the applicant 
resulted in a case-weighted cost threshold of $27,111 for these four 
DRGs. The average case-weighted standardized charge for cases using 
InFUSETM in these four DRGs would be $46,468. Therefore, the 
applicant maintains that InFUSETM for open tibia fractures 
meets the cost criterion.
    Further discussions with the applicant revealed that the more 
appropriate DRGs to which this device should be limited are DRGs 218 
and 219 (Lower Extremity and Humerus Procedures Except Hip, Foot and 
Femur Age > 17, With and Without CC). The manufacturer projects that 
there would be approximately 550 cases (based on the number of open 
tibia fractures that would have qualified for InFUSETM in 
the FY 2002 MedPAR) in FY 2005. Since FDA approval for use of 
InFUSETM for open tibia fractures, we have performed an 
analysis to determine the number of cases that may have already 
received InFUSETM for treatment of open tibia fractures. We 
identified 3,788 cases in DRGs 218 and 219 (Lower Extremity & Humerus 
Procedures except hip, foot, femur, age >17, with and without CCs) that 
also had procedure code 79.36 (Reduction, fracture, open, internal 
fixation, tibia and fibula) and any of the following diagnosis codes: 
823.30 (Fracture of tibia alone, shaft, open), 823.32 (Fracture of 
fibula with tibia, shaft, open), 733.81 (Malunion of fracture), or 
733.82 (Nonunion of fracture). We identified 38 cases in DRGs 218 and 
219 that contained a code identifying a BMP product (identified by the 
presence of procedure code 84.52) in the FY 2003 MedPAR.
    In t